The Freedom of Information Act 2000 (FOI) came fully into force in January 2005. All bodies must have in place a Publication Scheme (a list of classes of information available to the public).
The act also gave individuals and corporate bodies the right of access to all types of recorded information held by public sector bodies, with the exception of certain specified exemptions (for instance, personal information and commercially sensitive information). For more information about the act please visit the Information Commissioner’s website: www.ico.org.uk/for-the-public/official-information
Our Publication Scheme has most of the information frequently asked for by members of the public.
Before making a formal request to the Trust, please check our website to make sure that the information you require isn’t already available by clicking here. This data will be updated on a six monthly basis and FOI requests for this information will be exempt under Section 22 – Information intended for future publication.
You can also search this site below for information disclosed by the Trust following requests made under the Freedom of Information Act 2000 since 1 April 2015.
It is important that the public realises that the provision of recorded information from the Trust, requires busy Trust staff to spend time away from the core business of clinical, management and clerical functions that support patient care, in order to retrieve this information from complex data sources.
If the information you require is not held on our website, you can contact us either by emailing us at: mtw-tr.foiadmin@nhs.net or writing to us at Freedom of Information Officer, Trust Headquarters, Maidstone and Tunbridge Wells NHS Trust, Hermitage Lane, Maidstone ME16 9QQ.
Once we have received your request, we will send you an acknowledgement letter. We are required to give you a response within 20 working days of our acknowledgement letter. We will try to respond as quickly as possible. Sometimes, some or all of the information cannot be provided. If this is the case, we will explain the reasons why.
We are able to charge fees for requests, outlined in the Freedom of Information Guide. We will generally only charge you for hard copies or copying onto media eg CD. The charges will vary according to how information is made available. Legally, if the cost of obtaining and sending you the information is more than £450, we do not have to provide you with the information you requested. This amount is based on the DCA’s (Department of Constitutional Affairs) regulations of a national cost of 18 hours work at £25 per hour.
In the first instance you should appeal to us directly, in line with our FOI appeal process. Download a copy of the appeals process document, or email us at mtw-tr.foiadmin@nhs.net for a copy to be sent to you. If you are still dissatisfied after the appeals process, you have the right, under section 50 of the Act, to apply to the Information Commissioner to seek resolution to the matter.
You can search our FOI database below, or alternatively you can look through our recent responses here or by clicking on the right hand column.
Cyber Security
The Trust has a dedicated Cyber Security Team and has purchased and installed many different solutions to help protect us against cyber threats. However, we will not be publicising or sharing the details of these products, solutions or vendors because we believe that in doing so, we put our self at risk.
We will also not be publishing details around any system be it hardware or software that is either end of life or is coming to end of life as we believe that publishing this information also puts the Trust at risk. This would include but is not limited to items such as “does the trust have any machines running an out of date operating system or unsupported hardware”.
FOI requests in relation to Covid-19
Maidstone and Tunbridge Wells NHS Trust strive to be transparent and to work with an open culture. At the current time some administration and clerical resources have been diverted to support our front-line colleagues who are working tremendously hard to provide care for our patients, and to those in need of our services and therefore it may take longer than usual to respond to requests for information.
The Trust has received a number of Freedom of Information requests in relation to the Covid-19 pandemic. NHS England publish a significant amount of information relating to Covid-19 which is updated regularly. Please check the information available on the websites listed below before requesting information under the Act
Covid-19 Deaths:
Under Section 21 of the Act we are not required to provide information in response to a request if the information is already reasonably accessible to requesters. The information you requested is available from:
https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-daily-deaths/
This information is updated on a regular basis and is exempt under Section 22 of the Act.
All hospital recorded deaths:
Under Section 21 of the Act we are not required to provide information in response to a request if the information is already reasonably accessible to you. The information you requested is available from
https://digital.nhs.uk/data-and-information/publications/statistical/shmi/2020-12
This information is updated on a regular basis and is exempt under Section 22 of the Act.
Bed Availability and Occupancy Data – Overnight
Under Section 21 of the Act we are not required to provide information in response to a request if the information is already reasonably accessible to you. The information you requested is available from
This information is updated on a regular basis and is exempt under Section 22 of the Act.
Urgent and Emergency Care Daily Situation Reports 2020-21: (bed numbers)
Under Section 21 of the Act we are not required to provide information in response to a request if the information is already reasonably accessible to you. The information you requested is available from
This information is updated on a regular basis and is exempt under Section 22 of the Act.
Covid-19 Hospital Activity:
Under Section 21 of the Act we are not required to provide information in response to a request if the information is already reasonably accessible to you. The information you requested is available from
https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity/
This information is updated on a regular basis and is exempt under Section 22 of the Act.
Please note that further detailed information which is not held on these websites and which would require the manual checking of individual patient records by a clinical member of staff may be exempt under Section 12 of the Act: appropriate limit. The appropriate limit is specified in regulations and represents the estimated cost of one person spending 3½ working days in determining whether the Trust holds the information, locating, retrieving and extracting the information.
Search our FOI database
Choose a category:
Agency staff
Agency Staff
1) Total spend on agency staff split by each of the following staffing groups:
2) Total spend on internal bank staff (split by the following categories)
3) Total number of staff employed on the bank, and of which, the number that also hold substantive contracts with the trust.
4) Does the trust outsource bank staff to NHSP? If so, how much was spent on outsourced bank staff?
5) Does the trust use rostering software, if so which provider (Allocate, SMART, DRS, SMI etc.)?
6) Does the trust directly engage locum staff? If so, how much of the trust’s medical locum spend was put through direct engagement in the last financial year?
Download response Agency Staff 170815
3rd Party Temporary Staffing Providers. 110222.docx
Please can you provide the following information for financial years FY2016/17, FY2017/18, FY2018/19, FY2019/20, FY2020/21, current financial year to date (FY2021/22 YTD):
1) Please provide the top 5 ON framework 3rd Party providers for nursing staff, by name, used by your trust for each of the listed financial years
2) Please provide the total annual expenditure for each of the top 5 ON framework 3rd Party providers, for nursing staff, used by your trust for each of the listed financial years
3) Please provide the top 5 OFF framework 3rd Party providers for nursing staff, by name, used by your trust for each of the listed financial years
4) Please provide the total annual expenditure for each of the top 5 OFF framework 3rd Party providers, for nursing staff, used by your trust for each of the listed financial years
A&E agency staff 2016. 290317
1. The amount spent on employing agency/temporary/locum doctors in A&E departments in each month in 2016.
2. The number of FTE roles covered by agency/temporary/locum doctors in each month in 2016
3. The total number of FTE doctors working in the A&E department in each month in 2016.
A&E agency staff and cost. 141021.docx
1. The amount spent on employing agency, temporary and/or locum doctors in A&E departments in each month in 2019 and 2020.
2. The number of FTE roles in A&E departments covered by agency, temporary and/or locum doctors in each month in 2019 and 2020.
3. The total number of FTE doctors (including agency, temporary and/or locum and permanent staff) working in A&E departments in each month in 2019 and 2020.
A&E staffing. 080519
1. The amount spent on employing agency, temporary and/or locum doctors in A&E departments in each month in 2017 and 2018
2. The number of FTE roles in A&E departments covered by agency, temporary and/or locum doctors in each month in 2017 and 2018
3. The total number of FTE doctors (including agency, temporary and/or locum and permanent staff) working in A&E departments in each month in 2017 and 2018
Agency and Bank Doctors. 051218
You asked:
1) The total amount you spend on Agency Locum Doctors for 2017-2018: – £
2) For the above information to be broken down by grade and specialty (example provided below)
Specialty FY1/2 ST1/2 ST3-6 Staff Grade Consultant
A&E
Medicine
Anaesthetics
Medicine
Surgery
Paeds
Pathology
O & G
Ophthalmology
3) Your Bank spend on Doctors for 2017-2018 broken down as question (2): – £
4) The total number of hours filled and unfilled each month for Agency medical locums for 2017-2018.
5) The highest bank rate paid in 2017-2018, providing confirmation of the grade and speciality.
6) Your current Bank rates for each grade and speciality, including any specialities or sub specialities which have an escalated Bank rate.
7) The Trusts average rates for Agency medical locums from September, October, November and December collectively broken down by grade and specialty (example provided below).
Specialty FY1/2 ST1/2 ST3-6 Staff Grade Consultant
A&E
Medicine
Anaesthetics
Medicine
Surgery
Paeds
Pathology
O & G
Ophthalmology
(8) The spend for medical locums through off-framework agencies for 2017-2018 and confirmation of the off-framework agencies used.
(9) Please confirm any contracts you have in place for medical locums and please confirm the list of suppliers used for medical locums.
Agency and bank pay rates. 130421
Would you be able to provide me with the highest and lowest rates that have been paid for the below specialities please.
Could you please cover from January 2020 to present
General Nurse Band 5
ITU Nurse Band 6
Theatre Nurse Band 6
ODP Band 6
Advanced Scrub Practitioner
Radiographer Band 8
Pharmacist Band 8
Agency and bank staff. 021019
Sourced Staffing Arrangements
1a. Do you have a master vendor or neutral vendor arrangement in place for sourcing agency staff? If so, please state which arrangement is in place
1b. Please state the name of the appointed supplier for the above arrangement
1c. Please state the start date of the contract with this supplier
1d. Please state the end date of the contract with this supplier
1e. Annual cost of your supplier in 18/19?
Agency Spend and Supply
2a. Please state the organisations total expenditure on agency (non-contract) staff for the financial year 18/19 (April 2018 – March 2019). Split by the following staffing groups
2b. Please state the name of the framework(s) you source your agency staff under, for each of the following staffing groups
Direct Engagement
3a. Does the organisation use a third party to provide a Direct Engagement/Outsourced Employment Solution? (This is where the NHS organisation sources agency staff via a recruitment agency but hold a direct contract between the organisation and the worker – there is often VAT savings associated to this employment model)
3b. Please state the name of the Direct Engagement/Outsourced Employment supplier (e.g. 247Time/Allocate, PlusUs, Retinue, Liaison etc.)
3c. Please state all staffing groups that are managed via your direct engagement provider; for example; Medical, Admin, Scientific staff
3d. Please state the start date of the contract with the DE supplier
3e. Please state the end date of the contract with the DE supplier
3f. What was the annual cost to the organisation for the provision of the direct engagement service in 18/19?
3g. Did the organisation procure these services via a framework? If so, please provide the full name of the framework
Internal Bank Spend
4. Please state the organisations total expenditure on internal bank staff for the financial year 18/19 (April 2018 – March 2019). Split by the following staffing groups
Medical Bank Supplier
5a. Please state the name of the technology provider used to manage the supply of your medical bank staff, inclusive of any outsourced or managed arrangements (i.e. NHSP, Patchwork, Allocate, Liaison, PlusUs, Locum’s Nest etc., please state if in-house)
5b. Please state the start date of the contract with your medical bank provider
5c. Please state the end date of the contract with your medical bank provider
5d. What was the annual cost to the organisations for the provision of bank provider services/software in 18/19
5e. Did the organisation procure these services via a framework? If so, please provide the full name of the framework
Agency and Bank staff.100223.docx
1. The total amount spent on agency temporary staff for the year 2021/22 (April ’21 to March ‘22) and between 31/10/2021 to 31/10/2022 for the following categories:
• Doctors
• Nurses
• AHP (all categories)
• Health Care Assistants
2. Bank Spend – Total amount spent on bank staff for the year 2021/22 (April ’21 to March ‘22) and between 31/10/2021 and 31/10/2022 year split into the Trusts’ staff groups (E.g. Medical, Nursing, Admin, AHP etc.) and speciality/grade (E.g. Consultants, GP, ICU Nurse, Acute Nurse, Occupational therapists, Pharmacists, Health Care Assistants, etc.) depending on how this is reported within the Trust.
3. Confirmation on whether the trust bank is currently operated by the trust themselves or by a private provider. If the latter please confirm the name of the provider.
The names and contact information of the individual divisional directors of Surgery covering the following treatment areas:
• General Surgery
• Urology
• Trauma and Orthopaedic
• Ear, Nose and Throat
• Ophthalmology
• Oral Surgery
• Neurosurgical Service
• Cardiothoracic
• Cardiology Service
• Dermatology Service
• Respiratory Medicine Service
• Gynaecology Service
• Rheumatology Service
Agency and Bank Staff. 120320
1. Please quantify Agency recruitment splits (total spending and total WTE numbers) for medical, nursing and other employees (Forecasts 2019/20 and 2018/2019, and actuals 2018/19, 2017/2018, and 2016/2017)
2. Please quantify Bank recruitment splits (total spending and total WTE numbers) for medical, nursing and other employees (Forecasts 2019/20 and 2018/2019, and actuals 2018/19, 2017/2018, and 2016/2017)
Agency and Bank staff spend.181022.docx
1)The total amount spent by the Trust on bank staff in 2021/22
2) The total amount spent by the Trust on agency staff in 2021/22
3) The total amount spent by the Trust on bank nurses in 2021/22
4) The total amount spent by the Trust on agency nurses in 2021/22
5) The largest amount spent by the Trust on a single agency nurse shift in 2021/22
Agency and Bank staffing. 240620
1. Please provide agency spend for the staff group for 2019-20
2. Please provide bank spend for the staff group for 2019-20
3. Please confirm which model you have in place for managing the staff group: Email to preferred supplier List, a Master Vendor, a Neutral Vendor, or a Software cascade to a preferred supplier list
4. If you have a master vendor or neutral vendor in place, please confirm who this contract is with and the date on which this contract expires
5. Please confirm what percentage of bookings over the last 6 months have been within the NHSI/E agency caps (an approximation based on NHSI data submissions is fine)
6. Please confirm which provider manages your direct engagement process, the fee for the service and the date on which this contract expires (no this is not relevant for Nursing)
7. Please confirm what percentage of bookings are processed with a VAT savings by your direct engagement provider
8. Is your bank managed by an external bank provider (e.g. NHS Professionals, Bank Partners) or in-house? Please confirm who is the external bank provider and when the contract expires if relevant
9. Is your bank managed via software? If so, please confirm which software.
Is the Trust likely to undertake any procurement activity over the next 18 months related to provision or bank or agency services or software for the relevant staff group.
Agency and Bank staffing. 240620
1. Please provide agency spend for the staff group for 2019-20
2. Please provide bank spend for the staff group for 2019-20
3. Please confirm which model you have in place for managing the staff group: Email to preferred supplier List, a Master Vendor, a Neutral Vendor, or a Software cascade to a preferred supplier list
4. If you have a master vendor or neutral vendor in place, please confirm who this contract is with and the date on which this contract expires
5. Please confirm what percentage of bookings over the last 6 months have been within the NHSI/E agency caps (an approximation based on NHSI data submissions is fine)
6. Please confirm which provider manages your direct engagement process, the fee for the service and the date on which this contract expires (no this is not relevant for Nursing)
7. Please confirm what percentage of bookings are processed with a VAT savings by your direct engagement provider
8. Is your bank managed by an external bank provider (e.g. NHS Professionals, Bank Partners) or in-house? Please confirm who is the external bank provider and when the contract expires if relevant
9. Is your bank managed via software? If so, please confirm which software.
Is the Trust likely to undertake any procurement activity over the next 18 months related to provision or bank or agency services or software for the relevant staff group.
Agency and Bank staffing and spend.150822.docx
1. Please provide agency spend for the staff group for the Financial Year 2021-22 (please specify your start and end date used) Financial Year indicating what percentage is on and off-framework (for example, “£4,650,000 – c80% framework / 20% off-framework”).
2. Please provide bank spend for the staff group for Financial Year 2021-22 (please specify your start and end date used)
3. Please confirm which model you have in place for managing agency within the staff group: Email to preferred supplier List, a Master Vendor, a Neutral Vendor, or a Software cascade to a preferred supplier list
4. Please confirm what percentage of bookings over the last 6 months have been within the NHSI agency caps (an approximation based on NHSI data submissions is fine)
5. Please confirm which provider manages your direct engagement process, the fee for the service and the date on which this contract expires (no this is not relevant for Nursing)
6. Please confirm what percentage of bookings are processed with a VAT savings by your direct engagement (DE) provider (average for last 3 months –December, January and February)
7. Is your bank managed by an external bank provider (e.g., NHS Professionals, Bank Partners) or in-house? Please confirm who is the external bank provider and when the contract expires if relevant
8. Is your bank managed via software? If so, please confirm which software.
9. Is the Trust likely to undertake any procurement activity over the next 18 months related to provision or bank or agency services or software for the relevant staff group?
10. If you have a managed service, master vendor or neutral vendor in place for Agency medics/Agency doctors please confirm who this contract is with and the date on which this contract expires
11. If you have a managed service, master vendor or neutral vendor in place for Agency Nurses please confirm who this contract is with and the date on which this contract expires
Agency and Staff details.260423.docx
1.) A) Last financial year agency locum spend
B) Please break down into Specialty and Grade
2.) A) The retention rates for permanent and fixed term staff – Doctors and Nurses only
B) Please break down into Specialty and Grade
3.) A) Please provide the Names of agencies used to fill vacancies
B) how much each agency charges
4.) Please provide your trust wide budgeted establishment per specialty and grade for Doctors
– Name of Speciality / Division or Directorate
– Consultants, Locum Consultant Contract and Associate Specialists
– CT/ST3 – CT/ST7, Specialty Doctors, Senior Clinical Fellows, CESR Fellow or Middle Grade Level
– FY1-ST2, Trust Grade, Junior Clinical Fellow or SHO level
5.) Please what is your actual current establishment for Doctor
– Name of Speciality / Division or Directorate
– Consultants, Locum Consultant Contract and Associate Specialists
– CT/ST3 – CT/ST7, Specialty Doctors, Senior Clinical Fellows, CESR Fellow or Middle Grade Level
– FY1-ST2, Trust Grade, Junior Clinical Fellow or SHO level
Agency costs 2014/2015
1. Staff Numbers (Average over the whole year or the count on Tuesday, March 31st 2015)
2. Staff Cost
3. Agency Hours
4. Agency Spend
I would greatly appreciate it if you could supply this information for the year 2014/15 (April ’14 to March ‘15).
Agency doctor pay rates. 130421
1) Since 1st April 2020, what are the top three / most expensive hourly rates (including all cost elements i.e. pay, agency fee, NI, PAYE taxes, VAT and any associated managed service / master vendor fee) paid for agency doctors working at each of the following grades?
Please respond to question one by populating the template below as per the example.
Please clarify the Specialty for which each of the rates was paid as shown.
2) Since 1st April 2020, what are the bottom three / least expensive hourly rates (including all cost elements i.e. pay, agency fee, NI, PAYE taxes, VAT and any associated managed service / master vendor fee) paid for agency doctors working at each of the following grades?
Please respond to question one by populating the template below as per the example.
Please clarify the Specialty for which each of the rates was paid as shown.
3) For each of the “job titles” (Grade / Specialty) mention in your response to questions 1 and 2, please disclose the average hourly rate paid for agency doctors of the same Grade and Specialty since 1st April 2020.
There should be a maximum of 18 unique “job titles” in the tables above; please use the template below as per the example given at the bottom.
Agency doctors and nurses 2016-2017. 231117
• The total amount you spend on Agency Doctors & Nurses for the financial year 16/17 (April – March)
• For the above information to be broken down by Banding / Grade and also specialty
Download response Agency doctors and nurses 2016-2017. 231117
Agency expenditure 2016-2017. 050717
1. The trust’s completed ‘Detailed agency collection” for month 12 of 2016-17, showing the year to date figures. (Example attached)
If for any reason the trust is minded not to provide this document, please list the five specialties for which the trust had the highest agency staff costs – as a % of total pay costs for the specialty – in 2016-17 in the table below. Please also fill in the cells detailing expenditure. If the trust’s accounts have not yet been audited, please use the unaudited figures.
2. Please state the total number of shifts for which the trust breached the national pay cap for medical agency staff in 2016-17 (55% above basic rates), and break this total down for each specialty where the breach occurred (its fine to only detail the top five specialties).
3. Please state the total number of shifts for the trust breached the national pay cap for agency nursing staff in 2016-17 (55% above basic rates), and break this total down for each specialty where the breach occurred. (It’s fine to only detail the top five specialties).
4. Please state the total number of shifts which required CEO sign off, and break these down for each specialty.
5. Please state the ten shifts for agency medical staff for which the highest hourly rate was paid. Please state the rate paid and the specialty.
6. For individual medical locums who have incurred the greatest total expenditure for the trust in 2016-17, please state the total amounts paid by the trust in the year in relation to these individuals’ work. Please also state their specialty. E.g. Medical locum 1, emergency medicine, total expenditure by the trust in 2016-17; £196,000
Agency Locum Doctor spend for 2015-2016.
• The total amount you spend on Agency Locum Doctors for the financial year 15/16 (April – March)
• For the above information to be broken down by grade and specialty (example provided below)
Download response Agency Locum Doctor spend for 2015-2016 270616
Agency locum doctor supply. 151118
You asked:
1. What percentage fill rates (doctors) were reached between January and present?
2. Does your organisation use a Direct Engagement scheme? If so, who provides it and when does their contract expire?
3. What percentage of bookings are made outside of the DE model (non-DE)?
4. Do you outsource any of the following services to external companies:
• Provision of Residential Medical Officers
• Gastroenterology/Endoscopy
• Dermatology
• Radiology
5. Do you use agencies for national and international permanent doctor and/or nursing recruitment? If so, do you employ nurses from the Philippines?
Agency locum doctors and consultants spend for 2015-2016.
Please can you let us know what the Trust as a whole (including hospitals that are run by you) spent on employing agency locum Doctors and Consultants last year.
Download response Agency locum doctors and consultants spend for 2015-2016 010716
Agency, locum or bank staff. 181019
1. Over the last 5 years, broken down by year, the total number of hours of work provided to the trust by non-substantive doctors, either via a locum agency or a bank staffing system, and the total cost to the trust of those hours.
2. The above information broken down by staff sourced through agency and those sourced through your bank staffing arrangement.
3. The figures (hours and spend for each of locum and bank) provided in answer to 2. broken down first by specialty and then grade of doctor.
4. The standard hospital hourly rate of pay for each of the specialties and grades listed in answer to 3.
5. The hospital and NHS capped rates for each of the specialties and grades listed in 3. if different to the rate listed in 4.
6. For each category created in response to 3. (i.e bank haematology registrars), the percentage of hours worked at standard rate, above the standard rate, and above the capped rate if different from the standard rate.
7. What penalties, if any, are levied against the trust if it exceeds the ‘capped’ rate.
8. What penalties were levied against the trust for breaking the cap in each of the years for which data has been provided.
9. If the trust utilises a Bank Partner, what is the cost of said Partner and how does this cost manifest e.g. lump sum, fee per position filled etc.
Agency locum spend. 010818
How much did the trust spend on agency locums last year? Broken down into SHO, Middle Grade and Consultants
If I could please have this information on the following specialities: A&E, Acute Medicine, General Medicine, Radiology and Paediatrics I would be appreciative.
Agency locum spend 2015-2016.
Please could you send me the agency locum spend for the trust for the last financial year. I would like the spend for doctors only.
Please include the agency spend in each specialty breaking it down into the different grades (SHO, Middle Grade, Consultant).
Please could you also provide the spend on introductory fees for doctors for each specialty based on Doctors taken onto NHS contracts.
Agency locum spend in Cardiology. 040717
Could you please let me know the locum agency spend from May 2016 – Present? This refers directly to the cardiology department only; the staff will be Cardiographers, Cardiac Physiologists, Echo cardiographers, please note this is not referring to locum doctors or specialists.
These staff will fall under AHP/HSS or healthcare.
Agency locums and Doctors. 301120
1. Last financial year agency locum and bank spend
• Please break down into Specialty and grade
2. Names of agencies used to fill vacancies
– How much does each agency charge
3. What is your trust wide budgeted establishment per specialty and grade for doctors
– Name of Speciality / Division or Directorate:
– Consultants, Locum Consultant Contract and Associate Specialists:
– CT/ST3 – CT/ST7, Specialty Doctors, Senior Clinical Fellows, CESR Fellow or Middle Grade Level:
– FY1-ST2, Trust Grade, Junior Clinical Fellow or SHO level:
4. What is your actual current establishment for doctor
• Name of Speciality / Division or Directorate:
– Consultants, Locum Consultant Contract and Associate Specialists:
– CT/ST3 – CT/ST7, Specialty Doctors, Senior Clinical Fellows, CESR Fellow or Middle Grade Level:
– FY1-ST2, Trust Grade, Junior Clinical Fellow or SHO level:
Agency midwives and pay 2015.
1. What was the total cost for your trust, including fees and any other on-costs, for midwives supplied by an agency, broken down by the months in the table below?
2. What was the cost for your trust for the fees and any other on-costs, for midwives supplied by an agency, broken down by the months in the table below?
3. What was the total number of hours worked by midwives supplied by an agency, broken down by the months in the table below?
4. What was the total cost for your trust for midwives working overtime, broken down by the months in the table below?
5. What was the total number of hours worked by midwives working overtime, broken down by the months in the table below?
6. What was the total cost for your trust, for midwives supplied by the bank, broken down by the months in the table below?
7. What was the total number of hours worked by midwives supplied by the bank, broken down by the months in the table below?
8. Does your trust pay bank rates at the individual’s actual pay point or higher or lower than their pay point?
Agency Midwives and pay 2016. 300117
1. What was the total cost for your trust, including fees and any other on-costs, for midwives supplied by an agency, broken down by the months in the table below?
2. What was the total number of hours worked by midwives supplied by an agency, broken down by the months in the table below?
3. What was the total cost for your trust for midwives working overtime, broken down by the months in the table below?
4. What was the total number of hours worked by midwives working overtime, broken down by the months in the table below?
5. What was the total cost for your trust, for midwives supplied by the bank, broken down by the months in the table below?
6. What was the total number of hours worked by midwives supplied by the bank, broken down by the months in the table below?
Agency nurse and locum doctor expenditure. 261020
1. On how many occasions in the 2019/20 financial year did you spend £1,500 or more to employ an agency nurse for a single shift? For each occasion, please state the amount paid, how many hours they were asked to work as well as the job title and department the nurse was deployed in.
2. On how many occasions in the 2019/20 financial year did you spend £3,000 or more to employ an agency doctor for a single shift? For each occasion, please state the amount paid, how many hours they were asked to work as well as the job title and department the nurse was deployed in.
Download response Agency nurse and locum doctor expenditure. 261020
Agency nurse cover November 2015 – April 2016. 061216
1. Are off frame work agencies used to cover nurse shifts?
2. On a month by month basis, what was your spend on agencies supplying off frame work nurses from 1st November 2015 to date? Please break down this information by RGN, ITU, CRITICAL, ODP’S, SCRUBS, PAEDS, HDU, A&E, AMU, ADVANCED NURSE PRACTITIONER, HCA’S ETC. If this is not possible then please break down by nurse bands.
3. Which agencies supply off frame work nurses?
4. On a month by month basis, how many times was the break glass clause used from 1st November 2015 to date?
5. Please pick 10 random shifts which were filled via off frame work agencies between 1st November 2015 to date and provide the following for each of the 10 shifts picked at random (it is not essential to name the specific agencies which relate to the chosen shifts):
• Amount that was paid to the agency to fill each shift or the hourly rate paid to the agency
• Number of hours in the shift
• Date shift filled
• The type of nurse used to fill the shift e.g. RGN, ITU, HDU, CRITICAL, A&E, PAEDS etc.
• The type of shift or shift start time e.g. Long Day or Long Night or alternatively shift start time e.g. 08:00 etc.
Download response Agency nurse cover November 2015 – April 2016. 061216
Agency nurse expenditure for 2015-2016.
• The total amount you spend on Agency Nurses for the financial year 15/16 (April – March)
• For the above information to be broken down by banding and specialty (example provided below)
Download response Agency nurse expenditure for 2015-2016 010716
Agency Nurse Rates and hours. 130421
Average Band 5 Agency Nurse Rates
Please respond to question one by populating the template below.
a) Average cost per hour (inclusive of base pay, agency margin, NI, PAYE etc. but excluding VAT) paid for Band 5 agency Nurses for Standard Day hours between 1st April 2020 and 31st January 2021
b) Average cost per hour (inclusive of base pay, agency margin, NI, PAYE etc. but excluding VAT) paid for Band 5 agency Nurses for Saturday & Evening hours between 1st April 2020 and 31st January 2021.
c) Average cost per hour (inclusive of base pay, agency margin, NI, PAYE etc. but excluding VAT) paid for Band 5 agency Nurses for Sunday & Bank Holiday hours between 1st April 2020 and 31st January 2021
Part 2 – High Rate Band 5 Nurse Hours
For the below questions, please answer number of shifts rather than number of hours if this figure is easier to obtain – please clarify which unit you’re referring to within your response. Please also indicate how many individual nurses make up the figure in response to each of the below.
a) For Band 5 Agency Nurses, regardless of rate type (i.e. Days, Nights, Bank Holidays etc.), how many hours since 1st April cost £50 per hour or more?
b) For Band 5 Agency Nurses, regardless of rate type (i.e. Days, Nights, Bank Holidays etc.), how many hours since 1st April cost £75 per hour or more?
c) For Band 5 Agency Nurses, regardless of rate type (i.e. Days, Nights, Bank Holidays etc.), how many hours since 1st April cost £100 per hour or more?
Agency nurses. 041019
Could the trust please provide information on how much has been spent on agency nurses?
1) This financial year to date
2) 2018/19 financial year
3) 2017/18 financial year
Are these amounts higher, lower or within the budgets allocated for agency staff?
Are there any measures being implemented to lower the reliance or use of agency staff?
Agency nurses and midwives.240523.docx
Could you provide me with a breakdown of spend on agency nurses and midwives between May 2022 and May 2023 as below
1. Number of shifts invoiced by each provider trust has used for agency nursing
2. Framework spend on agency nursing and midwifery broken down to spend per Framework provider
3. Off-framework spend on agency nursing and midwifery broken down to spend per off-framework provider
Agency nursing costs – January and February and July to December 2015?
Please could you tell me what the cost was in wages to the trust for agency nursing during the months of January and February and July to December 2015? (Could the cost per month be separated, please?)
Please include the wage bill for the two sites, and, if at all possible, please can you break them down into departments and sites?
However, if this is not possible, please still provide me with the overall cost.
Please could you tell me what the cost was in wages to the trust for all agency staff during the months of January to December 2015? (Could the cost per month be separated, please?)
Please include the wage bill for the two sites, and, if at all possible, please can you break them down into departments and sites?
However, if this is not possible, please still provide me with the overall cost.
Download response Agency nursing costs – January and February and July to December 2015 080116
Agency nursing. 130421
1) How many agency nursing shifts have your Trust used SNG or Thornbury Nursing Services for between 1st October 2020 and 30th November 2020?
2) Please provide a breakdown of the amount of shifts per ward or department where SNG or Thornbury Nursing Services were used in 1st October and 30th November 2020?
3) How many agency nursing shifts have your Trust used Nutrix nursing agency for between 1st October 2020 and 30th November 2020?
4) Please provide a breakdown of the amount of shifts per ward or department where Nutrix were used between 1st October 2020 and 30th November 2020.
5) Please name any other OFF CONTRACT SUPPLIERS who have been utilised by the Trust between 1st October 2020 and 30th November 2020 above the NHS Improvement + 50% caps and how many shifts each of these agencies have filled.
Agency nursing shifts. 130421
1) How many agency nursing shifts have your Trust used SNG or Thornbury Nursing Services for between 01 December 2020 and 10 February 2021
2) Please provide a breakdown of the amount of shifts per ward or department where SNG or Thornbury Nursing Services were used between 01 December and 10 February 2021
3) How many agency nursing shifts have your Trust used Nutrix or Greenstaff for between 01 December 2020 and 10 February 2021?
4) Please provide a breakdown of the amount of shifts per ward or department where Nutrix, or Greenstaff were used between 01 December 2020 and 10 February 2021
5) Please name any other OFF CONTRACT SUPPLIERS who have been utilised by the Trust between 01 December 2020 and 10 February 2021above the NHS Improvement + 50% caps and how many shifts each of these agencies have filled.
6) If for any reason you are unable to supply data up until 10 February please provide the data until 31 January 2021
Agency nursing shifts. 210222.docx
1) How many agency nursing shifts have your Trust used SNG or Thornbury Nursing Services for between 1st December 2021 and 10th February 2022
2) Please provide a breakdown of the number of shifts per ward or department where SNG or Thornbury Nursing Services were used between 1st December 2021 and 10th February 2022
3) How many agency nursing shifts have your Trust used Nutrix, MED GEN, Greenstaff for between 1st December 2021 and 10th February 2022?
4) Please provide a breakdown of the number of shifts per ward or department where Nutrix, or Greenstaff were used between 1st December 2021 and 10th February 2022
5) Please name any other OFF CONTRACT SUPPLIERS who have been utilised by the Trust between 1st December 2021 and 10th February 2022
6) If for any reason you are unable to supply data up until 10th February please provide the data until 31st January 2022
Agency nursing shifts. 260919
1) How many agency nursing shifts have your Trust used Thornbury nursing services for between 1st July 2019 and 31st July 2019?
2) How many agency nursing shifts have your Trust used Thornbury nursing services for between the dates of 1/8/2019 and 18/8/2019?
3) Please provide a breakdown of the amount of shifts per ward or department where Thornbury were used in July 2019 and 1/8/19- 18/8/19/.
4) Please provide a breakdown for July 2019 of the amount of shifts filled at your Trust by other off contract nursing providers (ie non-framework). Please break this down in the same format (i.e. by ward or department) as question 3.
Agency Nursing shifts. 2609192
1. Which agency filled the most nursing shifts at your Trust in the last 30 days and how many hours or shifts did they fill?
2. How many of the shifts filled by agency nurses in the last 30 days were above cap?
3. Which wards or departments and sites within your Trust utilised agency nurses in the last 30 days and how many shifts were booked on each?
4. How many nursing shifts were filled by Framework agencies above the 50% NHS Improvement increased caps in the last 30 days?
5. Please list the nursing agencies utilised in the last 30 days above the 50% increased NHS Improvement capped rates by your Trust.
Agency nursing shifts. 2609193
1. How many agency nursing shifts have your Trust used Thornbury nursing services for in the last 30 days?
2. Please provide a breakdown of the amount of shifts per ward or Departments that Thornbury filled for agency nurses in the last 30 days.
3. What other nursing agencies do you use off contract/off framework?
4. How many nursing shifts did other off contract agencies fill in the last 30 days?
5. Are there any other services linked to your Trust that utilise TNS or any other off contract supplier re Prisons, or community based services? If so please provide a list of these services and the amount of nursing shifts filled in each over the last 30 days
Download response Agency nursing shifts. 2609193
Agency Nursing Spend.260822.docx
1. Can you confirm names of all agencies supplying into the trust directly or via the NHS Professionals platform for nursing staff specifically for both Band 2 and Band 5 requirements, including off-framework agencies.
a. With the above information, can this be broken down by
• Volume of supply (per month for the last 12 months)
• Total trust spend per agency (per month for the last 12 months)
• By AfC banding of shift request and speciality of nurse
2. Please can you confirm how many shifts have been filled by agencies supplying Band 5 Registered Nursing staff at or below NHSI agency capped rates within the last 12 month period?
3. Please can you confirm how many shifts have been filled by agencies supplying Band 5 Registered Nursing staff above NHSI agency capped rates within the last 12 month period?
4. For the same 12 month period, can you confirm the average charge rate per hour for Band 5 Nursing agency staff across:
Week Days:
Night Shift/Saturday shifts:
Sunday shift/Bank Holiday:
5. Lastly can you confirm the highest agency nurse hourly charge rate, and their speciality?
Agency nursing spending rules from October 01 2015
Questions on the trust’s ceiling for agency nurse spend, as per the rules introduced from October 1, 2015:
1) How many applications has your trust made to increase its ceiling for agency nurse spend?
2) How many of these applications were successful?
Questions on the agency pay caps – specifically regarding nurses – as per the rules introduced on November 23, 2015:
3) On how many shifts has your trust overridden the rules for hourly rate agency caps – specifically for nurses – since the rules were introduced?
4) Across how many weeks have these breaches (in question 3 above) occurred? .
5) How many band five nurses has your trust overridden the rules for?
6) How many band six nurses has your trust overridden the rules for?
7) How many band seven nurses has your trust overridden the rules for?
8) How many band eight nurses has your trust overridden the rules for?
Download response Agency nursing spending rules from October 01 2015 150216
Agency nursing usage. 250521
1. Breakdown of shifts (Numbers only) filled by individual Nursing Agencies (by name of agency) in Trust operated theatre wards for ‘Surgical First Assistants’, Operating Department Practitioners’ and ‘SCRUB Nurses’ for March 1st 2021- April 30th 2021
2. Individual Charge rates for nursing agencies for theatre staff March 1st 2021- April 30th 2021
3. Number of shifts filled by individual ‘Off Framework Agencies’ March 1st 2021-April 30th 2021
4. Total Cost for each Nursing Agency used by theatre departments financial year April 2020- April 2021
Agency Payments. 090419
1. Please provide the 10 largest individual agency payments for core hours your trust has authorised above the agency worker price caps set by NHS Improvement for each of the following medical grades for (a) 2017-18 and (b) 2018-19 (to date).
• Foundation Year 1
• Foundation Year 2
• Registrar ST1-2
• Registrar ST3
• Speciality staff/staff grade
• Associate specialist
• Consultant
Please provide the figures excluding VAT, as a rate per hour, what the cap was at that particular point in time, the month it was paid and the type of shift being filled.
2. Please provide the 10 largest individual agency payments for unsocial hours your trust has authorised above the agency worker price caps set by NHS Improvement for each of the following medical grades for (a) 2017-18 and (b) 2018-19 (to date).
• Foundation Year 1
• Foundation Year 2
• Registrar ST1-2
• Registrar ST3
• Speciality staff/staff grade
• Associate specialist
• Consultant
Agency Pharmacists and Pharmacy Technicians. 240119
I would like you to send me the locum agency spend in the AHP/HSS division of the hospital for Pharmacists and Pharmacy Technicians. I would like to know the spend for 2018 with each agency- if this is not possible then I’d like to know overall spend for the year for both Pharmacists and Pharmacy Technicians.
Download response Agency Pharmacists and Pharmacy Technicians. 240119
Agency price caps. 100821.docx
1. Can you provide the total number of times you have exceeded the agency price cap limits for each year from 2016 -2020 broken down by each quarter right up to the most recent available data?
2. Can you provide the maximum amount paid on a per hour basis for an agency shift for each year from 2016 -2020 broken down by each quarter right up to the most recent available data?
3. I am aware that there are country wide NHSI caps but for some areas (such as medical), there are agreed Pan London ceiling rates which are higher than the NHSI caps. Could another column in the data be provided to show when those London caps are exceeded?
Agency Recruitment. 051218
You asked:
1. How many doctors have been booked outside of IR35 since April 2017?
2. What is your yearly trust spend on agency locum doctors via framework agencies, broken down into grade and specialty?
3. What is your yearly trust spend on agency locum doctors via OFF-framework agencies, broken down into grade and specialty?
4. What is your average total charge rate for a locum consultant doctor?
5. Who is the highest paid locum Consultant, what is the hourly rate and in what specialty do they practice?
6. Please can you outline your spend per agency, broken down by grade and specialty of doctor over the past 12 months?
Agency Shift Cost
1. What was the highest amount you paid (including any agency commission/charges) for a single shift filled by each of the following a. a doctor b. a GP (if employed) c. a registered nurse and d. a non-registered support worker/healthcare assistant in the period March 28th to April 19th 2015? Please include date and length of shift and grade of doctor/nurse involved, the department they were needed for (e.g. A&E) and the agency which supplied the doctor/nurse in each case.
2. What percentage of shifts covered by agency staff during this time period were paid in accordance with either an NHS wide or a local framework, and what proportion were off framework?
3. What was your total spend on temporary (locum, agency and bank) clinical staff for 2014-15? Please include doctors, nurses and healthcare assistants/support workers in your answer. What were the comparable figures for 2013-14 and 2012-13?
Download response Agency Shift Cost 050515
Agency shifts. 250817
I am making a Freedom of Information Request to gain information on the volume of shifts that have been filled by agencies within nursing and medical locums (Doctors) at your organisation.
Further to this what is the percentage of shifts filled for Medical and for Nursing above the NHSi Cap.
Agency spend.260219
Please can you outline your agency spend into each 52 weeks or 12 months for the year 2018 (I understand the year has not finished yet so up to OCTOBER 2018) would be sufficient.
1. How many agencies did your trust use in the year of 2018?
2. How much was spent on agency nurses in 2018?
3. On December 25th 2017, how many shifts went nursing shifts went unfilled?
4. What is the highest hourly rate paid to a locum agency in 2018 and what band was this nurse i.e. band 5 general.
5. Please list the names of agencies that we used in year 2018 and list the total amount of spend for each used.
6. What is the total number of different nurse locums did the trust use in 2018.
7. What was the highest hourly rate paid to an agency for a nurse in 2018 – Please state what agency this was and what band they were.
8. Of all agencies used, were any off framework? If so, what are the agencies called?
9. Who is the head of procurement at your Trust who approves agency use?
10. Who approves above-cap and/or off-framework usage?
11. Who are your tier 1 and tier 2 agencies?
Agency spend for doctors. 240119
I would like you to send me the locum agency spend for Doctors for the hospital in acute settings as well as the community for each specialism.
I would like to know the spend from January 2018 – present, also including the amount of locums that this refers to per month, broken down on a monthly basis. In the breakdown if you could please include the agencies that provide the locums also broken down numerically.
Agency Spend for Doctors, Nurses and Allied Health Professionals. 070222.docx
The total amount spent on agency temporary staff between January 21 – December 21 for the following categories:
Doctors
Nurses
AHP’s
Agency Spend for Doctors, Nurses and Allied Health Professionals. 070222.docx
Agency spend for nursing and midwifery.211122.docx
I would like to request the below information from the trust for year 2021/2022.
1. What was your agency spend for nursing and midwifery for the year April 2021- April 2022?
2. How much of the spend was above the NHSI rate caps April 2021- April 2022?
3. Have you used off-framework in the last 6 months?
4. If so, what was the total spend?
5. Which off-framework agencies have you used?
6. How many unfilled shifts have you had for:
a. A&E
b. ITU
c. General
d. Theatres
e. Mental Health
f. CPN
g. Midwifery
h. Paediatrics
i. Neonatal
j. HCA
7. If this cannot be provided via speciality, please could I have an over-all number?
8. How many vacancies do you have for band 5/6 nurses in the following areas?
a. A&E
b. ITU
c. General
d. Theatres
e. Mental Health
f. CPN
g. Midwifery
h. Paediatrics
i. Neonatal
j. HCA
9. How many incident/critical incidents have been declared as a result of staffing?
10. Who is the nurse bank/temporary staffing manager?
11. What are the contact details for the Nurse Bank / Temporary Staffing Manager?
Agency spend for Radiology locum doctors December 2015 to May 2016.
Can you please assist me with retrieving the total Agency spend for Locum Doctors only within Radiology over the following months, within your Trust or Health Board?
Download response Agency spend for Radiology locum doctors December 2015 to May 2016 060916
Agency spend in Radiology August 2016 – January 2017. 240317
Can you please assist me with retrieving the total Agency spend for Medical Locum Doctors within Radiology over the following months, within your Trust or Health Board?
August 2016
September 2016
October 2016
November 2016
December 2016
January 2017
Download response Agency spend in Radiology August 2016 – January 2017. 240317
Agency spend and substantive vacancies. 091117
1. The total amount of agency spend on medical locums in the 2016/2017 tax year
2. The total amount of spend on agency nurses in the 2016/2017 tax year
3. The total amount of spend on agency AHPs in the 2016/2017 tax year
4. The percentage of substantive Doctor positions that are currently unfilled
5. The percentage of substantive Nurse positions that are currently unfilled
6. Do you have a managed service or master vendor arrangement, or an outsourced staff bank for any clinical staff groups and if so, who is/are the supplier(s)?
7. Do you have a Direct Engagement supplier and if so, who?
Download response Agency spend and substantive vacancies. 091117
Agency spend within Gastroenterology.
Can you please assist me with retrieving the total Agency spend within Gastroenterology over the following months, within your Trust or Health Board?
Agency staff. 010818
1. Since January 2018, have you allowed an Agency to fill a shift or booking above the April Cap (implemented in 2016) via the CPP Framework (otherwise known as the National Clinical Staffing Framework Agreement (Reference CPP2015/01))? For reference the term ‘shift’ can include any general nursing or critical nursing role.
2. If the answer is yes to the above question, please inform us of how many such shifts have been filled above cap via the CPP Framework.
3. What was the total value of charges paid under all of the call-off agreements identified in response to request 1 (above)?
4. Any information relating to the decision(s) of the Trust to enter into call-off agreements that include pay rates that exceed the maximum pay rates allowed under the Framework Agreement.
Agency staff.01118
1. In relation to the value of the contracts in your previous response of 1 August 2018, the value of which was £514,072.20, please state the total costs that the Trust paid in excess of the rates allowed under the fee caps (those fee caps being the April Caps (implemented in 2016) for the National Clinical Staffing Framework Agreement (Reference CPP20 15/011) (otherwise known as CPP Framework) (the “Framework Agreement”).
2. In relation to your answer to point 1, please state how much of this sum was attributed to shifts for Nursing & Midwifery staff.
3. In the event that the anticipated costs of providing all of the information requested under points 1 and 2 above are likely to exceed the appropriate limit specified in Regulation 3 of the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004, please provide instead the total costs that the Trust paid in excess of the rates allowed under the fee caps in June 2018.
4. In the event that you provided a substantive response to point 3, please provide us with how many such shifts have been filled above cap via the Framework Agreement in June 2018.
5. In the event that the anticipated costs of providing all of the information requested under point 3 above is likely to exceed the appropriate limit specified in Regulation 3 of the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004, please provide instead the total costs that the Trust paid in excess of the rates allowed under the fee caps for the period Monday 4 June 2018 to Sunday 10 June 2018.
6. In the event that you provided a substantive response to point 5, please provide us with how many such shifts have been filled above cap via the Framework Agreement, for the period Monday 4 June 2018 to Sunday 10 June 2018.
7. In your response of 1 August 2018, you stated that 16,754 shifts were for Medical & Dental staff. Please provide a breakdown of this figure and categorise the shifts into grades of staff.
Agency Staff.100822.docx
Please can you provide the following information regarding use of agency staff in your NHS Trust.
Please note there are three parts to this request.
1. Please can you provide the total spend on agency staff in your NHS Trust in the financial year ending April 2022
2. Please can you provide the total spend on agency staff in your NHS Trust in the financial year ending April 2019
3. Please can you provide the total spend on agency staff in your NHS Trust in the financial year ending April 2017
Agency Staff.210323.docx
1. What was your trust spend on agency for the period 1 January 2022 to 31 December 2022 inclusive for the following staff groups: –
a. Registered nurse (RN)
b. Health care support workers/healthcare assistants/nursing associates?
2. What was your trust spend on agency for the period 1 January 2021 to 31 December 2021 inclusive for the following staff groups: –
a. Registered nurse (RN)
b. Health care support workers/healthcare assistants/nursing associates?
3. What was your trust spend on agency for the period I January 2020 to 31 December 2020 inclusive for the following staff groups: –
a. Registered nurse (RN)
b. Health care support workers/healthcare assistants/nursing associates?
Agency Staff. 210917
I am looking at the other positions supplied, starting with AHP and HSS staff.
Namely:
Allied Health Professionals Health Science Services
Dieticians Biomedical Scientists
Occupational Therapists Cytologists
Orthoptists Dental Service Staff (excluding dental nurses)
Physiotherapists Genetic Counsellors
Podiatrists Healthcare Scientists
Psychologists Medical Technologists
Radiographers Optometrists
Speech and Language Therapists Pathologists
Pharmacy Services Staff
Please could you provide me with the following information:
1. Names of Agencies used to provide AHP or HSS staff over the last 12 months
2. Monthly spend, on Agency Staff, per job role over the last 12 months
3. Hours, per job role, filled each month by Agency over the last 12 months
4. Number of shifts offered to Agencies for each role, monthly for the last 12 months.
5. Number of shifts filled by Agency for each role, monthly for the last 12 months.
Agency staff. 260919
Please could you advise the number of hours or shifts filled from 01th April 2018 – 31st March 2019 with qualified nursing staff within the Trust with agency staff?
Agency Staff Bank.250322.docx
For Hospitals
1. Hospitals in trust
2. Names of off-framework agencies used between 2021- to date
3. Names of on-framework agencies used between 2021- to date
4. Do you have a master vendor in place?
5. If yes, please provide your account manager’s email
6. Temporary agency staff manager full name
7. Temporary agency staff manager email
8. Temporary agency staff manager telephone
9. Permanent agency staff manager full name
10. Permanent agency staff manager email
11. Permanent agency staff manager telephone
12. Off-framework agency spend between Feb 2021-date
13. Framework agency spend between Feb 2021 – date
14. Total agency shift cancelations Feb 2021-date
For Urgent Care Centres/Walk-in Clinics
1. Urgent treatment / walk-in centres
2. Names of off-framework agencies used between 2021- to date
3. Names of on-framework agencies used between 2021- to date
4. Do you have a master vendor in place?
5. If yes, please provide your account manager’s email
6. Temporary agency staff manager full name
7. Temporary agency staff manager email
8. Temporary agency staff manager telephone
9. Permanent agency staff manager full name
10. Permanent agency staff manager email
11. Permanent agency staff manager telephone
12. Off-framework agency spend between Feb 2021-date
13. Framework agency spend between Feb 2021 – date
14. Total agency shift cancelations Feb 2021-date
Agency Staff Cost
Under the freedom of information act 2000, I am writing to formally request the following information:
1. Staff Numbers
2. Staff Cost
3. Agency Hours
4. Agency Spend
I would greatly appreciate it if you could supply this information for the year 2013/14 (April ’13 to March ‘14).
Download response Agency Staff Cost 040815
Agency Staff costs.101122.docx
The total amount spent on agency temporary staff for the year 2021/22 (April ’21 to March ‘22) and between 31/10/2021 to 31/10/2022 for the following categories:
• Doctors
• Nurses
• AHP (all categories)
• Health Care Assistants
Agency staff spend 2013-2016. 221116
Please can you confirm your monthly Hospital and/or Trust spend on agency staff during the last three financial years (FYE Mar-14, Mar-15, & Mar-16). Ideally, this should be broken down into spend by Hospitals/Trusts, the agency supplying the staff and by month.
Download response letter Agency staff spend 2013-2016. 221116
Agency Staffing. 050718
1. Agency spend on Medical Locums/Doctors
2. Agency spend on AHP’s (Allied Health Professionals) and HSS (Health and Social Sciences)
3. Agency spend on Nursing
4. Agency spend on NMNC (Non-Medical, Non Clinical)
5. Do you use a Direct Engagement model to engage locum staff?
6. If so, please state the name of the company used
7. What is the expiry date for this contract?
Agency Staffing. 260919
1. (a) Who is the head of procurement at your trust responsible for approving Nursing agency usage?
(b)Secondly, who is the temporary / flexible staffing lead responsible for the management of this service?
2. Please can you provide the contact information in relation to both question 1 (a) and (b)
3. Please can you outline your Off-Framework agency spend for each of the following staff groups between April 2019 – June 2019: (a) RGN’s (b) RCN’s (c) RN’s and (d) HealthCare Assistants (e) RMN (f) Specialist RN (ITU) (g) Medical Locums
4. Following the same breakdown of staff groups in Question 3, how many Off-framework shifts have been unfilled between April 2019 – June 2019
5. Since the start of January 2019 – present, please provide the current charge rates from your Off Framework, Nursing providers, providing a clear breakdown between the workers pay rate and agency commission
6. Based on the above information, who are your current Nursing Off-Framework agencies and how many shifts have been booked for each month from January 2019 – June 2019
Agency staffing. 280621
1. Please can you confirm whether the Trust is contracted to a managed service provider for the supply of agency staff under each of the following categories
a. Medical Locums
b. Nurses
c. Allied Health Professionals or Health Scientists
2. Please confirm which company provides the managed service for each staff category and the contract expiry date
a. Medical Locums
b. Nurses
c. Allied Health Professionals or Health Scientists
3. For Medical Locums and for AHPs, please confirm whether the Trust utilises a Direct Engagement solution for VAT efficiency
a. Medical Locums
b. Nurses
c. Allied Health Professionals or Health Scientists
4. Please confirm which company provides the Direct Engagement solution and the contract expiry date
Agency staffing. 290621
1. What contractual relationships are in place for supplying agency Nursing and who is responsible for managing them?
2. Who is your primary point of contact for decision making regarding supply chain for Agency Nursing?
3. How many agencies are used to supply agency doctors?
4. Of these agencies, how many are off framework – please list them?
5. Over the past 6 months, how many shifts have been filled via an off framework agency?
6. Who is your highest paid agency nurse, what is their speciality and their hourly charge?
7. Please outline your spend per agency, broken down by grade and speciality of nurse over the past 6 months?
8. Do you have a Master Vendor for Agency Nurses In place? If so, who are they and when are they contracted until?
9. If you have a Master Vendor in place, how many hours of work for Nursing have been booked outside of your Master Vendor arrangement in the past 6 months?
10. If you have a Master Vendor in place, what % of bookings by your Master Vendor Provider are at the NHSI capped rates in the past 6 months?
11. What is your total (£) off framework agency spend for Agency Nursing?
Agency staffing and vacancies. 061119
1. Please can you confirm how and how regularly you confirm you and your suppliers are IR35 compliant?
2. Please can you confirm the percentage of agency shifts in the past financial year that were NHSI cap compliant? Please could you break this down by staff group?
a. Nursing
b. Doctors
c. AHP/HSS
d. Other clinical
3. Please can you confirm the number of permanent vacancies you have in the following staff groups?
a. Nursing
b. AHP/HSS
Agency usage. 240418
1. How many agencies do you engage with for your recruitment of temporary nurses and health care assistants and can you please list them?
2. How many agencies do you engage with for your recruitment of permanent nurses and can you please list them?
3. What has your spend been on temporary nurses?
4. What has your spend been on permanent nurses in 2017?
5. How many temporary shifts have been released to agencies for mental health nurses?
6. How many temporary shifts have been released to agencies for general nurses?
7. How many temporary shifts have been released to agencies for theaters nurses?
8. How many temporary shifts have been released to agencies for A&E nurses?
9. How many temporary shifts have been released to agencies for Community nurses?
10. How many temporary shifts that have been released to agencies for mental health nurses go unfilled?
11. How many temporary shifts that have been released to agencies for general nurses go unfilled?
12. How many temporary shifts that have been released to agencies for theaters nurses go unfilled?
13. How many temporary shifts that have been released to agencies for A&E nurses go unfilled?
14. How many temporary shifts that have been released to agencies for Community nurses go unfilled?
15. Are all temporary shifts released to all agencies at the same time or is there a tiering system?
16. Do you have any off framework spend for temporary agency staff?
Agency usage. 270521
1. For the last year (2020-2021) please supply a list of the agencies the trust uses for medical locums.
2. A breakdown of the monetary spend per agency for Medical Locums
3. Please supply the total number of days worked by locum RMO’s or junior doctors for 2020-2021 at your trust.
4. The hourly rate paid to agencies supplying casual RMO’s or junior doctors.
Agency usage for Physiotherapy, Occupational Therapy, Pharmacy, Radiography, Speech and Language Therapy and Sterile Services.220422.docx
1. Who is the head of procurement responsible for approving agency usage for Physiotherapy, Occupational Therapy, Pharmacy, Radiography, Speech and Language Therapy and Sterile Services?
2. Who are the managers responsible for agency usage (on and off framework) for the following departments at all hospitals associated with the Trust:
(a) Physiotherapy
(b) Occupational Therapy
(c) Pharmacy
(d) Radiography
(e) Sterile Services
(d) Speech and Language Therapy
3. Please can you provide the contact number and email addresses for the managers listed in relation to question 1 and 2?
4. Have you used off-framework agency staff between March 2021 – March 2022 in the following departments:
(a) Physiotherapy
(b) Occupational Therapy
(c) Pharmacy
(d) Radiography
(e) Sterile Services
(d) Speech and Language Therapy
5. How much was your Off-Framework agency spend for each of the following staff groups between March 2021 – March 2022?
(a) Physiotherapy
(b) Occupational Therapy
(c) Pharmacy
(d) Radiography
(e) Sterile Services
(d) Speech and Language Therapy
6. How many unfilled agency roles did you have between March 2021 – March 2022 for each of the departments outlined in question 5?
Agency usage for the Sonography and Ultrasound department.310323.docx
1. Who is the head of procurement responsible for approving agency usage for the Sonography/Ultrasound department at your trust?
2. Who is responsible for agency usage (on and off framework) in the Sonography/Ultrasound department at all hospitals associated with the Trust? 3. Please can you provide the contact number and email address for the manager(s) in question 1 and 2. 4. Have you used off-framework agency staff between March 2022 – March 2023 in Sonography/Ultrasound?
5. How much was your Off-Framework agency spend for Sonography/Ultrasound from March 2022 – March 2023?
Agency usage for the Sonography and Ultrasound department.310323.docx
Agency use. 010818
1) Which Frameworks do you use for the supply of;
a) Locum Doctors
b) Locum Nurses
2) Do you operate a master vend arrangement or preferred supplier list?
3) Please list the agencies on your preferred supplier list for a and b. Please provide the supply list in tearing order or PSL if applicable.
a) Locum Doctors
b) Locum Nurses
4) Please provide contact details for the member of staff in charge of this process.
AHP agency staff spend 2015-2016
Question 1
Please can you confirm what your total spend on Allied Health Professional (AHP) agency staff was during the financial year April 2015-January 2016?
Can you please break this financial information down by AHP specialism:
• Arts Therapists,
• Chiropodist/Podiatrist,
• Dietician,
• Occupational Therapist,
• Physiotherapist,
• Prosthetist / Orthotist,
• Imaging Professionals,
• Speech / Language Professionals.
Question 2
Please can you confirm the names of the organisation/s you procure temporary Allied Health Professionals (AHP) from and the total spend for each organisation/s. To provide additional clarity on my request, ‘temporary Allied Health Professionals’ is to mean all persons who are AHPs and are not on permanent contracts of employment with the Board, but are supplied via employment agencies.
Altrix and agency spend. 240919
For the last 12 months can you provide me details on the Trusts agreement with Altrix.
Specifically:
The monthly spend for the last 12 months.
The number of hours covered monthly for the last 12 months.
Agreed rates for shifts covered.
Clarification on workers under this models Tax/IR35 status and if they are paid in line with the NHS Frameworks expectations.
Amount spent on employing agency/temporary/locum doctors in A&E departments 2014 and 2015
Under the Freedom of Information Act, please can you provide me with the amount spent on employing agency/temporary/locum doctors in A&E departments, and the number of FTE roles covered by agency doctors, if possible for each month in 2014 and 2015, or for 2014 and for 2015 as whole years.
Please can you provide me with the number of FTE doctors working in the A&E department, if possible for each month in 2014 and 2015, or for 2014 and for 2015 as whole years?
If possible, please provide a breakdown between junior doctors and consultants.
Annual spend on agency nursing staff. 070417
1) What is your annual spend on Agency Nurses?
2) How is this spend on agency Nurses broken down by individual supplier and what status are they? (i.e. PSL, Tier 1, Tier 2, Master Vendor, or Managed Service Provider?
3) What is the end / renewal date of the current contract you have in place for agency nursing?
4) Which framework do you currently use? (CCS, HTE, LPP, other)
5) Who is your senior procurement contact?
6) Who is your senior medical staffing/ nurse bank contact?
Download response Annual spend on agency nursing staff. 070417
Bank and Agency spend 2016. 070417
1. The number of hours filled by agency for all categories of Allied Health Professionals and Health Science Services for calendar year 2016 – broken down by month, Job Title and Job Band
2. The number of hours filled by bank for all categories of Allied Health Professionals and Health Science Services for calendar year 2016 – broken down by month, Job Title and Job Band
3. The Trusts total spend on agency staff for all categories of Allied Health professionals and Health Science Services for calendar year 2016 – broken down by month, Job Title and Job Band
4. The Trusts total spend on bank staff for all categories of Allied Health professionals and Health Science Services for calendar year 2016 – broken down by month, Job Title and Job Band
5. The number of hours filled by agency for all Nursing Staff for calendar year 2016 – broken down by month, Job Title and Job Band
6. The number of hours filled by bank for all Nursing Staff for calendar year 2016 – broken down by month, Job Title and Job Band
7. The Trusts total spend on agency staff for all Nursing Staff for calendar year 2016 – broken down by month, Job Title and Job Band
8. The Trusts total spend on bank staff for all Nursing Staff for calendar year 2016 – broken down by month, Job Title and Job Band
Bank and Agency Midwife spend. 110319
How much did the Trust spend on a) agency midwives b) bank midwives in each calendar month in 2018 (calendar year)?
Bank and Agency spend.050423.docx
Please disclose the information listed in the below table rows for each of the 4 staff groups in the table columns by return email within 20 days as per the Freedom of Information Act 2000.
1. Please provide agency spend for the staff group for the year 2022.
2. Please provide bank spend for the staff group for the year 2022.
3. Please confirm which model you have in place for managing the staff group: Email to preferred supplier List, a Master Vendor, a Neutral Vendor, or a Software cascade to a preferred supplier list.
4. If you have a master vendor or neutral vendor in place, please confirm who this contract is with and the date on which this contract expires.
5. Please confirm what percentage of bookings over the last 6 months have been within the NHSI/E agency caps (an approximation based on NHSI data submissions is fine).
6. Please confirm which provider manages your direct engagement process, the fee for the service and the date on which this contract expires (no this is not relevant for Nursing).
7. Please confirm what percentage of bookings are processed with a VAT savings by your direct engagement provider
8. Is your bank managed by an external bank provider (eg. NHS Professionals, Bank Partners) or in-house? Please confirm who is the external bank provider and when the contract expires if relevant.
9. Is your bank managed via software? If so, please confirm which software.
10. Please confirm what the percentage is on framework (for example, “£6,650,000 – 99% framework /20% off-framework”) for the year 2022.
11. Please confirm what percentage is off-framework (for example, “£6,650,000 – 99% framework /20% off-framework”) for the year 2022.
12. Please confirm the direct engagement- DE% uptake for the year 2022.
13. Please confirm the direct engagement- DE provider.
14. Please confirm the direct engagement- DE contract end date.
Bank and agency spend and usage. 260421
1) Please detail your Bank and Agency Spend in the format provided by the following NHSIE Staff Groups for the past financial year (April 2020 – March 2021)
2) Please detail your Bank and Agency usage in hours in the format provided by the following NHSIE Staff Groups for the past financial year (April 2020 – March 2021)
Bank and Agency Staff 221116
Staff Bank
1. Do you use a nurse bank?
2. Is it outsourced?
a. If yes, who is the provider?
b. Is your outsourced bank used via a framework, e.g., CCS, HTE, LPP?
c. Do you use the bank for other staff groups?
d. What was the spend on your staff bank in 2015/2016?
3. Do you use Agency Nurses?
a. What was your spend on agency nurses during 2015/2016?
b. Which framework do you use for agency nursing staff? E.g.: CCS, HTE, LPP, NOECPP
4. Are you meeting the NHS Improvement price caps on?
a. Band 5 general nurses
b. Band 5 specialist nurses
c. HCAs
Bank and Agency staff in Audiology. 161120
1. The number of agency staff used in the Audiology department
2. The number of hours filled by agency staff in the Audiology department.
3. The number of hours filled by bank staff in the Audiology department.
4. The Trusts total spend on agency workers in the audiology department
5. The Trusts total spend on bank workers in the audiology department
I would like the above information for the 2019 calendar year (Jan-Dec) if possible.
Download response Bank and Agency staff in Audiology. 161120
Bank and Agency Staffing. 181019
1. Please could you confirm your current bank spend (FY 18/19), broken down by the following staff groups:
a. Nursing staff
b. Medical locums (Doctors)
c. AHP/HSS
d. Other clinical
e. Non-clinical
2. Please confirm your current bank fill rate (FY 18/19), broken down by the following staff groups:
a. Nursing staff
b. Medical locums (Doctors)
c. AHP/HSS
d. Other clinical
e. Non-clinical
3. Please could you confirm your current agency spend (FY 18/19), broken down by the following staff groups:
a. Nursing staff
b. Medical locums (Doctors)
c. AHP/HSS
d. Other clinical
e. Non-clinical
4. Please could you confirm your current agency engagement procedure (i.e. MV, PSL etc) and which agencies you are currently working with, broken down by the following staff groups:
a. Nursing staff
b. Medical locums (Doctors)
c. AHP/HSS
d. Other clinical
e. Non-clinical
5. Do you have DE supplier, if so who, broken down by staff group? When is the expiry date for this contract?
6. Do you have an MV supplier, if so who, broken down by staff group? When is the expiry date for this contract?
7. Do you have an external Bank supplier, if so who, broken down by staff group? When is the expiry date for this contract?
8. Please could you confirm what your agency spend is for permanent staff in the past 24 months, broken down by the following staff groups. How much of this is international recruitment?
a. Nursing staff
b. Medical locums (Doctors)
c. AHP/HSS
d. Other clinical
e. Non-clinical
9. How many permanent vacancies do you have as per the below table. Do you have a current supplier for these roles?
Bank and agency systems.080323.docx
1. Please confirm which model is in place for managing each staff group: preferred supplier list, master vendor or neutral vendor
Locum
Nurse
Allied Health Professionals
Non-medical/non-clinical
2. If you have a master vendor or neutral vendor in place, please confirm who this contract is with
3. Please confirm the contract end date with the provider
4. Is your bank managed by an external bank provider (e.g., NHS Professionals,
Bank Partners).
5. Please confirm who is the external bank provider and when the contract expires if relevant
6. Is your bank managed via software? If so, please confirm which software.
Bank staff. 310320
1. The total internal bank spend broken down by Dr, Nurses and AHP for period Jan 19 – Dec 19
2. Is this contracted to a third party or ran by the Trust (e.g. NHSP, Bank Partners etc.)
a. If contracted to a third party the expiry date of the agreement
Bank Staff costs.101122.docx
1. Bank Spend – Total amount spent on bank staff for the year 2021/22 (April ’21 to March ‘22) and between 31/10/2021 and 31/10/2022 year split into the Trusts’ staff groups (E.g. Medical, Nursing, Admin, AHP etc.) and speciality/grade (E.g. Consultants, GP, ICU Nurse, Acute Nurse, Occupational therapists, Pharmacists, Health Care Assistants, etc.) depending on how this is reported within the Trust.
2. Confirmation on whether the trust bank is currently operated by the trust themselves or by a private provider. If the latter please confirm the name of the provider.
Bank Staff (Medical Locums) Maidstone Hospital
Please complete the attached table with the relevant information regarding Bank Staff (Medical Locums) at your Trust.
Grade Core Hours Pay rate Unsocial Pay Rates
FY1
+FY2
Sp1-2
Sp3+
Dental Core Training
Specialty Doctor/staff grade
Associate Specialist
Consultant
Download response Bank Staff (Medical Locums) Maidstone Hospital 010216
Bank Staff (Medical Locums) Tunbridge Wells Hospital
Please complete the attached table with the relevant information regarding Bank Staff (Medical Locums) at your Trust.
Grade Core Hours Pay rate Unsocial Pay Rates
FY1
FY2
Sp1-2
Sp3+
Dental Core Training
Specialty Doctor/staff grade
Associate Specialist
Consultant
Download response Bank Staff (Medical Locums) Tunbridge Wells Hospital 010216
Bank Workforce & VMS Arrangements. 190421
1. Do you have a Master Vendor or Neutral Vendor arrangement in place?
2. If yes, who is your current Master Vendor or Neutral Vendor Provider and which disciplines do they supply?
3. What fill rates are achieved with your Master Vendor or Neutral Vendor Provider in the various disciplines?
4. Are you charged a fee for the service and if so, what is the cost?
5. What is the expiry date for your current contract/contracts?
6. Do you use any external/3rd parties to manage your bank workforce?
7. If so, please provide the name of the provider and contract start and end dates.
8. Which bank software do you use and how long are you in contract with them?
Break glass and escalated agency rates. 171218
1. Could you please provide me with a breakdown of all the healthcare staffing disciplines provided by agencies in which the trust are breaking glass / being charged escalated rates?
2. Could you please state how many agency workers, per discipline, the break glass / escalated rates applies to re question 1?
3. Could you please state how many healthcare agency workers, per discipline, the Trust are being charged the maximum capped rate as stipulated by their governed framework?
Download response Break glass and escalated agency rates. 171218
Clinical Coding staff. 060220
1. How many staff do you have in your clinical coding department?
2. How many vacancies do you currently have in your clinical coding department?
3. Do you have any 3rd party’s providing you with clinical coding service?
A. If yes, which external organisations (3rd parties or other NHS) provide you with clinical coding services?
B. When did you start these contracts, how long are they for and what procurement framework did you use?
4. How much did the Trust spend last year on bank staff for clinical coding?
5. How much did the Trust spend on consultancy relating to clinical coding last year?
Cloud21. 120422.docx
We would like to understand how much money MTW have spent with Cloud21 Broken Down for each financial year
16/17
17/18
18/19
19/20
20/21
21/22
Community Nursing. 010618
1. What was your trust spend for temporary community agency nursing in 2017?
2. How many rgn shifts are released to temporary agencies?
3. How many rgn shifts released to agency go unfilled?
4. How many hca shifts are released to temporary agencies?
5. How many hca shifts released to agency go unfilled?
6. How many agencies are on your proffered suppliers list for these requirements?
Cost of strike cover.120523.docx
Please could you tell me how much money your trust spent on bank and/or agency and/or locum staff – and/or non-contractual rates to consultants or other medical staff employed by the trust – to cover junior doctors’ shifts during industrial action by the British Medical Association on:
A) March 13-15 2023
and
B) April 11-15 2023
Please provide as much detail as possible on the staff category (i.e. agency or bank), department of the hospital and the day(s) of employment.
Dermatology locum doctors 060317
Can you please assist me with retrieving the total Agency spend for Medical Locum Doctors within Dermatology over the following months, within your Trust or Health Board?
Diagnostic radiology staff details. 260919
1. How many permanent staff are employed by the Radiography/Imaging department (Radiographers & Sonographers, not Radiologists)?
2. How many permanent vacancies are currently open/unfilled within the Radiography/Imaging department (Radiographers & Sonographers, not Radiologists)?
3. How many agency staff/locums are currently being used across the Radiography/Imaging department (Radiographers & Sonographers, not Radiologists)?
4. For agency staff/locums, what is the split in numbers between radiographers and sonographers?
5. How many bank temps are being used across the Radiography/Imaging department?
6. During the 2017-2018 financial year, how much did the Radiography/Imaging department spend on temporary agency staff?
7. During the 2018-2019 financial year, how much did the Radiography/Imaging department spend on temporary agency staff?
8. During the 2018-2019 financial year, how much did the Radiography/Imaging department spend on temporary bank staff?
9. During the 2018-2019 financial year, how much did the Radiography/Imaging department spend on permanent finders/introduction fees through recruitment agencies?
10. Does the Radiography/Imaging department have a dedicated breast screening unit?
11. Please provide me with the following contact names within the authority:
a) The name of the senior manager (Radiology Services Manager / Imaging Services Manager) with overall responsibility for the Radiography/Imaging department.
b) The name of the head of temporary staffing.
Download response Diagnostic radiology staff details. 260919
Engagement of locum staff using third parties. 181718
1. Does your organization use a Direct Engagement scheme?
2. If so, who provides it? And when did you start using it?
3. Did you take external legal advice before entering into it and, if so, from whom did you take external legal advice?
4. What has your total locum/temporary staffing spend since you started using the scheme? If you started using the scheme before April 2017 please also state the total locum/temporary staffing spend since April 2017.
5. How does the third party direct engagement facilitator save you money on the agency spend? Please answer in short point form
6. How much has been paid to the third party direct engagement facilitator thus far?
7. Was this payment calculated as a percentage of the savings generated by employing the services of the third party direct engagement facilitator? If so, what percentage is this?
Download response Engagement of locum staff using third parties. 181718
External temporary staff. 220321
1. A list of all the areas across the Trust that use external temporary staff.
2. The monthly and annual cost of having these staff supplied, averages are fine if exact data is unavailable.
3. The types of staff that are supplied.
4. Whether these staff are supplied via an approved NHS Framework, if not what is the nature of the contract or agreement in place.
Flexible staffing 071216
1. Does your Trust currently utilise a Direct Engagement (DE) model? – YES / NO
2. If Yes, who currently provides the service;
a. Brookson
b. Liaison/ PWC (StafFlow)
c. Liaison (TEMPre)
d. 24/7 Time
e. Other (please specify here)………………………..
3. What proportion (in percentage) of your agency workers for the following staff groups are directly engaged:
a. Medical Locums/Doctors (e.g. Acute, Emergency, General Surgery, Paediatrics, Gynaecology, Neurosurgery, Dermatology, Cardiology)
b. Allied Health Professionals/Health Science Staff (e.g. Biomedical Science, Clinical Physiology (Cardiology), Dietician, Occupational Therapy, Pharmacy, Physiotherapy, Radiography, Talking Therapy, Speech & Language Therapy, Psychology, Anatomical Pathology)
4. What percentage are you charged for the management of these services?
5. When was the DE contract awarded?
6. What is the contract duration?
7. What was the motivation with engaging with these services?
Framework and non-framework locum agencies
What framework and non-framework locum agencies you use for:
Doctors
Nursing staff
Doctors and nursing staff
I also want to know do you have a staff bank. Do you with any particular agencies as a rule and others when simply in need?
Download response Framework and non-framework locum agencies 260116
Full contact details for the HR staff member responsible for locum appointments
Please can you give me the contact details for the HR person that deals with Locum appointments?
Please can I have their full name, job title, email address and direct dial telephone number.
Cancelled operations
Cancelled appointments and procedures. 091220
1. How many of the following scheduled procedures/appointments were cancelled by the Trust:
i) Elective operations
ii) Appointments made via urgent cancer referrals
iii) Mammograms
iv) Organ transplant operations
v) Optical appointments/procedures
During the following periods:
i) 2019-2020
ii) 2020-to date
NB. I do not require the reasons for the cancellations.
2. How many of the following scheduled procedures/appointments were pushed back by the Trust:
i) Elective operations
ii) Appointments made via urgent cancer referrals
iii) Mammograms
iv) Organ transplant operations
v) Optical appointments/procedures
NB. I do not require the reasons behind the delay/re-scheduling.
For the following time frames:
i) Up to one month
ii) Up to three months
iii) Up to six months
iv) Up to a year
v) Indefinitely
During the following periods:
i) 2019-2020
ii) 2020-to date
Download response Cancelled appointments and procedures. 091220
Cancelled cancer operations. 220920
I would like to know how many cancer operations have been cancelled by your NHS Trust since March 1st 2020?
Cancelled children’s operations – 01.07.16. 050517
1. How many children’s operations have been cancelled each month since 1st July 2016? Please give additional details as to what the main reasons for the cancellations were, how many were urgent operations or elective operations, and what type of illness did they involve, e.g. cancer, breathing problems, broken limbs etc.
2. How many children’s operations have been cancelled over the last four financial years to date?
Kindly note a child is anyone up to the age of 18.
Download response Cancelled children’s operations – 01.07.16. 050517
Cancelled children’s operations. 131020
The total number of children’s operations cancelled for non-clinical reasons, broken down by the cause of the cancellation, for example due to lack of beds, operating theatre capacity, staffing issues, and equipment failures. Please provide this information for each of the past three financial years 2017/18, 2018/19, 2019/20). In the total number of operations, broken down by cancellation reason, please include:
· Elective children’s operations cancelled at the last minute. For the purposes of this request, last minute means on the day the patient was due to arrive, after the patient has arrived in hospital or on the day of the operation or surgery.
· Cancelled urgent children’s operations.
For the purposes of this FOI, Children will be defined as under 18’s.
Cancelled children’s operations.140323.docx
You asked: All questions are shown as received by the Trust.
1. The number of children (under 18s) who have an operation cancelled or delayed at your trust for non-clinical reasons, in each of the past five calendar years (2022, 2021, 2020, 2019, 2018).
2. For each of these years, please could you provide figures broken down by the reason behind the cancellation or delay, e.g. lack of staff, lack of bed capacity, or lack of equipment.
3. Please could you provide figures on the five longest waits for an operation currently faced by under-18s at your trust, e.g. 118 days, 116 days, 113 days. For each of these waits, please could you provide a summary of the surgical procedure in question, e.g. heart surgery.
Cancelled elective admissions and outpatient attendances. 150118
1) In the months of October, November and December, how many elective admissions and outpatient attendances had to be cancelled due to non-clinical reasons?
2) How many of these were able to be rescheduled within 28 days (please give actual figure)?
3) And how many were not able to be rescheduled within 28 days?
Download response Cancelled elective admissions and outpatient attendances. 150118
Cancelled elective operations 2010-2016. 200417
1. Since 1st April 2010 what has been the maximum cost to the Trust of an elective operation being cancelled last-minute for non-clinical reasons? Please give additional detail as to what the operation was and how many members of staff were supposed to be working on the operation.
2. Please provide the total number of elective operations cancelled last-minute for non-clinical reasons for each quarter going back to 2010.
3. Please provide the total quarterly cost of elective operations being cancelled last-minute for non-clinical reasons for each quarter going back to 2010.
Download response Cancelled elective operations 2010-2016. 200417
Cancelled elective operations for December 2015 and January 2016.
I would like to ask for each day over the past two months how many elective operations have had to be cancelled and what reasons were given?
And for each of those days, how many elective operations had been originally planned?
Download response Cancelled elective operations for December 2015 and January 2016 190416
Cancelled elective procedures.270722.docx
Question 1
How many booked elective invasive procedures (this includes but is not limited to procedures being performed in operating theatres, interventional radiology or other radiology suites, cardiac catheter labs, endoscopy and any other site not mentioned involving an invasive procedure, whether under local anaesthetic, general anaesthetic, spinal or epidural anaesthetic, peripheral nerve block, or sedation) did your trust cancel in the calendar years:
a. 2017
b. 2018
c. 2019
d. 2020
e. 2021
Question 2
How many booked elective invasive procedures (this includes but is not limited to procedures being performed in operating theatres, interventional radiology or other radiology suites, cardiac catheter labs, endoscopy and any other site not mentioned involving an invasive procedure, whether under local anaesthetic, general anaesthetic, spinal or epidural anaesthetic, peripheral nerve block, or sedation) did your trust cancel at the date of this request in this calendar year?
Cancelled operations. 011018
I would like to request the total number of operations cancelled for non-clinical reasons, broken down by the cause of the cancellation, for example due to lack of beds, operating theatre capacity, staffing issues, and equipment failures.
Please provide this information for each of the past five financial years (i.e. years running from April to March – 2013/14, 2014/15, 2015/16, 2016/17, 2017/18).
In the total number of operations, broken down by cancellation reason, please include:
1. Elective operations cancelled at the last minute. For the purposes of this request, last minute means on the day the patient was due to arrive, after the patient has arrived in hospital or on the day of the operation or surgery.
2. Cancelled urgent operations.
If the data is collected by the trust, please also provide a separate total for each year for all operations cancelled for non-clinical reasons, regardless of how soon before the scheduled operation time the cancellation occurred.
Cancelled operations.021222.docx
a) How many elective operations were cancelled for a non-clinical reason at the Trust in 2021/22, broken down by reason for cancellation?
b) Of the total elective operations cancelled for a non-clinical reason at the Trust in 2021/22, how many were:
i. urgent surgery
ii. paediatric surgery
iii. surgical oncology
Cancelled operations. 070721
a) How many operations in total has your Trust cancelled from 1 March 2020 – 1 March 2021 and can you give a breakdown of reasons for the cancellations? How many were urgent operations?
b) How many operations in total has your Trust cancelled from 1 March 2019 – 28 February 2020 and can you give a breakdown of reasons for the cancellations? How many were urgent operations?
c) How many operations in total has your trust cancelled for Under 16s from 1 March 2020 – 1 March 2021 and can you give a breakdown of reasons for the cancellations? How many were urgent operations?
d) How many operations in total has your trust cancelled for Under 16s from 1 March 2019 – 28 February 2020 and can you give a breakdown of reasons for the cancellations? How many were urgent operations?
Cancelled operations. 131021.docx
1. Please can you tell me the number of last minute elective operations cancelled for non clinical reasons at your trust or board for each month of 2020 and 2021 to date.
2. Please can you tell me the number of urgent operations cancelled for non-medical reasons during each month.
If giving the full data requested would be likely to exceed the costs cap, please provide data for the most recent month and then as many months as possible working backwards until the limit is reached.
3. If possible, please let me know how many of the cancelled elective operations had still not been carried out 28 days later.
4. If possible, please let me know how many of the cancelled urgent operations had still not been carried out 28 days later.
Cancelled operations.140323.docx
1. The number of people who have had an operation cancelled or delayed at your trust for non-clinical reasons, in each of the past five calendar years (2022, 2021, 2020, 2019, 2018).
2. For each of these years, please could you provide figures broken down by the reason behind the cancellation or delay, e.g. lack of staff, lack of bed capacity, or lack of equipment.
3. Please could you provide figures on the five longest waits for an operation currently faced by under-18s at your trust, e.g. 110 days, 98 days, 200 days. For each of these waits, please could you provide a summary of the surgical procedure in question, e.g. heart surgery.
Cancelled operations.2. 140323.docx
1. The number of elective operations scheduled. I would like this information for January 2022 to end of December 2022 broken down by week i.e. the total number of elective operations that were planned for Week 1, January 2022, Week 2 etc.
2. The number of elective operations performed. January 2022 to end of December 2022 broken down by week i.e. the total number of elective operations that were planned for Week 1, January 2022, Week 2, etc
3. The number of elective operations cancelled at the “last minute”, as defined by the NHS when providing data on cancelled elective operations. I would like this information for January 2022 to end of December 2022 broken down by week i.e. the total number of elective operations planned for Week 1, January 2022, Week 2 etc.
4. The total number of elective operations cancelled, regardless of how long cancellations were made before scheduled operation times, if this information is also collected. I would like this information for January 2022 to the end of December 2022 broken down by week i.e. the total number of elective operations planned for Week 1, January 2022, Week 2 etc.
Cancelled operations 2011 – 2016. 141216
1. Over the past five financial years (2011-12, 2012-13, 2013-14, 2014-15, 2015-16) please state the number of last minute elective surgery cancellations there have been for non-clinical reasons for the following branches of surgery: trauma and orthopaedics, neurology, cancer, and ophthalmology. Please break down by year and surgery type.
2. Over the past five financial years (2011-12, 2012-13, 2013-14, 2014-15, 2015-16) please state how many patients were not treated within 28 days of last minute elective cancellation of an operation for the following branches of surgery: trauma and orthopaedics, neurology, cancer, and ophthalmology. Please break down by year and surgery type.
Cancelled operations 2012-2017. 200917
1. The number of elective operations carried out by the Trust in the following financial years:
2012/13
2013/14
2014/15
2015/16
2016/17
2. The number of elective operations cancelled at the last minute* due to non-clinical reasons, in the following financial years:
2012/13
2013/14
2014/15
2015/16
2016/17
NOTE: Please use NHS England’s standard definition of last minute cancellations, “Last minute means on the day the patient was due to arrive, after the patient has arrived in hospital or on the day of the operation or surgery.” See: https://www.england.nhs.uk/statistics/statistical-work-areas/cancelled-elective-operations/
3. The number of elective operations cancelled at the last minute due to non-clinical reasons per financial year (2012/13 to 2016/17 inclusive), split into the following categories:
– Staff unavailable or sick (either anaesthetist, surgeon, theatre staff or other)
– Lack of available bed (either general or HDU, critical, or intensive care)
– Theatre list over-ran or no space on it (e.g. due to emergency case(s) coming in)
– Equipment missing / failure
– Any other reason
Cancelled operations 2013 to 2016.
1. In relation to (i) 2013/14, (ii) 2014/15 and (iii) 2015/16 financial year please provide me with the number of operations cancelled at your Trust on the day of operation or admission where the reason is recorded as there being no post-operative bed available for the patient.
2. For each year please state if possible how many of these cancellations were due to the fact that there was no critical care bed or intensive care bed available rather than the unavailability of a general ward bed?
Cancelled operations 2014 – April 2017. 050517
How many operations have been cancelled for non-clinical reasons IN THE 3 DAYS BEFORE a patient was due to be admitted?
Out of those cancellations, how many were rescheduled within 1 month?
How many operations have been cancelled for non-clinical reasons ON THE DAY a patient was due to be admitted?
Out of those cancellations, how many were rescheduled within the statutory time limit – e.g. 28 days?
Please provide this data by month for 2014, 2015, 2016 and 2017 – up to and including April 2017.
The following should be included in the figures for ‘operations’:
All planned or elective operations and day surgery
For ‘non-clinical reasons’ please include a break-down of the following:
· Bed-ward not available
· Staff unavailable
· Emergency operations taking priority
· Maintenance needed on equipment
· Patient unavailable
· Admin error
Download response Cancelled operations 2014 – April 2017. 050517
Cancelled operations and appointments. 210218
The National Emergency Preparedness Panel warned on 22 December that non-urgent operations should be cancelled, with a further update on 2 January advising that “day case and outpatient procedures” should also be put on hold to preserve emergency care.
Could the trust please provide the following details about cancellations for non-clinical reasons, and last minute (on the scheduled day of arrival at hospital or later) non-clinical cancellations.
Download response Cancelled operations and appointments. 210218
Cancelled operations for non-clinical reasons. 050919
The total number of operations cancelled for non-clinical reasons, broken down by the cause of the cancellation, for example due to lack of beds, operating theatre capacity, staffing issues, and equipment failures. Please provide this information for each of the past three financial years (2016/17, 2017/18, 2018/19). In the total number of operations, broken down by cancellation reason, please include:
• Elective operations cancelled at the last minute. For the purposes of this request, last minute means on the day the patient was due to arrive, after the patient has arrived in hospital or on the day of the operation or surgery.
• Cancelled urgent operations.
Download response Cancelled operations for non-clinical reasons. 050919
Cancelled operations for non-clinical reasons.2 050919
I would like to request the total number of operations cancelled for non-clinical reasons, broken down by the cause of the cancellation, for example due to lack of beds, operating theatre capacity, staffing issues, and equipment failures, in 2018/19 (financial year, April to March).
In the total number of operations, broken down by cancellation reason, please include:
• Elective operations cancelled at the last minute. For the purposes of this request, last minute means on the day the patient was due to arrive, after the patient has arrived in hospital or on the day of the operation or surgery.
• Cancelled urgent operations.
If the data is collected by the trust, please also provide a separate total for each year for all operations cancelled for non-clinical reasons, regardless of how soon before the scheduled operation time the cancellation occurred.
Download response Cancelled operations for non-clinical reasons.2 050919
Cancelled operations for non-clinical reasons 2013 to March 2016. 170516
How many operations have been cancelled for non-clinical reasons IN THE 3 DAY BEFORE a patient was due to be admitted?
Out of those cancellations, how many were rescheduled within 1 month?
How many operations have been cancelled for non-clinical reasons ON THE DAY a patient was due to be admitted?
Out of those cancellations, how many were rescheduled within the statutory time limit – e.g. 28 days?
Please provide this data by month for 2013, 2014, 2015 and 2016 – up to and including March 2016.
The following should be included in the figures for ‘operations’:
• All planned or elective operations and day surgery
For ‘non-clinical reasons’ please include a break-down of the following:
Bed-ward not available
Staff unavailable
Emergency operations taking priority
Maintenance needed on equipment
Patient unavailable
Admin error
Download response Cancelled operations for non-clinical reasons 2013 to March 2016. 170516
Cancelled operations March – September 2019 and 2020. 141020
a) How many adult’s operations were cancelled at your Trust from 1 March 2020 – 31 August 2020?
b) How many adult’s operations were cancelled at your Trust from 1 March 2019 – 31 August 2019?
c) How many children’s operations were cancelled at your Trust from 1 March 2020 – 31 August 2020?
d) How many children’s operations were cancelled at your Trust from 1 March 2019 – 31 August 2019?
Download response Cancelled operations March – September 2019 and 2020. 141020
Cancelled planned operations. 210318
How many planned operations were cancelled in January 2018 due to winter pressures? If possible, please provide a specific reason for each case.
Cancer and Haematology & Radiology
2-week urgent referral policy. 031121.docx
I have been looking on the MTW website for your “2 week urgent referral policy”. I have not been able to locate this or a leaflet. Would you please be able to email me a copy of this?
Download response 2-week urgent referral policy. 031121.docx
Active surveillance for prostate cancer. 260717
Please outline details of the active surveillance protocol below (or attach the protocol document when replying to our request email):
Download response Active surveillance for prostate cancer. 260717
Adult Haematology services.190522.docx
Please note the questionnaire refers only to Adult Haematology services.
1) Does your Trust have a Clinical Haematology service for Adults?
Yes / No (delete as appropriate)
If No, please return the questionnaire at this stage – there are no further questions that need to be answered.
2) If Yes, please complete the staffing table below:
3) If you have Haematology Clinical Nurse Specialists, please advise on how their jobs are split, for example 1.0WTE Myeloma CNS, 0.8WTE BMT CNS etc.
4) Which of the below haematological services does your Haematology service cover?
5) In the last 3 years, how many ‘New’ patients were seen by your Clinical Haematology Team?
6) If you have a BMT service, how many patients do you treat on average per year?
Advanced breast cancer.041122.docx
1) In the past 3 months, how many advanced/metastatic breast cancer patients have the status of;
a) HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]
b) HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]
2) In the past 3 months, how many breast cancer patients were treated with:
a. Abemaciclib (Verzenios) + aromatase inhibitor *
b. Abemaciclib (Verzenios) + Fulvestrant
c. (Faslodex) Alpelisib (Piqray) + Fulvestrant (Faslodex)
d. Atezolizumab (Tecentriq)**
e. Bevacizumab (Avastin)
f. Eribulin (Halaven)
g. Everolimus (Afinitor) + Exemestane
h. Fulvestrant (Faslodex) as a single agent
i. Gemcitabine + paclitaxel
j. Lapatinib (Tyverb)
k. Neratinib (Nerlynx)
l. Olaparib (Lynparza)
m. Palbociclib (Ibrance) + aromatase inhibitor*
n. Pertuzumab (Perjeta) + trastuzumab + docetaxel
o. Ribociclib (Kisqali) + aromatase inhibitor*
p. Ribociclib (Kisqali) + Fulvestrant (Faslodex)
q. Talazoparib (Talzenna)
r. Trastuzumab + paclitaxel Trastuzumab as a single agent
s. Trastuzumab emtansine (Kadcyla)
t. Trastuzumab Deruxtecan (Enhertu)
u. Tucatinib + Trastuzumab + Capecitabine (Tukysa)
v. Other active systemic anti-cancer therapy ** *aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole **e.g. docetaxel, vinorelbine or capecitabine as a single agent
Advanced Breast Cancer. 221019
1a. Does your trust treat advanced breast cancer?
1b. If none, where are your patients referred?
2. In the past 3 months, how many advanced breast cancer patients [Stage IV] have the status of;
HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]
HR+ and HER2- [Hormone receptor-positive and human epidermal growth factor 2-negative]
HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]
HR- and HER2- [Hormone receptor-negative and human epidermal growth factor 2-negative] – Triple negative disease
Not Known
3. In the past 3 months, how many breast cancer patients were treated with:
Abemaciclib (Verzenios) + aromatase inhibitor *
Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
Alpelisib (Piqray) + Fulvestrant (Faslodex)
Atezolizumab (Tecentriq)**
Bevacizumab (Avastin)
Eribulin (Halaven)
Everolimus (Afinitor) + Exemestane
Fulvestrant (Faslodex) as a single agent
Gemcitabine + paclitaxel
Lapatinib (Tyverb)
Neratinib (Nerlynx)
Olaparib (Lynparza)
Palbociclib (Ibrance) + aromatase inhibitor*
Pertuzumab (Perjeta) + trastuzumab + docetaxel
Ribociclib (Kisqali) + aromatase inhibitor*
Ribociclib (Kisqali) + Fulvestrant (Faslodex)
Talazoparib (Talzenna)
Trastuzumab + paclitaxel
Trastuzumab as a single agent
Trastuzumab emtansine (Kadcyla)
Other active systemic anti-cancer therapy **
*aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole
**e.g. docetaxel, vinorelbine or capecitabine as a single agent
Advanced hepatocellular carcinoma (Stage 3b and 4).230522.docx
Q1. How many patients have been diagnosed with advanced hepatocellular carcinoma (Stage 3b and 4) in the last 6 months?
Q2. How many hepatocellular carcinoma patients (any stage) have been treated in the last 6 months with the following treatments:
a. Lenvatinib
b. Sorafenib
c. Regorafenib
d. Atezolizumab + Bevacizumab
Q3. In the last 6 months, how many patients has your trust treated (for any condition) with the following treatments:
a. Avatrombopag
b. Eltrombopag
c. Fostamatinib
d. Romiplostim
Q4. In the last 6 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3) ONLY with the following treatments:
a. Avatrombopag
b. Mycophenolate mofetil
c. Rituximab
d. Surgery (splenectomy)
Q5. Does your trust participate in any clinical trials for the treatment of hepatocellular carcinoma? If so, can you please provide the name of each trial and the number of patients taking part.
Advanced hepatocellular carcinoma (Stage 3b and 4).230522.docx
Advanced Prostate Cancer 070317
1. Within your trust how many unique patients with Advanced Prostate Cancer have been treated in the past 12 months?
2. How many patients with Advanced Prostate Cancer have received:
Abiraterone (Zytiga)
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Enzalutamide (Xtandi)
Radium-223 (Xofigo)
Bicalutamide (Casodex)
Advanced prostate cancer June 2016 to May 2017. 090617
Within your trust how many unique patients with Advanced Prostate Cancer have been treated in the past 12 months?
How many patients with Advanced Prostate Cancer have received;
Abiraterone (Zytiga)
Cabazitaxel (Jevtana)
Docetaxel (Taxotere)
Enzalutamide (Xtandi)
Radium-223 (Xofigo)
Bicalutamide (Casodex)
Advanced prostate cancer is cancer that has spread outside the prostate to other parts of the body such as the bones
Download response Advanced prostate cancer June 2016 to May 2017. 090617
Advanced radiotherapy treatment SABR (Stereotactic ablative radiotherapy).180920
Which of the radiotherapy locations in the trust deliver the advanced radiotherapy treatment SABR ()?
Download response Advanced radiotherapy treatment SABR (Stereotactic ablative radiotherapy).180920
AI software within radiology.110821.docx
1. Does your trust use any AI software within radiology? If so could you please specify programme and its application?
2. If you use AI software within radiology – how often do/would you update, upgrade or swap them?
3. What is the decision-making criteria of choosing which AI software to use?
4. Do you make purchasing decision on your own and if not, what are the other stakeholders involved?
Antiretroviral therapies. 140521
Q1. How many patients were treated (for any condition) in the latest 6-month period with the following drugs:
a. Juluca (rilpivirine/dolutegravir)
b. Dovato (lamivudine/dolutegravir)
c. Triumeq (abacavir/lamivudine/dolutegravir)
d. Tivicay (dolutegravir)
e. Isentress (raltegravir)
f. Biktarvy (TAF/emtricitabine/bictegravir)
g. Genvoya (TAF/emtricitabine/elvitegravir/cobisistat)
h. Symtuza (TAF/emtricitabine/darunavir/cobisistat)
i. Odefsey (TAF/emtricitabine/rilpivirine)
j. Descovy (TAF/emtricitabine)
k. Truvada or generic TDF/emtricitabine
Q2. How many patients received any antiretroviral (ART) therapy for HIV treatment (excluding pre-exposure prophylaxis):
a. for the latest 6-month period
b. for the 6 months from July-December 2019
Q3. How many patients were treated in the latest 6-months period with Truvada or generic TDF/emtricitabine for?
a. HIV treatment
b. Pre-exposure prophylaxis (PrEP)
Q4. How many packs of Truvada or generic TDF/emtricitabine were dispensed in latest 6-month period for?
a. HIV treatment
b. Pre-exposure prophylaxis (PrEP)
Autoclaves.130223.docx
1. The number of Autoclaves commissioned and commissioned date.
2. The departments where Autoclaves are used.
Average and longest waiting times for cancer treatment. 141217
Firstly, in days what is the a) average and b) longest a single patient has waited to receive a First Consultant Appointment following a GP Urgent Referral (two week target) in calendar year 2017 (Year to Date), 2016, 2015, 2010 and 2009.
Secondly, in days what is the a) average and b) longest a single patient has waited for a First Treatment for Cancer following a Decision to Treat (31 days target) in calendar year 2017 (Year to Date), 2016, 2015, 2010 and 2009.
Thirdly, in days what is the a) average and b) longest a single patient has waited for a First Treatment for Cancer following a GP Urgent Referral (62 days target) in calendar year 2017 (Year to Date), 2016, 2015, 2010 and 2009.
Download response Average and longest waiting times for cancer treatment. 141217
Bevacizumab. 290121
1. How many patients have been treated by your trust (for any medical condition) in the past 6 months with Bevacizumab?
2. Please provide the number of patients treated in the past 6 months with Bevacizumab for the following conditions:
a. Colorectal cancer
b. Breast cancer
c. Renal cell carcinoma
d. Non-small cell lung cancer
e. Ovarian cancer (epithelial, fallopian tube or primary peritoneal)
f. Carcinoma of the cervix
Bisphosphonates. 160818
1. Does your Trust routinely provide bisphosphonates to postmenopausal women with primary breast cancer to reduce the risk of their cancer spreading to other parts of the body?
2. If your Trust does routinely provide bisphosphonates to reduce the risk of primary breast cancer spreading to other parts of the body, but is not providing them for all postmenopausal women, how is eligibility defined? For example, women at increased risk of recurrence.
3. If your Trust does routinely provide bisphosphonates for postmenopausal women to reduce the risk of primary breast cancer spreading to other parts of the body, which bisphosphonates do you prescribe? For example, zoledronic acid, ibandronic acid, sodium clodronate.
4. If your Trust does not routinely provide bisphosphonates for postmenopausal women to reduce the risk of primary breast cancer spreading to other parts of the body, what are your reasons for not doing so?
Blood collection tubes for liquid biopsies. 250521
1. How do you obtain blood collection tubes for liquid biopsies on cancer patients?
2. From what suppliers do you obtain these products?
3. Were these products purchased through a tender or framework? If so, which one? Please provide details including the name, reference and where this was published.
4. Are you under contract with your current supplier(s) for the above? If so, what is the start and end date of the contract?
5. Can you provide the name and contact details for the person(s) responsible for procuring these products?
6. Can you provide contact details for the department responsible for managing this service?
Download response Blood collection tubes for liquid biopsies. 250521
Blood Gas Analysers.111022.docx
Please provide details of the type (manufacturer and model), quantity, department, site where they are located and age of all Blood Gas Analysers listed on your trust’s asset register (or equivalent).
Bone Metastases. 240919
1. Within your health trust how many metastatic breast cancer patients are currently [within the past 6 months] being treated, with any therapy, surgery or palliative care.
2. Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;
a. disodium pamidronate (Arcadia)
b. ibandronic acid or ibandronate (Bondronat)
c. sodium clodronate (Bonefos, Clasteon, Loron)
d. zoledronic acid or zoledronate (Zometa)
e. denosumab (Xgeva)
3. Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated with adjuvant therapy with the following treatments;
a. disodium pamidronate (Aredia)
b. ibandronic acid or ibandronate (Bondronat)
c. sodium clodronate (Bonefos, Clasteon, Loron)
d. zoledronic acid or zoledronate (Zometa)
4. Within your health trust how many metastatic lung cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.
5. Within your health trust how many lung cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;
a. disodium pamidronate (Aredia)
b. ibandronic acid or ibandronate (Bondronat)
c. sodium clodronate (Bonefos, Clasteon, Loron)
d. zoledronic acid or zoledronate (Zometa)
e. denosumab (Xgeva)
6. Within your health trust how many metastatic renal cell cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.
7. Within your health trust how many renal cell carcinoma [RCC] patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;
a. disodium pamidronate (Aredia)
b. ibandronic acid or ibandronate (Bondronat)
c. sodium clodronate (Bonefos, Clasteon, Loron)
d. zoledronic acid or zoledronate (Zometa)
e. denosumab (Xgeva)
Brain Cancer Treatment.051022.docx
1. How many patients have been treated for glioblastoma brain cancer in the last 12 months, in your trust/ health board?
2. Which consultant is the nominated medical lead for the treatment or referral of glioblastoma brain cancer?
3.Does your trust/ health board treat all referred glioblastoma brain cancer cases, or are they referred to different centre’s? If so, which treatment centre(s) are they referred to?
Breast Biopsy. 280317
Under the Freedom of Information Act, please could you provide the following information for your Trust?
1. How many benign breast lesions has your Trust diagnosed per annum in the last three years?
2. How many benign breast lesions have been removed surgically per annum within your Trust in the last three years?
a. Of this total number, how many of these are classified as B2?
b. Of this total number, how many of these are classified as B3?
3. How many benign breast lesions have not been removed per annum in the last three years?
4. How many benign breast lesions have been removed by vacuum assisted excision (VEA) per annum in the last three years?
a. Of this total number, how many of these are classified as B2 (definition below)?
b. Of this total number, how many of these are classified as B3 (definition below)?
5. Is the Trust aware of NICE guidance promoting the use of VAE for removal of benign lesions?
6. Does the Trust have a referral pathway in place for vacuum assisted percutaneous excision of benign breast lesions?
With regards to this request, please note the following:
B3 Breast Lesion – Lesion of Uncertain Malignant Potential
Findings typical of this category include:
1. Clusters of tiny calcifications – round or oval
2. Non-calcified solid nodules (no size limitation but non palpable on physical examination), round, ovoid and well-defined.
3. Selected focal asymmetrical areas of fibroglandular densities (not palpable): This might include concave-outward defined margins, interspersed with fat and without central increased fibular density on two projections.
4. Miscellaneous focal findings, such as a dilated duct or post biopsy architectural distortion without central density
5. Generalized distribution in both breasts. For example, multiple similar lesions with tiny calcifications or nodules distributed randomly
B2 Breast Lesion – Benign Lesion
A definitive benign finding indicating something abnormal on a mammogram but not something that is breast cancer or malignant in any way. Findings often include:
1. Round opacities with macrocalcifications (typical calcified fibroadenoma or cyst)
2. Round opacities corresponding to a typical cyst at ultrasonography
3. Oval opacities with a radiolucent center
4. Fatty densities or partially fatty images (lipoma, galactocele, oil cyst, hamartoma )
5. Surgical scar
6. Scattered macrocalcifications (fibroadenoma, cyst, cytosteatonecrosis, secretory ductal ectasia);
7. Vascular calcifications
8. Breast implants, silicone granuloma
Breast cancer.090323.docx
Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab + Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fulvestrant as a single agent
j. Lapatinib
k. Neratinib
l. Parp Inhibitors (Olaparib/Talazoparib)
m. Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
n. Palbociclib + Fulvestrant
o. Pembrolizumab
p. Platinum (e.g. carboplatin or cisplatin) as a single agent
q. Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
r. Ribociclib + Fulvestrant
s. Sacituzumab Govitecan
t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
u. Taxane and/or Anthracycline in combination
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Any other active systemic anti-cancer therapy
Q2. Of the patients treated for breast cancer with Abemaciclib + Aromatase Inhibitor in the past the 3 months, please provide the number of patients with:
a. early/locally advanced breast cancer (Stages 1 to 3B)
b. advanced/metastatic breast cancer (Stages 3C and 4)
Breast cancer.090922.docx
1. In the past 3 months, how many Breast Cancer patients (any stage) were treated with:
a. Abemaciclib monotherapy
b. Aromatase inhibitor monotherapy (e.g. anastrazole, exemestane, letrozole)
c. Tamoxifen monotherapy
d. Abemaciclib + Tamoxifen
e. Abemaciclib + Tamoxifen + Goserelin
f. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) + Goserelin
g. Aromatase inhibitor + Goserelin
h. Tamoxifen+ Goserelin
2. How many patients have been treated for Triple-Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
b. Atezolizumab +Nab-paclitaxel/Paclitaxel
c. Pembrolizumab
d. Sacituzumab Govitecan
e. Parp Inhibitors (Olaparib/Talazoparib)
f. Eribulin as a single agent or in combination
g. Capecitabine as a single agent
h. Platinum (e.g. carboplatin or cisplatin) as a single agent
i. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
j. Taxane and/or Anthracycline in combination
k. Any other active systemic anti-cancer therapy
Breast cancer. 181019
1. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with early breast cancer in each year from 2013 to 2018.
If confirm, please release this data.
2. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with early breast cancer that were offered tumour profiling tests to guide adjuvant chemotherapy decisions, in each year from 2013 to 2018. If confirm, please release this data.
3. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with early breast cancer that were tested with tumour profiling tests to guide adjuvant chemotherapy decisions, in each year from 2013 to 2018. If confirm, please release this data.
4. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer in each year from 2013 to 2018. If confirm, please release this data.
5. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the numbers of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer that were offered tumour profiling tests to guide adjuvant chemotherapy decisions in each year from 2013 to 2018. If confirm, please release this data.
6. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer that were tested with tumour profiling tests to guide adjuvant chemotherapy decisions in each year from 2013 to 2018. If confirm, please release this data.
Breast Cancer.181122.docx
1. In the past 3 months, how many Breast Cancer patients (at any stage) were treated with:
a. Abemaciclib monotherapy
b. Aromatase inhibitor monotherapy (e.g. anastrazole, exemestane, letrozole)
c. Tamoxifen monotherapy
d. Abemaciclib + Tamoxifen
2. In the past 3 months, how many early/locally advanced Breast Cancer (Stages 1 to 3B) patients were treated with:
a. Abemaciclib + Aromatase inhibitor (e.g. anastrazole, exemestane, letrozole)
b. Taxane and/or Anthracycline (monotherapy or in combination)
c. Any other active systemic anti cancer therapy
3. How many patients have been treated for Triple Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti cancer therapies:
a. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
b. Atezolizumab +Nab-paclitaxel/Paclitaxel
c. Pembrolizumab
d. Sacituzumab Govitecan
e. Parp Inhibitors (Olaparib/Talazoparib)
f. Eribulin as a single agent or in combination
g. Capecitabine as a single agent
h. Platinum (e.g. carboplatin or cisplatin) as a single agent
i. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
j. Taxane and/or Anthracycline in combination
k. Any other active systemic anti-cancer therapy
Breast cancer. 251021.docx
Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the systemic anti-cancer therapies listed below?
a. Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent
b. Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
c. Abemaciclib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Carboplatin or Cisplatin as a single agent
h. Eribulin as a single agent or in combination
i. Everolimus + Exemestane
j. Fluorouracil
k. Fulvestrant as a single agent
l. Goserelin
m. Lapatinib
n. Neratinib
o. Olaparib
p. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
q. Palbociclib + Fulvestrant
r. Pertuzumab + Trastuzumab + Docetaxel
s. Platinum (e.g. carboplatin or cisplatin) as a single agent
t. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
u. Ribociclib + Fulvestrant
v. Talazoparib
w. Tamoxifen
x. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
y. Transtuzumab as a single agent
z. Trastuzumab emtansine
aa. Transtuzumab deruxtecan
bb. Any other active systemic anti-cancer therapy
Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, Letrozole) as a single agent?
Breast Cancer.310323.docx
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the latest three months for which you have data?
Name of medicine
1.1 Abemaciclib (Verzenios)
1.2 Alpelisib (Piqray)
1.3 Anastrozole (anastrozole or Arimidex)
1.4 Exemestane (exemestane or Aromasin)
1.5 Fulvestrant (fulvestrant or Faslodex)
1.6 Letrozole (letrozole or Femara)
1.7 Palbociclib (Ibrance)
1.8 Ribociclib (Kisqali)
Q2. How many patients received abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the latest three months for which you have data?
If you do not have data on early breast cancer, please state how many patients received abemaciclib (Verzenios) as adjuvant treatment.
Q3. How many patients received abemaciclib in combination with an aromatase inhibitor (anastrozole or exemestane or letrozole) for early breast cancer and locally advanced or metastatic breast cancer in the latest three months for which you have data?
3.1 Abemaciclib + aromatase inhibitor (anastrozole or exemestane or letrozole)
3.2 Abemaciclib + aromatase inhibitor (anastrozole or exemestane or letrozole)
Q4. How many patients received Olaparib (Lynparza) as adjuvant treatment for early breast cancer in the latest three months for which you have data?
If you do not have data on early breast cancer, please state how many patients received Olaparib (Lynparza) as adjuvant treatment.
Q5. How many patients were treated with the following medicines in combination in the latest three months for which you have data?
Name of combination
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)
4.2 Abemaciclib (Verzenios) + Anastrozole (anastrozole or Arimidex)
4.3 Abemaciclib (Verzenios) + Exemestane (exemestane or Aromasin)
4.4 Abemaciclib (Verzenios) + Letrozole (letrozole or Femara)
4.7 Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)
4.8 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)
4.9 Palbociclib (Ibrance) + Anastrozole (anastrozole or Arimidex)
4.10 Palbociclib (Ibrance) + Exemestane (exemestane or Aromasin)
4.11 Palbociclib (Ibrance) + Letrozole (letrozole or Femara)
4.12 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)
4.13 Ribociclib (Kisqali) + Anastrozole (anastrozole or Arimidex)
4.14 Ribociclib (Kisqali) + Exemestane (exemestane or Aromasin)
4.15 Ribociclib (Kisqali) + Letrozole (letrozole or Femara)
Q5. How many patients were treated with Olaparib (Lynparza) as monotherapy for locally advanced or metastatic breast cancer in the latest three months for which you have data?
Q6. Which of these protocols does your Trust follow when issuing prescriptions for aromatase inhibitors (anastrozole or exemestane or letrozole) prescribed in combination with CDK4/6 inhibitors (abemaciclib or palbociclib or ribociclib)?
6.1 Aromatase inhibitors and CDK4/6 inhibitors are issued together To Take Out at the hospital
6.2 Aromatase inhibitors and CDK4/6 inhibitors are issued separately. The CDK4/6 inhibitors (abemaciclib or palbociclib or ribociclib) are issued To Take Out at the hospital. The aromatase inhibitors (anastrozole or exemestane or letrozole) are issued as an FP10 to the patient or a request is sent to the GP to issue in the community
6.3 Both protocols above
Breast Cancer Services. 070417
Can you please tell me how many women were diagnosed and received treatment between the years 2014 – 2015 and 2015 – 2016. How many women in each year were treated by breast conserving surgery (lumpectomy) and how many by mastectomy. Of the women who underwent mastectomy how many received an immediate reconstruction.
Breast Cancer Surgery. 051017
Do you have data showing the outcome of breast cancer surgery at your trust in relation to?
1. Survival rates for patients five years after surgery?
1a. Can you tell me what the figure is?
1b. Do you have results for individual surgeons?
2. Survival rates for patients ten years after surgery?
2a. Can you tell me what the figure is?
2b. Do you have results for individual surgeons?
Do you have data showing the outcome of breast cancer surgery at your trust in relation to:
3. Local Recurrence rates for patients five years after mastectomy and breast conserving surgery.
3a. Can you tell me what the figures are.
3b. Do you have figures for individual surgeons?
Breast cancer treatment.110722.docx
Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
d. Atezolizumab +Nab-paclitaxel/Paclitaxel
e. Capecitabine as a single agent
f. Eribulin as a single agent or in combination
g. Everolimus + Exemestane
h. Fulvestrant as a single agent
i. Lapatinib
j. Neratinib
k. Parp Inhibitors (Olaparib/Talazoparib)
l. Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
m. Palbociclib + Fulvestrant
n. Pembrolizumab
o. Platinum (e.g. carboplatin or cisplatin) as a single agent
p. Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
q. Ribociclib + Fulvestrant
r. Sacituzumab Govitecan
s. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
t. Taxane and/or Anthracycline in combination
u. Trastuzumab as a single agent or in combination
v. Trastuzumab emtansine
w. Transtuzumab deruxtecan
x. Any other active systemic anti-cancer therapy
Q2. In the past 3 months, how many early/locally advanced breast cancer (Stages 1 to 3B) patients were treated with:
a. Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
b. Taxane and/or Anthracycline (monotherapy or in combination)
c. Any other active systemic anti-cancer therapy
Breast Cancer treatments.241219
1. Within your health trust how many patients are currently [within the past 3 months] being treated with the following for breast cancer?
Abemaciclib + aromatase inhibitor *
Abemaciclib + Fulvestrant
Alpelisib + Fulvestrant
Atezolizumab
Bevacizumab
Eribulin
Everolimus + Exemestane
Fulvestrant as a single agent
Gemcitabine + paclitaxel
Lapatinib
Neratinib
Olaparib
Palbociclib + aromatase inhibitor*
Pertuzumab + trastuzumab + docetaxel
Ribociclib + aromatase inhibitor*
Ribociclib + Fulvestrant
Talazoparib
Herceptin SC
Herceptin IV
Transtuzumab biosimilar SC
Transtuzumab biosimilar IV
Trastuzumab emtansine
Other active systemic anti-cancer therapy **
*aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole
**e.g. docetaxel, vinorelbine or capecitabine as a single agent
2. How many patients are being treated for
2a Neo-adjuvant breast cancer;
Transtuzumab total SC
Transtuzumab total IV
2.b Adjuvant breast cancer;
Transtuzumab total SC
Transtuzumab total IV
Breast radiotherapy access. 170120
1. In November and December 2019 how many requests/bookings for radical radiotherapy to the breast or chestwall were received by the radiotherapy department?
2. For those patients requested/booked in November and December 2019, how many commenced treatment?
3. Of those who received treatment what was the average length of time between the request/booking being made and the patient receiving treatment?
4. What is your average length of time for all radical radiotherapy requests/bookings to starting treatment?
Breast Screening & Breast Clinics. 031219
Breast Screening – (Asymptomatic)
1. Does the trust have a dedicated breast screening service/unit (Asymptomatic mammograms) – This could be separate from the main x-ray department?
2. If so, what is the name of the service?
3. Is this run in a static unit or on breast screening vans (Or Both)? How many vans does the service run? How many static sites does the service run?
4. How many ladies are scanned/screened on average, per day on each van/static unit?
5. Does the service scan on a 5 day or 7 day week?
6. Who has the overall responsibility for the breast screening service?
7. Please provide an organisational chart for the team/department with overall responsibility for the breast screening service
Symptomatic Mammography & Breast Clinics
1. Which department has the responsibility for symptomatic mammograms / Symptomatic Breast Lists/Clinics? Does this come under the breast screening unit or the main radiography department of the trust?
2. How many ladies are assessed on average per day in the symptomatic breast clinic?
3. Does the service scan on a 5 day or 7 day week?
4. Who has the overall responsibility for the symptomatic breast clinics?
5. Please provide an organisational chart for the team/department with overall responsibility for the symptomatic breast clinics
C-Arm provision. 250220
Please can you answer the following questions regarding the Mobile C-arm medical imaging equipment used within the Trust?
Please can you provide the following information for each piece of Mobile C-arm medical imaging equipment? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Type (Image Intensifier, Flat Panel Detector)
d. Generator Power
e. Location – Hospital Name
f. Location – Department
g. Method of Finance at Procurement
h. Initial cost of Equipment
i. Annual Maintenance cost
j. Acquisition Date
k. Planned Replacement Date
Cancelled cancer operations. 220920
I would like to know how many cancer operations have been cancelled by your NHS Trust since March 1st 2020?
Cancer care or treatment 2015-2016. 020317
1. In the years 2015 & 2016 of the patients that became resident for Cancer care/treatment with inside a hospital managed by your trust, please list the annual total for the patients as described?
2. Further to the above please also provide the annual total for those patients’ families who received a pass entitling free parking during the patients stay to reduce the financial burden on the family visiting?
Download response Cancer care or treatment 2015-2016. 020317
Cancer care or treatment 2015-2016. 020317
1. In the years 2015 & 2016 of the patients that became resident for Cancer care/treatment with inside a hospital managed by your trust, please list the annual total for the patients as described?
2. Further to the above please also provide the annual total for those patients’ families who received a pass entitling free parking during the patients stay to reduce the financial burden on the family visiting?
Download response Cancer care or treatment 2015-2016. 020317
Cancer complaints. 021121.docx
1) How many PALS enquiries and official complaints your Trust has received from patients concerned about
a) the impact of the coronavirus pandemic and your Trust’s response on their or their family member’s access to cancer treatment
b) and access to cancer testing – including tests to find out whether their or their family member’s cancer has spread, returned or occurred for the first time
2) For the five most recent PALS enquiries/official complaints received, please provide me with
a) a summary of the complaint (e.g. a patient with stage 4 lung and breast cancer has contacted PALS to complain about their chemotherapy being postponed for a month)
b) the exact wording of the complaint, with redactions to remove potentially identifying information
c) what action the Trust took in response
Cancer complaints. 170820
Could you please tell me between 1st March 2020 and the date of this email (31st July 2020):
1) How many PALS enquiries and official complaints your Trust has received from patients concerned about
a) the impact of the coronavirus pandemic and your Trust’s response on their access to cancer treatment
b) and access to cancer testing – including tests to find out whether their cancer has spread, returned or occurred for the first time
NOTE: I suggest you search for these complaints by using the keywords ‘cancer treatment’, ‘chemotherapy’, ‘cancer testing’, ‘coronavirus’, ‘COVID-19’ and other relevant terms.
2) For the five most recent PALS enquiries/official complaints received, please provide me with
a) a summary of the complaint (e.g. a patient with stage 4 lung and breast cancer has contacted PALS to complain about their chemotherapy being indefinitely suspended)
b) the exact wording of the complaint, with redactions to remove potentially identifying information
c) what action the Trust took in response
Cancer operations – Annual cancellations. 310117
In the years 2015, 2016 & 2017 from January 1st until the current date could you please provide me with the total number per month of cancer operations cancelled by Hospitals under the umbrella of your Acute NHS Trust?
Download response Cancer operations – Annual cancellations. 310117
Cancer pathway and treatment. 270821.docx
1. How many patients on the cancer pathway started treatment within the 62 days and over 62 days, from urgent GP referral to starting treatment in each month of 2020 and 2021.
2. How many patients referred under the 2 weeks wait pathway were seen within 14 days in each month of 2020 and 2021.
3. How many patients started cancer treatment in each month of:
a. 2019
b. 2020
c. 2021
Cancer patients. 240920
Please send me:
1. The total number of cancer patients receiving treatment within 62 days.
2. The total number of cancer patients waiting more than 104 days for treatment.
Cancer referrals.280521
What percentage of cancer referrals received an appointment within 12 weeks of the original referral from a GP, for each month in 2019 and for each month in 2020.
Cancer Services. 110221
1) What support do you offer for the family members of patients being treated for cancer within your NHS trust? (Support can include anything that would contribute to the emotional well-being of an individual, such as support groups, counselling or advice).
2) Does your NHS Trust provide any tailored support specifically for young people (under 25s) who have family members being treated for cancer?
3) If so, please could you provide details.
4) Are services actively offered to patients’ family members, or do they have to approach the Trust themselves to request support?
Cancer services.180522.docx
1. Over all how many Cancer trackers are employed by your Trust (WTE)?
2. Over all how many cancer MDT co-ordinators are employed by your Trust (WTE)?
3. Please provide the split of cancer tracker WTE by each tumour site of responsibility
a. Lung
b. Breast
c. Head & Neck
d. Lower GI
e. Upper GI
f. Gynaelogical
g. Children’s
h. Acute leukaemia
i. Haematological malignancies (excluding acute leukaemia)
j. Testicular
k. Urological
4. Please provide the split of cancer MDT co-coordinators WTE by each tumour site of responsibility
a. Lung
b. Breast
c. Head & Neck
d. Lower GI
e. Upper GI
f. Gynaelogical
g. Children’s
h. Acute leukaemia
i. Haematological malignancies (excluding acute leukaemia)
j. Testicular
k. Urological
5. What cancer PAS system is used by your organisation? I.e. Somerset, Infoflex other. If other please specify.
Cancer Services and Radiotherapy policies. 090620
I wonder if you could get a complete copy including finance of the Trusts Cancer Policy.
On another issue, we are trying to get hold of copies of the two trusts Radiotherapy policy.
Download response Cancer Services and Radiotherapy policies. 090620
Cancer treatment. 040817
Please provide the following information:
-The number of patients who have received NHS-funded treatment for cancer (including surgery, radiotherapy and medicines) at your trust who have also received cancer treatment privately at your trust (including directly and through private patient units located on trust premises), providing an annual total for each of the last five financial years.
-Where cancer treatment was provided privately for patients at your trust in addition to NHS-funded cancer treatment, the total value of treatments received, providing an annual total for each of the last five financial years.
-Where cancer treatment was provided privately for patients at your trust in addition to NHS-funded cancer treatment, the five cancer treatments that were most commonly provided privately, providing an annual total for each of the last five financial years.
-Where cancer treatment was provided privately for patients at your trust in addition to NHS-funded cancer treatment, please include a breakdown of patient numbers and value of treatment by type of cancer.
-The number of patients who have received NHS-funded treatment for cancer (including surgery, radiotherapy and medicines) at your trust who have also received cancer treatment from any private provider, providing an annual total for each of the last five financial years.
Cancer treatment. 081117
Please provide the following information:
-The number of patients who have received NHS-funded treatment for cancer (including surgery, radiotherapy and medicines) at your trust who have also received cancer treatment privately at your trust (including directly and through private patient units located on trust premises), providing an annual total for each of the last five financial years.
-Where cancer treatment was provided privately for patients at your trust in addition to NHS-funded cancer treatment, the total value of treatments received, providing an annual total for each of the last five financial years.
-Where cancer treatment was provided privately for patients at your trust in addition to NHS-funded cancer treatment, the five cancer treatments that were most commonly provided privately, providing an annual total for each of the last five financial years.
-Where cancer treatment was provided privately for patients at your trust in addition to NHS-funded cancer treatment, please include a breakdown of patient numbers and value of treatment by type of cancer.
-The number of patients who have received NHS-funded treatment for cancer (including surgery, radiotherapy and medicines) at your trust who have also received cancer treatment from any private provider, providing an annual total for each of the last five financial years.
Cancer treatment. 181019
1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the following
Paclitaxel
Gemcitabine
Osimertinib
Carboplatin and Pemetrexed
Cisplatin and Pemetrexed
Pembrolizumab monotherapy
Pembrolizumab in combination
Atezolizumab
Nivolumab
Other active systemic anti-cancer therapy
2a – Does your Health Trust participate in any ongoing clinical trails for the treatment of Metastatic Non Small Cell Lung cancer patients ?
2b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
3 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following:
Cetuximab not in combination with FOLFIRIE or FOLOX
Cetuximab in combination with FOLFIRI
Cetuximab in combination with FOLFOX
Panitumumab not in combination with FOLFIRI or FOLFOX
Panitumumab in combination with FOLFIRI
Panitumumab in combination with FOLFOX
Nivolumab
Aflibercept
Bevacizumab
Ramucirumab
Regorafenib
Sorafenib
Other active systemic anti-cancer therapy (eg 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU)
3a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Colorectal cancer patients ?
3b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
4 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Head and Neck Cancer (Squamous Cell Carcinoma) ?
4a – If your Trust is able to split these patients, how many are locally advanced and how many are recurrent and or metastatic Head and Neck Cancer patients ?
Locally advanced
Recurrent metastatic
Unable to split
4b – Of the Head and Neck cancer patients please split by their current drug treatment (if you are unable to split by locally advanced and recurrent please state the total)
Carboplatin (only or in combination with 5-FU)
Cisplatin (only or in combination with 5-FU)
Cetuximab with / without chemotherapy
Cetuximab with radiotherapy
Pembrolizumab monotherapy
Pembrolizumab with chemotherapy
Nivolumab
Docetaxel (only or in combination with 5-FU)
Fluorouracil (5-FU)
Radiotherapy only
Other
4c – Does your Health Trust participate in any ongoing clinical trials for the treatment of Head and Neck cancer patients ?
4d – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
5 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Carcinoma UCC) with the following:
Cisplatin single agent
Cisplatin in combination with another agent
Carboplatin single agent
Carboplatin in combination with another agent
Nivolumab
Pembrolizumab
Atezolizumab
Other active systemic anti-cancer therapy
5a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients ?
5b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
Cancer treatment. 181019
1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the following
Paclitaxel
Gemcitabine
Osimertinib
Carboplatin and Pemetrexed
Cisplatin and Pemetrexed
Pembrolizumab monotherapy
Pembrolizumab in combination
Atezolizumab
Nivolumab
Other active systemic anti-cancer therapy
2a – Does your Health Trust participate in any ongoing clinical trails for the treatment of Metastatic Non Small Cell Lung cancer patients ?
2b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
3 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following:
Cetuximab not in combination with FOLFIRIE or FOLOX
Cetuximab in combination with FOLFIRI
Cetuximab in combination with FOLFOX
Panitumumab not in combination with FOLFIRI or FOLFOX
Panitumumab in combination with FOLFIRI
Panitumumab in combination with FOLFOX
Nivolumab
Aflibercept
Bevacizumab
Ramucirumab
Regorafenib
Sorafenib
Other active systemic anti-cancer therapy (e.g. 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU)
3a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Colorectal cancer patients ?
3b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
4 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Head and Neck Cancer (Squamous Cell Carcinoma) ?
4a – If your Trust is able to split these patients, how many are locally advanced and how many are recurrent and or metastatic Head and Neck Cancer patients ?
Locally advanced
Recurrent metastatic
Unable to split
4b – Of the Head and Neck cancer patients please split by their current drug treatment (if you are unable to split by locally advanced and recurrent please state the total)
Carboplatin (only or in combination with 5-FU)
Cisplatin (only or in combination with 5-FU)
Cetuximab with / without chemotherapy
Cetuximab with radiotherapy
Pembrolizumab monotherapy
Pembrolizumab with chemotherapy
Nivolumab
Docetaxel (only or in combination with 5-FU)
Fluorouracil (5-FU)
Radiotherapy only
Other
4c – Does your Health Trust participate in any ongoing clinical trials for the treatment of Head and Neck cancer patients ?
4d – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
5 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Carcinoma UCC) with the following:
Cisplatin single agent
Cisplatin in combination with another agent
Carboplatin single agent
Carboplatin in combination with another agent
Nivolumab
Pembrolizumab
Atezolizumab
Other active systemic anti-cancer therapy
5a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients ?
5b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
Cancer treatment 2010 – 2016. 250917
How many patients were treated for cancer by your trust each year since 2010?
How many of these patients in each year were ‘self-funders’ or paid the trust for their treatment, either personally or through an insurer and other third party?
What was the total amount of money raised in this way for each year?
How many patients for each year were ordinary NHS patients, ie patients whose care was free at the point of delivery?
How many designated cancer wards does your trust have for each year since 2010?
How many wards, if any, were for ‘self-funders’ and how many were for ordinary NHS patients for each year since 2010?
Cancer treatment. 291118
You asked:
1. In the past 3 months, how many mNSCLC patients were treated with?
Afatinib
Atezolizumab
Becacizumab
Ceritinib
Crizotinib
Erlotinib
Gefitinib
Nitendaninb
Nivolumab
Pembrolizumab
Pemetrexed
Ramucirumab
Metastatic hepatocellular carcinoma
2. In the past three months, how many patients were treated with?
Bevacizumab
Cisplatin
Doxorubicin
Everolimus
Lapatinib
Levantinib
Regorafenib
Sorafenib
Sunitinib
TACE
Other active systemic anti-cancer therapy
Metastatic Thyroid Cancer
3. In the past three months, how many patients were treated with?
Axitinib
Cabozantinib
Levantinib
Pazopanib
Sorafenib
Sunitinib
Vandetanib
Others
Cancer Treatments. 040320
1a – How many melanoma patients undergoing treatment are BRAF+?
1b – In the past 3 months, how many melanoma patients were treated with the following:
Bevacizumab
Cobimetinib
Dabrafenib
Dabrafenib AND trametinib
Dacarbazine
Encorafenib AND binimetinib
Ipilimumab
Ipilimumab AND Nivolumab
Nivolumab
Pembrolizumab
Trametinib
Vemurafenib
Vemurafenib AND Cobimetinib
Other active systemic anti-cancer therapy
Palliative care
1c – In the past 3 months how many patients were seen who had stage III resectable melanoma
1d – Of all stage III patients seen, how many received a complete resection?
2 – In the past 3 months, how many Squamous Cell Non-small cell lung cancer (SqNSCLC) patients were treated with:
Afatinib
Atezolizumab monotherapy
Bevacizumab
Docetaxel monotherapy
Durvalumab
Erlotinib
Gemcitabine
Necitumumab
Nivolumab
Paclitaxel
Pembrolizumab monotherapy
Pembrolizumab chemo in combination
Pemetrexed
Ramucirumab
Vinorelbine and cisplatin / carboplatin
Other active systemic anti-cancer therapy [please state]
Palliative care only
3 – In the past 3 months, how many Non Squamous Cell Non-small cell lung cancer (Non SqNSCLC) patients were treated with:
Afatinib
Alectinib
Atezolizumab mono
Atezolizumab + bevacizumab + carboplatin + paclitaxel
Bevacizumab
Brigatinib
Ceritinib
Crizotinib
Dacomitinib
Docetaxel monotherapy
Erlotinib
Gefitinib
Nintedanib with docetaxel
Nivolumab
Osimertinib
Paclitaxel
Pembrolizumab monotherapy
Pembrolizumab chemo in combination
Pemetrexed with carboplatin
Pemetrexed with cisplatin
Ramucirumab
Other active systemic anti-cancer therapy [please state]
Palliative care only
Cancer treatments. 051121.docx
1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:
a. Total number of head and neck cancer patients
b. Number of locally advanced head and neck cancer patients
c. Number of recurrent and/or metastatic head and neck cancer patients
3. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?
a. Aflibercept
b. Bevacizumab
c. Capecitabine
d. CAPIRI
e. CAPOX (XELOX)
f. Cetuximab in combination with FOLFIRI
g. Cetuximab in combination with FOLFOX
h. Cetuximab not in combination with FOLFIRI or FOLFOX
i. Irinotecan only
j. FOLFIRI
k. FOLFOX
l. Fluorouracil (5FU) only
m. Oxaliplatin only
n. Panitumumab in combination with FOLFIRI
o. Panitumumab in combination with FOLFOX
p. Panitumumab not in combination with FOLFIRI or FOLFOX
q. Pembrolizumab
r. Nivolumab
s. Raltitrexed
t. Ramucirumab
u. Regorafenib
v. Sorafenib
w. Other SACT
Cancer treatments. 210920
1. Does your trust treat adult multiple myeloma [MM] ? – if you refer your multiple myeloma patients to another centre, please state which.
2. If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;
· Bortezomib [Velcade]
· Carfilzomib [Kyprolis]
· Ixazomib [Ninlaro]
· Lenalidomide [Revlimid]
· Daratumumab [Darzalex]
· Melphalan, prednisolone and thalidomide (known as MPT)
· Cyclophosphamide, thalidomide and dexamethasone (known as CTD)
· Pomalidomide [Imnovid]
3. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?
If possible, how many CLL patients treated were new to therapy in the past 3 months?
4. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;
· Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR)
· Bendamustine and rituximab (known as BR)
· Ibrutinib [Imbruvica]
· Chlorambucil
· Venetoclax
· Obinutuzumab
· Idelalisib
· Fludarabine and rituximab (known as FR)
· High-dose prednisone and rituximab
· Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)
· Alemtuzumab (Campath) with rituximab
Cancer treatments. 220120
1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?
2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?
Locally advanced
Recurrent metastatic
Unknown
3. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?
Carboplatin (only or in combination with 5-FU)
Cisplatin (only or in combination with 5-FU)
Cetuximab with/without chemotherapy
Cetuximab with radiotherapy
Pembrolizumab monotherapy
Pembrolizumab with chemotherapy
Nivolumab
Docetaxel (only or in combination with 5-FU)
Fluorouracil (5FU)
Radiotherapy only
Other
Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
4. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];
Aflibercept
Bevacizumab
Capecitabine
CAPIRI
CAPOX
Cetuximab not in combination with FOLFIRI or FOLFOX
Cetuximab in combination with FOLFIRI
Cetuximab in combination with FOLFOX
Irinotecan
FOLFIRI
FOLFOX
Oxaliplatin
Panitumumab not in combination with FOLFIRI or FOLFOX
Panitumumab in combination with FOLFIRI
Panitumumab in combination with FOLFOX
Nivolumab
Raltitrexed
Ramucirumab
Regorafenib
Sorafenib
5FU only
Tegafur Uracil + 5FU
Trifluridine–tipiracil
XELOX
Other
5. Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma :
Sunitinib
Avelumab + Axitinib
Axinitib
Cabozantinib
Everolimus
Lenvantinib + Everolimus
Nivolumab
Nivolumab + Ipilimumab
Pazopanib
Pembrolizumab + Axitinib
Sunitinib
Temsirolimus
Tivozanib
6. Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
Cancer treatments. 241019
1 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Kidney Carcinoma (Renal Cell – RCC);
If you do not treat, where do you refer these patients?
2 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Melanoma?
If you do not treat, where do you refer these patients?
2a – In the past 3 months, how many Melanoma patients were BRAF+?
3 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Liver Cancer (Hepatic Cell – HCC);
If you do not treat, where do you refer these patients?
4 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Thyroid Cancer;
If you do not treat, where do you refer these patients?
Cancer treatments. 260620
1. In the past 3 months, how many metastatic melanoma patients were treated by your Trust?
a. Dabrafenib
b. Dabrafenib + Trametinib
c. Densoumab
d. Encorafenib + Binimetinib
e. Ipilimumab
f. Ipilimumab + Nivolumab
g. Nivolumab
h. Pembrolizumab
i. Trametinib
j. Vemurafenib
k. Vemurafenib + Cobimetinib
l. Other active systemic anti-cancer therapy
Palliative care only
2. Within your health trust how many patients are currently [within the past 3 months] being treated for metastatic Non-small-cell lung cancer (NSCLC) with the following:
a. Afatinib
b. Atezolizumab monotherapy or combination
c. Brigatinib
d. Ceretinib
e. Crizotinib
f. Docetaxel monotherapy or combination
g. Erlotinib
h. Gefitinib
i. Gemcitabine
j. Nitendanib + docetaxel
k. Nivolumab
l. Osimertinib
m. Paclitaxel
n. Pembrolizumab monotherapy
o. Pembrolizumab chemo in combination
p. Pembrolizumab monotherapy
q. Pemetrexed monotherapy or combination
r. Ramucirumab
s. Vinorelbine monotherapy or combination
t. Other active systemic anti-cancer therapy
u. Palliative care only
3. Out of the metastatic NSCLC patients currently [within the past 3 months] being treated, are you able to provide the number of patients being treated for Squamous Cell Non-small-cell lung cancer (SqNSCLC ) with the following products?
a. Afatinib
b. Atezolizumab monotherapy or combination
c. Brigatinib
d. Ceretinib
e. Crizotinib
f. Docetaxel monotherapy or combination
g. Erlotinib
h. Gefitinib
i. Gemcitabine
j. Nitendanib + docetaxel
k. Nivolumab
l. Osimertinib
m. Paclitaxel
n. Pembrolizumab monotherapy
o. Pembrolizumab chemo in combination
p. Pembrolizumab monotherapy
q. Pemetrexed monotherapy or combination
r. Ramucirumab
s. Vinorelbine mono or combination
t. Other active systemic anti-cancer therapy
u. Palliative care only
Cancer treatments. 291020
1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?
2. Of these patients how many are locally advanced, recurrent, metastatic and unresectable head and neck cancer patients?
a. Locally advanced
b. Recurrent
c. Metastatic
d. Unresectable
e. Unknown
3. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?
a. Carboplatin (only or in combination with 5-FU)
b. Cisplatin (only or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (only or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
3b. Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
4. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];
a. Aflibercept
b. Bevacizumab
c. Capecitabine
d. CAPIRI
e. CAPOX
f. Cetuximab not in combination with FOLFIRI or FOLFOX
g. Cetuximab in combination with FOLFIRI
h. Cetuximab in combination with FOLFOX
i. Irinotecan
j. FOLFIRI
k. FOLFOX
l. Oxaliplatin
m. Panitumumab not in combination with FOLFIRI or FOLFOX
n. Panitumumab in combination with FOLFIRI
o. Panitumumab in combination with FOLFOX
p. Nivolumab
q. Raltitrexed
r. Ramucirumab
s. Regorafenib
t. Sorafenib
u. 5FU only
v. Tegafur Uracil + 5FU
w. Trifluridine–tipiracil
x. XELOX
y. Other
5. Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma:
a. Sunitinib
b. Avelumab + Axitinib
c. Axinitib
d. Cabozantinib
e. Everolimus
f. Lenvantinib + Everolimus
g. Nivolumab
h. Nivolumab + Ipilimumab
i. Pazopanib
j. Pembrolizumab + Axitinib
k. Sunitinib
l. Temsirolimus
m. Tivozanib
5b. Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
Cancer two week wait referral.110822.docx
Please can you let me know what your success rate in meeting the cancer two week wait referral is? What % of patients referred are actually seen within the two weeks?
Cancers. 050718
1. How many individuals diagnosed in the last 5 years with prostate cancer?
2. How many deaths attributable to prostate cancer in the last 5 years?
3. How many individuals diagnosed in the last 5 years with breast cancer?
4. How many deaths attributable to breast cancer in the last 5 years?
5. How many individuals diagnosed with brain cancer in the last 5 years?
6. Of those diagnosed with brain cancer how many with GBM4?
7. How many deaths attributable to brain cancer in the last 5 years?
8. Of those deaths how many due to GBM4?
9. How many children diagnosed with brain cancer in the last 5 years?
10. How many child deaths attributable to brain cancer in the last 5 years?
Download response Cancers. 050718
Carcinoma and melanoma
1. The number of patients with NON SMALL CELL LUNG CARCINOMA (Stage IIIB/Stage IV) treated in the last 6 months with the following:
Afatinib (Giotrif)
Ceritinib (Zykadia)
Crizotinib (Xalkori)
Erlotinib (Tarceva)
Gefitinib (Iressa)
Pemetrexed (Alimta)
Nivolumab (Opdivo)
Nintedanib (Vargatef)
2. The number of patients with METASTATIC MELANOMA Stage IV (advanced or metastatic), treated in the last 6 months with the following:
Ipilimumab (Yervoy)
Nivolumab (Opdivo)
Ipilimumab AND Nivolumab
Pembrolizumab (Keytruda)
Vemurafenib (Zelboraf)
Vemurafenib AND Cobimetinib
Dabrafenib (Taflinar)
Trametinib (Mekinist)
Dabrafenib AND trametinib
Dacarbazine (DTIC)
For the period 1/1/2016-30/06/2016
Cervical cancer and Endometrial cancer.171022.docx
Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for the following conditions?
a. Cervical cancer
b. Endometrial cancer
In case you do not provide SACT treatments for either of the above conditions, which other trust do you refer patients to for these treatments?
Q2. How many patients were treated for cervical cancer in the past 6 months with the following treatments:
a. Paclitaxel in combination with Platinum and/or Bevacizumab
b. Pembrolizumab in combination with Platinum and/or Bevacizumab
c. Platinum standalone or in combination with Bevacizumab
d. Toptecan in combination with Platinum and/or Bevacizumab
e. Any other SACT
Q3. How many patients were treated for endometrial cancer in the past 6 months with the following treatments:
a. Dostarlimab
b. Hormone therapy (Progesterone or Letrozole)
c. Pembrolizumab in combination with Lenvatinib
d. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
e. Any other SACT
Q4. How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months:
a. Hormone therapy (Progesterone or Letrozole)
b. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
c. Any other SACT
Q5. Does your trust participate in any clinical trials for the treatment of cervical cancer? If so, can you please provide the name of each trial and the number of patients taking part.
Q6. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.
Chemotherapies and anything specific to carboplatin. 170322.docx
We are seeking information for both general advice relevant to all chemotherapies and anything specific to carboplatin.
As part of this guidance and information we are seeking data including but not limited to:
1. The % and number of patients having the kidney function tests before chemo has begun and after it has begun, with associated outcomes, including mortality rates, split by chemo cycle stage undertaken.
2. The % and number of patients whose GFR tests taken prior to chemo starting, have indicated their kidneys were not functioning sufficiently to enable progression of chemotherapy.
3. It would then be helpful to understand which of those patients guided chemo cannot be progressed, did not progress and those that did (going against doctors wishes if that is possible to do?) and their outcomes.
It needs to reflect a time pre covid that is representative of more ‘normal’ time in treatment of cancers patients and also post pandemic peak when hospitals have been ramping up recovery.
We’d therefore be looking at two periods of data 1) 12 rolling months, February 2018 to Feb 2019 and then 5 months May 2021 to September 2021.
In addition to our questions below we’d like:
4. The specific data on number of patients during those periods who did not have a kidney function test prior to the first chemo cycle e.g total patients given chemo and not given chemo and the numbers of those that had gfr test before and those that did not.
5. For those patients that did not, also confirm of any subsequent kidney failure experienced and at what stage of chemo it was experienced.
6. To make a fair comparison, we’d welcome data of those who experienced kidney failure from chemo and at what stage chemo this happened – who undertook a gfr test prior and whose kidneys were deemed fit enough to withstand chemo treatment.
Chemotherapies and anything specific to carboplatin. 170322.docx
Chronic Myeloid Leukaemia (CML) 2015.
1. In your organisation, how many patients diagnosed with Chronic Myeloid Leukaemia (CML) have been treated in calendar year 2015?
2. Of these patients, how many are currently being treated with each of the following tyrosine kinase inhibitors (TKIs)?
· Dasatinib (Sprycel)
· Imatinib (Glivec)
· Nilotinib (Tasigna)
· Ponatinib (Iclusig)
· Bosutinib (Bosulif)
3. If possible, of these patients on a TKI, how many have had treatment with a previous TKI?
4. In your organisation, how many patients diagnosed with Philadelphia positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) have been treated in calendar year 2015?
5. Of these patients how many are currently being treated with each of the following TKIs?
· Dasatinib (Sprycel)
· Imatinib (Glivec)
· Nilotinib (Tasigna)
· Ponatinib (Iclusig)
· Bosutinib (Bosulif)
· Other (i.e. not on a TKI)
Download response Chronic Myeloid Leukaemia (CML) 2015 190416
Clinical Imaging Equipment. 150322.docx
A list of the current medical imaging equipment held by the Trust across all hospital sites, providing the following information:
Q1: What is your overall spend on medical imaging products and services for the current year?
Q2: How much do you spend on each modality requested below for the current year:
a) Computed Tomography (CT)
b) Magnetic Resonance Imaging (MRI)
c) Ultrasound
d) Fluoroscopy
e) Mammography
f) Nuclear
g) Mobile X-ray
h) Static X-ray
Q3: A list of the current equipment held by the Trust across all hospital sites for each of the following:
a) Supplier
b) Product
c) Contract start date
d) Contract expiry date
e) Number of devices
f) Age of product
Example Response: 3 x Siemens Acuson SC2000, Initial cost £ 29,000, Contract start date 10/02/2022 Contract end date 10/02/2026, 6 years old
Q4: Annual cost of maintenance of equipment
Q5: What percentage of your imaging equipment has an element of Artificial Intelligence?
Clinical Insourcing and Outsourcing. 111121.docx
1. Do you insource clinical services and if so, which ones?
2. Do you have any current contracts in place with a company for these insourced services, and if so which services?
3. How much have you spent on insourcing clinical services per annum for the past 3 years?
4. Do you outsource clinical services and if so, which ones?
5. Do you have any current contracts in place with a company for these outsourced services, and if so which services?
6. How much have you spent on outsourcing clinical services per annum for the past 3 years?
Download response Clinical Insourcing and Outsourcing. 111121.docx
Colonoscopies and colorectal cancer. 160322.docx
1. The total number of colonoscopies undertaken in Maidstone and Tunbridge Wells NHS Trust for the period
i) April 2019-March 2020
ii) April 2020-March 2021.
2. The total number of people diagnosed with colorectal cancer (or other clearly defined indications) within Maidstone and Tunbridge Wells NHS Trust for the period
i) April 2019-March 2020
ii) April 2020-March 2021.
3. The average adenoma detection rate (ADR) and post-colonoscopy colorectal cancer rate (PCCRC) for Maidstone and Tunbridge Wells NHS Trust for the period
i) April 2019-March 2020
ii) April 2020-March 2021
4. The total number of cancers detected, against cancer stage (e.g. 1,2,3 or 4), against colonoscopies performed in the prior three years within Maidstone and Tunbridge Wells NHS Trust in the period
i) April 2019-March 2020
ii) April 2020-March 2021
Colorectal Cancer. 280520
Name of organisation (NHS Trust):
Please list the acute hospital site/s within the Trust:
PLEASE ANSWER THE FOLLOWING QUESTIONS FOR EACH ACUTE HOSPITAL SITE LISTED ABOVE
HOSPITAL AND SERVICES
1. The hospital would be described as a:
District general
Teaching hospital
2. Total number of inpatient beds at this hospital:
3. Does the hospital provide colorectal cancer services
4. Is the hospital a specialist colorectal cancer care centre
5. How many dietitians are employed in the hospital (please answer in FTE units):
6. How many dietitians are commissioned to provide dietetic services in each cancer type (please answer in FTE units. Where no time is commissioned, please enter 0):
7. a. Is there any band 5, general dietetic cover for colorectal cancer care
b. If yes, how many dietitians are commissioned (please answer in FTE units):
8. If there is dietetic time commissioned for colorectal cancer care at the hospital, does this include outpatient or community follow up after discharge?
9. If dietetic time is commissioned for colorectal cancer care, where does the funding come from?
Colorectal cancer [CRC]. 091220
1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?
2. Of these patients how many are locally advanced, recurrent, metastatic and unresectable head and neck cancer patients?
Locally advanced
Recurrent
Metastatic
Unresectable
Unknown
3. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?
Carboplatin (only or in combination with 5-FU)
Cisplatin (only or in combination with 5-FU)
Cetuximab with/without chemotherapy
Cetuximab with radiotherapy
Pembrolizumab monotherapy
Pembrolizumab with chemotherapy
Nivolumab
Docetaxel (only or in combination with 5-FU)
Fluorouracil (5FU)
Radiotherapy only
Other
4. Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
5. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];
Aflibercept
Bevacizumab
Capecitabine
CAPIRI
CAPOX
Cetuximab not in combination with FOLFIRI or FOLFOX
Cetuximab in combination with FOLFIRI
Cetuximab in combination with FOLFOX
Irinotecan
FOLFIRI
FOLFOX
Oxaliplatin
Panitumumab not in combination with FOLFIRI or FOLFOX
Panitumumab in combination with FOLFIRI
Panitumumab in combination with FOLFOX
Nivolumab
Raltitrexed
Ramucirumab
Regorafenib
Sorafenib
5FU only
Tegafur Uracil + 5FU
Trifluridine–tipiracil
XELOX
Other
6. Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma :
Sunitinib
Avelumab + Axitinib
Axinitib
Cabozantinib
Everolimus
Lenvantinib + Everolimus
Nivolumab
Nivolumab + Ipilimumab
Pazopanib
Pembrolizumab + Axitinib
Sunitinib
Temsirolimus
Tivozanib
7. Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
Colorectal cancer [CRC].160922.docx
Q1. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?
a. Aflibercept
b. Bevacizumab
c. Capecitabine
d. CAPIRI
e. CAPOX (XELOX)
f. Cetuximab in combination with FOLFIRI
g. Cetuximab in combination with FOLFOX
h. Cetuximab not in combination with FOLFIRI or FOLFOX
i. Irinotecan only
j. FOLFIRI
k. FOLFOX
l. Fluorouracil (5FU) only
m. Oxaliplatin only
n. Panitumumab in combination with FOLFIRI
o. Panitumumab in combination with FOLFOX
p. Panitumumab not in combination with FOLFIRI or FOLFOX
q. Pembrolizumab
r. Nivolumab
s. Raltitrexed
t. Ramucirumab
u. Regorafenib
v. Sorafenib
w. Other SACT
Q2. In the last 3 months, how many patients has your trust treated (for any condition) with the following treatments
a. Avatrombopag
b. Eltrombopag
c. Fostamatinib
d. Romiplostim
Q3. In the last 3 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3)?
Q4. In the last 3 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3) ONLY with the following treatments:
a. Avatrombopag
b. Mycophenolate mofetil
c. Rituximab
d. Surgery (splenectomy)
Colposcopy appointments. 140421
I was wondering if you’d be able to share with me a copy of the letter and information leaflet that you send out to patients who receive a colposcopy appointment.
Community Diagnostic Centre.080922.docx
Please could you provide me with a copy of the business case for the Trust’s Community Diagnostic Centre project, including the capital budget for the entire project.
Complementary and Alternative Medicine (CAM) services.101022.docx
I am writing to obtain information, under the Freedom of Information Act, about your Trust’s funding of Complementary and Alternative Medicine (CAM) services they provided.
To outline my query as clearly as possible, I am requesting:
1. How much the Trust has spent on CAM services for the following financial years:
a. 2019-20
b. 2020-21
c. 2021-22
This includes salaries for those employed to carry out these services, costs of medicine, equipment and any additional costs involved.
2. A list of all services provided under CAM.
Complementary and Alternative Medicine (CAM) services.101022.docx
Consultations. 240521
1. What percentage of consultations were carried out in April 2021 via:
a. Phone
b. Video
c. Face-to-face
2. Did you carry out any patient satisfaction survey on each of the channels in April 2021:
a. Phone
b. Video
c. Face-to-Face
3. Did you introduce digital services (either as new services or expanding into new departments) as a response to the pandemic?
Yes (highlight below):
a. Telephone consultations
b. Video consultations
c. Online appointment booking/management
d. E-prescription services
4. Who are your suppliers for:
a. Telephone consultations
b. Video consultations
c. Online appointment booking/management
d. E-prescription services
5. What are the most common barriers to technology use within your trust?
a. The service requires face-to-face interactions
b. The staff member is unable to use the technology
c. The patient is unable to use the technology
d. Lack of funding
e. Other (please explain)
6. Are you collecting patient feedback following interactions with the digital services you offer?
a. Yes – feedback obtained for all services
b. Feedback obtained for some services:
c. Telephone consultations
d. Video consultations
e. Online appointment booking/management
f. E-prescription services
g. No – we are not collecting this feedback
h. If no – do you plan to introduce this feedback data collection in the next six months? yes/no
i. If yes, how do you collect feedback?
7. Did you stop your FFT during the pandemic when the requirement to submit data was paused?
a. If yes, why?
b. If no, why?
8. Will you be deploying PIFU?
9. Will you be collecting feedback on PIFU?
10. Who is your FFT supplier?
11. If the FFT contract is outsourced, when was the contract initiated?
12. When does the FFT contract with your current supplier end?
13. What is the expected value of this contract (£)?
Coronary CT angiography scans. 270918
1) How many Coronary CT angiography scans were performed in the trust in the financial year 2011-12?
2) How many Coronary CT angiography scans were performed in the trust in the financial year 2012-13?
3) How many Coronary CT angiography scans were performed in the trust in the financial year 2013-14?
4) How many Coronary CT angiography scans were performed in the trust in the financial year 2014-15?
5) How many Coronary CT angiography scans were performed in the trust in the financial year 2015-16?
CT and MRI machines.311022.docx
1) How many of each of the following machines do you have in use:
i) CT
ii) MRI
iii) X-ray
2) How many of each of the following machines are you using that are older than ten years old:
i) CT
ii) MRI
iii) X-ray
3) How old is your oldest in-use machine for each of:
i) CT
ii) MRI
iii) X-ray
4) How many of each of the following machines have you purchased in the past year:
i) CT
ii) MRI
iii) X-ray
5) How much did you spend repairing CT, MRI and X-ray machines in each of the past three years?
CT, MRI and Ultrasound Scanners and X-Ray machines. 170921.docx
1) The number of CT scanners in your Trust, where relevant please provide a number for each hospital.
2) The number of MRI scanners in your Trust, where relevant please provide a number for each hospital.
3) The number of ultrasound scanners in your Trust, where relevant please provide a number for each hospital.
4) The number of x-ray machines in your Trust, where relevant please provide a number for each hospital.
5) For each of the items 1-4, please also provide the number of machines that are more than 10 years old and if available the year that the machine was purchased.
Download response CT, MRI and Ultrasound Scanners and X-Ray machines. 170921.docx
CTCL (cutaneous T cell lymphoma) treatment centres. 110322.docx
We are looking to produce a map of the CTCL (cutaneous T cell lymphoma) treatment centres in the UK.
To help with this, please could you provide the following:
1. Which centre/s in your NHS Trust offer treatment for CTCL, if any
2. The type of CTCL treatment these centres offer (TSEB or ECP)
3. A contact phone number for referrals for each centre
CTCL (cutaneous T cell lymphoma) treatment centres. 110322.docx
Cutaneous Squamous Cell Carcinoma. 270220
1. How many patients with cutaneous squamous cell carcinoma have you treated?
2. How many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma have you treated?
3. Of these how many are not candidates for curative surgery or curative radiation?
4. In the past 3 months, how many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation have you treated with the following;
Libtayo (cemiplimab)
Non curative surgery only
Non curative surgery + chemotherapy*
Non curative surgery + radiotherapy
Non curative surgery + chemotherapy* + radiotherapy
Chemotherapy* only
Chemotherapy* + radiotherapy
Non curative radiotherapy only
No treatment
Palliative Care / Best Supportive care
Other [please state]
*chemotherapy such as cisplatin, doxorubicin, 5-fluorouracil (5-FU), capecitabine, topotecan, or etoposide
5. Does your trust treat adult multiple myeloma [MM]? – if you refer your multiple myeloma patients to another centre, please state which.
6. If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;
Bortezomib [Velcade]
Carfilzomib [Kyprolis]
Ixazomib [Ninlaro]
Lenalidomide [Revlimid]
Daratumumab [Darzalex]
Melphalan, prednisolone and thalidomide (known as MPT)
Cyclophosphamide, thalidomide and dexamethasone (known as CTD)
Pomalidomide [Imnovid]
7. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?
If possible how many CLL patients treated were new to therapy in the past 3 months?
8 How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;
Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR)
Bendamustine and rituximab (known as BR)
Ibrutinib [Imbruvica]
Chlorambucil
Venetoclax
Obinutuzumab
Idelalisib
Fludarabine and rituximab (known as FR)
High-dose prednisone and rituximab
Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)
Alemtuzumab (Campath) with rituximab
Cutaneous Squamous Cell Carcinoma. 271119
Question 1 – How many adult patients with Cutaneous Squamous Cell Carcinoma have you seen / treated (example Surgery, Radiotherapy, Chemotherapy or combinations of these) in the last 6 months?
Question 2 – How many adult patients with locally advanced (patients with Perineural invasion and local Lymphovascular or Bone involvement) or Metastatic Cutaneous Squamous Cell Carcinoma (patients with both local and distant Nodal involvement, as well as any other organ involvement) have you seen / treated (example Surgery, Radiotherapy, Chemotherapy or combinations of these) in the last 6 months?
Question 3 – Of these how many are not candidates for Curative surgery or Curative Radiation? *
Question 4 – In the past 6 months, how many adult patients with locally advanced or metastatic Cutaneous Squamous Cell Carcinoma have you treated with the following:
Question 5 – Are you participating in any clinical trials for Cutaneous Squamous Cell Carcinoma (CSCC)?
If yes, please state which?
*Example of factors to consider when deciding if locally advanced patients are suitable candidates for surgery: Disease recurrence after two or more surgical procedures and the treating clinicians expected that curative resection would be unlikely
CSCC in a anatomically challenging location where surgery would result in substantial complications or deformity or dysfunction significant local invasion that precludes complete resection
* Example of factors to consider when deciding if locally advanced patients are suitable candidates for radiation:
CSCC in a anatomically challenging location where radiation would be associated with unacceptable toxicity risk in context of the patients overall condition
Clinical judgement that tumour might not respond to RT
Factors / conditions contradicting for RT
Prior treatment with RT for CSCC, and further RT would exceed the threshold of acceptable cumulative does
** Chemotherapy such as Cisplatin, Doxorubicin, 5-Fluorouracil (5-FU), Capecitabine, Topotecan, Methotrexate or Etoposide
Da vinchi surgical robots. 100419
1. The number of da Vinci surgical robots in use throughout your trust and the number of each model (e.g. Si, X, Xi, SP)
2. The number of yearly procedures carried out using da Vinci systems with a breakdown by procedure type for the last 5 years
3. A breakdown of the cost per procedure using da Vinci systems including instrumentation, servicing, disposable accessories, sterilisation costs, depreciation and other costs incurred
4. The upfront cost of da Vinci system instruments per surgery or on a per instrument basis
5. Historical number/rate of occurrence of incidences where cross infection has resulted from improper sterilisation and the number of associated adverse events
6. The rate of surgical site infections associated with procedures where a da Vinci system has been used.
Dabrafenib + Trametinib.050722.docx
Please answer these questions relating to the usage of Dabrafenib + Trametinib in cancer treatment.
A) Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:
i) Metastatic Melanoma
ii) Adjuvant Melanoma
iii) BRAF mutated Lung Cancer
Dabrafenib + Trametinib.110423.docx
A) Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:
i) Metastatic Melanoma
ii) Adjuvant Melanoma
iii) BRAF mutated Lung Cancer
Dental X-Ray equipment. 210519
Please can you answer the following questions regarding the Dental X-Ray equipment used within the Trust?
1. Please can you provide the following information for each piece of Dental X-Ray equipment within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Location – Hospital Name or Site Name
d. Department equipment is primarily used in
e. Method of Finance at Procurement (Trust/Lease/MES/Charity/PFI)
f. Initial cost of Equipment
g. Annual Maintenance cost
h. Acquisition Date
i. Planned Replacement Date
2. Please can you provide the following information for each Cone Beam CT Imaging equipment within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Location – Hospital Name or Site Name
d. Department equipment is primarily used in
e. Method of Finance at Procurement (Trust/Lease/MES/Charity/PFI)
f. Initial cost of Equipment
g. Annual Maintenance cost
h. Acquisition Date
i. Planned Replacement Date
Diagnoses of cancer. 020822.docx
Please could you provide the figures for diagnoses of cancer within your hospital from January 2010 to date.
Please could you present these figures in a yearly format.
Diagnostic data on an MRI technique for men with suspected prostate cancer.270318
1. Please tell us which Trust, Health Board or Health and Social Care Trust you are responding on behalf of?
2. What percentage of men receive mpMRI before biopsy as part of the initial diagnostic process using T2-weighted, diffusion-weighted (multi-b ADC and high/long b) and dynamic contrast enhanced (DCE) sequences?
3. What are your eligibility criteria/exclusion criteria for men to receive pre-biopsy mpMRI?
4. Are you using mpMRI before biopsy to rule some men out of biopsy as part of the initial diagnostic process?
5. What mpMRI scores and/or other clinical factors are used to rule men out of biopsy?
6. Do you intend to use mpMRI to rule men out of biopsy in the future?
7. How many men annually are referred?
8. If you are unable to provide numbers for question 6, please estimate the percentage of all men referred for b, c and d.
9. Do you carry out targeted biopsies in men with mpMRI lesions in addition to systematic biopsies?
(Please indicate with a X below)
If No, what are the reasons for not carrying this out? (e.g. expertise, equipment, don’t believe it makes a difference)
10. If you do not currently carry out targeted biopsies, but wish to in the future, what are the current barriers to doing so?
(Please indicate with a X below)
11. Please indicate the number of uroradiologists undertaking prostate MRI
12. How many scanners do you have available for mpMRI before biopsy?
Has this increased in the last 12 months?
13. What percentage of scanner time is dedicated to mpMRI before biopsy?
Download response Diagnostic data on an MRI technique for men with suspected prostate cancer.270318
Diffuse Large B Cell Lymphoma (DLBCL).270722.docx
Q1. Does your trust treat patients with Diffuse Large B Cell Lymphoma (DLBCL)? If not, then which trust do you refer DLBCL patients to?
Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL)?
Q3. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
a. R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
b. R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
c. Other immuno-chemotherapy
d. Other chemotherapy
e. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
f. Pola-BR (polatuzumab vedotin with rituximab and bendamustine) – any line of treatment
g. Pola-BR (polatuzumab vedotin with rituximab and bendamustine) – third-line treatment only
h. Tisagenlecleucel
i. Axicabtegene ciloleucel
j. Lisocabtagene maraleucel
Q4. In the last 6 months, how many Diffuse Large B Cell Lymphoma (DLBCL) patients have you referred to other trusts for:
a. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
b. CAR-T therapy (Tisagenlecleucel, Axicabtegene ciloleucel, Lisocabtagene maraleucel)
Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part?
DXA Facilities Audit.020323.docx
Infrastructure:
1) Do you outsource your DXA scans? If Yes- please state the organisation providing this service and forward this FOI to your provider for completion (please continue to complete for any of the elements of the DXA pathway that are provided by your Trust/board)
2) In January 2023 how many DXA scanning machines did you have at your trust/board for clinical use?
a. n. Operational
b. n. not in use
c. n. accessible outside of Trust
3) What is the average weekly capacity for clinical scans? (N. of scans per week)
4) What was your average DNA rate over the last 3 months? (n. DNA/total n. scans booked)
5) What age range do you include in your clinical scans? Please tick all that apply
a. <20 years b. 20-40 years c. 40-60 years d. 60-75 years e. 75-80 years f. >80 years
6) What is the duration of your routine DXA appointment:
a. 15 minutes or less
b. 16-25 minutes
c. 26-30 minutes
d. >30 minutes
7) What was the average wait for clinical patients from referral to scan in January 2023?
a. <2 weeks (move to Q9) b. 2-6 weeks (move to Q9) c. 6-13 weeks d. >13 weeks
8) What are your perceived barriers to delivering DXA scans within 6 weeks from referral? Please tick all that apply
a. Scanner capacity (DXA equipment)
b. Clinical capacity (operator)
c. Other- please state
9) What was the average time from the scan to the report being available to the referrer in January 2023?
a. <3 weeks (move to Q11) b. 4-6 week c. 6-13 weeks d. >13 weeks
10) What are your perceived barriers to referrers receiving DXA scan reports within 3 weeks from scan? Please tick all that apply
a. Clerical- internal
b. Clinical- internal
c. Factors external to this service (please state)
d. Other (please state)
11) What hospital department is responsible for delivery of DXA scans:
a. Radiology
b. Medical physics
c. Nuclear medicine
d. Rheumatology
e. Other- please state
12) Which DXA examinations are included in routine protocols for the clinical service? Please tick all that apply
a. Lumbar spine
b. Proximal femur
c. Long femur (AFF assessment)
d. Total body
e. Vertebral fracture assessment (VFA)
f. Peripheral/forearm
13) What access facilities do you have available? Please tick all that apply
a. Overhead hoist
b. Portable hoist
c. Wheelchair transfers
d. Bed/trolley transfers
e. Changing room
f. Assistance for transfers
g. Other- please state
Workforce:
1)
i) What professional groups perform DXA scan measurements at your centre? (DXA operators)
a. Radiographer
b. DXA technician
c. Assistant practitioner
d. Clinical scientist
e. Nurse
f. Medical Dr- please state specialism
g. Other- please state
h. Unknown]
ii) Please indicate WTE for each group selected
2) What DXA-specific training (outside of professional training) have the DXA operators performing scans had?
a. In house
b. Manufacturers applications training
c. Recognized/accredited national training programme (please state the name of the training programme/provider)
d. Other- please state
e. Unknown
3) What professional groups report your DXA scans at your centre? ()
a. Radiographer – internal
b. Radiographer – external
c. DXA technician – internal
d. DXA technician – external
e. Assistant practitioner – internal
f. Assistant practitioner – external
g. Clinical scientist – internal
h. Clinical scientist – external
i. Nurse -internal
j. Nurse – external
k. Medical Dr – internal – please state specialism(s)
l. Medical Dr – external – please state specialism(s)
m. Other- please state
n. Reporting is outsourced
o. Unknown
4) What training (outside of professional training) have those reporting DXA scans had- specifically in DXA reporting?
a. In house
b. Manufacturers applications training
c. Recognized/accredited national training programme (please state the name of the training programme/provider)
d. Other- please state
e. Unknown
5) What professional group provides clinical leadership for your service?
a. Radiographer
b. DXA technician
c. Assistant practitioner
d. Clinical scientist
e. Nurse
f. Medical Dr- please state specialism(s)
g. Other- please state
h. Unknown
6) Please indicate how many (WTE) clinical vacancies in your DXA service do you have in January 2023? (Free text)
Quality:
1) Is your service accredited as part of a national programme?
a. ISAS
b. IOS
c. Other- please state
d. None
e. Unknown
2) What clinical audits do you routinely undertake? Please tick all that apply
a. DXA scan technique
b. Reporting (double reporting)
c. Reporting (clinical review)
d. Scanner QA review
e. Other- please state
f. Unknown
3) What IR(ME)R audits do you routinely undertake? Please tick all that apply
a. Patient pregnancy
b. DXA dose audit
c. Referrer entitlement
d. Scan justification
e. Other- please state
f. Unknown
4) What clinical protocols do you have in place? Please tick all that apply
a. Scan site
b. Scan mode
c. Reference data selection
d. Patient positioning
e. Scan analysis
f. Interpretation- T&Z-scores
g. Reporting
h. Other- please state
i. Unknown
5) Which of the following are routinely included in the DXA report issued to the PRIMARY CARE referrer? Please tick all that apply
A. Admin. details
i. Date of assessment
ii. Patient ID and demographics
iii. Reason for referral
iv. Reporter’s ID
B. BMD results for each measurement site
i. T score (after peak bone mass)
ii. Z score
iii. Rate of change for serial measurements
C. Comment on reliability of measurements
i. BMD results
ii. Documentation of excluded measurements eg. vertebrae
iii. Statistical significance of rate of change
iv. Clinical significance of rate of change
D. WHO diagnostic category (for adults after peak bone mass)
E. Results of additional investigations performed at DXA appointment
i. VFA
ii. X-ray or other imaging
iii. Laboratory tests
F. Summary of clinical risk factors for fracture
G. Summary of fracture history
H. Clinical interpretation to quantify absolute fracture risk
i. FRAX+BMD
ii. FRAX + TBS
iii. FRAX+BMD plus comment on additional adjustment
iv. Statement on level of risk based on clinical judgement (eg. low/moderate/high)
I. Management advice
i. Reference to national guideline (NICE/NOGG/ROS)
ii. Reference to local management guideline
iii. Individualised advice
J. Recommendations on:
i. Need for onward referral eg. falls assessment or additional investigation
ii. Timing of future scan
6) Which of the following are routinely included in the DXA report issued to the SECONDARY CARE referrer? Please tick all that apply
A. Admin. details
i. Date of assessment
ii. Patient ID and demographics
iii. Reason for referral
iv. Reporter’s ID
B. BMD results for each measurement site
i. T score (after peak bone mass)
ii. Z score
iii. Rate of change for serial measurements
C. Comment on reliability of measurements
i. BMD results
ii. Documentation of excluded measurements eg. vertebrae
iii. Statistical significance of rate of change
iv. Clinical significance of rate of change
D. WHO diagnostic category (for adults after peak bone mass)
E. Results of additional investigations performed at DXA appointment
i. VFA
ii. X-ray or other imaging
iii. Laboratory tests
F. Summary of clinical risk factors for fracture
G. Summary of fracture history
H. Clinical interpretation to quantify absolute fracture risk
i. FRAX+BMD
ii. FRAX + TBS
iii. FRAX+BMD plus comment on additional adjustment
iv. Statement on level of risk based on clinical judgement (eg. low/moderate/high)
I. Management advice
i. Reference to national guideline
ii. Reference to local management guideline
iii. Individualised advice
J. Recommendations on:
i. Need for onward referral eg. falls assessment or additional investigation
ii. Timing of future scan
K. The secondary care report is the same as the primary care report
Early Melanoma.020323.docx
Q1. I am researching the usage of Pembrolizumab for the treatment of Melanoma. How many patients have you treated with Pembrolizumab in the three months from October to December 2022 for:
a. Melanoma – any stage
b. Melanoma – Stage IIb/IIc
c. Melanoma – Stage III
d. Melanoma – Metastatic
Q2. How many Stage IIb/IIc melanoma patients were on a “Watch and Wait” strategy in the three months from October to December 2022? These would be patients where a decision has been made to wait before commencing any treatment.
Elastomeric Infusion Devices (E.I.D) 020320
Information request in respect to Elastomeric Infusion Devices
Please could you kindly advise which departments and healthcare professionals within your Trust use elastomeric infusion devices?
Information request in respect of Elastomeric Infusion Devices
1. Please could you also advise if you purchase E.I.D and if so:
a. What brand(s) do you purchase?
b. What quantities do you purchase on an annual basis?
c. Who are the main clinicians responsible within your Trust for the prescribing and administration of elastomeric devices?
d. What medicines do you fill the devices with?
e. Do you fill elastomeric devices in your pharmacy aseptic unit if you have one?
2. Please could you also advise if you purchase pre-filled elastomeric devices from a commercial compounder and if so:
a. What drugs are provided pre-filled?
b. What quantities do you purchase on an annual basis?
Download response Elastomeric Infusion Devices (E.I.D) 020320
EMB Biopsy 060317
Do any hospitals in the trust perform Endomyocardial Biopsy?
– Yes
– No
a) If so how many were performed in 2014-15 financial year?
b) How many were performed for investigation of Myocarditis?
2) How many patients in 2014-15 were diagnosed with Myocarditis in the trust?
3) Does the Trust refer patients to other centres or trusts for Endomyocardial Biopsy?
4) If so which centres or trusts do you refer to?
5) Does your trust receive referrals from other centres or trusts for Endomyocardial biopsy?
Ensuring MHRA Compliance.190422.docx
1. Please state what software/ systems the Trust utilises for managing medical equipment/ devices in order to be compliant with MHRA Guidance (see URL below) from the list below. If not listed, please specify:
a. EMAT
b. F2
c. RAM
d. e-Quip
e. Other – please specify
2. Please state the name and contact for the person responsible for ensuring compliance with the MHRA guidance quoted above.
Extravasation Incidents. 310118
Name of person completing request:
Hospital Trust/Health Board:
Telephone No:
E-mail Address:
1. Does your organisation provide a chemotherapy service – this may include inpatient, outpatient or a community service? 0 Yes 0 No
2. In the past financial year, how many doses of chemotherapy did you deliver? (April 2016 – March 2017)
3. In the past financial year, how many doses of anthracyclines did you administer? (April 2016 – March 2017)
4. In the past financial year, how many anthracycline extravasations have been reported due to chemotherapy? (April 2016 – March 2017)
5. In the past 3 financial years, how many patients have submitted a claim for medical negligence and/or damages against the Trust/Health Board due to an anthracycline extravasation injury?
6. In the past 3 financial years, how much compensation has the Trust/Health Board had to pay to those claimants who have suffered an anthracycline extravasation injury and have been successful in their medical negligence and/or damages case?
7. Does your Trust/Health Board have in place guidelines as to how to recognise and manage an extravasation injury? If not, is this available via your Cancer Alliance/Network or another source? If other, please state source ………………………………………………….
Trust/Health Board Guidelines 0 Yes 0 No If yes, when were they last updated?…………………………………………
8. Does your Trust/Health Board stock or have readily available any of the following extravasation treatments for chemotherapy?
a. Sodium Thiosulfate 0 Yes 0 No If yes, how often used in the past financial year? (April 2016 – March 2017)……………………
b. Hyaluronidase 0 Yes 0 No If yes, how often used in the past financial year? (April 2016 – March 2017)……………………
c. DMSO 0 Yes 0 No If yes, how often used in the past financial year? (April 2016 – March 2017)……………………
d. Dexrazoxane (Savene) 0 Yes 0 No If yes, how often used in the past financial year? (April 2016 – March 2017)……………………
9. In the past 3 financial years, how many annual reconstruction operations have been carried out by the Trust/Health Board due to an extravasation injury?
10. Does your Trust/Health Board’s plastics and/or nursing team have the expertise/core competency to undertake the wash-out/flush-out technique if an extravasation occurs?
0 Yes 0 No
11. If you answered yes to question 10, in the past 3 financial years, how many wash-out/flush-out procedures have been carried out by the Trust/Health Board due to an extravasation incident?
Flushing and locking of intravenous catheters.010722.docx
Could you please tell me, do you have such services as ‘Flushing and locking of intravenous catheters’ in your clinic?
Fundus and Optical Biometer. 220421
1. Fundus Camera
a. How many devices do you have and which model?
b. When were these devices installed?
c. When are these due to be replaced?
d. Is there a replacement budget allocated?
e. Do you have a service contract? When does it expire?
2. Optical Biometer
a. How many devices do you have and which model?
b. When were these devices installed?
c. When are these due to be replaced?
d. Is there a replacement budget allocated?
e. Do you have a service contract? When does it expire?
3. Capsular Tension Ring
a. Which Brand do you use?
b. How many did you use in 2019?
Gamma camera (Nuclear Medicine imaging system). 080422.docx
1 The manufacturer & model name of each gamma camera (Nuclear Medicine imaging system) installed in your Trust
2 The hospital name where each system is installed
3 The date that the current service/maintenance contract on each gamma camera started
4 The date that the current service/maintenance contract on each gamma camera expires
General Anaesthetics. 180319
1. How many general anaesthetics were administered by your NHS Trust in 2018, 2017, 2016 and 2015?
2. How many patients died as a result of general anaesthesia in 2018, 2017, 2016 and 2015?
3. How many patients were given a general anaesthetic for the purpose of carrying out a diagnostic scan/test (MRI, CT etc.) in 2018, 2017, 2016 and 2015?
4. How many patients died as a result of being given a general anaesthetic for the purpose of carrying out a diagnostic scan/test (MRI, CT etc.) in 2018, 2017, 2016 and 2015?
5. How many patients were given a general anaesthetic for the purpose of carrying out an MRI scan in 2018, 2017, 2016 and 2015?
6. How many patients died as a result of being given a general anaesthetic for the purpose of carrying out an MRI scan in 2018, 2017, 2016 and 2015?
7. How many patients were given any other form of sedation for the purpose of carrying out a diagnostic scan/test (MRI, CT etc.) in 2018, 2017, 2016 and 2015?
8. How many patients were given any other form of sedation for the purpose of carrying out an MRI scan in 2018, 2017, 2016 and 2015?
9. How many diagnostic scans/tests (MRI, CT etc.) were aborted at your NHS Trust in 2018, 2017, 2016 and 2015 as a result of patients failing to attend the appointment or the process being stopped mid-way.
10. How many MRI scans were aborted at your NHS Trust in 2018, 2017, 2016 and 2015 as a result of patients failing to attend the appointment or the process being stopped mid-way.
Genesiscare. 270919
1. Please can you tell me if the Trust sends NHS Patients to GenesisCare for Cancer treatment?
2. Does the Trust send private patients to GenesisCare for cancer treatment?
3. How many Maidstone & Tunbridge Wells NHS Trust patients were treated by GenesisCare in 2018 and 2019? Please break the numbers down into NHS and private.
4. How long is the Trusts contract with GenesisCare?
Genetic Haemochromatosis. 190320
a. For the period 1st January 2018 to 31st December 2018 (or the most recent 12 month period available), the number of patients diagnosed with genetic haemochromatosis (GH) under your care.
b. For the period 1st January 2018 to 31st December 2018 (or the most recent 12 month period available), the average time in days from first referral from primary care to the patient’s first appointment within your trust.
c. A copy of the protocol and/or patient pathway applicable to the care of people with genetic haemochromatosis.
d. The date that your protocol/patient pathway for genetic haemochromatosis was last reviewed or revised.
e. A copy of your clinical protocol(s) for therapeutic venesection.
f. The date that your protocol(s) for therapeutic venesection were last reviewed or revised.
Gonadorelin (GnRH) Analogues.
1 Within your organisation, which healthcare professional (role) clinically recommends the LHRH that is prescribed?
2 Which healthcare professional (role) within your organisation usually administers the first injection?
3 Where is the first injection usually given (hospital or primary care)?
4 Which healthcare professional (role) within your organisation usually administers subsequent injections?
5 Where are subsequent injections usually given (hospital or primary care)?
6 For subsequent injections, does the patient still remain under the care of the hospital (e.g. attends hospital clinics although injections are given in primary care), and if so, for how long?
7 If injections are administered in primary care, what recommendation/advice comes from the hospital?
Haematology.281222.docx
I am researching the use of certain types of drugs used in haematology. Could you please provide the number of patients treated (for any disease in the past 3 months with:
1. Aragam
2. Berinert
3. Cinryze
4. Cutaquig
5. Cuvitru
6. Firazyr
7. Flebogamma DIF
8. Gammagard
9. Gammanorm
10. Gammaplex
11. Gamunex
12. Hizentra
13. Hyqvia
14. Intratect
15. Iqymune
16. Kiovig
17. Octagam
18. Orladeyo
19. Panzyga
20. Privigen
21. Ruconest
22. Subgam
23. Takhzyro
Haemonetics. 311019
1. Please can you tell me how many of the following two devices – MCS+ 9000 Mobile Platelet Collection System and/or MCS+ 8150 Multicomponent Collection System both from a company called Haemonetics – the trust has used over the last 10 years and how many of these devices are currently in operation.
2. Please provide a figure for each device and each year over the last 10 years. If possible, please also state how many patients have had this device used on them.
Haemonetics plasma device. 220120
Please can you tell me how many deaths have been reviewed by the trust or reported to a coroner in the past 10 calendar years where the hospital used a Haemonetics plasma device (any model number) on the patient before they died.
Where the death was investigated please can you send me the report (redacted to remove personal details if necessary) and include the age, gender and diagnosis of the patient. If the death was reported to the coroner please include a copy of their report.
Head and neck and urothelial cancer.030822.docx
1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:
a. Total number of head and neck cancer patients
b. Number of locally advanced head and neck cancer patients
c. Number of unresectable recurrent and/or metastatic head and neck cancer patients
3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:
a. Avelumab
b. Atezolizumab
c. Carboplatin with Gemcitabine
d. Carboplatin single or in any other combination
e. Cisplatin with Gemcitabine
f. Cisplatin single or in any other combination
g. Nivolumab
h. Pembrolizumab
i. Any other regimen including Paclitaxel
j. Any other chemotherapy regimen
k. Other active systemic anti-cancer therapy [please state]
l. Palliative care only
4. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
Head and Neck Cancer
Within your health trust how many patients are currently [within the past 6 months] being treated for head and neck cancer (Squamous cell carcinoma)?
April to September 2015 – 26 patients
Of these how many are treated with the following therapies;
Carboplatin
Cetuximab
Cisplatin
Docetaxel
5-Fluorouracil (5FU)
Radiotherapy Only
Please see the table below:
If your health trust has a protocol or pathway for the treatment of head and neck cancer patients [including referral pathway to other trusts], please could you provide details?
Please see the attached document.
Within your health trust how many patients are currently [within the past 6 months] being treated for Colorectal Cancer?
April to September 2015 – 136 patients
Of these how many are treated with the following therapies;
Bevacizumab
Cetuximab
Panitumumab
Aflibercept
Oxaliplatin
Irinotecan
5-Fluorouracil
Irinotecan with 5-fluorouracil (5FU) and folinic acid [FOLFIRI]
Oxaliplatin with 5-fluorouracil (5FU) and folinic acid [FOLFOX]
Capecitabine and oxalipatin (CAPOX / XELOX)
Capecitabine and irinitecan (CAPIRI)
Download response letter Head and Neck Cancer 201115
Head and Neck Cancer (Squamous cell carcinoma).
1. Within your health trust how many patients are currently [within the past 6 months] being treated for head and neck cancer (Squamous cell carcinoma)?
2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?
A. Locally advanced
B. Recurrent and/or metastatic
Of the these patients please split by their current drug treatment;
Carboplatin (Only or in combination with 5-FU)
Cetuximab (Erbitux) and chemotherapy or radiotherapy
Cetuximab (Erbitux) Only
Cisplatin (Only or in combination with 5-FU)
Docetaxel (Taxotere), (Only or in combination with 5-FU)
Fluorouracil (5FU)
Radiotherapy Only
Other – Specify
3. Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so please could you provide details?
4. Within your health trust how many patients are currently [within the past 6 months] being treated for metastatic Colorectal Cancer?
Of those patients please split by their current drug treatment;
Bevacizumab
Cetuximab
Panitumumab
Aflibercept
Oxaliplatin
Irinotecan
5-Fluorouracil
Irinotecan with 5-fluorouracil (5FU) and folinic acid [FOLFIRI]
Oxaliplatin with 5-fluorouracil (5FU) and folinic acid [FOLFOX]
Capecitabine and oxalipatin (CAPOX / XELOX)
Capecitabine and irinitecan (CAPIRI)
Other – Specify
Download response Head and Neck Cancer (Squamous cell carcinoma) 270616
Head and Neck Cancer (Squamous Cell Carcinoma). 081116
1. Within your health trust how many patients are currently [within the past 6 months] being treated for head and neck cancer (Squamous cell carcinoma)?
Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?
A. Locally advanced
B. Recurrent and/or metastatic
Of these patients please split by their current drug treatment;
Carboplatin (Only or in combination with 5-FU)
Cetuximab (Erbitux) and chemotherapy or radiotherapy
Cetuximab (Erbitux) Only
Cisplatin (Only or in combination with 5-FU)
Docetaxel (Taxotere), (Only or in combination with 5-FU)
Fluorouracil (5FU)
Radiotherapy Only
Other – Specify
2. Within your health trust how many patients are currently [within the past 6 months] being treated for metastatic Colorectal Cancer?
Of those patients please split by their current drug treatment;
Bevacizumab
Cetuximab
Panitumumab
Aflibercept
Oxaliplatin
Irinotecan
5-Fluorouracil
Irinotecan with 5-fluorouracil (5FU) and folinic acid [FOLFIRI]
Oxaliplatin with 5-fluorouracil (5FU) and folinic acid [FOLFOX]
Capecitabine and oxalipatin (CAPOX / XELOX)
Capecitabine and irinitecan (CAPIRI)
Other – Specify
Download response Head and Neck Cancer (Squamous Cell Carcinoma). 081116
Head and neck cancer (squamous cell carcinoma). 301120
1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma)? Of these patients, how many are locally advanced, recurrent and/or metastatic?
a. Total squamous cell carcinoma
b. Locally advanced
c. Recurrent and/or metastatic
2. For the metastatic head and neck cancer patients treated in the past 3 months, could you specify (if possible) how many received first-line treatment versus second-line treatment?
3. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
4. Within your health trust, how many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:
a. Sunitinib
b. Avelumab + Axitinib
c. Axinitib
d. Cabozantinib
e. Everolimus
f. Lenvantinib + Everolimus
g. Nivolumab
h. Nivolumab + Ipilimumab
i. Pazopanib
j. Pembrolizumab + Axitinib
k. Sunitinib
l. Temsirolimus
m. Tivozanib
n. Other
5. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
6. Does your trust participate in any ongoing clinical trials for the treatment of renal cell carcinoma? If so, can you please provide the name of each trial along with the number of patients taking part?
Download response Head and neck cancer (squamous cell carcinoma). 301120
Head and Neck cancer (squamous cell carcinoma) and Urothelial cancer. 140422.docx
1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:
a. Total number of head and neck cancer patients
b. Number of locally advanced head and neck cancer patients
c. Number of recurrent and/or metastatic head and neck cancer patients
3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:
a. Atezolizumab
b. Carboplatin with Gemcitabine
c. Carboplatin single or in any other combination
d. Cisplatin with Gemcitabine
e. Cisplatin single or in any other combination
f. Nivolumab
g. Pembrolizumab
h. Any other regimen including Paclitaxel
i. Any other chemotherapy regimen
j. Other active systemic anti-cancer therapy [please state]
k. Palliative care only
4. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
Head and Neck cancer (squamous cell carcinoma) and Urothelial cancer. 140422.docx
Head & neck and urothelial cancer.281122.docx
1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:
a. Total number of head and neck cancer patients
b. Number of locally advanced head and neck cancer patients
c. Number of unresectable recurrent and/or metastatic head and neck cancer patients
3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:
a. Avelumab
b. Atezolizumab
c. Carboplatin with Gemcitabine
d. Carboplatin single or in any other combination
e. Cisplatin with Gemcitabine
f. Cisplatin single or in any other combination
g. Nivolumab
h. Pembrolizumab
i. Any other regimen including Paclitaxel
j. Any other chemotherapy regimen
k. Other active systemic anti-cancer therapy [please state]
l. Palliative care only
4. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
5. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
Head & Neck Cancer (H&N), Renal Cancer (RCC) and Colorectal Cancer (CRC). 050321
We are researching the incidence and treatment of Head & Neck Cancer (H&N), Renal Cancer (RCC) and Colorectal Cancer (CRC). Could you please answer the following questions for patients treated by your trust?
1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
2. Within your health trust, how many patients have been treated in the past 3 months with the following agents for renal cell carcinoma :
a. Sunitinib
b. Avelumab + Axitinib
c. Axinitib
d. Cabozantinib
e. Everolimus
f. Lenvantinib + Everolimus
g. Nivolumab
h. Nivolumab + Ipilimumab
i. Pazopanib
j. Pembrolizumab + Axitinib
k. Sunitinib
l. Temsirolimus
m. Tivozanib
n. Other
3. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?
a. Aflibercept
b. Bevacizumab
c. Cetuximab monotherapy
d. Cetuximab in combination with FOLFOX or FOLFIRI
e. Panitumumab monotherapy
f. Panitumumab in combination with FOLFOX or FOLFIRI
g. Nivolumab
h. Ramucirumab
i. Regorafenib
j. Sorafenib
Download response Head & Neck Cancer (H&N), Renal Cancer (RCC) and Colorectal Cancer (CRC). 050321
Head and Neck Cancer (Squamous cell carcinoma). 260418
1. Within your health trust how many patients are currently [within the past 6 months available] being treated for head and neck cancer (Squamous cell carcinoma)?
2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?
a. Locally advanced
b. Recurrent metastatic
3. Of the locally advanced/ recurrent or metastatic head and neck cancer patients how many are currently [within the past 6 months available]
Carboplatin (only or in combination with 5-FU)
Cisplatin (only or in combination with 5-FU)
Cetuximab (Erbitux) with/without chemotherapy
Cetuximab (Erbitux) with radiotherapy
Docetaxel (Taxotere) -only or in combination with 5-FU
Fluorouracil (5FU)
Radiotherapy only
Other
4. Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials?
5. Within your health trust how many patients are currently [within the past 6 months available] being drug treated for metastatic colorectal cancer?
Of those patients please split by their drug treatment;
Cetuximab (Erbitux) with/without chemotherapy
Panitumumab (Vectibix) with/without chemotherapy
Nivolumab (Opdivo) with/without chemotherapy
Chemotherapy + other mAb
Chemotherapy alone
Other
6. Does your health trust participate in any ongoing clinical trials for the treatment of colorectal cancer patients, if so how many patients are currently taking part in clinical trials?
Download response Head and Neck Cancer (Squamous cell carcinoma). 260418
Helium consumption.271022.docx
1. Could you detail the quantity of helium that has been purchased each year for the last 5 years?
2. What are the main uses for helium within the Trust?
3. Could you outline the various grades/types of helium purchased?
4. What has the cost of helium been for each of those 5 years?
5. Who are your suppliers of helium and can you provide a copy of the supply contracts?
6. Can you detail your procurement process for obtaining helium and send any tender documents relating to helium?
HER2 Breast Cancer. 080517
In your trust, how many patients with HER2 breast cancer are currently being treated (in the past 3 months available) with the following products;
Herceptin IV (trastuzumab IV) only
Herceptin SC (trastuzumab SC) only
Perjeta (pertuzumab) combined with Herceptin/Docatexel
Kadcyla (trastuzumab emtansine)
Tyverb (lapatinib)
Imaging. 041120
1. What proportion of emergency department images (x-ray, CT, MRI) were reported within the four-hour target* in December 2018 and December 2019, categorised by each examination?
2. What proportion of inpatient images (x-ray, CT, MRI) were reported within the 24-hour target**, in December 2018 and December 2019, categorised by each examination.
3. How many radiology examinations (CT, MRI, x-ray) did your organisation conduct in 2018, 2019 and the first six months of 2020. Please can you provide the total number for each examination category for each year?
4. Did you have a backlog of unreported radiology examinations (CT, MRI, x-ray) in 2018, 2019 and the first six months of 2020? Please can you provide the average number of unreported images for each examination category for each year?
Imaging. 210421
1. How many CT scanners do you have in your Trust?
2. How many of these CT scanners are over 10 years old?
3. How many MRI scanners do you have in your Trust?
4. How many of these MRI scanners are over 10 years old?
5. Is your Trust a member of an imaging or pathology network/alliance?
6. Has your Trust been working in partnership with a community health setting offering diagnostics services (i.e. a dedicated diagnostic service not part of a Trust or GP practice, such as a community diagnostic hub)?
7. What proportion of your pathology diagnostic equipment is over 10 years old?
8. What are the daily running and ongoing maintenance costs of the cardiorespiratory diagnostic facilities in your Trust?
9. What were the installation costs of the cardiorespiratory diagnostic facilities in your Trust?
10. What proportion of your genomics equipment is over 10 years old?
11. Is your Trust working in collaboration with a genomics laboratory hub?
12. If the answer to (11) was ‘Yes’, what proportion of total genomics diagnostic procedures that your Trust is responsible for are allocated to the genomics hub?
Imaging. 270918
1. How many CDs does your department produce per annum for the distribution of patient images?*
2. How many CDs does your department produce per annum for interested 3rd parties such as insurance companies or solicitors?*
3. What is the cost of CD production for patient images, e.g. materials for your department per annum?*
4. What are the time/resource costs associated with CD production for patient images for your department per annum?*
5. What are the costs of postage/couriering of CDs of patient images for your department, per annum?*
6. Please provide a breakdown of total costs of CDs for patient images to other hospitals for your department, per annum?*
7. Please provide a breakdown of total costs of CDs to patients for your department, per annum?*
8. Please provide a breakdown of total costs of CDs to interested 3rd parties for your department such as insurance companies or solicitors, per annum?*
9. Are the CDs dispatched from your department that contain patient data consistently encrypted / password protected?*
10. Can you provide information on the number of CDs that are lost or misplaced before they reach the intended recipient?*
*If you use a centralised administration team to administer imaging for your department please include this information to the above questions.
Please provide these answers for the following departments:
• Radiology
• Cardiology
• Medical illustration
• Theatres
• Endoscopy
• Colposcopy
• Diabetic Retinopathy
• Medical Photography
• Dermatology
• Podiatary
Imaging and Cancer referrals. 240720
1. How many patients are currently awaiting an appointment for imaging studies/scans that have been requested? And how many are awaiting the results of scans that are yet to be assessed?
1a. Please can you specify how many of these are on a cancer pathway.
1b. Please also specify the date your records go up to.
1c. Please can you also provide the data for how many were waiting during the same time period last year.
2. How many two-week wait cancer referrals had to wait longer than 14 days for an appointment in May 2020, May 2019, and May 2018? Please break this down by year and specialty receiving referral.
3. How many more scanners are needed to address the shortfall in imaging capacity?
Imaging equipment. 230921.docx
1. Please can you provide the following information for each piece of MRI scanners within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Tesla – 0.5 to 1.4, 1.5, 3.0, 3.0 +
d. Location – Hospital Name or Site Name
e. Mobile / Static
f. Department equipment is primarily used in
g. Method of Finance at Procurement – Trust/Lease/MES/Charity/PFI
h. Initial cost of Equipment
i. Annual Maintenance cost
j. Acquisition Date
k. Planned Replacement Date
2. Please can you provide the following information for each CT scanners within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Slices – 8, 16, 64, 128, 264
d. Location – Hospital Name or Site Name
e. Mobile / Static
f. Department equipment is primarily used in
g. Method of Finance at Procurement – Trust/Lease/MES/Charity/PFI
h. Initial cost of Equipment
i. Annual Maintenance cost
j. Acquisition Date
k. Planned Replacement Date
3. Please can you provide the following information for each Ultrasound scanner within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Location – Hospital Name or Site Name
d. Department equipment is primarily used in
e. Method of Finance at Procurement – Trust/Lease/MES/Charity/PFI
f. Initial cost of Equipment
g. Annual Maintenance cost
h. Acquisition Date
i. Planned Replacement Date
Immune thrombocytopenia (ITP).031122.docx
Q1. How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the following treatments:
a. Revolade (eltrombopag)
b. Nplate (romiplostim)
c. Doptelet (avatrombopag)
d. Tavlesse (fostamatinib)
Q2. In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)?
Q3. Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:
a. rituximab
b. mycophenolate mofetil
c. surgery (splenectomy)
Q4. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?
Impact of COVID-19 on prostate cancer diagnosis, treatment and support. 021020
1. Did you suspend your MRI before biopsy service for patients with suspected prostate cancer as a result of the COVID-19 pandemic?
a. Yes
b. No
c. We did not offer MRI before biopsy before the pandemic
2. If yes, have you now resumed MRI before biopsy for patients with suspected prostate cancer?
a. Yes
b. No
c. No, but we refer patients elsewhere (Please state the referral area:)
d. N /A
3. Do you currently use a pre-MRI clinical triage for patients with suspected prostate cancer? By pre-MRI clinical triage, we mean a process, often Clinical Nurse Specialist led, that determines patient suitability for MRI before biopsy
a. Yes
b. No
4. Has your radiology department introduced any new MRI exclusion criteria for patients with suspected prostate cancer as a result of COVID-19?
a. Yes (please specify:)
b. No
c. N/A
5. If yes, do you plan to maintain any of these exclusion criteria once restrictions to limit patients’ COVID-19 risk are lifted?
a. Yes (please specify:)
b. No
c. N/A
6. Did you stop conducting biopsies for patients with suspected prostate cancer as a result of COVID-19 infection risks?
a. Yes
b. No
7. If yes, have you resumed biopsy services for patients with suspected prostate cancer?
a. Yes
b. Yes, but only for a subset of patients (please specify:)
c. No
d. No, but we refer patients elsewhere for prostate biopsy (Please state the referral area:)
8. Do you offer transperineal biopsy under local anaesthetic?
a. Yes
b. No
c. No, but we plan to in future (please specify when if possible:)
9. Following an MRI scan for suspected prostate cancer, what criteria do you use to select patients for biopsy? Please include all that apply:
a. Patients with a PI-RADSs or Likert score of 1 or greater
b. Patients with a PI-RADS or Likert score of 2 or greater
c. Patients with a PI-RADS or Likert score of 3 or greater
d. Patients with a PI-RADS or Likert score of 3 or greater, but only if PI-RADS or Likert score 3 patients have other clinical indications (such as age, ethnicity, PSA density) that make them higher risk
e. Patients with a PI-RADS or Likert score of 4 or greater
f. We do not offer MRI before biopsy
g. We do not currently biopsy patients
10. Did you delay radiotherapy treatment for prostate cancer patients as a result of COVID-19?
a. Yes
b. No
c. Partially (please specify:)
d. N/A (please specify:)
11. If yes, have you cleared your backlog for prostate cancer radiotherapy treatment?
a. Yes
b. No
c. N/A – We did not delay prostate cancer radiotherapy treatment
12. Did you delay radical prostatectomy for prostate cancer patients as a result of COVID-19?
a. Yes
b. No
c. Partially (please specify:)
d. N/A (please specify:)
13. If yes, have you cleared your radical prostatectomy backlog?
a. Yes
b. No
c. N/A – We did not delay radical prostatectomy for prostate cancer patients
14. To address your backlog did or are you using a protocol to risk stratify patients and prioritise patients with high-risk and locally advanced prostate cancer for treatment within 3 months?
a. Yes
b. No
c. No, we did not have a sufficient backlog to require patient prioritisation
15. Does your protocol apply to new patients with high-risk and locally advanced prostate cancer with the intention to radically treat them within 3 months of diagnosis?
a. Yes
b. No
c. N/A – We do not have a protocol for patient prioritisation
16. Do you have prostate cancer Personalised Stratified Follow Up (PSFU) protocols in place?
a. Yes
b. No
c. We are in the process of developing PSFU protocols
17. If Yes, do you have a digital remote monitoring system in place for follow up?
a. Yes (Please specify the name of the system used: e.g My Medical Record, Patient Knows Best)
b. No
18. If no, do you plan to implement a digital remote monitoring system for follow up?
a. Yes – (Please specify the name of the system you plan to implement: e.g My Medical Record, Patient Knows Best)
b. No
19. Which of the following criteria are part of your follow up protocols? (please mark all that apply:)
a. Patients have access to a Support Worker who acts as their key worker for the duration of their follow up care.
b. Patients have access to an online patient service that allows them to check test results, complete assessments, view patient information and message their clinical team.
c. Patients attend a 4-hour supported self-management workshop with a group of 8 to 10 men to develop knowledge, skills and confidence to self-manage their condition
d. Patients do not need to attend routine appointments unless an issue arises.
Download response Impact of COVID-19 on prostate cancer diagnosis, treatment and support. 021020
Implementation of digital pathology in Histopathology. 240222.docx
1. Has your histopathology laboratory outsourced any cases for reporting in the past year?
2. If yes, approximately what percentage of your work is outsourced?
3. Does your histopathology laboratory use any form of digital pathology?
4. Can you name the supplier(s) of your digital pathology solution?
5. If the answer to question 3 is “no”, can you indicate if you are looking to procure a digital pathology solution in the next year?
6. How much funding does the Trust have to implement this?
7. What would you use digital pathology for?
a. Research
b. Training
c. Primary diagnosis
d. Second opinion
e. MDT preparation and review
(Tick all that apply)
8. What LIS does your department currently use?
9. How old is your current LIS?
10. Does your laboratory workflow incorporate a barcoded tracking system?
11. If yes, what tracking system do you use?
12. To reduce the initial capital outlay, would you favour a cost per scan pricing model?
13. Would you consider an insourcing model where the digital pathology solution is tailored to your needs with scanners placed on site and images stored and streamed to your consultant workforce for reporting on your LIS?
14. Would you use an outsourcing model where your slides are sent offsite for scanning and cases reported by an external consultant team with reports returned direct to your LIS?
15. Would you prefer to purchase your own scanners and IMS and work directly with a partner provider to handle, store, and report your own images?
Implementation of digital pathology in Histopathology. 240222.docx
IMRT Radiotherapy Machines. 121119
IMRT Radiotherapy Machines
Could you please advise whether we are using the above modern machines in the Kent and Canterbury Hospital (K&C) and Maidstone?
Incidence and treatment of breast cancer.110322.docx
Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) as a single agent
b. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
c. Abemaciclib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Carboplatin or Cisplatin as a single agent
h. Eribulin as a single agent or in combination
i. Everolimus + Exemestane
j. Fulvestrant as a single agent
k. Lapatinib
l. Neratinib
m. Parp Inhibitors (Olaparib/Talazoparib)
n. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
o. Palbociclib + Fulvestrant
p. Pembrolizumab
q. Pertuzumab + Trastuzumab + Docetaxel
r. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
s. Ribociclib + Fulvestrant
t. Sacituzumab Govitecan
u. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Vinorelbine as a single agent
z. Any other active systemic anti-cancer therapy
Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrazole, exemestane, letrozole) as a single agent?
Incidence and treatment of breast cancer. 110621
1. How many patients have you treated (using surgery, radiotherapy or any systemic anti-cancer therapy) in the last three months for:
a. Breast cancer (any stage)
b. Early breast cancer (both early-stage and locally advanced, inclusive of stages I-IIIC)
c. Metastatic breast cancer (stage IV)
2. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
d. Atezolizumab +Nab-paclitaxel/Paclitaxel
e. Capecitabine as a single agent
f. Carboplatin or Cisplatin as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fluorouracil
j. Fulvestrant as a single agent
k. Lapatinib
l. Neratinib
m. Olaparib
n. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
o. Palbociclib + Fulvestrant
p. Pertuzumab + Trastuzumab + Docetaxel
q. Platinum (e.g. carboplatin or cisplatin) as a single agent
r. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
s. Ribociclib + Fulvestrant
t. Talazoparib
u. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
v. Transtuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Any other active systemic anti-cancer therapy
Download response Incidence and treatment of breast cancer. 110621
Incidence and treatment of breast cancer.311022.docx
Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a.Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fulvestrant as a single agent
j. Lapatinib
k. Neratinib
l. Parp Inhibitors (Olaparib/Talazoparib)
m. Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
n. Palbociclib + Fulvestrant
o. Pembrolizumab
p. Platinum (e.g. carboplatin or cisplatin) as a single agent
q. Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
r. Ribociclib + Fulvestrant
s. Sacituzumab Govitecan
t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
u. Taxane and/or Anthracycline in combination
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Any other active systemic anti-cancer therapy
Q2. Does your trust participate in any clinical trials for breast cancer? If so, can you please provide the name of each trial and the number of patients taking part.
Incidence and treatment of different types of cancer.220621
1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?
· Carboplatin (monotherapy or in combination with 5-FU)
· Cisplatin (monotherapy or in combination with 5-FU)
· Cetuximab with/without chemotherapy
· Cetuximab with radiotherapy
· Pembrolizumab monotherapy
· Pembrolizumab with chemotherapy
· Nivolumab
· Docetaxel (monotherapy or in combination with 5-FU)
· Fluorouracil (5FU)
· Radiotherapy only
· Other
2. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer (squamous cell carcinoma)? If so, can you please provide the name of each trial along with the number of patients taking part?
3. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?
· Aflibercept
· Bevacizumab
· Capecitabine
· CAPIRI
· CAPOX (XELOX)
· Cetuximab in combination with FOLFIRI
· Cetuximab in combination with FOLFOX
· Cetuximab not in combination with FOLFIRI or FOLFOX
· Irinotecan only
· FOLFIRI
· FOLFOX
· Fluorouracil (5FU) only
· Oxaliplatin only
· Panitumumab in combination with FOLFIRI
· Panitumumab in combination with FOLFOX
· Panitumumab not in combination with FOLFIRI or FOLFOX
· Nivolumab
· Raltitrexed
· Ramucirumab
· Regorafenib
· Sorafenib
· Other SACT
Download response Incidence and treatment of different types of cancer.220621
Incidence and treatment of Lung cancer. 091020
Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:
a. Afatinib
b. Alectinib
c. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
d. Atezolizumab monotherapy
e. Bevacizumab
f. Brigatinib
g. Ceritinib
h. Crizotinib
i. Dacomitinib
j. Docetaxel monotherapy
k. Durvalumab
l. Erlotinib
m. Gefitinib
n. Gemcitabine
o. Necitumumab
p. Nintedanib with Docetaxel
q. Nivolumab
r. Osimertinib
s. Paclitaxel
t. Pembrolizumab chemo in combination
u. Pembrolizumab monotherapy
v. Pemetrexed
w. Pemetrexed with Carboplatin
x. Pemetrexed with Cisplatin
y. Ramucirumab
z. Vinorelbine and cisplatin/carboplatin
Q2. Could you please provide the total number of patients with any treatment in the last three months for:
a. Total non-small cell lung cancer (NSCLC)
b. Squamous non-small cell lung cancer (Sq NSCLC)
c. Non-squamous non-small cell lung cancer (Non-Sq NSCLC)
Download response Incidence and treatment of Lung cancer. 091020
Incidents of Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL).170622.docx
Q1. How many patients has your trust treated in the past 3 months for the following conditions:
a. Chronic Lymphocytic Leukaemia (CLL)
b. Mantle Cell Lymphoma (MCL)
c. In case you do not treat either of the above conditions, please tell us which trust or hospital you refer patients to.
Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:
a. BR (bendamustine + rituximab)
b. Calquence (acalabrutinib)
c. FCR (fludarabine + cyclophosphamide + rituximab)
d. Gazyva (obinutuzumab) + chlorambucil
e. Imbruvica (ibrutinib)
f. Venclexta (venetoclax)
g. Venclexta (venetoclax) + Gazyva (obinutuzumab)
h. Venclexta (venetoclax) + rituximab
i. Zydelig (idelalisib) + rituximab
j. Any other systemic anti-cancer therapy
Q3. How many Mantle Cell Lymphoma (MCL) patients have been treated in the past 3 months with the following:
a. BR (bendamustine + rituximab)
b. Imbruvica (ibrutinib)
c. Imbruvica (ibrutinib) + rituximab
d. R-BAC (rituximab, bendamustine and cytarabine)
e. R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone)
f. Nordic Protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, cytarabine & prednisolone)
g. Velcade (bortezomib) + chemotherapy
h. Any other systemic anti-cancer therapy
i. Stem cell transplant
j. Tecartus (CAR-T) – Autologous anti-CD19-transduced CD3+ cells
Q4. Does your trust currently participate in any ongoing clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL)? If so, can you please provide the name of each trial along with the number of patients taking part?
Q5. Does your trust currently participate in any ongoing clinical trials for the treatment of Mantle Cell Lymphoma (MCL)? If so, can you please provide the name of each trial along with the number of patients taking part?
Incidents of Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL).170622.docx
Car parking
Car Parking Charges
How much money did the trust raise from car parking charges in each of the last four years (state the amount and the years for which figures are available)?
Do you charge for disabled parking? If so, how much of the total amount raised by the trust from car parking charges came from disabled parking?
Do you employ a private firm to run the car park for you? If so, how much of the money generated by parking fees is taken by the private firm?
Please provide a breakdown of your car park charges – per hour/per day/per week.
Do you provide concessions for long-term visitors? What are these?
Download response Car Parking Charges 181115
Hospital Parking Charges
How much money was generated by your hospital trust through parking charges in the hospital car parks during 2013-14 and 2014-15?
How many parking fines were issued for parking infringements in your car parks during 2013-14 and 2014-15?
How many parking fines were written off during 2013-14 and 2014-15?
Download response Hospital Parking Charges 200515
Abandoned motor vehicles
1) How many instances of abandoned motor vehicles were recorded between 2004-15? If the data doesn’t stretch back to 2004, please use the earliest you have.
2) If a 3rd party was called to recover, what was the average cost involved?
Download response Abandoned motor vehicles 181215
Cancer care or treatment 2015-2016. 020317
1. In the years 2015 & 2016 of the patients that became resident for Cancer care/treatment with inside a hospital managed by your trust, please list the annual total for the patients as described?
2. Further to the above please also provide the annual total for those patients’ families who received a pass entitling free parking during the patients stay to reduce the financial burden on the family visiting?
Download response Cancer care or treatment 2015-2016. 020317
Car park management 070317
1. Please could you confirm when your contract for Car Park Management will expire and also when the contract will be re-tendered?
2. Do you currently manage your own car parks or use a Car Park Management company?
3. Which Portal does the trust use when they tender the Car Park Management out?
Car parking
1. Please state what the income was to the Trust from parking income in patient car parks in (i) the (14/15) financial year and (ii) the (15/16) financial year?
2. What is the highest hourly rate for parking charged to patients in any of your car parks?
Car parking 071116
1. How much revenue did the Trust receive from car parking fees between 1st October 2015 and 1st October 2016?
2. What are the Trusts rates per hour and per day (can you indicate if this varies between hospitals in the Trust)? Is there any way to get a reduction in this rate?
3. Has the Trust increased the parking charge in the last two years and if so by how much?
4. If the Trust car parks are run by an outside firm and can you please say who that is?
Car parking 071116
1. How much revenue did the Trust receive from car parking fees between 1st October 2015 and 1st October 2016?
2. What are the Trusts rates per hour and per day (can you indicate if this varies between hospitals in the Trust)? Is there any way to get a reduction in this rate?
3. Has the Trust increased the parking charge in the last two years and if so by how much?
4. If the Trust car parks are run by an outside firm and can you please say who that is?
Car parking. 091220
1. Do you currently manage your car parking in-house or do you contract to a third party?
2. If you do employ a parking operator to manage your parking services, who is your current parking provider?
3. What is the exact date your current contract/s terminate?
4. Does the Trust receive the income generated from the hospital parking and notice charges or does the income go to a third party?
5. Please confirm the revenue amount generated from the third-party provider if there is one
6. What are the key challenges that the Trust face with regards to the parking provision?
7. Can you confirm the expenditure on maintenance for the car park equipment for 2019/2020?
8. Overall what was the profit generated by the trust after the cost of maintaining and staffing the car park for 2019/2020?
Car parking. 190717
1. Hourly Car Parking Charges
2. Daily Car Parking Charges
3. Weekly Car Parking Charges
4. Car Parking Charges for Blue Badge Holders
5. Car Parking Charges for Staff
Car parking 2015-2016 221216
1. Are your carparks managed by a private contractor? If yes, please provide the name of the contractor.
2. How many parking enforcement tickets were issued in your carparks between 1st April 2015 and 31st March 2016?
3. What is the cost of a parking enforcement fine in your carparks?
4. How many parking enforcement ticket appeals did you receive between 1st April 2015 and 31st March 2016?
5. How many parking enforcement ticket appeals were successful between 1st April 2015 and 31st March 2016?
Car parking. 210318
1. The income earned from hospital car parking charges for the financial years:
1. 2014-2015
2. 2015-2016
3. 2016-2017
2. The money spent on maintenance for car parking facilities in the financial years:
1. 2014-2015
2. 2015-2016
3. 2016-2017
3. Where the income earned from hospital car parking facilities was spent in the financial years:
1. 2014-2015
2. 2015-2016
3. 2016-2017
Car parking. 240119
Subject to the Freedom of Information Act, I would like to request the following information in the relation to the Trust and associated hospitals.
1. Do you currently manage your car parking in-house or do you contract to a third party?
2. If you do employ a parking operator to manage your parking services, who is your current parking provider?
3. What is the exact date/s your current contract/s terminate?
4. What date do you expect to go to tender?
Car parking at the Trust sites 261015
Under the Freedom of Information Act 2000, I am seeking the following pieces of information in relation to parking at the hospitals covered under your trust.
1. The parking ticket costs at the hospitals under your trust.
2. How much does your trust – or a third party contracted by the trust – charge in fines and/or penalty notices if people are deemed to have breached parking rules?
3. What is the revenue from visitors paying for parking tickets? I would like this broken down for each hospital. I would like this information annually for 2012-2013, 2013-2014, and 2014-2015.
4. What is the revenue received from the payment of fines and/or penalty notices? I would like this broken down for each hospital. I would like this information annually for 2012-2013, 2013-2014, and 2014-2015.
Car parking charges. 011118
1. Do hospitals in your area charge patients/visitors to park in their own car park?
2. If so, how much do they charge?
3. Do the hospitals operate their car park under a PFI contract?
Car parking charges 041116
How much money did the trust raise from car parking charges in each of the last four financial years (state the amount and the years for which figures are available)? Include a breakdown of staff and visitor/patient parking if possible.
How much money was raised from parking fines in each of the last four financial years (state the amount and the years for which figures are available)? Include a breakdown of staff and visitor/patient fines if possible.
Do you charge for disabled parking?
Do you employ a private firm to run the car park for you? If so, how much of the money generated by parking fees is taken by the private firm?
Car parking charges. 111217
1. How much money did the trust raise from car parking charges in each of the last four financial years – up to and including 2016/17 (state the amount and the years for which figures are available)? Include a breakdown of staff and visitor/patient parking if possible.
2. How much money was raised from parking fines in each of the last four financial years (state the amount and the years for which figures are available)? Include a breakdown of staff and visitor/patient fines if possible.
3. Do you charge for disabled parking?
4. Do you employ a private firm to run the car park for you? If so, how much of the money generated by parking fees is taken by the private firm?
Car parking charges. 160519
1. How much money did the trust raise from car parking charges in each of the last two financial years – 2017/18 and 2018/19? Include a breakdown of staff and visitor/patient parking if possible.
2. How much money was raised from parking fines in each of the last two financial years – 2017/18 and 2018/19? Include a breakdown of staff and visitor/patient fines if possible.
3. Have you increased the cost of parking in your car parks during the last financial year – between 2017/18 and 2018/19? Please give a breakdown of how much parking has increased by.
4. Do you charge for disabled parking?
5. Is your car park managed by a private firm? If so, what proportion of revenue created by a) parking income and b) parking fines does the firm take?
Car parking charges. 181019
1. How much money did the trust raise from car parking charges in each of the last two financial years – 2017/18 and 2018/19? Include a breakdown of staff and visitor/patient parking if possible.
2. How much money was raised from parking fines in each of the last two financial years – 2017/18 and 2018/19? Include a breakdown of staff and visitor/patient fines if possible.
3. Have you increased the cost of parking in your car parks during the last financial year – between 2017/18 and 2018/19? Please give a breakdown of how much parking has increased by.
4. Do you charge for disabled parking?
5. Is your car park managed by a private firm? If so, what proportion of revenue created by a) parking income and b) parking fines does the firm take?
Car parking charges 2015/2016 to date.
1. How much money has the trust raised from car parking charges so far this year?
2. How many parking fines were issued for parking infringements in your car parks so far this year?
3. How many parking fines were written off so far this year?
Download response Car parking charges 2015/2016 to date 100516
Car parking charges 2016. 140317
1. Name of your organisation
2. Does your Trust use a private contractor to oversee the car park?
Yes (if yes please provide name of contractor)
No
Parking Charges
3. Parking charges made to general public (patients, visitors, etc.)
4. Parking charges made to staff
5. Agreed exemptions from charges
6. How income from charges is used
Parking Fines (fines issued from 1 January 2016 to date)
7. Number of fines issued to the general public
8. Income from those fines
9. Number of fines issued to staff
Income from those fines
10. How income from fines is used
11. Does the policy for fining staff differ from the fines policy for the general public?
Yes (if yes, please advise how the policy differs) No
12. Please provide details of any policy or agreements covering car parking charges (e.g. collective agreement with NHS Trade Unions)
Car parking charges. 280918
1. How much money did the trust raise from car parking charges in each of the last two financial years – 2016/17 and 2017/18? Include a breakdown of staff and visitor/patient parking if possible.
2. How much money was raised from parking fines in each of the last two financial years – 2016/17 and 2017/18? Include a breakdown of staff and visitor/patient fines if possible.
3. Have you increased the cost of parking in your car parks during the last financial year – between 2016/17 and 2017/18? Please give a breakdown of how much parking has increased by.
4. Do you charge for disabled parking?
Car parking charges and fines. 070618
1) How much revenue was made by Maidstone and Tunbridge Wells NHS Trust on all car parking charges and fines in 2015, 2016 and 2017. Please break this down by charges and fines.
2) How much profit was made by Maidstone and Tunbridge Wells NHS Trust on all car parking charges and fines in 2015, 2016 and 2017. Please break this down by charges and fines.
Car parking contract. 051021.docx
Can you please confirm if you planning to extend the current contract with APCOA or extend, if so could you please confirm for how long?
Car parking contractor
Could you please advise me if you manage the Car Parking facilities on your own or do you employ a contractor to manage the facilities for you? I.e. ANPR, POF’s and PCN’s etc. If you use a contractor can you please advise me who they are and when their existing contract with yourselves expire?
Download response Car parking contractor 080515
Car parking facilities.180123.docx
1. Could you please advise me if you manage the car parking facilities on your own, or do you employ a private operator/contractor to manage the facilities for you i.e., ANPR, POFs and PCNs etc?
2. If you use a private operator/contractor, can you please advise me who they are and when their existing contract with yourselves expires?
Car parking income. 290620
1. How much money was generated by your hospital trust through parking charges in the hospital car parks during 2019-20?
2. How many parking fines were issued for parking infringements in your car parks during the year stated above?
3. How many parking fines were written off during the year stated above?
Car Parking Management Services and Security Services Management. 150421
Car Parking Management Services and Security Services Management for Maidstone & Tunbridge Wells NHS Trust:
https://procontract.due-north.com/Advert?advertId=db2f64cd-fa28-e711-80df-005056b64545
The details we require are:
1. Suppliers who applied for inclusion on each framework/contract and were successful & not successful at the PQQ & ITT stages
2. Actual spend on this contract/framework (and any sub lots), from the start of the contract to the current date
3. Start date & duration of framework
4. Is there an extension clause in the framework(s)/contract(s) and, if so, the duration of the extension?
5. Has a decision been made yet on whether the framework(s)/contract(s) are being either extended or renewed?
6. Who is the senior officer (outside of procurement) responsible for this contract?
Download response Car Parking Management Services and Security Services Management. 150421
Car parking revenue. 241017
How much revenue the hospital trust made through the charging of hospital car parking in 2016?
Contract for MTW car parking and Security provider
Can you please provide a copy of your current Security Contract?
Download response Contract for MTW car parking and Security provider 060416
Cost and revenue of car parking 2010 – 2016
1. The total amount of revenue generated by in each of the last 5 years by car parking.
2. What was the cost for an hour of car parking in 2010 and 2016?
Download response Cost and revenue of car parking 2010 – 2016 060916
Disabled parking for staff. 030719
1. How many staff members at the trust are declared disabled?
2. How many staff members with a disability use the staff car park?
3. Do the trust charge disabled staff for parking?
4. If yes in Q3 is this charge at a discounted rate compared to a non-disabled staff member?
5. How much is staff car parking for disabled staff and non-disabled staff?
Disclosure and Barring checks and staff parking. 221116
1) How many nurses and midwives (from Band 5 upwards) waiting to take up employment with your trust are awaiting completion of Disclosure and Barring Service (DBS) checks?
2) How long is the average wait for DBS approval for new starters at your organisation?
3) How many parking spaces at your hospitals are exclusively for staff use and how much do they pay to use them?
4) What is your FTE nursing and midwifery staff establishment (from Band 5 upwards)?
Download response Disclosure and Barring checks and staff parking. 221116
Electric Vehicle charging points.
1) Does your organisation already offer charging facilities (Electric Vehicle Charging Points EVCP) for electric vehicles and if so, how many charge points?
2) If there is currently no charging provision, what plans do you have to install EVCP and when?
3) Will the charge points be for fleet usage or public charging?
4) Within your organisation, which department is responsible for the selection and installation of EVCP?
Free NHS Staff Parking.220722.docx
1. Do you provide free parking for NHS staff and/or patients?
2. If not, how much do you charge staff to park?
3. how long does it take for staff to be issued a permit when joining your trust?
Hospital parking. 190719
1. Please state the current fee for parking at the trust for one hour. (If there is no specific fee for one hour, please state the lowest possible time and cost)
2. Please state the fee for parking for one hour in 2018.
3. Please tell me whether the hospital provides free parking for any of the following groups a) cancer patients b) disabled patients c) other patients who are frequent visitors to the trust d) the relatives of patients who are frequent visitors.
4. Please tell me if the hospital provides reduced parking for any of the following groups a) cancer patients b) disabled patients c) patients who are frequent visitors d) the relatives of patients who are frequent visitors 5. If yes to question 4, please provide details.
6. Please state how much the trust collected in parking charges and fines in a) 2018/19 and b) 2017/18.
7. Does the trust hire any private firms to issue parking fines or clamp vehicles?
8. If yes to question 7, please provide the names of these firms
Hospital parking 2013-2017. 060617
1. How much money was generated by your hospital trust through parking charges in the hospital car parks during 2013-14, 2014-15, 2015-16 and 2016-17?
2. How many parking fines were issued for parking infringements in your car parks during the years stated above?
3. How many parking fines were written off during the years stated above?
Hospital parking overstaying fines.300621
1. How many fines have been issued by the hospital for overstaying at Maidstone Hospital and Tunbridge Wells Hospital in Pembury?
2. Can this be broken down year by year from 2018 to 2021 (to date)
– 2018
– 2019
– 2020
– 2021
3. Can you also confirm how much the fines cost, where the money goes to and the outcome of the fines (e.g. paid for, rescinded or other action)
Children's Services
6-in-1 vaccine. 170718
a) The number of 6-in-1 vaccines offered to be given to babies in the financial years 2017/18, 2016/17, and 2015/16.
b)The number of 6-in-1 vaccines that were refused by parents or guardians of the baby in the financial year 2017/18, 2016/17, and 2015/16.
c) The number of children diagnosed with any of the following in 2017/18 alone, who had not received the 6-in-1 vaccine when they were a baby because their parent or guardian had refused it. If a child was diagnosed with more than one of the below, please provide that information: diphtheria, hepatitis B, Hib, polio, tetanus, or whooping cough
Acute Trust CYP Healthcare. 050821.docx
For every month from 1 January 2019 to 31 May 2021, please answer the following questions:
1 In that month, how many children and young people (CYP) aged 18 and under did you refer to CAMH services after they arrived in your emergency department(s)?
2 In that months, of these CYP in question one, how many were referred to CAMH services for treatment of a suspected or confirmed eating disorder? If helpful, please search against the ICD Code F50.0, which may be included in the referral.
3 In that month, how many CYP were admitted to or treated by your acute hospital trust for the following:
3 a Treatment of an eating disorder, such as refeeding and medical stabilisation? If helpful, please search against the ICD Code F.50, which should cover all relevant eating disorder diagnoses.
3 b Treatment of self-inflicted injury? If helpful, please search against ICD Codes X60 to X69.
3 c Treatment of drug or other toxic substance overdose, whether accidental or intentional? If helpful, please search against ICD Codes X70 to X84.
4 In this month, how many CYP were admitted to your acute trust for compulsory treatment with use of the Mental Health Act?
5 In this month, of those CYP admitted to your acute trust for compulsory treatment with use of the Mental Health Act, how many had an eating disorder diagnosis (ICD Code in the F50 category)?
A&E and Outpatient Paediatric attendances. 250419
1- Number of paediatric patient attended A/E in 2018, Tunbridge wells hospital
2- Number of patient attended paediatric OPD (outpatient department) in 2018, Tunbridge wells hospital
Download response A&E and Outpatient Paediatric attendances. 250419
Ankylossia (tongue-tie). 270918
1. How many babies (i.e.) below the age of 1) were diagnosed with issues of Ankylossia (tongue-tie) in each financial year since 2013/14.
2. Of the babies diagnosed with issues of Ankylossia (tongue-tie) in 2017 how many had a surgical procedure carried out by NHS surgeons to resolve these specific issues, and how long did they wait (on average, in calendar days) for the procedure following diagnosis?
3. In 2017, what was the mean age of babies with such issues when the Ankylossia (tongue-tie) procedure was performed?
Anorexia and bulimia in under 14 year olds.
The number of children under the age of 14 your trust has treated for anorexia and bulimia from 1 January 2010 up until the date this request was received.
Please provide the information in yearly breakdowns;
Please break the numbers down by age and, if possible, by gender;
Please keep the data for anorexia and bulimia separate;
Download response Anorexia and bulimia in under 14 year olds 060916
Ante natal screening or diagnostic results for Down syndrome. 100519
Please send me an example of all of the following that are in use:
a) Letter/email reporting low chance combined or quadruple screen results
b) Letter/email reporting high chance combined or quadruple screen results
c) Letter/email reporting low chance NIPT results
d) Letter/email reporting high chance NIPT results
e) Letter/email reporting ‘no result’ NIPT results
f) Letter/email reporting negative QF-PCR/FISH CVS results
g) Letter/email reporting positive QF-PCR/FISH CVS results
h) Letter/email reporting negative full karyotype CVS results
i) Letter/email reporting positive full karyotype CVS results
j) Letter/email reporting negative amniocentesis result
k) Letter/email reporting positive amniocentesis result
Download response Ante natal screening or diagnostic results for Down syndrome. 100519
ASD waiting times.230522.docx
QUESTION 1
A. How many children are currently waiting to receive a first assessment appointment?
B. What is the average wait time for these children, starting from the point of initial referral?
C. How many of these children have been waiting longer than 13 weeks?
D. What are the longest three wait times for these children?
QUESTION 2
A. How many children are currently waiting to receive a second assessment appointment?
B. What is the average wait time for these children to receive a second appointment, since their first appointment?
C. What are the longest three wait times for these children, since their first appointment?
QUESTION 3
A. How many children are currently waiting to receive a diagnosis (ie. waiting for an assessment outcome to find out whether they do or do not have ASD)?
B. What is the average wait time, since the point of initial referral?
C. What are the longest three wait times for these children, since their initial referral?
QUESTION 4
A. In the year up to 31 March 2022, how many children with suspected autism received a first assessment appointment?
B. What was the average wait time for these children to receive a first assessment appointment, since their initial referral?
C. What were the longest three wait times for these children to receive a first diagnostic appointment, since their initial referral??
QUESTION 5
A. In the year up to 31 March 2022, how many children with suspected autism received a second assessment appointment?
B. What was the average wait time for these children to receive a second diagnostic appointment, since their first appointment?
C. What were the longest three wait times for these children to receive a second assessment appointment, since their first appointment?
QUESTION 6
A. In the year up to 31 March 2022, how many children with suspected autism received an ASD diagnosis?
B. What was the average wait time for these children to receive an ASD diagnosis, since their initial referral?
C. What were the longest three wait times for these children to receive an ASD diagnosis, since their initial referral?
QUESTION 7
A. In the year up to 31 March 2021, how many children with suspected autism received a first assessment appointment?
B. What was the average wait time for these children to receive a first assessment appointment, since their initial referral?
QUESTION 8
A. In the year up to 31 March 2021, how many children with suspected autism received a second assessment appointment?
B. What was the average wait time for these children to receive a second diagnostic appointment, since their first appointment?
QUESTION 9
A. In the year up to 31 March 2021, how many children with suspected autism received an ASD diagnosis?
B. What was the average wait time for these children to receive an ASD diagnosis, since their initial referral?
QUESTION 10
A. In the year up to 31 March 2020, how many children with suspected autism received a first assessment appointment?
B. What was the average wait time for these children to receive a first assessment appointment, since their initial referral?
QUESTION 11
A. In the year up to 31 March 2020, how many children with suspected autism received a second assessment appointment?
B. What was the average wait time for these children to receive a second diagnostic appointment, since their first appointment?
QUESTION 12
A. In the year up to 31 March 2019, how many children with suspected autism received an ASD diagnosis?
B. What was the average wait time for these children to receive an ASD diagnosis, since their initial referral?
QUESTION 13
A. In the year up to 31 March 2020, how many children with suspected autism received an ASD diagnosis?
B. What was the average wait time for these children to receive an ASD diagnosis, since their initial referral?
QUESTION 14
A. In the year up to 31 March 2019, how many children with suspected autism received a first assessment appointment?
B. What was the average wait time for these children to receive a first assessment appointment, since their initial referral?
QUESTION 15
A. In the year up to 31 March 2019, how many children with suspected autism received a second assessment appointment?
B. What was the average wait time for these children to receive a second diagnostic appointment, since their first appointment?
Asthma treatment and care for Children. 240321
Please provide numbers spanning the last 3 years – please segment by year where possible (i.e. 2018, 2019, 2020 – to date) for the following questions:
1. How many children age 7 and under have been admitted/treated for asthmatic symptoms in your Trust in these 3 instances:
a. Have been diagnosed as displaying asthmatic symptoms
b. Have been prescribed home treatment (reliever at home)
c. Have been admitted to A&E / ER for emergency treatment
2. For what number of children aged 7 and under was their admission to A&E/ER/Emergency GP (for asthmatic symptoms) their first instance of having asthmatic symptoms diagnosed and treated (i.e. the first instance of the NHS being made aware of asthmatic symptoms)?
3. How many children age 7 or under have had to be treated due over-medication of prescribed asthma medication?
4. How many children age 7 or under have had to be treated due under-medication of prescribed asthma medication?
5. What number of children age 7 and under are referred to a paediatrician/3rd party to help manage their asthmatic symptoms?
6. Yes/No: Has your trust seen a decline in parents seeking medical help for children aged 7 and under with asthma/asthmatic symptoms since March 2020?
Download response Asthma treatment and care for Children. 240321
Audiology services for children and young people.150317
1. Thinking about the 2015/16 financial year, did your service experience longer waiting times for?
2. Were there any changes in policy or practice in what your audiology service provided in 2015/16?
3. If you have ticked yes to any of the above, please tell us what has changed and the reasons for the
Change
4. At what age does your service transfer deaf young people to adult services?
5. Were there any changes to how your audiology service for deaf children is commissioned in 2015/16?
6. Were there any changes in the number and skill-mix of full time equivalent (FTE) staff in your team, including administrative staff, in 2015/16?
7. If you have ticked yes to any of the above, please describe in more detail what has changed (including the number of staff reductions, if any) and the reasons for the change.
8. Was there a training programme in place for audiologists in your service in 2015/16?
9. If yes, were there any changes to the availability of training in 2015/16?
10. Looking ahead to the 2016/17 financial year, are you aware of any planned changes to any of the below?
11. Did your service provide informal family support services such as parent coffee mornings, playgroups, use of voluntary sector, etc. in 2015/16?
12. If yes, were there any reductions in informal family support services in 2015/16?
13. Is anyone from the audiology team involved in the development of Education Health and Care plans?
14. Have you faced any barriers to being involved in developing Education Health and Care plans?
15. If yes, what were the barriers?
16. Did your service provide any assistive listening devices or take any action to ensure they work effectively with the child’s personal amplification in 2015/16?
17. If you have ticked any of the above, were there any reductions in the provision of assistive learning devices or services to ensure they work effectively with the child’s personal amplification in 2015/16
18. Has your service gained accreditation with (Improving Quality in Physiological Diagnostic Services) IQIPS?
19. Has your service registered for the IQIPS process?
20. Has your service started using the Self-Assessment and Improvement Tool (SAIT)?
21. Has your service applied to UKAS to begin the accreditation peer review process?
22. Has your service booked or completed its onsite assessment with UKAS?
23. If you have not registered with the SAIT for IQIPS, what are your reasons for not doing so?
24. What are the most successful aspects of your audiology service at the moment?
25. What are main challenges or problems facing your audiology service at the moment?
26. Is there anything else you would like to tell us about the audiology service and any future plans?
* 27. Your name:
* 28. Your role:
* 29. Name of audiology service (please don’t use abbreviations):
* 30. Name of Trust that provides the paediatric audiology service (please don’t use abbreviations):
* 31. Sites where paediatric audiology is delivered by your service (please don’t use abbreviations):
Download response Audiology services for children and young people.150317
Babies born in 2015 whose birth-weight was 12lbs or 5443g or more.
In the 2015 calendar year were there any babies born at your hospitals where the weight of the baby was 12lbs (5443g) or more? If so please state how many and what their birth-weights were.
Download response Babies born in 2015 whose birth-weight was 12lbs or 5443g or more 280416
Babies born with neonatal abstinence syndrome 2016-2017. 150517
How many babies were born with neonatal abstinence syndrome (showing signs of drug addiction because of their mother taking drugs during pregnancy) at hospitals run by your trust in the past financial year, April 2016 to April 2017? Please break the figures down by hospital.
Download response letter Babies born with neonatal abstinence syndrome 2016-2017. 150517
Babies born to drug dependent mothers. 151118
You asked:
For each year between 2009 and up-to the end of 2017, how many babies born under your trust were born to drug dependent mothers and once born, were transferred to a drug treatment programme to wean them off their addiction?
Download response Babies born to drug dependent mothers. 151118
Babies injured during assisted delivery. 280317
1) Please state the number of babies that were injured during delivery when tools to assist in delivery were used, for example a vacuum extractor or forceps.
Please provide information for each of the following calendar years:
i) 2014
ii) 2015
iii) 2016
iv) 2017 to date
2) Of these babies injured, please provide a breakdown of injuries that they suffered. Please provide a summary of each incident, including the cause of the injury.
Please provide information for each of the following calendar years:
i) 2014
ii) 2015
iii) 2016
iv) 2017 to date
3) Please state the number of babies injured during delivery due to hospital error.
Please provide information for each of the following calendar years:
i) 2014
ii) 2015
iii) 2016
iv) 2017 to date
Download response Babies injured during assisted delivery. 280317
Babies over 12lbs (5443g) at birth. 070421
1. In the 2018 calendar year were there any babies born at your hospitals where the weight of the baby was 12lbs (5443g) or more? If so please state how many and what their birthweights were.
2. In the 2019 calendar year were there any babies born at your hospitals where the weight of the baby was 12lbs (5443g) or more? If so please state how many and what their birthweights were.
3. In the 2020 calendar year were there any babies born at your hospitals where the weight of the baby was 12lbs (5443g) or more? If so please state how many and what their birthweights were.
Download response Babies over 12lbs (5443g) at birth. 070421
Babies weighing 12lbs (5443g) or more at birth 2016. 250417
In the 2016 calendar year were there any babies born at your hospitals where the weight of the baby was 12lbs (5443g) or more? If so please state how many and what their birthweights were.
Download response Babies weighing 12lbs (5443g) or more at birth 2016. 250417
Baby weights 2015-2016
I would like to know the following regarding live births:
1. The weights of the five heaviest babies that were born in the Trust last year – financial (2015-16) or calendar (2015) year, whichever is easiest.
2. The weights of the five lightest babies that were born in the Trust last year for pregnancies that reached around full term (i.e. that weren’t born prematurely).
Bed shortages and overcrowding. 310117
1. Do you have any strategy or informal policy that allows adults to be treated in beds/wards that are usually used for paediatric care to help with overcrowding?
2. What is that wording of that strategy?
3. When as it first drawn up?
4. How many times since January 2016 year has this been implemented? If applicable, how many times was it implemented between Jan 2015 and Jan 2016?
5. How many individual adult patients since January 2016 have been treated on child wards/bed -with dates if possible? And the same figure Jan 2015-16.
6. Were there any occasions when adults and children were treated on the same ward?
7. How many times has the hospital been on a) black alert and b) red alert for capacity since January 2016? How many times was it put on a and b from January 2015 – 2016?
Bereavement of babies
(a) Does your trust have a bereavement suite available for use by parents in the event of limited life expectancy of an anticipated birth of a child?
(b) If the answer to (a) is no, what alternative arrangements are available?
(c) If the answer to (a) is yes, would parents of a baby who turn up at hospital with a sudden infant death be allowed to use the bereavement suite?
(d) If the answer is yes to (a) where in relation to the Labour ward is the suite located?
(e) Do you have bereavement trained midwives? If yes, how many?
(f) Do you have a trained bereavement councillor at the hospital? If yes, what is the average waiting time to be able access support from that councillor?
(g) Do you provide any written information to parents following the loss of a baby? If yes, please name the third sector organisation information is provided from.
(h) Can you list the guidelines around infant death which are implemented by the hospital?
(i) Does the hospital provide support around funeral arrangements for infants or babies who have died at the hospital?
Births and deaths.100223.docx
For the time period 1 April 2022 to 31 December 2022, if you do not have figures available for the whole period, please provide the most up-to-date figures and state the period they cover.
LIVE BIRTHS
1. How many live births were there at your hospital Trust in the following periods?
(Please exclude home births from this number and detail them separately in brackets.)
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
STILL BIRTHS
2a. How many stillbirths were there at your hospital Trust in the same periods?
Stillbirth is defined as occurring when a baby is born dead after 24 completed weeks of pregnancy.
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
2b. Of these stillbirths (in answer 2a) how many were Intrapartum stillbirths?
Intrapartum stillbirth is defined as when a baby was thought to be alive at the start of labour but was born, beyond 37 weeks of gestation, with no signs of life.
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
2c. Of the Intrapartum stillbirths (in answer 2b) how many were referred to HSIB?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
2d. Of the Intrapartum stillbirths referred to HSIB (in answer 2c), how many did HSIB investigate?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
NEONATAL DEATHS
3a. In the same periods, how many Neonatal deaths were there at your hospital Trust?
Neonatal deaths are defined as a baby that dies within 28 days of birth of any cause or, for the purposes of this process, a baby who dies that has not left hospital since birth.
If a baby was born at your hospital Trust and was transferred to another hospital and died at another hospital Trust, please exclude them from these numbers and specify the number separately in brackets.
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
3b. Of these Neonatal deaths (in answer 3a) how many were ‘early Neonatal deaths’?
Early Neonatal deaths are defined as a baby that dies within the first week of life (0-6 days) of any cause.
If a baby was born at your hospital Trust and was transferred to another hospital and died at another hospital Trust, please exclude them from these numbers and specify the number separately in brackets.
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
4a. Of the Neonatal deaths (in answer 3a) at your hospital Trust, in how many cases was the medical cause identified?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
4b. Of the Early Neonatal deaths (in answer 3b) at your hospital Trust, in how many cases was the medical cause identified?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
5a. Of the Neonatal deaths at your hospital Trust, where the medical cause was identified (in answer 4a), how many were referred to the Coroner?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
5b. Of the Early Neonatal deaths at your hospital Trust, where the medical cause was identified (in answer 4b), how many were referred to the Coroner?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
6a. Of the Neonatal deaths at your hospital Trust, in how many cases was the medical cause not identified?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
6b. Of the Early Neonatal deaths at your hospital Trust, in how many cases was the medical cause not identified?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
7a. Of the Neonatal deaths at your hospital Trust, where the medical cause was not identified, how many were referred to the Coroner?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
7b. Of the Early Neonatal deaths at your hospital Trust, where the medical cause was not identified, how many were referred to the Coroner?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
8a. Of the Early Neonatal deaths (in answer 3b) at your hospital Trust, how many were referred to HSIB?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
8b Of the Early Neonatal deaths referred to HSIB (in answer 8a), how many did HSIB investigate?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
HYPOXIC ISCHEMIC ENCEPHALOPATHY
9a. Of the Neonatal deaths at your hospital Trust, in how many cases was the cause of death recorded as Hypoxic Ischemic Encephalopathy?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
9b. Of the Neonatal deaths at your hospital Trust, where the cause of death was recorded as Hypoxic Ischemic Encephalopathy, how many were referred to the coroner?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
9c. Of the Neonatal deaths at your hospital Trust, where the cause of death was recorded as Hypoxic Ischemic Encephalopathy (in answer 9a), how many were referred to HSIB?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
9d. Of the Neonatal deaths at your hospital Trust, where the cause of death was recorded as Hypoxic Ischemic Encephalopathy (in answer 9c), how many did HSIB investigate?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
Please provide a copy of your hospital Trust’s current policy in respect of referring Neonatal deaths to a coroner and advise the date it was last updated.
MATERNAL DEATHS
10a. How many maternal deaths were there at your hospital Trust in the same periods?
Maternal deaths are defined as the death of a woman while pregnant or within 42 days of the end of the pregnancy from any cause related to or aggravated by the pregnancy or its management, and not from accidental or incidental causes. Excludes death by suicide.
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
10b. In how many cases of maternal death was a Neonatal death also recorded?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
10c. In how many cases of maternal death where a Neonatal death also recorded, was the death an Early Neonatal death?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
11. Of the maternal deaths at your hospital Trust (in answer 10a), how many were referred to HSIB?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
Birthweights. 250419
In the 2018 calendar year were there any babies born at your hospitals where the weight of the baby was 12lbs (5443g) or more? If so please state how many and what their birthweights were.
Bounty. 110219
In the 12 months to date (23.08.18) please confirm the following:
1) Whether the Trust currently is, or has been in the past 12 months, engaged in a contract or written agreement with Bounty UK Limited. If the Trust is currently engaged in a contract please attach a copy of it, making necessary redactions in order to comply with the Act. Please provide the date that the contract began and/ or ended. Please provide an overview of the terms of payment. (i.e. per mother visited / per photo pack purchased).
2) Please confirm how much money has been paid to the Trust by Bounty UK Limited in the past 12 months and how many new mothers are recorded as having been approached by Bounty representatives (if held).
3) Please provide details of the policies the Trust has in place with regards to protecting new mothers (i.e. are representatives allowed on any ward at any time, or do they have restricted access? Are mothers given the option to opt out of being visited?)
4) Please confirm the number of complaints made to the Trust by new parents. If not time prohibitive, please provide details of the complaints.
Bounty Packs. 110219
Q1) Please provide the name of your Trust
Q2) Do you have a contract with Bounty, whose representatives hand out ‘Bounty Packs’ to new mothers on maternity wards?
Q3) If you answered YES to Question 2, how much money did your trust receive from Bounty in the financial years;
Q4) Please explain how the payment from Bounty is calculated (i.e. a pre-agreed figure, or a set payment per child born in your care).
Q5) How many babies were born in your care during the financial years?
Brain cooling in babies. 011217
1. Please provide the number full term babies at 36 weeks or later who , because of HIE, were transferred for consideration of brain cooling to a tertiary centre for the following calendar years 2014,2015, 2016 and 2017 to date. ( if you are already one of those tertiary centres then please let me know how many babies were considered for brain cooling because of HIE.)
2. For those same babies, and years, please let me know how many were subject to a serious incident report relating to childbirth?
CAMHS. 170818
1) How many children received treatment from your local CAMHS in the financial years:
a. 2014/15
b. 2015/16
c. 2016/17
d. 2017/18
2) Please can you breakdown the figures given in answer to Q1a-d by (i) the type of mental health issue that was being treated, and (ii) the ethnicity of the child?
CAMHS. 270618
How many referrals were made to CAMHS from any possible referrer for the last three financial years (April 1 2015 – March 31 2016, April 1 2016 – March 31 2017, April 1 2017 – March 31 2018)?
How many were accepted for each of the years above?
Of those accepted, how many had any of the below factors known or believed to be evident (if information is available), for each of the years above?
– Previous contact with CAMHS
– Recurrent threats or acts of self-harm
– High levels of risk
– Eating disorders
How many accepted were from each type of referrer (e.g. GP, A&E etc.) for each of the years above?
What was the mean and median waiting time between referral and treatment for each of the years above?
How many were declined for each of the years above?
Of those rejected, how many had any of the below factors known or believed to be evident (if information is available), for each of the years above?
– Previous contact with CAMHS
– Recurrent threats or acts of self-harm
– High levels of risk
– Eating disorders
How many rejected were from each type of referrer (e.g. GP, A&E etc.) for each of the years above?
CAMHS treatment.160721.docx
For each month between (and including) January 2018 and June 2021, please could you tell me the mean average number of days to elapse between a patient being assessed by your CAMHS service and that patient having their first appointment with an appropriate specialist as part of an ongoing treatment plan under CAMHS (as opposed to an appointment with a non-specialist; or supportive care while waiting for therapist availability; or an unscheduled call, letter or other contact that does not qualify as a treatment appointment)?
For each month, please could you specify which specialist or specialists were in attendance at those first treatment appointments, expressed as percentages of the total number of first treatment appointments that month (e.g., 74% of patients had their initial appointment as part of an ongoing treatment plan with a clinical psychologist, 20% with a CBT therapist etc)
Cancelled children’s operations – 01.07.16. 050517
1. How many children’s operations have been cancelled each month since 1st July 2016? Please give additional details as to what the main reasons for the cancellations were, how many were urgent operations or elective operations, and what type of illness did they involve, e.g. cancer, breathing problems, broken limbs etc.
2. How many children’s operations have been cancelled over the last four financial years to date?
Kindly note a child is anyone up to the age of 18.
Download response Cancelled children’s operations – 01.07.16. 050517
Cancelled children’s operations. 131020
The total number of children’s operations cancelled for non-clinical reasons, broken down by the cause of the cancellation, for example due to lack of beds, operating theatre capacity, staffing issues, and equipment failures. Please provide this information for each of the past three financial years 2017/18, 2018/19, 2019/20). In the total number of operations, broken down by cancellation reason, please include:
· Elective children’s operations cancelled at the last minute. For the purposes of this request, last minute means on the day the patient was due to arrive, after the patient has arrived in hospital or on the day of the operation or surgery.
· Cancelled urgent children’s operations.
For the purposes of this FOI, Children will be defined as under 18’s.
Cerebral Palsy (CP). 270618
1. What is the total number of children and young people diagnosed with Cerebral Palsy by your Trust/Health Board in the last five years? (N.B.: this should be recorded as a total figure rather than figures for each year individually.)
2. What is the care pathway for children and young people with cerebral palsy in your Trust/Health Board? Please provide a copy of this if possible.
3. Is there a specific timescale set out in your care pathway for referral to a child development service for diagnosis of cerebral palsy from the point when symptoms are initially identified? If so, please provide this data.
4. What is the total number of:
a. Health visitors employed by your Trust/Health Board?
b. Specialist health visitors for children with special needs employed by your Trust/Health Board?
5. What training is given to healthcare professionals, including health visitors and GP’s, to recognise the risk factors and possible symptoms for Cerebral Palsy?
6. What is the total number of specialist staff employed by your Trust/Health Board, who are trained to work with children and young people with Cerebral Palsy, from the following disciplines:
a. Paediatric speech and language therapy
b. Paediatric physiotherapy
c. Paediatric occupational therapy
7. How many children and young people with Cerebral Palsy are currently on a waiting list to access any of the above services within your Trust/Health Board?
Child and Adult Mental Health Services. 260218
How many people under specialist Child and Adolescent Mental Health Services were issued with the ICD-10 code F12. – ‘mental and behavioural disorders due to use of cannabinoids’, during the 2016/17, 2015/2016, 2014/2015, 2013/2014, 2012/2013, 2011/2012, 2010/ 2011, 2009/ 2010, 2008/ 2009, 2007/ 2008, 2006/ 2007 periods?
Download response Child and Adult Mental Health Services. 260218
Child and Adolescent Mental Health Services (CAMHS).
For the purposes of this request we define children and young adults as being between the ages of 0 and 25 years.
1. The information request:
Please can you provide us with the following information?
• The (a) budget and (b) expenditure for all mental health services.
• The (a) budget and (b) expenditure for Child and Adolescent Mental Health (CAMHS) services (total spend) – if you attribute to a CAMHs Tier 1-4 please specify.
• The (a) budget and (b) expenditure for mental health urgent and emergency care (including mental health crisis care) for children and young people – if only total spend is available please approximate proportion that is spent on children and young adults.
• Any additional, discretionary monies (a) budgeted for and (b) spent on child, adolescent or young adult mental health – please specify source.
We are requesting information for the financial years: 2010/11, 2011/12, 2012/13, 2014/15, 2015/16, 2016/17.
And if available – we are also requesting the projected budget (or settlement) for the financial years covering the remainder of Future in Mind and the Five Year Forward View for Mental Health, which includes: 2017/18, 2018/19, 2019/2020, 2020/21.
2. Clarifications:
If the requested information does not relate to your activity, please answer ‘not applicable’ (N/A).
If you share a budget with another organisation, please specify:
a. The name of the other organisation(s) (for example a Clinical Commissioning Group, Local Authority or NHS Trust).
b. Whether the expenditure / budget reported is the total amount of the shared budget, or your organisation’s contribution to the shared budget.
Download response Child and Adolescent Mental Health Services (CAMHS) 270616
Child drug and alcohol related admissions. 241016
This request relates to drug and alcohol related admissions of children. Please include cases where the relevant diagnoses were recorded as both the primary and secondary condition.
I) Broken down by each of the following calendar years a) 2012, b) 2013, c) 2014, d) 2015 and e) 2016 so far, please state the total number of children aged under 13 admitted to hospitals in your trust due to:
1. The toxic effect of alcohol
2. Mental and behavioural disorders due to use of alcohol
3. Poisoning by drugs, medicaments and biological substances
4. Mental and behavioural disorders due to drug and psychoactive substance use
5. Poisoning by antidepressants (subset of question 3)
6. Poisoning by ecstasy (subset of question 3)
II) Broken down by each of the following calendar years a) 2012, b) 2013, c) 2014, d) 2015 and e) 2016 so far, please state the total number of children aged 13-16 admitted to hospitals in your trust due to:
1. The toxic effect of alcohol
2. Mental and behavioural disorders due to use of alcohol
3. Poisoning by drugs, medicaments and biological substances
4. Mental and behavioural disorders due to drug and psychoactive substance use
5. Poisoning by antidepressants (subset of question 3)
6. Poisoning by ecstasy (subset of question 3)
III) Broken down by each of the following calendar years a) 2012, b) 2013, c) 2014, d) 2015 and e) 2016 so far, please state the total number of children aged 16-17 admitted to hospitals in your trust due to:
1. The toxic effect of alcohol
2. Mental and behavioural disorders due to use of alcohol
3. Poisoning by drugs, medicaments and biological substances
4. Mental and behavioural disorders due to drug and psychoactive substance use
5. Poisoning by antidepressants (subset of question 3)
6. Poisoning by ecstasy (subset of question 3)
Download response Child drug and alcohol related admissions. 241016
Child and Mental Health Services. 170817
What was the average waiting time for patients referred to the Child and Mental Health Services at your trust between May 31st 2016 and May 30th 2017?
What was the average waiting time for patients referred to the Child and Mental Health Services at at your trust between May 31st 2015 and May 30th 2016?
What was the longest waiting time for a patient referred to the Child and Mental Health Services at your trust between May 31st 2016 and May 30th 2017?
What was the longest waiting time for a patient referred to the Child and Mental Health Services at your trust between May 31st 2015 and May 30th 2016?
How often did limited capacity mean your trust had to decline access to services for patients referred to the Child and Mental Health Services between May 31st 2016 and May 30th 2017?
How often did limited capacity mean your trust had to decline access to services for patients referred to the Child and Mental Health Services between May 31st 2015 and May 30th 2016?
What’s the furthest distance a patient has had to travel from your trust to find adequate, available care from the Child and Mental Health Services between May 31st 2016 and May 30th 2017, having been turned away due to a lack of resources?
What’s the furthest distance a patient has had to travel from your trust to find adequate, available care from the Child and Mental Health Services between May 31st 2015 and May 30th 2016, having been turned away due to a lack of resources?
What age was the youngest patient dealt with by the Child and Mental Health Services at your trust between May 31st 2016 and May 30th 2017?
Child and Mental Health Services. 200418
1.a. What was the average waiting time for patients referred to the Child and Mental Health Services at your trust during the financial year 2017-2018, and what was their age and gender?
1.b. What was the average waiting time for patients referred to the Child and Mental Health Services at your trust during the financial year 2016-2017, and what was their age and gender?
1.c. What was the average waiting time for patients referred to the Child and Mental Health Services at your trust during the financial year 2015-2016, and what was their age and gender?
2.a. What was the longest waiting time for a patient referred to the Child and Mental Health Services at your trust during the financial year 2017-2018, and what was their age and gender?
2.b. What was the longest waiting time for a patient referred to the Child and Mental Health Services at your trust during the financial year 2016-2017, and what was their age and gender?
2.c. What was the longest waiting time for a patient referred to the Child and Mental Health Services at your trust during the financial year 2015-2016, and what was their age and gender?
3.a. How often did limited capacity mean your trust had to decline access to services for patients referred to the Child and Mental Health Services during the financial year 2017-2018?
3.b. How often did limited capacity mean your trust had to decline access to services for patients referred to the Child and Mental Health Services during the financial year 2016-2017?
3.c. How often did limited capacity mean your trust had to decline access to services for patients referred to the Child and Mental Health Services during the financial year 2015-2016?
4.a. What’s the furthest distance a patient has had to travel from your trust to find adequate, available care from the Child and Mental Health Services during the financial year 2017-2018, having been turned away due to a lack of resources, and what was their age and gender?
4.b. What’s the furthest distance a patient has had to travel from your trust to find adequate, available care from the Child and Mental Health Services during the financial year 2016-2017, having been turned away due to a lack of resources, and what was their age and gender?
4.c. What’s the furthest distance a patient has had to travel from your trust to find adequate, available care from the Child and Mental Health Services during the financial year 2015-2016, having been turned away due to a lack of resources, and what was their age and gender?
5.a. What age was the youngest patient dealt with by the Child and Mental Health Services at your trust during the financial year 2017-2018?
5.b. What age was the youngest patient dealt with by the Child and Mental Health Services at your trust during the financial year 2016-2017?
5.c. What age was the youngest patient dealt with by the Child and Mental Health Services at your trust during the financial year 2015-2016?
Childhood obesity services. 160320
What is the name of your acute trust?
(1) Does your trust provide a weight management service for children living with obesity?
Yes ☐ No ☐
If No, you need not answer further.
If yes, what is the name of the service and where delivered:
Who leads this service?
It is a hospital ☐ or community-based☐ clinic
(2) What if any are the criteria for eligibility to attend (for instance BMI >98th percentile)?
None ☐
Eligible if:
(3) Through what mechanism is the service funded?
CCG ☐
NHS England ☐
Research ☐
Charity ☐
Trust Self-Funding ☐
Other ☐
Please specify
(4) Who are the key personnel providing service? Please tick all who apply:
a. Paediatricians ☐
b. Dieticians ☐
c. Psychologists ☐
d. Trained volunteers ☐
e. Hospital or Community based Nursing staff ☐
f. Exercise specialists ☐
g. Social workers ☐
h. CAHMS ☐
i. Youth workers ☐
(5) How many new cases are seen each year?
(6) Over how many weeks is the clinic intervention delivered?
(7) What is the usual follow up period (entry to discharge?)
(8) What final outcomes are collected: Examples: change in BMI, BMI SDS, Self Esteem, Waist Circumference, recruitment, retention.
Please list all.
Children and Adolescent Mental Health Service (CAMHS). 051021.docx
1. The number of low secure Children and Adolescent Mental Health Service (CAMHS) and medium secure CAMHS beds within your Authority or Trust and how many of those are currently available for new admissions.
2. The number of low secure CAMHS beds within your Authority or Trust and how many of those are currently available for new admissions.
3. The number of medium secure CAMHS Service beds within your Authority or Trust and how many of those are currently available for new admissions.
4. The number of welfare social care secure beds within your Authority or Trust and how many of those are currently available for new admissions.
5. The number of forensic secure beds within your Authority or Trust and how many of those are currently available for new admissions.
Further, please could you kindly provide details of:
6. The number of young people within your Authority area or Trust area who have been assessed as requiring a CAMHS Tier 4 mental health bed but have not been admitted due to a shortage in resource (we do not require personal details or reasons for the conclusion reached, just numbers).
7. The number of young people within your Authority area or Trust area who have been assessed as requiring a CAMHS low secure mental health bed but have not been admitted due to a shortage in resource.
8. The number of children accommodated within your Authority area or Trust area in unapproved, unregulated settings.
Download response Children and Adolescent Mental Health Service (CAMHS). 051021.docx
Children attending A&E due to mental health. 120422.docx
1. Number of children attending A&E per month, since Jan 2019 due to a mental health related issue.
2. The top 10 longest stays in A&E of a child who is presenting a mental health issue over the last 12 months.
Children treated for alcohol dependency or misuse. 151118
You asked:
Please may you tell me the number of people, under the age of 18, who were treated by the trust for alcohol dependence and/or alcohol misuse in 2012, 2013, 2014, 2015, 2016, 2017, and 2018?
May you please tell me the youngest person you treated for this in 2016, 2017 and 2018?
Download response Children treated for alcohol dependency or misuse. 151118
Children’s Dental Hospital. 250417
1. As of March 31st, 2017, can you tell me how many children were on the waiting list to visit the Trust’s children’s dental hospital?
2. How long is the present waiting list, in terms of months/weeks to be seen?
3. How long is the wait for teeth extractions?
4. How many children are affected by the wait for teeth extractions?
5. Is there a wait for youngsters to be added to the waiting list? if, so how many children are waiting to be placed on to the waiting list?
6. How many dental nurses does the Trust employ at the children’s dental hospital?
7. How many vacancies does it have at present?
8. How many children were on the waiting list to visit the Trust’s children’s dental hospital on?
a) March 31st, 2016?
b) March 31st 2015?
c) March 31st 2014?
d) March 31st 2013?
9. How many children received treatment at the children’s dental hospital between January 1, 2016 and December 31, 2016?
Children’s Unit. 250919
1. Between 1st April 2018 and 31st March 2019 how many visits to/patients were/are seen at Riverbank Children’s unit? (Volume)
2. Between 1st April 2018 and 31st March 2019 how many individual patients were/are seen at Riverbank Children’s unit? (Reach)
3. How many of these were transferred to Pembury?
4. On a typical day / on average how many patients are transferred from Riverbank to woodlands every day?
5. What are the main reasons for these transfers?
6. On a typical day/ on average many patients transfer each day due to the Riverbank closing time?
7. How often/ on average how many times a week do the staff at Riverbank have to stay past 8.00pm to accommodate patients needs/ transfer to Pembury?
8. Between 1st April 2018 and 31st March 2019 how many visits to/patients were/are seen at Woodlands and hedgehog Children’s unit? (Volume)
9. Between 1st April 2018 and 31st March 2019 how many individual patients were are seen at Woodlands and hedgehog Children’s unit? (Reach)
10. How many of these were transferred from Riverbank?
Cooling-Therapeutic Hypothermia Protocol. 101220
We require sight of the Cooling/Therapeutic hypothermia protocol in the neonatal and/or Special Care Baby Unit at Maidstone & Tunbridge Wells NHS Trust, that was in force in November 2015. We are merely requesting this to provide us with knowledge in accordance with the act.
Download response Cooling-Therapeutic Hypothermia Protocol. 101220
Cord blood stem cells. 300819
1) Do you allow private stem cell companies to promote their services on your sites, e.g. leaflets?
2) Do you allow representatives from stem cell companies on any of your sites to promote or collect cord blood, e.g. in delivery suites?
3) Does the Trust allow its staff to work for stem cell companies, e.g. collecting umbilical cord blood for private companies?
4) How long (how many minutes) does the Trust consider ‘optimal’ cord clamping?
5) Please supply the following information for each of the individual calendar years: 2015, 2016, 2017, 2018 and 2019 to date:
a) The number of babies born whose umbilical cord blood was collected for banking by a private company.
b) The number of babies born whose umbilical cord blood was collected for banking by the NHS.
c) The income received from stem cell companies.
Cord clamping. 011121.docx
Please provide under the FOI act, the figures for each of the last 5 years (please provide data for each calendar year data 2015-2020)
Please provide the following figures per calendar year:
1. How many live births occurred in your organisation (please break this down to premature and term babies)
2. How many of these live births had cord clamping as being recorded at being at or after one minute? (please break this down to premature and term babies)
3. Please provide the numbers where cord clamping occurred before one minute (please break this down to premature and term babies)
4. How many times this was not documented (please break this down to premature and term babies)
5. Please provide any audits in the last 5 years on cord clamping times.
6. Is it mandatory to record the cord clamping time on any of your systems?
Court intervention. 141119
1. “Since 01 January 2017, please specify the number of individual cases where the Court has had to intervene in the treatment of a critically ill child, when there has been a difference of opinion between parents and doctors, over the course of treatment for that child?”
Cow’s milk protein Allergy (CMPA) 090916
1) Does your organisation use any guidelines when prescribing specialised infant formula for cow’s milk protein allergy (CMPA)?
2) If yes, please provide a link to, or a copy of the guidelines referenced by your organisation.
3) Please can you confirm whether we are permitted to reuse any information provided under the Open Government Licence?
Digital devices inside Paediatric Wards. 081121.docx
PART 1: ABOUT PAEDIATRIC COMMUNICATION
1. Is there a psychologist dedicated to paediatric wards?
2. Who is in charge to communicate about care and hospitalization practices? (multiple answers)
3. What kind of communication material do you use inside your ward in order to support and enhance the experience of the child and his/her family in hospital, providing information on his/her clinical condition, exams and treatment?
* If you choose “Paper” or “We don’t use communication material” go to PART 3
PART 2: ABOUT THE USE OF TECHNOLOGICAL DEVICES
1. IF YOU USE TECHNOLOGICAL DEVICES, which of the following ones are used in the ward to communicate with and support THE CHILD : (multiple answers)
2. If you use technological devices, which of the following ones are used in the ward to communicate with THE PARENTS: (multiple answers)
3. If you use technological devices, which of the following ones are used in the ward to communicate with THE SIBLINGS: (multiple answers)
4. If you use technological devices, which of the following ones are used in the ward to communicate with THE CHILDREN OF HOSPITALIZED PARENTS: (multiple answers)
5. If you use technological devices to communicate with the child and his family, what do they apply to, CONSIDERING THE CLINICAL CONDITIONS? (multiple answers)
6. If you use technological devices to communicate with the child and his family, what do they apply to, CONSIDERING THE TYPE OF INTERVENTION? (multiple answers)
7. What are the goals of the technological devices you use? (multiple answers)
8. Can you mention some examples of the technological devices you use?
9. Have you published an assessment study on the efficacy of the tool?
10. If your answer was YES, could you please give us references?
* If you use technological devices DON’T answer to PART 3
PART 3: ABOUT THE EVENTUAL USE OF TECHNOLOGICAL DEVICES
1. IF YOU DON’T USE TECHNOLOGICAL DEVICES – Do you think they could be useful tools to improve the quality of communication directed to the child and his family?
2. IF YOUR ANSWER WAS YES – For which clinical conditions? (multiple answers)
3. AND – For which type of intervention? (multiple answers)
4. Which purpose should they set themselves? (up to 3 answers)
5. Why don’t you use technological devices to communicate with the children and their families? (up to 3 answers)
Download response Digital devices inside Paediatric Wards. 081121.docx
Disorders of Sex Development in Children. 150222.docx
We seek information about the evaluation and care given to those with Disorders of Sex Development. In particular, we would like to know more about the number of international referral requests received by your trust from Malta.
We have put together a list of questions, which we would be grateful if you could answer in this order:
1) Since 2015, how many children receiving diagnostic tests and/or treatment for DSDs have been referred to this trust from Malta?
2) Of these children, how many are government-sponsored patients?
a. How many pay privately?
3) Of these referrals, how many have undergone genital surgeries?
4) Which specific DSDs have been referred from Malta? (e.g. Congenital Adrenal Hyperplasia, Androgen Insensitivity Syndrome, Turners Syndrome). If possible, please list them.
5) Are there specific legal or ethical guidelines tailored for Maltese patients?
Disorders of Sex Development in the UK. 070818
1. Who provides expert evaluation of gender assignment in newborns with Disorders of Sex Development?
2. Does the trust use a multidisciplinary team that deals with the evaluation and long-term management and needs of patients with Disorders of Sex Development?
3. If yes to question 2, can you provide contact details for the team?
4. What specialties are represented on the multidisciplinary team (e.g. paediatric subspecialists in endocrinology, surgery, and/or urology, psychology/psychiatry, gynaecology, genetics, neonatology, and, if available, social work, nursing, and medical ethics)? Please list them.
5. When dealing with Disorders of Sex Development, what guidelines, if any, do decision makers follow?
6. How many people are referred to this team per year (please give numbers for the last five years)?
Download response Disorders of Sex Development in the UK. 070818
Drug and alcoholism in children aged under 15 2013-2017. 280417
Can I ask for the following information: for each of the last four financial years (including the current one) I request disclosure of data relating to children aged 15 and under who have been diagnosed with alcoholism or drug related conditions.
1. For each year I would like a table containing patients’ ages, from 0 to 15 years old accompanied by a figure for the number of children of that age who were diagnosed as alcoholic, alcohol poisoning, treated for alcoholism or excessive alcohol consumption (for example 2016/17: Age 15– 33 Age 14 – 3). Can you outline the figures for each?
2. For each financial year I would also like a table set out in the same way detailing the numbers of children aged 15 or below who were admitted to A&E suffering alcohol-related illness.
3. For each year I would like a table containing patients’ ages, from 0 to 15 years old accompanied by a figure for the number of children of that age who were diagnosed for drug related illnesses or over-consumption (for example 2016/17: Age 15– 33 Age 14 – 3).
4. For each financial year I would also like a table set out in the same way detailing the numbers of children aged 15 or below who were admitted to A&E suffering drug-related illness. Can you outline the figures for each?
5. For each admission in Q1 and Q3, please tell me a) the sex of the child c) a brief summary of the problem, e.g. child was drunk
Download response Drug and alcoholism in children aged under 15 2013-2017. 280417
Each Baby Counts. 140322.docx
The Royal College of Obstetricians and Gynaecologists ran an initiative called Each Baby Counts aimed at reducing the number of intrapartum stillbirths, early neo-natal deaths and babies born with severe brain injuries. Please provide the total number of notifiable cases reported to the initiative by your organisation and the time period the data relates to, e.g. 1 January 2015 – 31 December 2019.
Eating disorders. 160119
1) How many admissions of children (under 18’s) presenting with eating disorders your trust has recorded in the past five years?
2) I would like to know how many of these children treated were male/female/transgender.
3) Please present all this information simply and clearly and break it down by year. Please provide as much detail as possible about the nature of their illness (I understand that some children may present with multiple illnesses). I would like this information broken down by type of eating disorder e.g. bulimia, anorexia etc.
Eating disorders in paediatric patients 2014-2016.
The number of paediatric patients you have seen between January 1st 2014 and December 31st 2014 for the treatment of eating disorders
The number of paediatric patients you have seen between January 1st 2015 and December 31st 2015 for the treatment of eating disorders
The number of paediatric patients you have seen between January 1st 2016 and December 31st 2016 for the treatment of eating disorders
How many of the paediatric patients were aged 10 and under between January 1st 2014 and December 31st 2014
How many of the paediatric patients were aged 10 and under between January 1st 2015 and December 31st 2015
How many of the paediatric patients were aged 10 and under between January 1st 2016 and December 31st 2016
How many of the paediatric patients were aged 11-16 between January 1st 2014 and December 31st 2014
How many of the paediatric patients were aged 11 -16 between January 1st 2015 and December 31st 2015
How many of the paediatric patients were aged 11 -16 between January 1st 2016 and December 31st 2016
Download response Eating disorders in paediatric patients 2014-2016.
Electronic Patient Records systems in Mental Health, Community Health or Child Health.
1. What are the main Electronic Patient Records systems you operate in Mental Health, Community Health or Child Health?
2. Can you provide a name for these systems?
3. How much are you currently spending on these systems annually for licensing and support fees?
4. What is the date of contract expiry for the systems?
5. How many users? (An estimation if unsure)
6. How are the systems hosted?
7. Who is responsible for your local implementation of the objectives set out by the NHS in the Five Year Forward View?
FGM C 2013-2016
1) How many females have you treated in connection to/relating to/as a result of FGM/C (female genital mutilation or cutting) practices?
2) Please can you break your answer down by financial years:
– 2015/16
– 2014/15
– 2013/14
3) Can you also break down and categorise the numbers by “reason for treatment”? So for example, i. bleeding ii. infection
4) Can you break down and categorise the numbers by what the treatment was? So for example, i. amputation ii. cosmetic surgery
5) Can you break down and categorise the numbers by the females’ ages? Ideally in these age brackets: i. 0 – 9 ii. 10 – 18 iii. 19 – 27 (and continue by nine-year age brackets)
Foetal Alcohol Syndrome 2014-2016. 070417
1. For 2016,
a) How many people were diagnosed as being on the Foetal Alcohol Spectrum. With a breakdown of ages and hospitals.
2. and 3. Same for 2015/2014
Foetuses that were miscarried, stillborn or aborted and children up to one year old from 1988 to the present day (Nov 2016). 011216
Please supply information for all of the questions below relevant to – foetuses that were miscarried, stillborn or aborted and children up to one year old from 1988 to the present day (Nov 2016).
1. Are you holding organs or tissue samples or bodies of foetuses that were miscarried, stillborn, aborted or of children up to one year old, pending disposal?
2. If yes to Q1, please report how many organs, tissue samples, body parts or bodies of foetuses that were miscarried, stillborn, aborted or of children up to one year old you have retained and still have?
3. In how many of these cases of foetuses that were miscarried, stillborn or aborted or of children up to one year old which have been retained and you still have was consent given by the nearest relatives to take, use and dispose of organs or tissue samples or body parts or bodies?
4. In how many of these cases of foetuses that were miscarried, stillborn or aborted or of children up to one year old which were retained but have since been disposed of was consent given by the nearest relatives to take, use and dispose of organs or tissue samples or body parts or bodies?
Free promotional disposable nappies.260219
1. Do you distribute any free promotional disposable nappies (such as Pampers) or reusable nappies to parents at any services, including (but not exhaustive of) antenatal, maternity, midwife, post-natal and family services?
If the answer is yes to 1, please answer questions 2-7.
2. Which disposable or reusable nappy brand do you allow to distribute their promotional nappies?
3. Which services are they distributed at and how many parents use these facilities annually?
4. How frequently a year have these disposable or reusable nappy brands been able to distribute their promotional material at these services?
5. What is the process for allowing disposable or reusable nappy brands to distribute at your services and who signs it off?
6. Is there any remuneration for the NHS from these disposable or reusable nappy brands for distributing their promotional material?
Download response Free promotional disposable nappies.260219
General anaesthesia (GA) paediatric dental waiting times.140223.docx
1. Total number of children currently on your waiting lists and for each of the past five years.
2. The average waiting time from referral to treatment by year for each of the past five years.
3. The total number of children currently on the waiting list who have waited more than a) six months b) one year c) 18 months
3. The five longest waits faced by people currently on the waiting list in days.
4. The number of children (under 18s) who have a surgical procedure cancelled or delayed at your trust, in each of the past five calendar years (2022, 2021, 2020, 2019, 2018).
General anaesthesia (GA) paediatric dental waiting times.140223.docx
Haemolytic disease of the newborn (HDN) also known as Rhesus Disease-Maternal Antibodies. 300920
I write under the Freedom of Information Act to request copies of all Clinical policies and procedures, guidelines and standards that were in use to govern the clinical decisions concerning the treatment of Haemolytic disease of the newborn (HDN) also known as Rhesus Disease/Maternal Antibodies made in the Neo-natal units within the Maidstone & Tunbridge Wells NHS Trust from 1998 to 2002.
These documents will include but not be limited to the management of :
Rhesus Disease
Haemolytic Disease of the newborn (HDN)
Neo natal jaundice in pre-term and term neonates
Hyperbilirubinemia in the newborn
Phototherapy
Exchange transfusions in neonates
And any other interventions/guidelines into how to treat Haemolytic Jaundice in newborns.
These documents pre-date NICE guidelines and the parameters of 1998 – 2002 are especially important.
Hypoxic ischemic encephalopathy (HIE). 271120
1. An anonymised list of babies born in the Trust who underwent controlled cooling as result of confirmed or suspected hypoxic ischemic encephalopathy(HIE), between 1 September 2010 and 1 September 2020;
a. the grade of HIE; and
b. the ethnic origin of mother and baby
2. An anonymised list of babies born in the Trust who died as a result of confirmed or suspected hypoxic ischemic encephalopathy(HIE), between 1 September 2010 and 1 September 2020;
a. the grade of HIE; and
b. the ethnic origin of mother and baby
Download response Hypoxic ischemic encephalopathy (HIE). 271120
Infant Formula. 140319
1. Details of the brand(s) of infant formula milk provided in maternity services and the form in which it is provided (e.g. powdered, ready-made bottles, ready-made bottles with teets etc.)
2. Details of your infant formula milk provider, the amount paid and volume received in the last available financial year, and details of whether the infant formula milk is purchased from them at full price, a reduced rate (including details of the reduction if applicable) or received free of charge.
Infant skincare advice.031022.docx
1. What antenatal advice does the trust routinely give to mothers about infant skincare including the bathing of babies?
2. What postpartum advice does the trust routinely give to mothers about infant skincare including the bathing of babies?
Complaints, PALS and Legal Services
Allegations of misconduct. 081117
For each of the past five financial years (12/13 – 16/17) please tell me the following:
The total number of allegations of misconduct made by employees of your trust against another employee, broken down by:
• The job category of the complainant, for example doctor, nurse, porter, receptionist.
• The nature of the alleged misconduct. For example sexual harassment, sexual assault, physical assault, theft, bullying, racism.
• The outcome of the complaint. For example, unsubstantiated, written warning, dismissed, training requirement, police informed.
Allegations of sexual misconduct.040123.docx
1. Between 1 September 2018 and 1 September 2022, how many complaints of sexual misconduct were made by patients, visitors and Trust employees against staff members in your NHS Trust.
2. How many of the complaints were upheld?
3. What was the outcome of the upheld complaints? Outcomes can include but are not limited to verbal warning, written warning, suspension, or dismissal
If it does not push the request over the cost limit, please can you also include:
4. The nature of the allegation
5. The gender of the complainant
6. The gender of the staff member
Allegations of sexual assault or sexual harassment. 081117
1- How many allegations of a) sexual assault and b) sexual harassment has your trust received against staff members in each of the past four years?
2- In how many of the cases were any of the alleged victims aged 18 or under at the time of the alleged offence?
3- In how many of the cases were any of the alleged victims current or former patients?
4- For each case, did it lead to i) internal disciplinary proceedings, ii) external disciplinary proceedings (i.e. through a regulator) and/or iii) a financial settlement.
5- For each case, please provide a broad description of the allegations involved, including the number of alleged victims / alleged perpetrators; their age (within a 10-year band); the date of the alleged offence and whether the alleged perpetrator occupied a managerial position.
6- For each case, please list the gender of the alleged perpetrator and the alleged victim. Alternatively, provide totals for the genders of the alleged perpetrators and alleged victims across all of your cases.
7- For each case which was dealt with by disciplinary proceedings, how many alleged offenders were i) fired; ii) suspended, iii) received written or verbal warnings.
8- Please provide the value of any financial settlement in each case.
9- Did any settlements (financial or otherwise) include clauses placing any restriction on the ability of the alleged victim to discuss the events involved or the institution? If so, how many?
Download response Allegations of sexual assault or sexual harassment. 081117
Amputation operations. 201119
1. A list of every amputation operation at your hospital over the past ten years.
2. The amount of cases of the above that have resulted in claims of medical negligence.
3. The amount of cases of the above that have resulted in your informing your insurers of a possible claim for medical negligence.
4. The details of each incident.
Breaches of the Data Protection Act.
1a.Approximately how many members of staff do you have?
1b.Approximately how many contractors have routine access to your information?
2a.Do you have an information security incident/event reporting policy/guidance/management document(s) that includes categorisation/classification of such incidents?
2b.Can you provide me with the information or document(s) referred to in 2a? (This can be an email attachment of the document(s), a link to the document(s) on your publicly facing web site or a ‘cut and paste’ of the relevant section of these document(s))
3a.Do you know how many data protection incidents your organisation has had since April 2011? (Incidents reported to the Information Commissioners Office (ICO) as a Data Protection Act (DPA) breach)
Answer: Yes, No, Only since (date):
3b.How many breaches occurred for each Financial Year the figures are available for?
Answer FY11-12: FY12-13: FY13-14: FY14-15:
4a.Do you know how many other information security incidents your organisation has had since April 2011? (A breach resulting in the loss of organisational information other than an incident reported to the ICO, eg compromise of sensitive contracts or encryption by malware. )
Answer: Yes, No, Only since (date):
4b.How many incidents occurred for each Financial Year the figures are available for?
Answer FY11-12: FY12-13: FY13-14: FY14-15:
5a.Do you know how many information security events/anomaly your organisation has had since April 2011? (Events where information loss did not occur but resources were assigned to investigate or recover, eg nuisance malware or locating misfiled documents.)
Answer: Yes, No, Only since (date):
5b.How many events occurred for each Financial Year the figures are available for?
Answer FY11-12: FY12-13: FY13-14: FY14-15:
6a.Do you know how many information security near misses your organisation has had since April 2011? (Problems reported to the information security teams that indicate a possible technical, administrative or procedural issue.)
Answer: Yes, No, Only since (date):
6b.How many near-misses occurred for each Financial Year the figures are available for?
Answer FY11-12: FY12-13: FY13-14: FY14-15:
Download response Breaches of the Data Protection Act 230516
Breast augmentation claims. 010319
1. How much money has been paid out in compensation for botched breast augmentation or botched breast enlargements? Please provide information for the last three years.
2. How many people have made successful compensation claims for botched breast augmentation or botched breast enlargements? Please provide information for the last three years.
3. How many unsuccessful claims for compensation for botched breast augmentation or botched breast enlargements has there been in the last three years?
By last three years I mean 2015, 2016 and 2017. Please provide information for each calendar year.
Cancer complaints. 170820
Could you please tell me between 1st March 2020 and the date of this email (31st July 2020):
1) How many PALS enquiries and official complaints your Trust has received from patients concerned about
a) the impact of the coronavirus pandemic and your Trust’s response on their access to cancer treatment
b) and access to cancer testing – including tests to find out whether their cancer has spread, returned or occurred for the first time
NOTE: I suggest you search for these complaints by using the keywords ‘cancer treatment’, ‘chemotherapy’, ‘cancer testing’, ‘coronavirus’, ‘COVID-19’ and other relevant terms.
2) For the five most recent PALS enquiries/official complaints received, please provide me with
a) a summary of the complaint (e.g. a patient with stage 4 lung and breast cancer has contacted PALS to complain about their chemotherapy being indefinitely suspended)
b) the exact wording of the complaint, with redactions to remove potentially identifying information
c) what action the Trust took in response
Claims relating to deep vein thrombosis (DVT) and pulmonary embolism (PE). 010319
1. How many hospital negligence claims have been made against the Trust relating to deep vein thrombosis and pulmonary embolism (blood clots) in the last five financial years?
2. Of the legal claims referred to in question 1, how much money has been paid to those who have brought claims against the Trust?
3. Please break down the data to questions 1 and 2 by hospital.
Download response Claims relating to deep vein thrombosis (DVT) and pulmonary embolism (PE). 010319
Communication and consent. 031117
1. In the past 5 years how many complaints have you had regarding communication with or supplying information to patients (written and oral)?
2. In the past 5 years how many complaints have you had regarding the inappropriate or incorrect taking of consent?
3. If the level of detail in questions 1 and 2 is unknown then please say how many complaints have you had in the past 5 years categorised as communication complaints?
4. In the past 5 years how many claims for compensation have you had involving the inappropriate or incorrect taking of consent?
5. If the level of detail in question 4 is unknown please say how many claims for compensation have you had categorised as communication claims?
6. How much did you pay the NHSLA for insurance last year?
7. Can I have a copy of your Consent to Examination or Treatment Policy?
8. If no Consent to Examination or Treatment Policy exists then can you supply me with your approved documented process for obtaining consent, as specified in the NHSLA Risk Management Standards 2013-14?
9. Can you tell me how information is provided to patients to support their decision making, including risks, benefits and alternatives where appropriate?
10. Can you tell me how the discussion and provision of information to patients is recorded?
11. Can you tell me the process for recording that consent has been given?
12. Can you tell me how your organisation monitors compliance with points 9 to 11?
13. Who has overall responsibility for your Consent to Examination or Treatment Policy? (There name would helpful)?
Compensation claims by staff. 070417
I would like information on the number and nature of compensation claims brought against your organisation by members of staff who have sustained an injury or contracted a disease while employed your organisation in the past five years.
I would like a year by year breakdown, preferably on an excel document via email, detailing:
Details of the injury (i.e. moving and handling injury, slips/trips/falls and so on)
Staff role if known (i.e. staff nurse, doctor)
Whether compensation was paid
The total amount of compensation paid
If information available, any action taking following the incident (i.e. additional training, non-slip flooring and so on)
Compensation pay outs and court costs.010422.docx
1. Between January 2018 and February 2022 how much in total did the Trust spend on compensation pay outs, including court costs
2. Could you also provide the number of claims by category and the total amount of compensation for this category since 2018? e.g. ‘inadequate nursing care’ or ‘maternity
Complaints. 090719
1) How many compliments did your trust receive in 2017?
2) Do you have a procedure for handling compliments?
3) Do you respond to the authors?
4) Do you pass the compliments onto to the complimentees?
5) Do management see copies of compliments?
6) Do you analyse the content of compliments?
Complaints.220323.docx
I am seeking information about the number of complaints received by your hospital trust in the past five years for the following specialties: neurosurgery, orthopaedic surgery, cardiothoracic surgery, and vascular surgery.
Specifically, I would like to request the following information for each specialty:
1. The total number of complaints received for each specialty in each of the past five years;
2. The nature of the complaint;
3. The outcome of the complaint, including any actions taken by the hospital trust to address the issue;
I did have a quick question as to whether I could incorporate two further questions into my request. This would put any complaint data you able to provide into an appropriate context (e.g. to contextualise 10 complaints with the fact 1,000 operations were performed):
4. Number of operations performed in the past five calendar years for the following specialties: neurosurgery, orthopaedic surgery, cardiothoracic surgery, and vascular surgery;
5. Number of reportable / recordable patient safety incidents in the past five calendar years for the following specialties: neurosurgery, orthopaedic surgery, cardiothoracic surgery, and vascular surgery
a. Breakdown by incident category (if available);
Complaints.220323.docx
Complaints. 280119
1. Does the Trust routinely publish the complaints data it reports to NHS Digital (KO41a) via any other public channel, i.e. on your website (please indicate YES or NO in the box below)? If YES, please provide details of where and how frequently you publish this data.
Further information on publication:
2. Does the Trust routinely publish, make public or evidence the outcomes and/or learning taken from complaints received (please indicate YES or NO in the box below)? If YES, please provide details of where and how frequently you publish this data.
Further information on publication:
3. Do you record complaints made by third parties who don’t have the expressed consent of the patient(s)? I.e. members of the public, people visiting other patients and/or external non-medical contractors who have concerns about the way patients are being treated or cared for.
4. If you record complaints made by third parties, please could you provide the numbers of complaints received by your NHS Trust for the following financial years?
5. Do you record complaints made by third parties in your official complaints figures as reported to NHS Digital (KO41a)?
Complaints about noise for 2013 – 2016.
How many noise-related complaints the organisation has received in the past three years? For each year, I would like to know:
The department/ward the noise-related complaint refers to
Who made the complaint (patient/relative/staff member etc.)
The nature of the complaint – i.e. if it is noise from staff, noise from another patient, equipment, building work etc.
I would also to know if your organisation has a noise policy or any noise-reduction measures in place – for example soft-closing doors, not transferring patients at night, ‘sleep kits’ for patients and so on.
Download response Complaints about noise for 2013 – 2016 270616
Complaints against consultants.270422.docx
I would like to know how many complaints/issues have been lodged or raised in any way about this/these consultants.
Complaints and Racism. 040121
1) Please can you tell me the name of your Trust?
2) How many patient complaints has your Trust received, for any given reason?
Please break down into the following calendar years
2017
2018
2019
3) How many patient complaints has your Trust received, citing racism as one of the problems during the patient’s treatment?
Please break down into the following calendar years
2017
2018
2019
4) How many complaints relate to the treatment of women who have given birth in your Trust?
Please break down into the following calendar years
2017
2018
2019
5) How many of those from Q4 included racism in their complaint?
2017
2018
2019
6) How many members of staff have received some form of disciplinary action due to a complaint by a patient?
Please break down into the following calendar years and please list what action was taken.
2017
2018
2019
7) How many members of staff have received some form of disciplinary action, whereby racist behaviour towards the patient was included? Please break down into the following calendar years and please list what action was taken where possible.
2017
2018
2019
8) How many members of staff have made a complaint regarding racism from a patient?
Please break down into the following calendar years
2017
2018
2019
Complaints data for 2018-19. 151119
1. How many complaints were upheld by the Ombudsman?
2. How many complaints were partly upheld by the Ombudsman?
3. What was your complaints (3 working days) performance as a percentage?
4. What was your complaints (final response) performance target in days?
5. What was your performance as a percentage in response to this target? (e.g. 75% of complaints are answered within 25 working days or as agreed with the complainant)
6.How many days does it take on average for you to respond to a complaint?
Complaints for patients admitted to A&E.241219
1. For each of the last three calendar years (2019, 2018, 2017), please provide a monthly list of the chief complaints for patients admitted to A&E, broken down by:
• The name of the chief complaint.
• The number of patients admitted to A&E for each chief complaint.
• The number of male patients admitted for each chief complaint.
• The number of female patients admitted for each chief complaint.
Please note that the Chief Complaint is the presenting symptom rather than the primary diagnosis.
2. For each of the last three calendar years (2019, 2018, 2017) please disclose the total number of patients that were admitted to A and E.
3. For each of the last three calendar years (2019, 2018, 2017) please disclose the total number of patients admitted to A and E that were not GP registered.
Download response Complaints for patients admitted to A&E.241219
Complaints made regarding communication.201222.docx
1. In your trust, in each of the last 5 calendar years, how many formal patient/family complaints were made regarding communication?
2. How many of these complaints were regarding lack of updates to Next of kin or patient families?
3. In your trust in the last 5 years, what were the top 5 categories for complaints? For example, ‘communication’ or ‘clinical care’ may be examples
Complaints made to the End of Life Care Strategy Group. 070219
Please detail the number and type of complaints made to your End of Life Care Strategy Group in the last four years. Please break the information down into complaints per month (where possible) and whether the complaint was to do with, for example poor communication, issues to do with consent or the care itself etc. Where recorded, please also detail the outcome of the complaint.
Download response Complaints made to the End of Life Care Strategy Group. 070219
Complaints or concerns raised by staff members
1) Name of:
a) Your trust
b) The hospitals in your trust
2) Between April and October 2015, how many complaints/concerns were raised by Trust staff members regarding?
a) Staffing levels/staffing shortages
b) Shifts being filled by under-qualified staff/staff “acting up”/agency staff/locums
c) Staff overwork/unpaid overtime
d) Staff not being able to take breaks
3) What is the longest time (in days) one patient has remained in a bed at your NHS Trust due to delays in transfer of care (DTOC) from September 2014 to September 2015?
4) What was the age of the patient (from question 3) and the reason for delay?
5) What is the longest time (in days) one patient has remained in a bed at your NHS Trust due to delays in transfer of care (DTOC) from September 2013 to September 2015?
6) What was the age of the patient (from question 5) and the reason for delay?
Download response Complaints or concerns raised by staff members 270516
Complaints reported by members of staff (including locums, agency workers or casual staff) against other members of staff. 030322.docx
Q1.) For each of the past five years please state the number of complaints reported by members of staff (including locums, agency workers or casual staff) against other members of staff received of:
2016 2017 2018 2019 2021
a) Sexual Misconduct
b) Sexual Harassment
c) Sexual Assault
d) Rape Allegation
Q2.) By year for each of the complaints recorded above can you state the outcome following each allegation:
a) Complaint withdrawn
b) Insufficient evidence to make a finding of fact.
c) Perpetrator cautioned – or similar note made on their employment file
d) Disciplinary action
e) Sacked
Q3.) By year can you state in each category in the table how many of the complaints were referred to the police?
Q4.) By year, please state the number of settlement/compromise agreements which contain non-disclosure clauses your organisation made with current or former staff which involve or relate to sexual misconduct, sexual harassment, sexual assault, rape. For each of these, please state the number and financial value of the settlements.
Counter Fraud. 030619
1. How many people does your organisation employ?
2. What is the total annual expenditure budget of your organisation?
3. How many full-time employment staff does your organisation employ dedicated to counter fraud activities?
4. If you employ such staff, how many full-time employment staff are directly employed by your organisation?
5. If any of your counter fraud staff are supplied by another organisation, could you identify the name of the organisation(s) which supplies them?
6. Approximately how much did you spend on counter fraud activities in the last reporting year?
7. How many referrals for fraud investigation has your counter fraud team received in the last reporting year?
8. How many fraud cases has your counter fraud team successfully investigated? I.e. leading to sanction and/or recovery of monies in the last reporting year.
Counter fraud provision. 230920
1. Staff headcount at your organisation?
2. Annual budget of your organisation for the financial year 2019-2020?
3. What is your organisation provider type (as recorded on your SRT submission – i.e. Acute teaching, Ambulance)?
4. Who provides your organisations counter fraud provision? (In house – NHS consortium – Private provider)
5. How many days were recorded for proactive counter fraud work (Strategic governance, Inform and Involve & Prevent & Deter) carried out at your organisation during the financial year 2019-20?
6. How many days were recorded for carrying out reactive investigation work at your organisation during the financial year 2019-20 (hold to account)?
7. How many counter fraud referrals did your organisation receive during the financial year 2019-2020?
8. What was the recorded fraud loss identified by your organisation during the financial year 2019-2020?
9. What was the amount of fraud losses recovered by your organisation during the financial year 2019-2020?
10. How many criminal sanctions relating to fraud, bribery and corruption did your organisation apply during the financial year 2019-2020?
11. How many disciplinary sanctions relating to fraud, bribery and corruption did your organisation apply during the financial year 2019-2020?
12. What was the cost of counter fraud staffing or outsourced counter fraud provision to your organisation during 2019-2020 for – Strategic Governance, Inform and Involve and Prevent and Deter?
13. What was the cost of counter fraud staffing or outsourced counter fraud provision to your organisation during 2019-20 for – Hold to Account?
Court intervention. 141119
1. “Since 01 January 2017, please specify the number of individual cases where the Court has had to intervene in the treatment of a critically ill child, when there has been a difference of opinion between parents and doctors, over the course of treatment for that child?”
Delayed discharge and court action. 070317
1. Since 1.1.15 how many times have you taken court action to evict a patient from a hospital in your trust because you believe they are fit for discharge but they have failed to leave their hospital bed? For each occurrence please state how many days they had occupied a hospital day for while considered fit for discharge?
2. Of those patients discharged from your hospital in either 2014/15 or 2015/16 please state how many patients had been considered fit to discharge but remained in hospital in excess of one full calendar year before they were discharged? For each patient please state how many days they occupied a hospital bed while considered fit to discharge?
3. Using the most recent convenient date do you have any patients in your hospital who are considered fit to discharge but have been in hospital and been fit to discharge in excess of one full calendar year? For each patient please state how many days they have occupied a hospital bed while considered fit to discharge?
Download response Delayed discharge and court action. 070317
Employees who have left the Trust as a result of judicial mediation 2011 – 2016
1. For each of the past five financial years, what was the total number of employees that left your trust through judicial mediation?
2. For each of the last five financial years how much was paid to departing employees through judicial mediation? Again, I am looking for annual breakdowns of the data.
The annual breakdown should include the following three elements;
A – The statutory amount the employee received (i.e. the sum to which they were legally entitled for redundancy).
B – The amount paid in special severance payments.
C – The overall total of statutory and special severance payments.
3. For each of the past five financial years, how many of the employees who left through judicial mediation signed a settlement agreement (formerly known as a compromise agreement)?
4. For each of the past five financial years, how many employees who left through judicial mediation agreed a confidentiality clause?
5. Taking the definition of confidentiality clauses used in Question 4, for each of the past five financial years, how many fell under the definition 1? 2? 3? Other?
6. For each of the past five financial years, how many staff who left via judicial mediation received an agreed reference?
7. For each of the past five financial years, how many of the judicial mediation cases were referred to the Department for Health/Treasury for sign off?
Download response Employees who have left the Trust as a result of judicial mediation 2011 – 2016
Enforced DNR. 300317
The number of patients who have been taken to the Royal Courts of Justice Court of Protection, to have a DNR placed upon their lives by your hospital. I would like to know if the patient had a Lasting Power of Attorney and the sex, age, ethnicity of the patients and the length of time each case took & outcomes of each case. From when the hospital opened to the present day.
External law firm services. 161121.docx
1. What is your spend with external law firms
2. Do you use eBilling technology to manage your law firms billing (e.g. systems such as Legal Tracker, Brightflag, Apperio, CT Tymetrix, Mitratech etc.)
3. Who is your head of legal / general counsel
4. Do you have a law firm panel / preferred supplier list / use a framework to buy your external law firm services
External legal advice
1. How many members of staff are directly employed at the Trust at present as of 24 August 2015?
2. What was your external legal advice expenditure from 01/04/2014 to 31/03/2015?
3. What is your budget for external legal advice for the current financial year?
4. Please provide the list of the solicitors instructed for external legal advice from 01/04/2014 to 31/03/2015.
5. Please provide the full structure of your legal services team (titles of the positions- no names are required).
6. Please provide your Trust’s policy which relates to the process of provision of internal legal advice to the members of staff within your Trust.
7. Please provide the name of the software or system which you use for the claims management.
8. Please provide the annual cost of your claims management system.
9. Please provide the name of the software or system which you use for the complaints management.
10. Please provide the annual cost of your claims management system.
11. How many active Coroner’s Inquest cases are you managing at your Trust as of 24 August 2015?
12. How many active clinical negligence claims against your Trust as of 24 August 2015 (claims reported to the NHSLA)?
13. How many active clinical negligence claims against your Trust as of 24 August 2015 (claims not reported to the NHSLA)?
14. How many active Employer’s Liability claims against your Trust as of 24 August 2015 (claims reported to the NHSLA)?
15. How many active Employer’s Liability claims against your Trust as of 24 August 2015 (claims not reported to the NHSLA)?
16. How many active Public Liability claims against your Trust as of 24 August 2015 (claims reported to the NHSLA)?
17. How many active Public Liability claims against your Trust as of 24 August 2015 (claims not reported to the NHSLA)?
18. Please attach a relevant policy and a flowchart which describe the process of how your legal services team communicates the lessons learned from the claims and coroner’s inquests to the relevant teams across the Trust, to ensure the effective risk management and prevention of similar incidents and to improve care provided.
19. Please provide two, most recent, monthly claims management/ legal services reports. If you do not have monthly reports please provide two most recent quarterly reports.
External legal spend
1. What does your organisation spend on legal fees e.g. external legal advice and what is the breakdown of fees and expenses.
2. What is the breakdown of spend e.g. what percentage of work is completed on an hourly rate basis, capped fee, fixed fee etc. We do not break it down in these terms.
3. Who in your organisation is responsible for managing external legal spend-
4. What controls do you have in place to manage external legal counsel spend?
5. Do you use any of the eBilling (also known as Enterprise Legal Management or Legal Spend Management) tools (e.g. Serengetti, Mitratech, CT Tymetrix, Datacert etc.) available in the market to manage your legal spend – if yes what are you currently paying for this system and does the vendor charge your firms to use the same
6. Do you use a matter management system and if yes how much do you pay for the system.
7. How do you decide if work is completed internally or by external counsel?
8. What performance management do you complete with your external legal counsel to ensure you are receiving value for money?
9. What is the breakdown of spend e.g. % of time billed by partner, by senior associate, junior associate, trainee and paralegals etc.
10. What is the breakdown of your legal spend by location e.g. how much work is performed in London, Manchester, Birmingham, Edinburgh, Glasgow, Cardiff, Belfast etc.
11. How do you measure what value added services law firms provide to you (e.g. free advice, free training, free secondees etc.)
12. Do you use external consultants to advice on how to manage your legal spend more effectively. If yes, who and what have you spent with them in the last 12 months
Fat shaming 2021.270522.docx
1) How many official complaints and PALS concerns your Trust received from patients alleging they had been discriminated against or badly treated by a member of staff because of their being overweight or obese
2) Can you select the first five such complaints from 2021 and provide me with the following details:
a. What type of staff member was the complaint levelled against? E.g. healthcare assistant, junior doctor, consultant, cleaner, kitchen staff
b. Please quote the words allegedly used by the hospital staff or summarise the offending action
c. Please tell me what, if any, action was taken by your trust in response to these five sample complaints from the beginning of 2021
Fat shaming complaints. 020620
Could you please tell me for the calendar year 2019:
1) How many complaints through the patient advice and liaison system (PALS) your Trust received from patients alleging they had been discriminated against or badly treated by a member of staff because of their being overweight or obese
Please do this by searching for complaints containing any of the words “weight”, “fat”, “obese”, “overweight” and “bariatric” and filtering these to find those that refer to fat-shaming comments made by a member of staff.
2) Can you select the first five such complaints from 2019 and provide me with the following details:
a. What type of staff member was the complaint levelled against? E.g. healthcare assistant, junior doctor, consultant, cleaner, kitchen staff
b. Please quote the words allegedly used by the hospital staff or summarise the offending action
c. Please tell me what, if any, action was taken by your trust in response to these five sample complaints from the beginning of 2018
Fat shaming complaints. 140521
1) How many complaints through the patient advice and liaison system (PALS) your Trust received from patients alleging they had been discriminated against or badly treated by a member of staff because of their being overweight or obese
Please do this by searching for complaints containing any of the words “weight”, “fat”, “obese”, “overweight” and “bariatric” and filtering these to find those that refer to fat-shaming comments made by a member of staff.
2) Can you select the first five such complaints from 2020 and provide me with the following details:
a. What type of staff member was the complaint levelled against? E.g. healthcare assistant, junior doctor, consultant, cleaner, kitchen staff
b. Please quote the words allegedly used by the hospital staff or summarise the offending action
c. Please tell me what, if any, action was taken by your trust in response to these five sample complaints from the beginning of 2020
Fat-shaming complaints. 210519
Could you please tell me for each of the years 2016, 2017 and 2018
How many complaints through the patient advice and liaison system (PALS) your trust received from patients alleging they had been discriminated against or badly treated by a member of staff because of their being overweight or obese.
Please do this by searching for complaints containing any of the words “weight”, “fat”, “obese”, “overweight” and “bariatric” and filtering these to find those that refer to fat-shaming comments made by a member of staff.
Can you select the first five such complaints from 2018 and provide me with the following details:
1. What type of staff member was the complaint levelled against? E.g. healthcare assistant, junior doctor, consultant, cleaner, kitchen staff
2. Please quote the words allegedly used by the hospital staff or summarise the offending action
3. Please tell me what, if any, action was taken by your trust in response to these five sample complaints from the beginning of 2018
Food poisoning. 020819
1. How many inpatients developed food poisoning (relating to E.coli, listeria, campylobacter, salmonella or other) during a stay at the hospitals in your trust between the end of May 2018 and the end of May 2019?
2. How many inpatients developed food poisoning (relating to E. coli, listeria, campylobacter, salmonella or other) during a stay at the hospitals in your trust between the end of May 2013 and the end of May 2014?
3. Are meals prepared on site or off the premises by an outside provider?
4. How many complaints did you receive about hospital food between the end of May 2019 and the end of May 2018?
5. How many complaints did you receive about hospital food between the end of May 2013 and the end of May 2014?
Grievance complaints in the last five years.
1. The number of all the Grievance complaint cases dealt with by MTW Trust in the last five years?
2. The outcome of these cases:
a. Numbers and percentage of Grievance cases accepted
b. Numbers and percentage of Grievance cases upheld
c. Number of staff members suspended, demoted or sacked within a year of making a grievance complaint.
3. Numbers and percentage of cases made by BME members of staff.
4. Outcome of BME grievance complaints in numbers and percentage as successful or upheld
5. Number of BME staff members suspended, demoted or sacked within a year of making a grievance complaint.
Download response Grievance complaints in the last five years 270616
Grievances and bullying and harassment complaints.141222.docx
1. Please can you detail the number of grievances & bullying and harassment complaints that have been raised in the last 5 years.
1st April 2018 – 31st March 2019
1st April 2019 – 31st March 2020
1st April 2020 – 31st March 2021
1st April 2021 – 31st March 2022
1st April 2022 – 31st November 2022
2. How many of the above cases remain unresolved as of 31st November 2022.
3. What number of employees, who have raised a grievance or B&H complaint since 1st April 2018, remained at the Trust, in their same role, one year after their complaint was concluded?
4. What number of respondents* involved in grievance or B&H complaints since 1st April 2018, remained at the Trust, in their same role, one year after their complaint was concluded?
*respondent refers to the person who is the subject of the grievance or bullying and harassment complaint.
Grievances and bullying and harassment complaints.141222.docx
Healthcare Safety Investigation Branch (HSIB). 220921.docx
I understand the HSIB have written a “letter of concern” to MTW about maternity services (particularly about Crowborough Birthing Centre).
Under the FOI, could I see a copy of their correspondence please and the Trust’s response.
Download response Healthcare Safety Investigation Branch (HSIB). 220921.docx
Coronavirus COVID-19
BAME staff. 131120
Background Information:
How many clinical staff do you employ and how many are BAME? (inc locum/bank/agency)?
Questions:
1.How many BAME staff and how many non BAME staff have been working in ‘Covid wards’:
• In March/In April/In May so far.
2.How many redeployment requests were received from BAME and non BAME staff (inc locums/bank/agency)? And how many have been redeployed as a result?
• In March/In April/In May so far.
3.Since the NHS England guidance on Risk Assessments was issued during the Covid crisis, how many Risk Assessments have you carried out of your BAME staff?
4.How many BAME staff (inc locums/bank/agency) have been successfully redeployed since this Risk Assessments guidance was issued, as a direct result of it?
5.How many complaints or reports of discrimination by BAME and non BAME staff (inc locum/bank/agency) have been made regarding deployment since Covid hit i.e start of March?
BAME staff risk assessments. 100620
Q1. Please state (yes or no) whether your trust has carried out a risk-assessment of staff at potentially greater risk of COVID-19, including people from Black, Asian and Minority Ethnic backgrounds. [If answer to Q1 is yes, please answer questions 2-5]
Q2. Please state when this risk assessment was carried out.
Q3. Please provide a short summary of what the risk assessment entailed.
Q4. Please provide a copy of the findings of the risk assessment.
Q5. Please list and provide brief details of any measures that your trust has subsequently put in place to offer protection to staff who are at higher risk from COVID-19.
Bed capacity and hospital admissions.110722.docx
“1) Bed Capacity – last 5 years: Please provide average bed capacity for the previous five years as follows:
Total Bed Capacity (all wards).
Covid-19 Bed Capacity
2) Bed Capacity for 2021: Please provide bed capacity for the current year so far. For comparative purposes please use the following period each month: The first Wednesday of every month between the hours of 12noon and 4.00pm.
Total Bed Capacity (all wards)
Covid-19 Bed Capacity
3) Hospital Admissions – last 5 years: Please provide number of Admissions (all causes) for the previous five years as follows:
All Admissions
Admissions – where the patient has received 1 or more dose of an authorised Covid-19 Vaccination
Admissions – where the patient has NOT received any Covid-19 vaccination
4) Hospital Admissions for 2021: Please provide total number of admissions (for all causes) by month for the current year so far, split by Covid-19 vaccinated and unvaccinated.
All Admissions
Admissions – where the patient has received 1 or more dose of an authorised Covid-19 Vaccination
Admissions – where the patient has NOT received any Covid-19 vaccination
5) PCR Result of Hospital Admissions: Please provide breakdown of number of patients testing positive/negative with a Covid-19 PCR Test 2019 and 2020
Number of Patients testing positive with a Covid-19 PCR Test
Number of Patients testing negative with a Covid-19 PCR Test
6) PCR Result of Hospital Admissions for 2021: Please provide breakdown of number of patients testing positive/negative with a PCR test for the current year
At the time of Admission
No of Patients testing positive
No of patients testing Negative
7) Covid-19 Specific Admissions: Please provide total number of patients admitted where the primary reason for treatment was Covid-19 in 2019 and 2020.
Total number of Admissions where the primary treatment was for Covid-19
8) Covid-19 Admissions for 2021: Please provide number of Covid-19 admissions for 2021 where the primary reason for treatment was Covid-19
Total number of patients admitted where the primary reason for treatment was Covid-19”
Completely unvaccinated Covid-19 admissions and those who have had one or more vaccinations. 170322.docx
Could I please ask for an honest breakdown of your covid admissions? A surgeon in your employment has shared the above information and I’d just like to know how many are completely unvaccinated and who have had one or more vaccinations.
Coronavirus outreach working. 310320
Due to recent concerns and government changes in advice related to working (regarding the Coronavirus), we are putting together our plan for our staff that are working from outreach locations.
We are getting in touch with all outreach locations our staff work from to ask for their plans/policies in light of the Coronavirus. Are we able to get your plan also?
Coronavirus transmission in hospital. 071020
1. The number of patients in your hospital(s) who tested positive for Covid-19, having tested negative at their time of admission
2. The number of these patients who subsequently died from Covid-19.
Download response Coronavirus transmission in hospital. 071020
Covid-19. 020321
1. Confirmation that all reported cases of SARS-COV2 in your Trust have been diagnosed and confirmed by PCR test;
2. If not with a PCR test, provide details of what method was employed to confirm the presence of SARS-COV2;
3. Details of the laboratories performing the PCR tests producing the confirmation of SARS-COV2 on behalf of your Trust;
4. Details of the Ct thesholds currently employed in the PCR tests performed by the labs at 3.;
5. Details of the Ct thresholds used to confirm all reported cases of SARS-COV2 in your Trust between 01/01/2020 and 18/12/2020;
6. Details of the manufacturers of the PCR tests used to confirm the presence of SARS-COV2 in your Trust;
7. In the document “Understanding cycle threshold (Ct) in SARS-CoV-2 RT-PCR” published on the UK government website, page 7 includes the statement “Some commercial RT-PCR techniques are closed ‘black box’ systems whereby the operator cannot observe the reaction in real-time and the result is interpreted by software into a qualitative non-interrogatable positive or negative result.”
a. Please confirm which manufacturers have been engaged that employ such a ‘black box’ method,
b. which labs have used such a manufacturer, and
c. which results confirming the presence of SARS-COV2 in the UK have been based on such techniques;
8. Where such results have been produced using the ‘black box’ method, please describe what further action was taken to confirm the results produced by the ‘black box’ method.
Covid-19. 040221
1. The number of hospital patients who tested positive for Covid-19 after initially testing negative between November 30 2020 and 31 January 2021.
2. The number of these patients who subsequently died
3. If available, please could I have details of the date of admission, the reason for their initial hospital admission e.g. fractured bone, chest infection, the date of the positive test and the date of their death.
Covid-19. 110621
1. How many people have dies from Covid-19 in the Maidstone & Tunbridge Wells NHS Trust hospitals from 1st January 2020 to 1 May 2021? This is only to include patients who have had Covid-19 tests and have not died with pre-existing conditions.
2. How many patients at Maidstone & Tunbridge Wells NHS Trust hospitals are currently there, currently confirmed with Covid-19?
Covid-19. 130121
1. Please can you provide a breakdown of data of actual Covid-19 cases that the Maidstone and Tunbridge Wells Trust have dealt with since the start of the pandemic? This includes the following:
Actual cases
By age group
Survival rates by age group
Death rates by age group and if they have underlying conditions (comorbidities)
2. Can you also confirm what treatments you are using to treat real cases.
Covid-19. 150221
1. Number of beds that are currently being used for COVID-19 patients across the health authority covering Tunbridge Wells and Maidstone
2. The information for the number of beds that were being used for the same winter period last year
3. The actual number of fatalities due to COVID-19 this year for this area.
4. The number of flu cases last year that resulted in death for the same period
5. The numbers of COVID-19 cases pre lockdown and post lockdown
Covid-19. 181220
1. How many people have died from Covid 19, without any pre-existing medical conditions?
2. How many Covid 19 patients are you currently treating at hospitals in the Trust (Maidstone and Tunbridge Wells)?
3. How many of those patients are in intensive care units?
4. What is the total number of beds available in the Trust?
Covid-19. 220421
Since 1 March 2020 up to the present day (17th December)
1. Please can you tell me how many patients with respiratory conditions were admitted to covid-19 wards at the trust.
a. Please include the date they were admitted.
b. Please can you also tell me how many of these patients were tested for covid-19
c. please also include the date of the first test,
d. the date of the result
e. whether the result was positive or negative.
If you are unable to answer these questions,
2. Please could you tell me how many patients with respiratory conditions were admitted to covid-19 wards at the trust?
3. How many of these patients tested positive for covid-19 before they were admitted to a covid-19 ward.
COVID-19. 220920
How many people have been admitted to the Trust’s Hospitals with Covid 19 since the 1st August 2020 and how many have survived or died as a consequence please up to today’s date of the 18th August 2020.
Covid-19. 260321
You asked:
Please can you supply me with the following monthly data for the trust, for March, April, May, June, July, August, September, October, November and December 2020?
1. How many people were unable to have treatments for illnesses and conditions due to the Covid-19/Coronavirus crisis?
2. How many of these cases were for life threatening illnesses and conditions?
3. How many people had further health complications because of missing these treatments?
4. How many people died because of missing these treatments?
5. How many mental health admissions were due to COVID 19/coronavirus issues?
6. How many Covid 19/Coronavirus patients were in intensive care units?
7. Total number of beds in the trust at the time?
8. How many of these beds were occupied?
If applicable, could you also provide the following:
9. Community Occupancy %
10. Adult Mental Health Beds Occupancy %
11. Older Adult Mental Health Occupancy %
12. How many of the patients died FROM Coronavirus/Covid-19
13. How many of the patients died WITH Coronavirus/Covid-19
Covid-19. 30.04.21
1) Between 1 March 2020 and 1 March 2021 (or the most recent date for which figures are available), how many Covid-19 infections in patients were hospital acquired?
i) of these, how many were probable infections (i.e. within 8-14 days of admission to hospital)?
ii) and how many were definite infections (15 days or more after admission to hospital)?
2) Of those who acquired Covid-19 while in hospital between 1 March 2020 and 1 March 2021 (or the most recent date for which figures are available), how many died?
3) What was the total number of Covid-19 deaths at your trust between 1 March 2020 and 1 March 2021 (or the most recent date for which figures are available)?
4) How many members of staff contracted Covid-19 between 1 March 2020 and 1 March 2021 (or the most recent date for which figures are available)?
5) How many members of staff were absent from work due to Covid-19 between 1 March 2020 and 1 March 2021 (or the most recent date for which figures are available)?
6) How many members of staff died due to Covid-19 between 1 March 2020 and 1 March 2021 (or the most recent date for which figures are available)?
7) What is the total number of Covid-19 infections a) among patients and b) among staff recorded at your trust between 1 March 2020 and 1 March 2021?
Covid-19. 300421
Please provide me with freedom of information on the evidence that COVID-19 has been isolated (a pure sample containing no other genetic material other than COVID-19 i.e. just COVID-19).
Covid-19 and patients resident in care homes. 240620
1) How many covid-19 outbreaks have there been in care homes in your region between March 1st and June 16th 2020?
2) How many care homes did you provide oxygen to as a result of covid-19 outbreaks between?
a) March 1st to April 15th
b) April 15th to June 16th
3) How many hospital patients were discharged to care homes between?
a) March 1st to April 15th
b) April 15th to June 16th
4) How many hospital patients discharged to care homes were tested for covid-19? Please give totals for:
a) March 1st to April 15th
b) April 15th to June 16th
5) How many of the test results in Q4 were:
a) positive
b) negative
c) inconclusive/ void
6) How many of the hospital patients discharged to care homes who tested positive for covid-19 were asymptomatic?
7) How many covid-19 related ambulance call-out requests did you receive from care homes between?
a) March 1st to April 15th
b) April 15th to June 16th
8) How many of the call-out requests referred to in Q6 did you send an ambulance to between?
a) March 1st to April 15th
b) April 15th to June 16th
9) How many care home residents did you admit to hospital between March 1st to June 16th. Please give totals for:
a) Those with suspected or confirmed covid-19
b)Non-covid-19 related patients
Download response Covid-19 and patients resident in care homes. 240620
Covid-19 and pregnancy. 310321
1. The number of pregnant women your trust has treated for Covid-19 between 1st March 2020 and 31st January 2021?
2. The number of pregnant women your trust has treated in ICU for Covid-19 between 1st March 2020 and 31st January 2021?
3. The number of women who had recently given birth that required treatment for Covid-19 by your trust between 1st March 2020 and 31st January 2021?
4. The number of women that had recently given birth and required treatment for Covid-19 in ICU at your trust between 1st March 2020 and 31st January 2021?
5. The number of maternal deaths in your trust where Covid-19 or a Covid-19 related illness was recorded as the cause of death between 1st March 2020 and 31st January 2021?
6. The total number of maternal deaths (from all causes) in your trust for the period 1st March 2020 to 31st January 2021?
7. The total number of maternal deaths (from all causes) in your trust for the period 1st March 2019 to 31st January 2020?
8. The number of pregnant workers in your trust (employees, agency workers, self-employed or locum) that are currently in patient-facing roles?
Covid-19 and suicide deaths. 160621
I would like to know how many people died of covid-19 in this trust with no pre-existing health conditions from march 2020 until present and how many suicide deaths you have had vs the same time frame can I also have this in age breakdown please.
Covid-19 antibody testing. 150720
Of the Covid-19 antibody tests conducted to date among staff at your trust, please provide information on:
• The proportion of staff that are antibody positive
• The proportion of BAME staff who are antibody positive
Covid-19 deaths. 101220
1. The number of actual deaths within the trust (for both hospitals) due to Covid-19 for the period February 2020 to September 2020 (inclusive).
2. All Deaths from October 2020 to present.
Covid-19 deaths. 1012202
I would like to know how many deaths the hospital has recorded of Covid 19 in the months between February 1st and December 1st.
Covid-19 deaths. 1012203
The actual number of Covid-19 deaths for the period- February 2020 to November 2020 within the Maidstone and Tunbridge Wells Trust In addition the number of Covid-19 deaths with underlining medical conditions.
Covid-19 deaths. 130121
How many people have died in your hospitals from Covid 19 alone? As in they died only due to Covid 19. I can see the figures that you publish online, but these are deaths within 28 days of a positive Covid test, so they could have died from other causes. I just want to know the exact figure from 1st February 2020 until the 20th December of people that have died due to Covid-19 and not anything else please.
Covid-19 deaths. 151220
I would like to enquire as to the amount of Covid 19 deaths with no pre-existing health conditions.
Covid-19 deaths. 151220
I am writing to ask how many deaths you have had of covid-19 or coronavirus since March 2020.
Covid-19 deaths.200522.docx
All questions pertain to the following dates: 01/12/2019 to 30/11/2021. I would like to know the following:
1.a) How many people have died in your hospitals within 28 days of testing positive for COVID-19?
1.b) Of those people, how many had underlying health conditions / co-morbidities and how many did not? Please provide absolute numbers and percentages.
1.c) Please also state the top 5 underlying health conditions / co-morbidities of those people.
1.d) Please state how many of those people were vaccinated and how many were not. Please provide absolute numbers and percentages. For vaccinated people, please break down the response in the following way: i) received one dose, ii) received two or more doses.
2.a) How many people have died in your hospitals purely and only due to COVID-19?
2.b) Of those people, how many had underlying health conditions / co-morbidities and how many did not? Please provide absolute numbers and percentages.
2.c) Please also state the top 5 underlying health conditions / co-morbidities of those people.
2.d) Please state how many of those people were vaccinated and how many were not. Please provide absolute numbers and percentages. For vaccinated people, please break down the response in the following way: i) received one dose, ii) received two or more doses.
Please keep the numbers/figures/percentages/etc. provided in response to questions 2.a-d separate from the numbers/figures/percentages/etc. provided in response to questions 1.a-d. If that is not possible, please clearly indicate which numbers are combined.
Covid-19 deaths. 221221.docx
I am requesting that within the dates of 01/03/2020 – 01/11/2021 can you supply the total number of deaths from COVID-19 alone, not within 28 days of a positive test, from all the hospitals in your trust.
Covid-19 deaths. 241220
I am writing to ask how many patients admitted to the Trusts hospitals to date have died of COVID-19 (SARS COV2) I am excluding patients who died from something else and at the time tested positive for covid-19.
I am excluding cases where covid-19 is mentioned on the death certificate but the patient did not test positive.
Covid-19 deaths. 311220
• How many people have died in your hospital only due to Covid 19 alone? As in they died only due to Covid 19.
I can see the figures that you publish online, but these are deaths within 28 days of a positive covid test, so they could have died from other causes. I just want to know the exact figure from 1st February 2020 until 30th November 2020 of people that have died due to covid 19 and NOT anything else please.
Covid-19 deaths. 311220 2
Under the freedom of information act, please could you send me the exact numbers of people who have died of Covid 19 or Corona virus from February 2020 to December 31st 2020.
I would like the numbers you provide to only include people who have died without any other underlined illnesses.
Covid-19 deaths and adverse vaccination effects. 020721
1. How many patients have been reported to have died from “Covid -19” as the main / primary cause of death with no major underlying health issues between March 2020 – December 2020?
2. How many patients have been reported to have died from “Covid -19” as the main / primary cause of death with no major underlying health issues between January 2021 – June 2021?
3. How many patients have been reported to have died having suffered severe adverse effects from the covid-19 “vaccinations? From January 2021 – June 2021?
4. How many patients have reported and been hospitalised following adverse effects from the Covid-19 “vaccinations? From January 2021 – June 2021?
Download response Covid-19 deaths and adverse vaccination effects. 020721
Covid-19 deaths and PCR testing. 020721
1. Please could you give me the number of deaths whereby covid is the sole cause of death listed. There were no pre-existing conditions or comorbidities noted on the death certificate covering the period March 2020 until present day. Please also provide the average age of death.
2. I would also like the number of cycles you run your PCR tests on normally as well as the number of cycles you run when you are aware the patient has been vaccinated.
If there is a difference between cycles used on patients compared to vaccinated patients please explain why.
Covid-19 deaths and still births. 041021.docx
Please could you send me the figures for all hospitals covered under the Maidstone and Tunbridge Wells trust.
1. How many pregnant ladies have died of covid with no pre-existing medical conditions in 2020 and 2021.
2. How many new born babies with no medical conditions have died of covid in 2020 and 2021.
3. How many still births you have had as a result of a pregnant mother having covid in 2020 and 2021.
4. The total number of still births for the last 5 years per year.
Download response Covid-19 deaths and still births. 041021.docx
Covid-19 deaths and suicides. 160621
1. I would like to know how many people died of cover 19 in this trust with no pre-existing health conditions from March 2020 until present.
2. How many suicide deaths you have had vs the same time frame can I also have this in age breakdown please.
Covid-19 deaths and vaccinations. 060421
1. I would like to know how many people have died in your hospitals from COVID-19 alone. As in they died only due to COVID-19. I can see the figures that you publish online, but these are deaths within 28 days of a positive COVID test, so they could have died from other causes. I just want to know the exact figure from 1st February 2020 until 28th March 2021 of people that have died due to COVID-19 and not anything else.
2. The percentage & number of people with underlying health conditions in the overall total.
3. The percentage & number of those without underlying health conditions.
4. If someone had died outside of the 28 days of testing positive would COVID-19 still be their cause of death i.e. Covid-19 (pneumonia) or would it just be pneumonia?
5. Lastly, the vaccination is authorised for emergency use only and is still in live clinical trials until 2023, do you make patients aware of this before they are given their vaccine?
Covid-19 deaths of staff members. 170321
We would like to know between the dates of Jan 1st 2020 and March 1st 2021 the number of healthcare workers employees within your trust have died due to COVID-19.
COVID-19 discharges into care homes. 120820
1) Between 01/02/2020 to 01/07/2020, how many patients were discharged from hospitals run by your Trust into care homes? Please provide a weekly breakdown.
2) Of those patients who were discharged into care homes in the specified period, how many were tested for COVID-19 prior to leaving hospital? Please provide a weekly breakdown.
3) Finally, please tell me how many tested positive but were nonetheless discharged into care homes. Please provide a weekly breakdown.
Download response COVID-19 discharges into care homes. 120820
Covid 19 Local guidelines. 140422.docx
Could you please reply to this email attaching a copy of your hospital’s full local guidelines on the following topics?
1. Current local guidelines for the treatment and management of Covid 19.
2. Current local infection control guidelines regarding testing and quarantining/isolation of Covid positive patients
Covid-19 PCRs, treatments and deaths.130622.docx
1) Is your hospital still running the PCR tests for SARS-Cov-2 at 40-45ct cycles?
2) Is the NHS still classifying any death as a Covid death for anyone who has tested positive with a PCR test within the past 28 days, as previously stated in the March 2020 update on the NHS website about dealing with excess deaths?
3) Is the NHS aware that the PCR is a non-diagnostic test and becomes 100% unreliable after 27ct cycles?
4) How does the NHS testing system determine which variant a patient has and is this via the PCR tests?
I am aware of the online statistics site where a lot of information can be found, however i would like some more detailed information regarding specifics so my following questions are;
5.a) How many people have died in your hospital from Covid alone since February 1st 2020 to December12th 2021 without any other underlying conditions or possible causes of death?
b) How many of these patients were prescribed Midazolam?
6) What are the annual numbers of prescriptions of Midazolam for the past 10 years within your hospital?
7) What are the annual numbers of DNR’s issued in the past 10 years at your hospital?
8) Have the following viruses/strains, to your knowledge, been isolated or purified;
-SARS-Cov-2?
-Kent variant B117?
-Delta variant?
-Omicron variant?
9.a) How many patients have been admitted to your hospital for Covid and were vaccinated against it since December 5th 2020?
b) How many died while in your care?
10.a) How many patients have been admitted to your hospital for Covid and were unvaccinated against it since December 5th 2020?
b) How many of them died while in your care?
11) What are the annual numbers of patients diagnosed with myocarditis for the past 10 years within your hospital?
12) What are the annual numbers of blood clot related deaths for the past 10 years within your hospital?
13) What are the annual numbers of miscarriages for the past 10 years within your hospital?
14) What percentage of your beds are allocated for Covid patients?
COVID-19 positive staff. 101220
1) How many of your clinical staff have tested positive for COVID-19 at your Trust?
2 How many of those staff who tested positive, worked in clinical areas designed to cater for positive / likely positive Covid Cases?
3 How many of these positive staff, work directly in areas not designated to cater for non COVID-19 patients?
COVID-19 recoveries. 150520
1 – The number of people who have entered MTW NHS Trust ICU’s with Covid-19 and been released back to wards alive and on the road to recovery.
2 – The number of patients who have recovered from Covid-19 and released from MTW NHS Trust hospitals.
3 – The numbers of people who have had a second infection from covid-19 and returned to a MTW NHS Trust hospital.
COVID-19 recoveries. 150520
1 – The number of people who have entered MTW NHS Trust ICU’s with Covid-19 and been released back to wards alive and on the road to recovery.
2 – The number of patients who have recovered from Covid-19 and released from MTW NHS Trust hospitals.
3 – The numbers of people who have had a second infection from covid-19 and returned to a MTW NHS Trust hospital.
Covid-19 related admissions, deaths and vaccinations. 070122.docx
1) Please provide the number of patients admitted to any hospitals within your trust between 1st January 2021 and 21st December 2021, where the reason for hospitalisation is solely COVID-19 or any complication of this and not due to any other underlying issues. Please exclude from this number any patients who have had any complications or adverse reactions following the COVID-19 vaccine.
2) Please provide a breakdown of how many of those patients, during the period between 1st January 2021 and 21st December 2021, have been admitted after receiving one dose of the COVID vaccination, 2 doses, 3 doses and how many have not been vaccinated at all.
In order that there is no room for misunderstanding here about vaccination status, please use the following definitions in your reply:
• Unvaccinated means the patient has had no COVID-19 jab/vaccine/injection
• 1st Dose solely means a patient has been injected once against COVID-19, regardless of how many days have passed since the intervention or how many subsequent doses are available. (i.e., a single dose when a second one is available does not render them unvaccinated for the purpose of this FOI request)
• 2nd Dose solely means a patient has been injected twice against COVID-19, regardless of how many days have passed since the interventions or how many subsequent doses are available. (i.e., a double dose when a third one is available does not render them unvaccinated for the purpose of this FOI request)
3) Please provide the number of patients who have died at any hospital in your trust between 1st January 2021 and 21st December 2021 that are solely as a result of COVID-19 or any complications thereof and not due to other underlying health issues. Please also exclude any patients who have died as a complication of the COVID-19 vaccine.
4) Please provide the number of patients, for the same period mentioned above, who have died as a result of reactions or complications from the COVID-19 vaccine.
5) Please provide the number of patients who have died at any hospital in your trust from complications or adverse reactions arising from the COVID-19 vaccine.
6) Please note that for all the above questions, any reference to a patient with COVID-19 is a patient that has been confirmed as someone who has tested positive to a PCR test or Lateral Flow Test.
7) When there is confirmation of a positive test, please include whether it was through PCR or LFT and the number of cycles of amplification used when processing the results.
Download response Covid-19 related admissions, deaths and vaccinations. 070122.docx
COVID-19 staff risk assessment. 020620
1. Has your organisation completed risk assessments on all Black Asian and Minority Ethnic (BAME) staff?
2. What precautions, if any, have you put in place to protect BAME staff once they’ve been risk assessed?”
COVID-19 testing. 300720
1. Please can you tell me how many coronavirus tests the trust has used on patients between 1st March 2020 and today’s date (4th June 2020).
2. Please can you tell me both the number of patients that have been tested, and the number of tests carried out (i.e. if a patient has been tested more than once).
3. In each case, please can you tell me how long it took for the trust to receive the patients’ test result. If you do not have data for every patient please can you provide me with the average length of time it has taken to get test results for all patients.
Covid-19 treatments. 301220
Can you advise when it comes to Covid, are your hospitals actually treating cases and if you are not why not?
Covid-19 vaccinated and unvaccinated deaths. 270821.docx
1. Please can you provide me with all admissions in Maidstone hospital in the past 5 Years 2016-2020 with the current year so far?
2. Of those who died of any cause this year, how many had received the Covid -19 vaccine and how many were unvaccinated?
3. Out of those admitted in 2021 how many of them had got the vaccine?
Download response Covid-19 vaccinated and unvaccinated deaths. 270821.docx
Covid-19 vaccination status of Trust staff. 220222.docx
1) What percentage of Trust all staff have had a) one dose b) two doses c) three doses of the Covid-19 vaccine
2) What percentage of each the following staff members have had two or more doses- Medical and dental, nursing and midwifery, healthcare scientists, pharmacists, admin and clerical, estates and ancillary, allied health professionals, students, additional professional scientific and technical, additional clinical services.
Covid-19 vaccinations. 030321
Please can you tell me how many of your staff have declined to have a coronavirus vaccine. If possible, please give the reason why the vaccine was declined.
Covid-19 vaccinations. 130121
Would it be possible to be provided with the following information please in relation to the hospital vaccination hubs being run by your trust?
1. Between 8 December and 8 January, how many doses of the Pfizer Covid vaccine were administered at each of your hospital vaccination hubs?
2. Between 8 December and 8 January, how many doses of the Pfizer Covid vaccine were destroyed/discarded/thrown away at each of your hospital vaccination hubs? Do you have a daily breakdown of these figures? If so, can I be sent these please?
3. In those instances where doses were destroyed/discarded/thrown away, what reasons were given for staff not being able to administer them to patients?
Covid-19, vaccinations and Healthcare acquired infection (HCAI). 081221.docx
1. How many NHS staff currently working at your trust remain unvaccinated with a Covid19 vaccine? Including bank/agency workers.
2. What percentage of your overall staff does this equate to?
3. Since the start of the pandemic (01/03/20), with your data from staff absence due to Covid19, contact tracing and Healthcare acquired infection (HCAI), what percentage of HCAI is directly attributable to Covid19 infection in an NHS frontline worker?
4. Since the vaccination programme has started (Approx. Dec 2020), what is the breakdown of this being from
a. a covid 19 vaccinated NHS worker
b. unvaccinated NHS worker?
5. If not directly attributable, what is the rate of your patients in non Covid19 wards/area getting a HCAI and becoming infected with Covid19 within a set time frame (~10days) of an NHS worker in that ward/area testing positive for Covid 19?
6. What is the breakdown of this being
a. a Covid19 vaccinated NHS worker
b. non-vaccinated NHS worker?
Download response Covid-19, vaccinations and Healthcare acquired infection (HCAI). 081221.docx
Covid-19 vaccine uptake. 200521
1. Please tell me what percentage of front-line staff at your trust have received their first dose of the Covid vaccine?
2. If possible, please tell me what percentage of a) doctors b) nurses and midwives c) other front-line staff have received their first dose of the Covid vaccine?
3. Please also tell me the total numbers of front-line staff who have received their first dose of the Covid vaccine and the total numbers of front-line staff who have not received their first dose of the Covid vaccine
4. If possible, please tell me the total numbers of staff who have received the first dose of the vaccine and who have not yet been vaccinated broken down by a) doctors b) nurses and midwives c) other front-line staff.
5. Please tell me what percentage of front-line staff at your trust have received their second dose of the Covid vaccine?
6. Again, if possible, please break this down by a) doctors b) nurses and midwives c) other front-line staff
7. Please also tell me the total numbers of front-line staff who have received their second dose of the Covid vaccine and the total numbers of front-line staff who have not received their second dose of the Covid vaccine
8. Please provide the total numbers for staff who have received their second dose and not yet received their second dose broken down by a) doctors b) nurses and midwives c) other front-line staff
Covid Booster Informed Consent.131022.docx
What steps you and your organisation will be taking to fulfil your ethical and legal obligations to ensure patient and staff submission to Covid vaccination is given with free, voluntary, and fully informed consent.
Covid cycle testing for vaccinated and unvaccinated people.221122.docx
All questions are shown exactly as received by the Trust.
i would like all latest data on covid cycle testing for vaccinated and unvaccinated people i am aware there will be 2 separate test cycles of amplification thank you.
Your response is in correct.i asked what are the current test cycle to date for omnicrom variant you have a base number for cycle amplification that you start with .you dont get a cycle numbed AFTER the test ,you have a start point and that is the data i am asking for. The starting amplification cycle number for un vaccinated people and the cycle start number for vaccinated.thank you..this will be fact checked by my associates thank you.
Covid cycle testing for vaccinated and unvaccinated people.221122.docx
Covid-related capital bids. 091220
I would like to know how many Covid-related capital bids have been approved centrally since March 17 and was hoping you could answer a few questions.
To avoid confusion, covid-19 related capital refers to bids submitted in respect of the covid-19 capital expenditure scheme https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/04/COVID-19-capital-reimbursement-process-27-04-20.pdf. All other types of capital bids should not be included.
In addition, can you please tell me?
• The total value of your Covid-related capital bids
• The total in funding you’ve received for Covid-related capital bids.
• How many bids you have made and how many are awaiting central approval.
Covid Swab Tests. 101220
1. Is my DATA/DNA etc. kept on file, stored and shared in any way?
2. On the swab/tube (or before being placed into the tube) have the following: “Hydrogel”. or “Quantum Dot” used and or applied?
3. Do you have a “Magnetic Testing System” which “alters” your “DNA” via these “Covid Swab Tests”?
4. Are these `one hour Covid Swab Tests` (or for all tests?) stored and shared with my DNA and other information, third party or otherwise?
Covid, vaccination and deaths 280122.docx
1. Please confirm how many of the 1367 patients admitted from 1 January to 21 December 2021 were admitted where the sole reason for hospitalisation was COVID-19 or any complication of this, who were then confirmed by positive PCR test within 8 days. Please exclude from this figure any patients who were admitted due to other reasons who tested positive within 8 days, as well as any patients who may have been admitted due to adverse reactions following the COVID-19 vaccine.
2. According to your breakdown below, the grand total of patients who have received at least one COVID-19 vaccine was 651. Since you claim 1367 patients were admitted during the stated period who tested positive within 8 days, this would render 716 patients who were unvaccinated.
2a. The 10th column on your table stated 267 patients had no vaccine. Can you please confirm this is the case and also explain why these 267 patients have a category of “no vaccine” on their own and why the other 716 patients (total admissions – grand total provided by you) have not been included in this category?
2b. Can you confirm that the 716 patients, that is, the total admissions of patients who tested positive within 8 days (1367) minus the grand total of patients on your table (651) had not received any COVID-19 injection or booster? Just to clear and avoid misunderstandings, I am asking you to use the word unvaccinated to mean somebody who has not had any vaccine injected in their body at any time and conversely, vaccinated means someone who has had a vaccine irrespective of how long it has been since they had received it or the number of vaccines they have received.
3. Your answer to my third question was “Total number of patients admitted within 8 days of a positive swab from 1 January to 21 December 2021 who died – 149”.
Similarly, to question 1, this may include patients who had died due to complications of other issues such as cancer, a road traffic accident or a heart attack who had tested positive within 8 days of admission.
3a. Please confirm how many of the 149 patients you stated died solely due to COVID-19 or any complication thereof and exclude from this number any patient who died due to other medical conditions, including complications from taking a COVID-19 vaccine.
4. Your reply to my last question was “Confirmation of Sars CoV2 is by PCR testing. Cut off for positive is 28 CT”.
4a. Can you please confirm that all 1367 patients who were admitted to hospital between 1st January 2021 and 21st December 2021 had tested positive by returning a positive PCR test result at 28 CT?
4b. Has the CT cut off benchmark varied within the period in question? If so, please provide a breakdown of any periods where the cut off benchmark has been altered.
Covid vaccine wastage. 110122.docx
1. Between 8 December 2020 and 31 December 2021, how many doses of the Pfizer Covid vaccine were administered at each of your vaccination centres/hospital sites?
2. Between 8 December 2020 and 31 December 2021, how many doses of the Pfizer Covid vaccine were destroyed/discarded/thrown away at each of your vaccination centres/hospital sites? Do you have a weekly/monthly breakdown of these figures? If so, can I be sent these please?
3. Between 4 January 2021 and 31 December 2021, how many doses of the AstraZeneca Covid vaccine were administered at each of your vaccination centres/hospital sites?
4. Between 4 January 2021 and 31 December 2021, how many doses of the AstraZeneca Covid vaccine were destroyed/discarded/thrown away at each of your vaccination centres/hospital sites? Do you have a weekly/monthly breakdown of these figures? If so, can I be sent these please?
5. Between 7 April 2021 and 31 December 2021, how many doses of the Moderna Covid vaccine were administered at each of your vaccination centres/hospital sites?
6. Between 7 April 2021 and 31 December 2021, how many doses of the Moderna Covid vaccine were destroyed/discarded/thrown away at each of your vaccination centres/hospital sites? Do you have a weekly/monthly breakdown of these figures? If so, can I be sent these please?
7. In those instances where doses of the Pfizer/AstraZeneca/Moderna vaccines were destroyed/discarded/thrown away, what reasons were given for staff not being able to administer them to patients?
Covid Visiting Policies. 070122.docx
1) In the period 1 February 2020 to 31 October 2021 what is the total number of complaints that your Trust has received from the public including service users (i.e. complaints on any issue)?
2) In the period 1 February 2020 to 31 October 2021 how many complaints from the public including service users has your Trust received about (or that include mention of) restrictions to patient visiting or patient visiting policies?
3) In the period 1 February 2020 to 31 October 2021 how many incident reports (including Datix, Ulysses or other internal reporting system) have been raised by staff regarding abuse received from the public including service users that include mention of restrictions to patient visiting or patient visiting policies (i.e. where visiting restrictions may have contributed to the cause of the abuse)?
4) Does your Trust know what circumstances, or have a set of defined criteria, under which it would revert patient visiting policy back to what it was before the emergence of Covid 19?
Ct (Cycle Threshold) being used for PCR testing of SARS Covid-19. 280621
I would like to know the Ct (Cycle Threshold) being used for PCR testing of Sars Covid at the moment and in the past.
Download response Ct (Cycle Threshold) being used for PCR testing of SARS Covid-19. 280621
Cycle threshold (Ct) PCR testing. 280621
1. The Cycle threshold (Ct) used by your organisation since 01 March 2020 for each of the Government Pillar classifications.
2. Any changes made to the Ct during this period and when any such changes were made.
Cycle threshold in PCR tests for patients and staff. 040122.docx
which cycle threshold(ct) are you using in your hospital in PCR test for patient and staff since the declaration of the pandemic in 2020.
Download response Cycle threshold in PCR tests for patients and staff. 040122.docx
Data analytics to support in the management of the response to Covid 19. 220620
1) Is your Trust using data analytics to support in the management of its response to Covid 19?
2) If so, please could you confirm the use cases (i.e. medical resource management, monitoring patients that have tested for the virus and those that have tested positive, tracking the patient journey for those that have tested positive for the virus, ward management for patients that have test positive for the virus, identifying which healthcare workers have been exposed to the virus, etc.)?
3) If so, please could you confirm which roles in the Trust will have access to your Trust’s data analytics results regarding Covid 19 (please confirm for each of the following roles listed): Physician, Nurse, Pharmacist, Management, Accountant/Finance, HR and Recruitment, IT Office, Administrative Assistants, Data analyst/scientist (including roles such as Performance Reporting and Informatics)
Download response Data analytics to support in the management of the response to Covid 19. 220620
Date of discharge or date of death of patients with hospital acquired Covid-19 since 1st March 2020. 080421
Thanks very much, but can you specify which figures relate to a patient who was discharged and which relate to a patient who died?
Date of discharge or date of death of patients with hospital acquired Covid-19 since 1st March 2020. 260321
In relation to patients who had caught the virus in hospital and their outcome e.g. the date the first positive test result came back and the date they died or were discharged. Is it possible to provide the outcome dates please?
Deaths associated to Covid, flu and all other causes. 020721
I am asking for the real number of covid deaths ,?how many died with covid and underlying issues ? How many died with covid with no underlying issues ?
How many off covid with underlaying issues ? How many died off covid with no underlaying issues ? How many people died of flu in between Dec 2019 and to present date ?
I would like to know all off these number is statics in between November 2019 up until present date ? How many people died in this time frame off other illnesses not related to covid ?
Download response Deaths associated to Covid, flu and all other causes. 020721
Deaths that occurred due to Covid 19. 101220
I am trying to gather information regarding actual deaths within the trust due to Covid 19 for the period 1st February 2020 to 1st October 2020.
By this I mean the deaths that occurred due to Covid 19 alone without any comorbidities.
Download response Deaths that occurred due to Covid 19. 101220
Discharge of known and possible COVID-19 patients by the trust into care homes. 271020
1) Of those 233 patients discharged to care homes as above, how many were coded as having a diagnosis of
a) COVID-19 or
b) Suspected COVID-19 but did not receive a test before being discharged to a care home?
2. NHS Providers reports that it approached all NHS trusts for information about how trusts discharged possible COVID-19 patients into care homes
Please confirm if NHS Providers approached Maidstone and Tunbridge Wells NHS Trust for such information
Please share the records of NHS Providers’ enquiry to the trust, and the trust’s response
3. Has Maidstone and Tunbridge Wells NHS Trust been advised by local Public Health services, Public Health England or care home providers of any care home COVID-19 outbreaks that have been traced back to patients discharged from a trust hospital to the care homes in question?
Specifically, is the trust aware of any transmission from any of the 24 COVID-19 positive patients, discharged by the trust to care homes, to other care home residents following discharge into those care homes?
If so, please advise of the details.
Fit testing. 060520
1) The sex-breakdown of all those who failed fit tests for all available masks at your trust between 1st February 2020 and 30th April 2020.
2) The sex-breakdown of all those who had to use a powered air purifying respirator at your trust between 1st February 2020 and 30th April 2020.
3) The sex-breakdown of all those who failed their fit test for a FFP3 mask at your trust between 1st February 2020 and 30th April 2020.
4) The sex breakdown of all those who failed their fit test for a Disposable Healthcare Respirator, FFP3, Valved, 1873V+ at your trust between 1st February 2020 and 30th April 2020.
5) The sex breakdown of all those who failed their fit test for a Disposable Healthcare Respirator, FFP3, Type IIR, 1863+ at your trust between 1st February 2020 and 30th April 2020.
6) And finally, during the period 1st February 2020 to 30th April 2020, has your trust been doing fit tests or just fit checks?
Fit-testing of respiratory protective equipment. 160720
1. How many medical staff were working with tight-fitting respiratory protective equipment in February 2020, March 2020, April 2020 and May 2020? Please give the numbers broken down by the months; and, if it is possible, please break it down by type of staff member (nurse, doctor, etc) and setting. If it is possible, please separate out those working in Covid-affected environments (I do not know if you hold a separate register for Covid and non-Covid).
2. How many of the medical staff working with tight-fitting respiratory protective equipment in Covid-affected environments were fit-tested for that equipment in February 2020, March 2020, April 2020 and May 2020? Please give the numbers broken down by the months; and, if it is possible, please break it down by type of staff member (nurse, doctor, etc) and setting. Again, if it is possible, please separate out those working in Covid-affected environments
If the data is sensitive enough to show where the same staff were fit-tested multiple times, please include that information.
3. Do you collect data on medical staff working with tight-fitting respiratory protective equipment being fit-tested when they change brand/type of RPE? If so, please give the figures for Feb, March, April and May 2020 as above.
4. Do you track the ethnicity of the staff member with this data? If so, please give the ethnicity breakdowns for the above data for all questions.
Download response Fit-testing of respiratory protective equipment. 160720
Healthcare associated Covid 19 infection deaths. 210421
1. The number of probable healthcare associated Covid 19 infection deaths at hospitals within the trust since the start of the pandemic. (We understand a probable test relates to a positive Covid test 8-14 days after admission.)
2. The number of definite healthcare associated Covid 19 infection deaths at hospitals in the trust since the start of the pandemic. (We understand a definite test relates to a positive Covid test 15 days after admission.)
Download response Healthcare associated Covid 19 infection deaths. 210421
Hospital acquired Covid-19. 030920
1. Have records of Covid-19 infections in patients which were hospital acquired been kept? If so:
a) How many Covid-19 infections in patients were hospital acquired?
b) Of those who acquired Covid-19 while in hospital, how many died?
c) What was the total number of Covid-19 deaths in hospital?
2. Have records been kept of members of staff who contracted Covid-19? If so:
a) How many members of staff contracted Covid-19?
b) How many members of staff were absent from work due to Covid-19?
c) How many members of staff died due to Covid-19?
3. What is the total number of Covid-19 infections recorded in hospital?
4. What is the procedure for when a patient is diagnosed with Covid-19 outside a Covid-19 ward?
a) Has this procedure remained the same throughout the time period set out above?
5. What is the procedure for when a member of staff is diagnosed with Covid-19?
a) Has this procedure remained the same throughout the time period set out above?
Hospital acquired Covid-19. 050221
Please provide me with the monthly figures for patients who have caught covid-19 while in the Trusts care for the period March 2020 to Jan 6th 2021.
Hospital-acquired Covid-19. 101220
1. Please can you tell me how many cases of hospital-acquired Covid-19 the trust has had since 1st March 2020?
2. Please state the date the case was discovered, the name of the hospital and the ward/department where the patient was, the outcome for the patient (i.e. recovered, died), and whether any staff were also affected (if so, please state how many and the area of the hospital where they work).
3. Please also include any information that was shared with Public Health England on these cases.
Hospital acquired Covid-19.120522.docx
1. The number of people who were infected with Covid-19 inside your hospitals – so the patients who tested positive for Covid-19 after testing negative when they were first admitted. Please may I have the figures broken down for the number of hospital-acquired infections for each individual hospital.
2. The number of people who after being infected with Covid inside the hospital, then died of or with the virus, whilst in hospital, or after discharge. Please may I also have these figures broken down for the number of deaths for each individual hospital.
Hospital-acquired Covid-19. 150321
1. Please can you tell me how many cases of hospital-acquired Covid-19 the trust has had since 1st March 2020?
2. Please state the date the case was discovered.
Hospital acquired Covid-19. 270821.docx
1. Please can you tell me how many cases of hospital-acquired Covid-19 the Trust has had since 1st March 2020 to the present day. Please break this down by probable and definite nosocomial infections if this data is available.
2. Please also give me the number of deaths from hospital acquired infections (probable and definite cases).
3. If you are able, in each case, please could you state whether you have informed the patient’s relative that it was a hospital acquired infection.
Hospital acquired Covid-19. 280521
1 – Please provide me with all the nosocomial infection – (Hospital Acquired Covid) figures for March 2020 to July 2020.
2 – Please provide me with the number of nosocomial deaths – caused by Hospital Acquired Covid – in all your hospitals by month for the period March 2020 to present.
Hospital acquired Covid-19 deaths.270521
Also could I check how many of the patients who probably caught Covid -19 (i.e. 8-14 days post admission) died? Your answer only relates to 15+ days so I don’t know if this is because none of the patients in the 8-14 category died or because you haven’t given me that number.
Hospital-acquired Covid infections.280422.docx
For all the information below please could you provide data from between the dates 01/12/2021 to 25/03/2022, and could you please provide the figures for each individual month. An Excel form has been included for this information to be easily filed.
1) The monthly number of probable hospital-acquired Covid-19 infections (8-14 days after admission)
2) The monthly number of definite hospital-acquired Covid-19 infections (>14 days)
3) The monthly number of patients who died in hospital after acquiring a ‘probable’ hospital-acquired Covid-19 infection
4) The monthly number of patients who died in hospital after acquiring a ‘definite’ hospital-acquired Covid-19 infection
Hospital-acquired Covid infections or deaths. 050821.docx
For each month from April 2020 to March 2021:
1.
A) The number of deaths of patients at the trust who had been diagnosed with covid-19, and where the diagnosis had been made between 15 days or more after hospital admission. Please include instances only where the patient’s death occurred while they were inpatients at the trust.
B)The number of deaths of patients of the trust who had been diagnosed with covid-19, and where the diagnosis had been made 8 days or more after hospital admission. Please include instances only where the patient’s death occurred while they were inpatients at the trust.
2.
A) The number of deaths of patients at the trust where covid-19 was given as a cause of death, and where the patient had been diagnosed with Covid 15 days or more after hospital admission. Please include instances only where the patient’s death occurred while they were inpatients at the trust.
B) The number of deaths of patients at the trust where covid-19 was given as a cause of death, and where the patient had been diagnosed with Covid 8 days or more after hospital admission. Please include instances only where the patient’s death occurred while they were inpatients at the trust.
3.
A) The number of patients at the trust who had been diagnosed with covid-19, and where the diagnosis had been made between 15 days or more after hospital admission.
B) The number of patients of the trust who had been diagnosed with covid-19, and where the diagnosis had been made 8 days or more after hospital admission.
Download response Hospital-acquired Covid infections or deaths. 050821.docx
Impact of COVID-19 on prostate cancer diagnosis, treatment and support. 021020
1. Did you suspend your MRI before biopsy service for patients with suspected prostate cancer as a result of the COVID-19 pandemic?
a. Yes
b. No
c. We did not offer MRI before biopsy before the pandemic
2. If yes, have you now resumed MRI before biopsy for patients with suspected prostate cancer?
a. Yes
b. No
c. No, but we refer patients elsewhere (Please state the referral area:)
d. N /A
3. Do you currently use a pre-MRI clinical triage for patients with suspected prostate cancer? By pre-MRI clinical triage, we mean a process, often Clinical Nurse Specialist led, that determines patient suitability for MRI before biopsy
a. Yes
b. No
4. Has your radiology department introduced any new MRI exclusion criteria for patients with suspected prostate cancer as a result of COVID-19?
a. Yes (please specify:)
b. No
c. N/A
5. If yes, do you plan to maintain any of these exclusion criteria once restrictions to limit patients’ COVID-19 risk are lifted?
a. Yes (please specify:)
b. No
c. N/A
6. Did you stop conducting biopsies for patients with suspected prostate cancer as a result of COVID-19 infection risks?
a. Yes
b. No
7. If yes, have you resumed biopsy services for patients with suspected prostate cancer?
a. Yes
b. Yes, but only for a subset of patients (please specify:)
c. No
d. No, but we refer patients elsewhere for prostate biopsy (Please state the referral area:)
8. Do you offer transperineal biopsy under local anaesthetic?
a. Yes
b. No
c. No, but we plan to in future (please specify when if possible:)
9. Following an MRI scan for suspected prostate cancer, what criteria do you use to select patients for biopsy? Please include all that apply:
a. Patients with a PI-RADSs or Likert score of 1 or greater
b. Patients with a PI-RADS or Likert score of 2 or greater
c. Patients with a PI-RADS or Likert score of 3 or greater
d. Patients with a PI-RADS or Likert score of 3 or greater, but only if PI-RADS or Likert score 3 patients have other clinical indications (such as age, ethnicity, PSA density) that make them higher risk
e. Patients with a PI-RADS or Likert score of 4 or greater
f. We do not offer MRI before biopsy
g. We do not currently biopsy patients
10. Did you delay radiotherapy treatment for prostate cancer patients as a result of COVID-19?
a. Yes
b. No
c. Partially (please specify:)
d. N/A (please specify:)
11. If yes, have you cleared your backlog for prostate cancer radiotherapy treatment?
a. Yes
b. No
c. N/A – We did not delay prostate cancer radiotherapy treatment
12. Did you delay radical prostatectomy for prostate cancer patients as a result of COVID-19?
a. Yes
b. No
c. Partially (please specify:)
d. N/A (please specify:)
13. If yes, have you cleared your radical prostatectomy backlog?
a. Yes
b. No
c. N/A – We did not delay radical prostatectomy for prostate cancer patients
14. To address your backlog did or are you using a protocol to risk stratify patients and prioritise patients with high-risk and locally advanced prostate cancer for treatment within 3 months?
a. Yes
b. No
c. No, we did not have a sufficient backlog to require patient prioritisation
15. Does your protocol apply to new patients with high-risk and locally advanced prostate cancer with the intention to radically treat them within 3 months of diagnosis?
a. Yes
b. No
c. N/A – We do not have a protocol for patient prioritisation
16. Do you have prostate cancer Personalised Stratified Follow Up (PSFU) protocols in place?
a. Yes
b. No
c. We are in the process of developing PSFU protocols
17. If Yes, do you have a digital remote monitoring system in place for follow up?
a. Yes (Please specify the name of the system used: e.g My Medical Record, Patient Knows Best)
b. No
18. If no, do you plan to implement a digital remote monitoring system for follow up?
a. Yes – (Please specify the name of the system you plan to implement: e.g My Medical Record, Patient Knows Best)
b. No
19. Which of the following criteria are part of your follow up protocols? (please mark all that apply:)
a. Patients have access to a Support Worker who acts as their key worker for the duration of their follow up care.
b. Patients have access to an online patient service that allows them to check test results, complete assessments, view patient information and message their clinical team.
c. Patients attend a 4-hour supported self-management workshop with a group of 8 to 10 men to develop knowledge, skills and confidence to self-manage their condition
d. Patients do not need to attend routine appointments unless an issue arises.
Download response Impact of COVID-19 on prostate cancer diagnosis, treatment and support. 021020
Critical Care
Acute venous thromboembolism (VTE).170322.docx
Acute management of Venous thromboembolism:
1. Confirm whether the Trust routinely prescribes direct oral anticoagulants (DOACs) in preference to low molecular weight heparin (LMWH) and warfarin for the management of standard acute venous thromboembolism (VTE)?
2. Please provide a copy of the Trusts’ management policy on management of acute venous thromboembolism (VTE).
3. Does the Trust provide all patients with an unprovoked VTE a medical opinion from a thrombosis physician?
4. Does the Trust definition of an ‘unprovoked VTE’ include women using the combined oral contraceptive pill or hormone replacement therapy (HRT)?
5. Do investigations after an unprovoked VTE follow NICE guidance?
6. Per week, how many clinics are devoted to seeing patients with VTE in the Trust?
7. How many full-time equivalents are employed by the Trust to provide thromboprophylaxis and care of thrombosis patients from?
a) Nursing
b) Pharmacists
c) Medical
Thromboprophylaxis
8. Does the Trust routinely meet the 95% VTE Risk Assessment level required by NHS England?
9. Please provide the monthly percentage (admissions numbers/VTE risk assessments carried out) for VTE risk assessments carried across the Trust between 1st October 2021 – 31 December 2022.
10. Does the Trust have dedicated funding for a team ensuring VTE prevention occurs?
COVID-19
11. Please provide a copy of the Trust’s thromboprophylaxis protocols used to treat in-patients with COVID- 19 pneumonia.
Psychological care
12. Do VTE patients within the Trust have access to clinical psychological support?
13. How many sessions per week are provided by the Trust for VTE clinical psychological support?
Cancer-associated VTE
14. Does the Trust have a dedicated clinical lead for cancer associated thrombosis (CAT)?
15. Does a protocol exist for managing VTE in those with cancer?
16. Please provide a copy of the Trusts’ protocol for managing VTE in those with cancer.
VTE prevention and management in the community
17. Please provide copies of VTE care pathways developed to support community clinicians with regards to:
(i) Anticoagulation medication changes
(ii) Anticoagulation dosing.
18. Does the Trust have specific VTE guidance for:
(i) System wide protocols?
(ii) E-consultation facilities?
(iii) On call clinician to discuss problems and seek advice from?
19. Please provide copies of the Trust’s protocol documents for VTE prevention and management in
(i) System wide protocols
(ii) E-consultation facilities
(iii) On call clinician to discuss problems and seek advice from
Adult Dying and Deceased Patient Policy and Procedure and Bereavement procedures. 230821.docx
1] My question 2 was to supply email copies of appendices to the Adult Dying and Deceased Patient Policy and Procedure. The response was aimed at those using a windows-based computer system. I use a Mac so I was unable to access any of them. Please find a way for me to access the documents requested.
Not being able to access them and requesting them in a different format so that I can access them does not, in my view, constitute a DIFFERENT or FURTHER request. It is still the original request which was not met. Millions of people use Mac computers. A pdf format would, I believe, have allowed universal access, where the assumption of Windows use, automatically cuts out a whole swathe of the population.
2] In response to my question 5, point number 1, of the response, states that:
‘ On the day death notified to Bereavement, healthcare records are removed from the ward/unit, taken to bereavement for scanning ready for scrutiny by the Medical Examiner ‘
Then on the last page it states ” Previously and before the ME service started…’
So:
A] I would like to know when the ME service started.
B] i. Did Bereavement use the scanning process of healthcare records in April/May 2020?
B] ii. If so, what system did they scan the healthcare records onto during April/May 2020?
B] iii. If not, then when did Bereavement start scanning healthcare records?
Adult Level three Critical Care beds.240522.docx
1. How many Adult Level three Critical Care beds do you currently have with an invasive ventilator?
2. How many of these are currently staffed and therefore available for use (either vacant or occupied)?
3. When considering relevant guidelines concerning these beds, how many have Carbon Dioxide (CO2) monitoring available for Invasively ventilated patients?
4. Thinking about the new (January 2022) NICE Guidelines concerning inhaled sedation, how many of your Level three beds have inhaled anaesthetic gas monitoring available?
Agency spend for locum doctors in Acute Medicine. 240317
Can you please assist me with retrieving the total Agency spend for Medical Locum Doctors within Acute medicine over the following months, within your Trust or Health Board?
August 2016
September 2016
October 2016
November 2016
December 2016
January 2017
Download response Agency spend for locum doctors in Acute Medicine. 240317
Anchors. 050418
Name of your Trust
Hospitals within Trust (select multiples as needed)
The number of anchors used between Jan 2017-Dec 2017
The supplier name(s) of knotless anchors (select multiple suppliers as needed)
The supplier name(s) of knot tying anchors (select multiple suppliers as needed)
Procurement Route
Procurement agreement end date (DD/MM/YY)
Estimated annual value, Jan 2017-Dec 2017 (£s)
Number of Rotator Cuff repairs completed between Jan 2017-Dec 2017
Number of instability/stability repairs completed between Jan 2017-Dec 2017
Antiseptic skin preparation prior to invasive surgery. 150721.docx
1) Please confirm if Maidstone and Tunbridge Wells NHS Trust follows NICE guidance 125 (Surgical Site Infections: Prevention and Treatment) when carrying out antiseptic skin preparation?
a. If yes, please provide a copy of Maidstone and Tunbridge Wells NHS Trust s most up-to-date surgical site infection prevention protocol.
2) How does Maidstone and Tunbridge Wells NHS Trust communicate the category difference between antiseptic products that are medicines vs biocides and their intended use?
a. Please share any communication materials.
3) Can you please specify which antiseptic skin preparation products are used in Maidstone and Tunbridge Wells NHS Trust s operating theatres for the purposes of prevention of surgical site infections?
4) Does Maidstone and Tunbridge Wells NHS Trust obtain patient consent prior to surgical procedures?
a. If yes, please provide the written material that Maidstone and Tunbridge Wells NHS Trust uses to obtain consent.
Download response Antiseptic skin preparation prior to invasive surgery. 150721.docx
Cardiology digital systems.241219
1) Regarding echocardiograms:
a) Which digital system is used by healthcare professionals in your trust to request echocardiograms?
b) On what digital system(s) are echocardiogram images stored?
c) On what system are echocardiograms reported?
d) On what system(s) are the reports for echocardiograms available for review?
2) Regarding coronary angiograms:
a) Which digital system is used by healthcare professionals in your trust to request coronary angiograms?
b) On what digital system(s) are images from coronary angiograms stored?
c) On what system are coronary angiograms reported?
d) On what system(s) are the reports from coronary angiograms available for review?
3) Regarding cardiac pacemakers:
a) Which digital system is used by healthcare professionals in your trust to request pacemaker insertion?
b) On what system are pacemaker procedure reports written?
c) On what system(s) are pacemaker procedure reports available for review?
d) On what system(s) are cardiac pacemaker routine outpatient checks available for review?
4) Regarding cardiology patient documentation:
a) On what system(s) are outpatient letters available for review?
b) On what system(s) are discharge letters available for review?
c) Are copies of ECGs stored electronically? If so, on what system(s) are they available?
5) Regarding CT coronary angiograms:
a) Which digital system is used by healthcare professionals in your trust to request CT coronary angiograms?
b) On what digital system(s) are images from CT coronary angiograms stored?
c) On what system are CT coronary angiograms reported?
d) On what system(s) are the reports from CT coronary angiograms available for review?
6) What RIS system does your hospital use?
7) What PACS system does your hospital use?
Cardiopulmonary Resuscitation of Elderly and Vulnerable Patients. 260820
I am making a formal written request for a complete copy of the Maidstone and Tunbridge Wells NHS Trust policy regarding the Cardiopulmonary Resuscitation of Elderly and Vulnerable Patients.
Download response Cardiopulmonary Resuscitation of Elderly and Vulnerable Patients. 260820
Clinically Artificial Nutrition and Hydration (CANH). 170120
• In your Trust is there any formal register kept of deaths occurring as a result of withdrawal of Clinically Artificial Nutrition and Hydration (CANH) that occur under the provisions of the Mental Capacity Act 2005 and BMA/RCP/GMC Guidelines 2018?
• If such a register is kept can you advise if there is any independent internal or external audit made of such deaths and the degree to which there Is compliance with the BMA/RCP/GMC Guidelines, 2018 when such deaths occur?
• Where deaths due to withdrawal of CANH are recorded and an audit is made of these, can you give an indication of the number such deaths in 2018 and in 2019 and the percentage of cases where the BMA/RCP/GMC Guideline Checklist has been used and fully completed?
Download response Clinically Artificial Nutrition and Hydration (CANH). 170120
Complaints regarding end of life care.
1. How many complaints in the following years has the Trust received relating to the end of life care/palliative care of a patient? Please answer each year by breaking down month by month e.g. January: 9, February 10…
a) In 2015
b) So far in 2016 (up to 16/5/2016)
2. Of the number of complaints above what numbers were related to:
a) Communication that the patient is actually dying
b) The patient or relatives was unaware that lifesaving drugs had been withdrawn
c) Care, including dignity, respect and privacy
d) Lack of pain relief
e) Access to specialised support and information
f) Lack of access to care through the night, at weekends and over holiday’s periods
Download response Complaints regarding end of life care 060616
Continuous renal replacement therapy (CRRT). 010217
1. How many machines do you have for continual renal replacement (CRRT) in the intensive care unit/critical care unit?
1. a. Can you split these by manufacturer and age of machine please?
2. Are you in a contract for your machines, if so when does the contract expire?
3. How many CRRT treatments were carried out in 2016 (or the latest 12 month period you have data for)?
4. How many bags of fluid did you use for CRRT in 2016 (or the latest 12 month period you have data for)?
5. Who is your current manufacturer of fluids for CRRT? And for Vascular access? (Double Lumen catheters)
6. Are you in a contract for fluids, if so, when does this expire and is it linked in with the machine contract?
7. What was your total spend on CRRT fluids in 2016 (or the latest 12 month period you have data for)?
8. What was your total spend on CRRT consumables (e.g. consumable sets for the machines) in 2016 (or the latest 12 month period you have data for)?
9. What is the typical renal dose you prescribe to the patients? (In ml/kg/h)
10. Are your units using Citrate Anticoagulation? If yes how frequent (in % vs. Heparin).
Download response Continuous renal replacement therapy (CRRT). 010217
Continuous Renal Replacement Therapy (CRRT) machine. 070921.docx
I’m seeking potential solutions for a customer to replace their existing Continuous Renal Replacement Therapy (CRRT) machine.
The machine must be capable of offering both CVVH (Continuous Veno-Venous Hemofiltration) and CVVHDF (Continuous Veno-Venous Hemodiafiltration).
Also, of equal importance is for the machine to use volumetric rather than gravimetric (weights and balances) technology to ensure accurate and safe fluid loss.
This system will not be used in a hospital environment, so it cannot use weights and balances for its accuracy.
Download response Continuous Renal Replacement Therapy (CRRT) machine. 070921.docx
Covered stents. 030118
What is the total number of Covered stents deployed in Arterio venous (AV) fistula/graft access procedures in 2016-17?
Critical care. 200718
The hospitals under your trust?
Number and types of operating theatres.
Number of beds within the critical/intensive care unit(s).
Number of endoscopy treatment rooms/theatres.
If possible I would like to know the make, model and age of the following equipment if applicable:
1.0 Ultra clean ventilation systems
2.0 General Theatres
3.0 Ceiling mounted medical service pendants
4.0 Operating lights
5.0 Theatre control panels
6.0 AHU Units
7.0 Class 1,2 & 3 Cabinets
Critical care bed capacity. 090617
Question 1: What is the total number of critical care beds (Level 2 and Level 3) per 100,000 of the population your trust serves?
1. If you cover both secondary and tertiary care, please provide your TOTAL bed:population ratio for the whole trust, AND a figure for both types of service
Question 2: How many critically ill patients were transferred from your hospital to another hospital’s critical care unit for non-clinical reasons in 2016-17?
Question 3: How many days in 2016-17 was the occupancy of your critical care beds over 85% at least one point during those 24 hours?
Question 4: How many patients had an elective operation cancelled due to lack of a critical care bed capacity in 2016-17?
Question 5: How many days in 2016-17 was at least one critical care bed closed due to lack of staff for at least part of the day?
Do Not Attempt Resuscitation (DNAR) notices. 101220
1. Please can you tell me how many Do Not Attempt Resuscitation (DNAR) notices were issued by the Trust between 1st March 2020 and the present date (8th December 2020)? Please include the date each DNAR was issued.
2. Please can you also tell me how many DNARs were issued for the same period last year (i.e. 1st March 2019 – 8th December 2019).
3. Please can you also tell me how many complaints you have received related to a DNAR being issued at any point between 1st March 2019-8th December 2020 and please provide as much detail as possible about the nature of the complaint.
Download response Do Not Attempt Resuscitation (DNAR) notices. 101220
Domiciliary services for medicines review and palliative care. 281116
I am currently setting up (1) domiciliary visiting medicines review (focussing on both medicines optimisation and medicines adherence) and (2) palliative care services (to ensure the timely and appropriate availability of end of life medicines) within Norfolk using the community pharmacy network and GP practice based pharmacy network, working in conjunction with our NHS community services teams. I am therefore writing to ask if you could send me any reports (service specifications, audit reports, service evaluations etc.) which you may have relating to any services of a similar nature delivered in your area.
Download response Domiciliary services for medicines review and palliative care. 281116
Emergency admissions for Asthma, Epilepsy and Diabetes 2014 – 2016. 270317
1. For the last 4 quarters from January 2016 – December 2016, please provide a breakdown of the number of emergency admissions by age group, broken down by quarter, for the following conditions: (a) asthma (b) epilepsy (c) diabetes type 1 & type 2.
2. For the last 4 quarters from January 2016 – December 2016, please could you provide a breakdown of the number of emergency attendances by age group, broken down by quarter, for the following conditions: (a) asthma (b) epilepsy (c) diabetes type 1 & type 2.
3. For the 4 quarters January 2015 – December 2015, please could you provide a breakdown of the number of emergency admissions by age group, broken down by quarter, for the following conditions: (a) asthma (b) epilepsy (c) diabetes type 1 & type 2.
4. For the 4 quarters January 2015 – December 2015, please could you provide a breakdown of the number of emergency attendances by age group, broken down by quarter, for the following conditions: (a) asthma (b) epilepsy (c) diabetes type 1 & type 2.
5. For the 4 quarters January 2014 – December 2014, please could you provide a breakdown of the number of emergency admissions by age group, broken down by quarter, for the following conditions: (a) asthma (b) epilepsy (c) diabetes type 1 & type 2.
6. For the 4 quarters January 2014 – December 2014, please could you provide a breakdown of the number of emergency attendances by age group, broken down by quarter, for the following conditions: (a) asthma (b) epilepsy (c) diabetes type 1 & type 2?
Download response Emergency admissions for Asthma, Epilepsy and Diabetes 2014 – 2016. 270317
Escalation procedures for ITU/ICU/HDU.
This is FOI request, please tell me what happens if you get patients for ITU / ICU / HDU but they are full with other patients, what do you do?
Download response Escalation procedures for ITU/ICU/HDU 190416
EVAS for AAA repairs. 220920
Has your Trust ever used the Nellix Endovascular Aneurysm Sealing (EVAS) System in patients to treat abdominal aortic aneurysms (AAA)?
Follow-up of Critical Care patients.
Please could you send me any policies relating to intensive care/ critical care follow up of patients?
Download response Follow-up of Critical Care patients 130116
Guidance and protocol on monitoring patients on 35% Oxygen, and protocol regarding the NEWS Scores that are given to monitor a patient’s condition, and their escalation. 260421
I have requested the trusts guidance and protocol on monitoring patients on 35% Oxygen, and protocol regarding the NEWS Scores that are given to monitor a patient’s condition, and their escalation.
ICU medicines. 231220
1) Confirm or deny whether disruption to supply of ICU medicines is included as a risk on the Trust’s risk register
2) Confirm or deny whether disruption to supply of noradrenaline is included as a risk on the Trust’s risk register
3) With regards to the above 2 questions:
a. When were the risks put on the register b. When are they to be reviewed c. What significance status have they been given. e.g. use of a RAG-rating system
4) Provide the number of safety incidents recorded at your Trust which relate to the preparation and /or the manipulation/mixing of medicines in critical care areas between 1 January 2019 and 1 September 2020
5) Provide the number of safety incidents recorded at your Trust which relate to administration, preparation, and/or the manipulation/mixing of noradrenaline at the bedside between 1 January 2019 and 1 September 2020. Provide details of the reported cases.
6) Confirm or deny if your Trust has taken action to adhere to the guidance published by the Royal Pharmaceutical Society, titled Safe and Secure Handling of Medicines (December 2018), specifically with regards to appendix C and, “as outlined in the core guidance, manipulation of medicines in clinical areas is minimised and medicines are presented as prefilled syringes or other ‘ready-to-administer’ preparations wherever possible…” https://www.rpharms.com/recognition/setting-professional-standards/safe-and-secure-handling-of-medicines/professional-guidance-on-the-safe-and-secure-handling-of-medicines
7) Confirm or deny if your Trust subscribes to and follows the guidance provided on IV administration of medication by the MEDUSA injectable medicines guide.
8) Supply evidence of the process the Trust has taken to address the principles outlined in the guidance above, specifically with regards to “the manipulation of medicines in clinical areas is minimised and medicines are presented as prefilled syringes or other ‘ready-to-administer’ preparations…”
9) Confirm or deny whether your Trust is stockpiling ready-to-use or ready-to-administer noradrenaline for the likely increased demand over the next 6 months (stockpiling is defined as retaining medicines with a shelf-life of at least 12 months)
Delayed transfer of care
12 hour trolley waits. 141217
a) How many patients spent longer than 12 hours from decision to admit to admission at your Trust between October 2016 and October 2017?
b) Of those patients waiting longer than 12 hours from decision to admit to admission, what was the longest wait over 12 hours between October 2016 and October 2017?
c) If possible, please provide a reason for the delay.
Delayed discharge. 160119
1) How many delayed discharges from inpatient wards were recorded by your trust during the following date ranges (please break down the data into the date ranges specified below):
a. 1st November 2017 to October 31st 2018
b. 1st November 2016 to October 31st 2017
c. 1st November 2015 to October 31st 2016
2) What was the total amount of time spent by delayed discharge patients in hospital wards managed by your trust between patients being ready for transfer and the patients being fully discharged from hospital during the following date ranges (please break down the data into the date ranges specified below. Please use whichever time measurement is used by default by your trust):
a. 1st November 2017 to October 31st 2018
b. 1st November 2016 to October 31st 2017
c. 1st November 2015 to October 31st 2016
3) What is the average cost per day to your trust of a patient staying in hospital to your trust, excluding costs specific to their medical condition (i.e. the basic cost of providing a bed, food and care but excluding condition specific drugs, care or medical procedures)
4) Does your trust currently have a plan in place to reduce the delayed discharge of patients in the future?
Delayed discharge 2013-2017 150217
What is the longest continual stretch of days that have been lost to delayed discharge by one patient in?
a) 2013/14
b) 2014/15
c) 2015/16
d) 2016/17 (YTD)
Delayed discharge and court action. 070317
1. Since 1.1.15 how many times have you taken court action to evict a patient from a hospital in your trust because you believe they are fit for discharge but they have failed to leave their hospital bed? For each occurrence please state how many days they had occupied a hospital day for while considered fit for discharge?
2. Of those patients discharged from your hospital in either 2014/15 or 2015/16 please state how many patients had been considered fit to discharge but remained in hospital in excess of one full calendar year before they were discharged? For each patient please state how many days they occupied a hospital bed while considered fit to discharge?
3. Using the most recent convenient date do you have any patients in your hospital who are considered fit to discharge but have been in hospital and been fit to discharge in excess of one full calendar year? For each patient please state how many days they have occupied a hospital bed while considered fit to discharge?
Download response Delayed discharge and court action. 070317
Delayed discharge from the stroke rehabilitation unit at Tunbridge Wells Hospital at Pembury. 011216
1. Please could you provide details of the current number of patients whose discharge from the stroke rehabilitation unit at Pembury Hospital is being delayed while social services arrange personal care packages?
2. Please could you provide details of the number of patients whose discharge has been delayed for more than 7, 14, 21 and 28 days for the same reasons for each month of 2016?
3. Please state the longest number of days for which an individual patient had to wait for a discharge from the stroke rehabilitation unit at Pembury hospital due to a lack of social services capacity to provide personal care 2016?
Delayed discharges.070722.docx
1) the total number of patients in hospital on 30 November whose discharge was delayed because they were awaiting residential home placement or availability, awaiting nursing home placement or availability, or awaiting a care package in their own home.
2) For each of the last 12 months (starting with November 2020 and ending with November 2021), can you please provide the number of hospital patients whose discharge was delayed because they were awaiting residential home placement or availability, awaiting nursing home placement or availability, or awaiting a care package in their own home.
Delayed discharges. 080517
1 – Number of adult patients who are medically fit to leave hospital but are currently unable to be safely discharged. Most recent figures are preferential however the latest on record would also be of use.
2 – Please provide the number of packages of care that are currently delayed due to lack of staffing resources within the community.
3 – Data on agency spend between March 2016 to present date for nursing services within the community.
Delayed discharges. 081020
1. Please could you provide the number of patients whose discharge has been delayed by 28 days or more in the year to March 31 2020?
2. Please including the longest number of days for which an individual patient had to wait for a discharge?
3. Would you please state on April 1 2020 how many beds were occupied in your trust by patients who were classed as a DTOC?
Delayed discharges. 091117
For the financial year 16/17 how many people were classed as bed-blocking; who was responsible for delayed discharges and over the length of time they were bed blocking by weeks. A simple table showing councils/relevant body holding up the discharge down the side and weeks along the top and number of patients in the data will suffice.
Delayed discharges.130922.docx
Please can I get data on all of the patients discharged in August 2022, broken down by the number of days by which their discharges were delayed.
Delayed discharges 2014-2017 111116
In two of the questions we ask for information collected on 28th September, 2016. This date has been chosen because it is the most recent data collection day for NHS England.
When giving reasons for the delay in discharging a patient, please chose one of the ten categories used by NHS England – awaiting completion of assessment, awaiting public funding, awaiting further non-acute NHS care, awaiting residential home placement or availability, awaiting care package in own home, awaiting community equipment and adaptations, patient or family choice, disputes or housing.
If you record it differently please supply information using the official categories for your nation.
1) Please state the five longest delays (in days) which patients who were ready for discharge, have had before they were able to leave the hospital during the period 1st April 2014 to 31st September 2016.
For each of these delayed discharges, please state:
i) The age of the person concerned.
ii) The original reason for admission to hospital.
iii) The reason for the delayed discharge.
iv) The date on which the patient was ready for discharge.
v) The date on which they were in fact discharged.
2) Please state how many patients, who were ready for discharge, had to wait 28 days or more to leave the hospital.
Please break these figures down by the cause of the delay.
Please provide this information for the following financial years:
i) 2014/15
ii) 2015/16
iii) 2016/17 to date
3) On the day of the 28th September 2016, please state:
i) The five longest waits in days that patients ready for discharge had had as of this date.
ii) For each of these waits, please state the age of the person concerned and the reason for their admission.
iii) For each of these waits, please state the reason for the delay.
4) Please state how much your trust spent on delayed discharges in each of the following financial years.
i) 2011/12
ii) 2012/13
iii) 2013/14
iv) 2014/15
v) 2015/16
vi) 2016/17 to date.
5)
i) On the 28th September 2016, how many of your acute beds were occupied by people who were ready for discharge?
ii) What proportion of your overall number of acute beds were being used by people who were ready for discharge?
iii) Have you had to open extra transitional, reablement or similar beds to meet the additional demand caused by delayed discharges?
iv) If yes, please state how many beds and the cost of providing these.
Delayed discharges. 210218
1. Between 1.2.16 and 31.1.17 how many times have you written to a patient, or the family members of a patient, or the legal guardians of a patient, stating that in the Trust’s view they are fit for discharge and should vacate their hospital bed? For each occurrence please state how many days they had occupied a hospital day for while considered fit for discharge prior to the date of the letter being sent to them or their representatives? For the most recent occasion that a letter was sent please provide me with a copy of the letter accepting that any details that might identify the patient will be redacted to comply with S.40.
2. Of those patients discharged from your hospital in either 2014/15 or 2015/16 please state how many patients had been considered fit to discharge but remained in hospital in excess of one full calendar year before they were discharged? For each patient please state how many days they occupied a hospital bed while considered fit to discharge?
3. Using the most recent convenient date do you have any patients in your hospital who are considered fit to discharge but have been in hospital and been fit to discharge in excess of one full calendar year? For each patient please state how many days they have occupied a hospital bed while considered fit to discharge?
Delayed discharges. 300519
Are you able to let me know the number of bed days lost because medically fit patients are waiting for placements in care homes? If you have this data for the most current reporting period that would be useful.
I’m not sure if the data includes the number of patients who are medically fit but need accommodation due to dementia. Would that data include the average length of delay for dementia patients or just all patients?
Delayed transfer of care 2013-2016. 070317
1. Over the last 3 years (2013-2016) how many patients have been involved in long-term delayed transfer of care (broken down into a delay of over six months; over one year; over two years etc.)
2. Over the last three years (2013-2016) what is the longest someone has been medically fit to be discharged but is still in the hospital?
3. Currently, what is the longest duration a patient has occupied a hospital bed because they are refusing to leave/disputing/family or patient not accepting the care package available?
4. How many times has the Trust applied for court orders to evict a patient over the last three years?
5. (If this figure is available) How much a year does delayed transfer for care cost the Trust?
Download response Delayed transfer of care 2013-2016. 070317
Delayed transfer of care. 190320
1. The number of patients stuck in hospital due to delayed transfers of care, also known as bed blocking. Please tell me the reasons for their delayed transfer and be as specific as possible.
2. The length of time these patients were stuck in hospital.
3. The number of patients stuck in hospital due to delayed transfers of care (bed blocking) because they have hoarding disorder.
4. The length of time these patients were stuck in hospital.
I request the information for the following years:
2015-16
2016-17
2017-18
2018-19
2019-20
2020-present
Delayed transfers of care 060317
1. The number of patients who have died in hospital while experiencing a delayed transfer of care. Please could I have these figures for the years 2014, 2015 and 2016, broken down by year?
Delayed transfers of care 2016-2017. 150517
What is the longest amount of time in days a patient had been kept in hospital due to delayed transfer in the past 12 months?
Could you give me details for the three longest delayed transfer stays, the name of the hospital concerned and if possible the age and gender of the patients concerned and the department they were in (i.e. elderly care/general surgery, paediatrics etc.)?
Are you also able to give a brief reason for the delay in each instance (i.e. lack of beds in care facility/delay equipping home etc.)?
Download response Delayed transfers of care 2016-2017. 150517
Delayed transfers of care. 041121.docx
1. For each month in 2021 for which data is held, please state the number of ‘delayed days’ in acute care that month due to delayed transfers of care
2. Please provide any breakdown the Trust holds of the question 1 data by reason for the delay (e.g. awaiting care package in own home, patient or family choice etc)
3. For each month in 2021 for which data is held, please state the number of ‘delayed days’ in non-acute care that month due to delayed transfers of care
4. Please provide any breakdown the Trust holds of the question 3 data by reason for the delay (e.g. awaiting care package in own home, patient or family choice etc)
5. For each month in 2021 for which data is held, please state the number of ‘DTOC beds’ in acute care that month
6. For each month in 2021 for which data is held, please state the number of ‘DTOC beds’ in non-acute care that month
Delayed transfers of care.150523.docx
1. (FOI TO ALL NHS PROVIDERS – DELAYED TRANSFERS OF CARE)
Under the FOI Act please provide me with the information below.
Please confirm receipt of this request as soon as possible.
The number of inpatients who are currently medically fit to leave hospital in your area, but still reside there.
Please provide this as a series of data points for the last calendar year and the year to date, broken down by day. For each day, please break the data into further categories which detail the reason behind the delayed discharge.
Delays in transfer of care (DTOC) in 2013-14, 2014-15, 2015-16.
1. What is the longest time (in days) one patient has remained in a bed at your NHS Trust due to delays in transfer of care (DTOC) in 2013/14, 2014/15, 2015/16;
2. In each case, please provide the age of the patient and reason for delay.
Download response Delays in transfer of care (DTOC) in 2013-14, 2014-15, 2015-16.
Delays in transfer of care (DTOC) in 2013-14, 2014-15, 2015-16. 190417
1. What is the longest time (in days) one patient has remained in a bed at your NHS Trust due to delays in transfer of care (DTOC) in 2013/14, 2014/15, 2015/16;
2. In each case, please provide the age of the patient and reason for delay.
Download response Delays in transfer of care (DTOC) in 2013-14, 2014-15, 2015-16. 190417
Delays in transfer of care (DTOC) in 2013/14, 2014/15, 2015/16.190416
1. What is the longest time (in days) one patient has remained in a bed at your NHS Trust due to delays in transfer of care (DTOC) in 2013/14, 2014/15, 2015/16;
2. In each case, please provide the age of the patient and reason for delay.
Download response Delays in transfer of care (DTOC) in 2013/14, 2014/15, 2015/16.190416
DTOC and missed target fines. 280119
1) What is the name of?
a) Your trust
b) The hospitals run by your trust
2) What is the longest time (in days) one patient has remained in a bed at your trust due to delays in transfer of care (DTOC) from October 2016 to October 2018?
3) What was the age of the patient (from question 2) and the reason for delay?
4) How much money has your trust been fined or had withdrawn/withheld for not meeting the percentage target for A&E waiting time (4 hours) in the following financial years: (If possible please breakdown by quarters, if not just give the whole sum for that period)
a) 2017/2018
b) so far 2018
5) How much money has your trust been fined or had withdrawn/withheld for not meeting the percentage target for referral to treatment time of 18 weeks for patients in the following financial years: (If possible please breakdown by quarters, if not just give the whole sum for that period)
a) 2017/2018
b) so far 2018
6) How much money has your trust been fined or had withdrawn/withheld for not meeting the 15 minute target of handing over a patient from an ambulance to your hospital in the following financial years: (If possible please breakdown by quarters, if not just give the whole sum for that period)
a) 2017/2018
b) so far 2018
DTOC patients. 300819
1. Could the authority state how they use agencies and/or software to expedite the discharge of DTOC patients?
2. How much did they spend with agencies to arrange placements with care homes or home care for DTOC patients in each of the last three financial years?
3. Do they use Capacity Tracker or any other software of services to identify care homes or home care packages? Please state which software or services are used.
DTOC and self-funding patients. 240817
DTOC and Self-Funding Patients
1. How many self-funding adult social care patients waiting for placements causing DTOCs in 2015-16, 2016-17 and 2017 to date?
2. Are there currently any care home placements and / or care package brokerage services being offered to the self-funders at the moment?
MH / Alcohol Related A&E Admissions
3. How many Alcohol and Mental Health A&E admissions and related occupied bed days? And total cost for this?
4. Is there an Alcohol Nurse Liaison service available at the hospital?
Acute Bed Days DTOCs
5. What is the average cost of an acute hospital bed in your NHS Trust
6. The gross cost to the Trust due to delayed transfers of care (DTOC) (before taking into account reimbursements from local authorities).
7. The gross cost to the Trust due to delayed transfers of care where Social Care was responsible for the delay (before taking into account reimbursements from local authorities).
8. The total sum received from local authorities in reimbursements for delayed transfers of care.
9. How many bed days were lost as a result of delayed transfers of care in your NHS Trust for the years 2014/2015 , 2015/2016 & 2016 /2017
10. What is the longest time (in days) one patient has been a delayed transfer of care (DTOC) in your NHS Trust for the years 2014/2015 2015/2016 2016/2017
11. In each case, please provide the age of the patient and reason for the delay and responsible CCG/local authority.
12. What is the longest time in (in days) one patient has been a delayed transfer of care awaiting further assessment in your NHS Trust for the years 2014/2015 2015/2016 2016/2017.
13. In each case, please provide the age of the patient and responsible CCG/ Local authority
14. Has the Trust ever taken legal action to remove a patient whose transfer of care was delayed? a) If so please provide details of when and the reason for delay in transfer of care and responsible CCG/local authority
Contact Details
15. Discharge and DTOC lead within the Trust
16. Alcohol Liaison Service
Elderly patients delayed transfer of care (DTOC). 040117
I would like some information on the number of elderly patients who have been kept in hospital when they are well enough to be discharged due to a lack of suitable social care provision in the last 5 years.
Download response Elderly patients delayed transfer of care (DTOC). 040117
Diagnostics, Therapies, Pathology & Pharmacy
Pain relief prescriptions 031016
For each of the questions, please can you provide answers for each of the financial years 2013/14, 2014/15 and 2015/16:
1. PARACETAMOL
a. Which suppliers did you buy paracetamol from?
b. How many packets of paracetamol did you buy from each supplier? Please disclose how many tablets were in the packets.
c. How many packets of paracetamol did you buy in total? Please disclose how many tablets were in the packets.
d. How much did you pay each supplier for paracetamol?
e. How much did you spend on paracetamol in total?
f. How many prescriptions in total did you make for paracetamol?
g. How many of these prescriptions were free for the patient?
h. How much money were you paid by patients for paracetamol?
2. IBRUPROFEN
a. Which suppliers did you buy ibuprofen from?
b. How many packets of ibuprofen did you buy from each supplier? Please disclose how many tablets were in the packets.
c. How many packets of ibuprofen did you buy in total? Please disclose how many tablets were in the packets.
d. How much did you pay each supplier for ibuprofen?
e. How much did you spend on ibuprofen in total?
f. How many prescriptions in total did you make for ibuprofen?
g. How many of these prescriptions were free for the patient?
h. How much money were you paid by patients for ibuprofen?
3. ASPIRIN
a. Which suppliers did you buy aspirin from?
b. How many packets of aspirin did you buy from each supplier? Please disclose how many tablets were in the packets.
c. How many packets of aspirin did you buy in total? Please disclose how many tablets were in the packets.
d. How much did you pay each supplier for aspirin?
e. How much did you spend on aspirin in total?
f. How many prescriptions in total did you make for aspirin?
g. How many of these prescriptions were free for the patient?
h. How much money were you paid by patients for aspirin?
4. CODEINE PHOSPHATE
a. Which suppliers did you buy codeine phosphate from?
b. How many packets of codeine phosphate did you buy from each supplier? Please disclose how many tablets were in the packets.
c. How many packets of codeine phosphate did you buy in total? Please disclose how many tablets were in the packets.
d. How much did you pay each supplier for codeine phosphate?
e. How much did you spend on codeine phosphate in total?
f. How many prescriptions in total did you make for codeine phosphate?
g. How many of these prescriptions were free for the patient?
h. How much money were you paid by patients for codeine phosphate?
Aciclovir sodium. 170420
Information request 1
Has your hospital dispensed the products listed below from March 1, 2019 till February 29, 2020?
1. Aciclovir sodium 250mg/5ml powder for intravenous infusion B.P.
2. Aciclovir sodium 500mg/5ml powder for intravenous infusion B.P.
ACR Laboratory Device.080922.docx
1) The name of the laboratory device that is used to analyse albumin:creatinine ratio in the urine.
2) The name of the chemistry kit (if not included in the first question) that is used to analyse albumin:creatinine ratio in the urine.
Acromegaly. 070918
1. Does your trust treat patients for Acromegaly
2. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs;
• Ocreotide
• Lanreotide
• Pasireotide
• Pegvisomant
Acupuncture treatments 2010 to 2015
Please provide the following for the years 2010 to 2015 inclusive:
1. The names of the hospitals, clinics or other settings in which you provided acupuncture treatments.
2. The number of acupuncture treatments provided and the number of patients treated at each of these locations.
3. The types of clinicians who provided these treatments, e.g. physiotherapists, doctors, acupuncturists.
4. The total cost of providing acupuncture treatments at each of these locations.
5. The cost of acupuncture needles purchased included in the total cost.
Download response Acupuncture treatments 2010 to 2015 241016
Adult allergy services. 250321
1. Does your trust offer an adult allergy service? Yes/ No
2. Does this service cover more than one hospital? Yes/ No
2a. If yes, which other hospitals are covered by this service?
3. Who is the lead consultant for this service?
Adult formulary
We would like to request the following information regarding the prescribing of growth hormones within Maidstone and Tunbridge Wells NHS Trust
1. We have the following formularies listed as used by your organisation. Please confirm if they are correct and if not, please provide a link/copy of relevant formularies.
West Kent Interface Adult Formulary
2. Please provide a copy or link to any supporting guidelines containing growth hormone product prescribing recommendations that are in addition to the published formulary. If none are available, please confirm if they are currently being developed/drafted.
3. Where guidelines are held in addition to the published formulary, please confirm which has dominance when prescribing growth hormones.
AeroChamber with and without mask January – December 2015. 290617
I am writing to request the prescribed annual units (for the period January 2015 – December 2015) of the below:
• AeroChamber with Mask
• AeroChamber without Mask
Download response AeroChamber with and without mask January – December 2015. 290617
Agency Pharmacists and Pharmacy Technicians. 240119
I would like you to send me the locum agency spend in the AHP/HSS division of the hospital for Pharmacists and Pharmacy Technicians. I would like to know the spend for 2018 with each agency- if this is not possible then I’d like to know overall spend for the year for both Pharmacists and Pharmacy Technicians.
Download response Agency Pharmacists and Pharmacy Technicians. 240119
Agency spend in Radiology August 2016 – January 2017. 240317
Can you please assist me with retrieving the total Agency spend for Medical Locum Doctors within Radiology over the following months, within your Trust or Health Board?
August 2016
September 2016
October 2016
November 2016
December 2016
January 2017
Download response Agency spend in Radiology August 2016 – January 2017. 240317
Agency usage for Radiography.180822.docx
1. Who is the head of procurement responsible for approving agency usage for the Radiography Department at your trust?
2. Who is responsible for agency usage (on and off framework) in the Radiography department at all hospitals associated with the Trust:
3. Please can you provide the contact number and email address for the manager(s) in questions 1 and 2.
4. Have you used off-framework agency staff between March 2021 – March 2022 in Radiography?
5. How much was your Off-Framework agency spend for Radiography between August 2021 and August 2022?
Aimovig (Erenumab). 130619
Does your trust treat patients with Aimovig [Erenumab]?
If yes, how many patients have been treated in the past 12 months?
Alternative medicine
1. Do you offer complementary therapies within the trust?
2. If yes, do you offer Reiki therapy?
3. Which types of services or departments offer Reiki therapy?
4. Have you conducted a formal evaluation of the Reiki service? If so, please provide brief details.
Anaemia and blood transfusions. 290118
1. Number of RBC units utilised by ward and/ or department in a) 2015 and b) 2016
2. Number of elective surgical procedures cancelled in 2016 due to the patient being identified as anaemic
3. Number of elective surgical procedures occurring for patients who were anaemic on the day of surgery
4. Of the above, the number of these procedures that required a blood transfusion
5. Following the NICE Quality Standards published in December 2016 on blood transfusion, is able to meet Quality Standard 1? Please see Quality Standard Review form attached. We are partially compliant with Standard 1. The Pre-Assessment Teams are referring patients for IV iron if they are found to be anaemic at Clinic, if there is time pre-operatively. Post-op iron therapy does not appear to be standard practice as yet.
Anti-infective medications. 090421
Q1. How many patients have been treated in the last 6 months for Urinary Tract Infections (ICD10 code N39.0) with the following?
a. Ceftazidime/avibactam (Zavicefta)
b. Ceftolozane/tazobactam (Zerbaxa)
c. Meropenem/vaborbactam (Vaborem)
d. Cefiderocol (Fetcroja)
e. Meropenem
Q2. How many patients have been treated in the last 6 months for Post-procedural Respiratory Disorders (ICD10 code J95.8) with the following?
a. Ceftazidime/avibactam (Zavicefta)
b. Ceftolozane/tazobactam (Zerbaxa)
c. Meropenem/vaborbactam (Vaborem)
d. Cefiderocol (Fetcroja)
e. Meropenem
Q3. How many patients have been treated in the last 6 months for Hospital Acquired Pneumonia (ICD10 codes J15 and Y95 in the same inpatient spell) with the following?
a. Ceftazidime/avibactam (Zavicefta)
b. Ceftolozane/tazobactam (Zerbaxa)
c. Meropenem/vaborbactam (Vaborem)
d. Cefiderocol (Fetcroja)
e. Meropenem
Q4. How many patients who underwent a laparotomy/laparoscopic approach to the abdominal cavity (any one of OPCS codes Y502, Y751, Y752 or Y755) in the last 6 months, were treated with the following?
a. Ceftazidime/avibactam (Zavicefta)
b. Ceftolozane/tazobactam (Zerbaxa)
c. Meropenem/vaborbactam (Vaborem)
d. Cefiderocol (Fetcroja)
e. Meropenem
Anti Infectives. 221020
1 – How many patients have you treated in the last 12 months for complicated Intra Abdominal Infections with the following:
Drug Name Total
Amoxicillin/clauvanate
Piperacillin/tazobactam
Ceftazidime/avibactam (Zavicefta)
Ceftolozane/tazobactam (Zerbaxa)
Carbapenems (such as: Meropenem, Imipenem/cilastatin, Ertapenem)
Aminoglycosides (such as: Gentamicin, Amikacin, Tobramycin)
Cephalosporins (such as: Cefotaxime, Ceftazidime, Ceftriaxone)
Quinolones (such as: Ciprofloxacin, Levofloxacin, Ofloxacin)
Polymixins (such as: Colistin)
2 – How many patients have you treated in the last 12 months for Complicated Urinary Tract Infections with the following:
Drug Name Total
Amoxicillin/clauvanate
Piperacillin/tazobactam
Ceftazidime/avibactam (Zavicefta)
Ceftolozane/tazobactam (Zerbaxa)
Carbapenems (such as: Meropenem, Imipenem/cilastatin, Ertapenem)
Aminoglycosides (such as: Gentamicin, Amikacin, Tobramycin)
Cephalosporins (such as: Cefotaxime, Ceftazidime, Ceftriaxone)
Quinolones (such as: Ciprofloxacin, Levofloxacin, Ofloxacin)
Polymixins (such as: Colistin)
3 – How many patients have you treated in the last 12 months for hospital acquired Pneumonia and / or Ventilator acquired Pneumonia (HAP/VAP) with the following
Drug Name Total
Amoxicillin/clauvanate
Piperacillin/tazobactam
Ceftazidime/avibactam (Zavicefta)
Ceftolozane/tazobactam (Zerbaxa)
Carbapenems (such as: Meropenem, Imipenem/cilastatin, Ertapenem)
Aminoglycosides (such as: Gentamicin, Amikacin, Tobramycin)
Cephalosporins (such as: Cefotaxime, Ceftazidime, Ceftriaxone)
Quinolones (such as: Ciprofloxacin, Levofloxacin, Ofloxacin)
Polymixins (such as: Colistin)
Anti-microbial resistance. 230817
Please could you provide me with the number of cases between 2010-2017?
– In which patients were unable to be treated with anti-biotics due to anti-microbial resistance.
– In which patients had to undergo an operation to remove the site of resistance due to anti-microbial resistance.
– In which patients had amputations due to anti-microbial resistance.
ANTI TNF (originator and biosimilar). 200820
1 How many patients (in the Trust) were initiated on ANTI TNF (originator and biosimilar) over the last 12 months?
2 How many patients (in the Trust) have been initiated on biosimilar adalimumab?
• and what is the split by brand in the last 12 months for the following products?
o Amgevita
o Imraldi
o Hulio
o Hyrmioz
o Idacio
3 How many patients have been initiated on these products?
o guselkumab (Tremfya)
o risankizumab (Skyrizi)
o brodalumab (Kyntheum)
o ixekizumab (Taltz)
Download response ANTI TNF (originator and biosimilar). 200820
Anti-VEFG treatments for eye conditions. 011221.docx
1. For the 4-month period from January to April 2021, how many patients has your trust treated with the following anti-VEGF treatments:
2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
3. Within your trust, how many intra-vitreal injections/implants of each the following treatments have been used (for any eye condition) in the four-month period from January to April 2021:
4. If your trust is able to identify intra-vitreal injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from January to April 2021 for each of the following conditions:
Diabetic Macular Oedema (DMO)
Retinal Vein Occlusion – Central (CRVO) or Branch (BRVO)
Download response Anti-VEFG treatments for eye conditions. 011221.docx
Anti-VEFG treatments for eye conditions. 081221.docx
1. For the 4-month period from September to December 2020, how many patients has your trust treated with the following anti-VEGF treatments:
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Fluocinolone acetonide
f. Ranibizumab
2. Within your trust how many intra-vitreal injections/implants of each of the following treatments have been used in the four-month period from September to December 2020:
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Fluocinolone
f. Ranibizumab
3. If your trust is able to identify intra-vitreal injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from September to December 2020 for each of the following conditions:
Wet Age Related Macular Degeneration (wAMD)
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Ranibizumab
Diabetic Macular Oedema (DMO)
a. Aflibercept
b. Bevacizumab
c. Dexamethasone
d. Ranibizumab
Retinal Vein Occlusion – Central (CRVO) or Branch (BRVO)
a. Aflibercept
b. Bevacizumab
c. Dexamethasone
d. Ranibizumab
Download response Anti-VEFG treatments for eye conditions. 081221.docx
Anti-VEGF treatment. 240720
1. Within your Trust, how many patients, in the most recent 12-month period for which data are available, have received anti-VEGF treatment for the first time (i.e., excluding patients who previously had any anti-VEGF therapy)?
2. Of these first-time patients, please provide a breakdown by the treatments listed below:
Aflibercept
Brolucizumab
Dexamethasone
Ranibizumab
All other anti-VEGF treatments
3. Of these first-time patients, how many were treated for Wet Age-Related Macular Degeneration (wAMD) by each treatment?
Aflibercept
Brolucizumab
Dexamethasone
Ranibizumab
All Other anti-VEGF treatments
Antibiotic guidelines. 040117
1) Please provide, in full, the antibiotic guidelines used by your trust.
2) Is antibiotic prophylaxis routinely given for urinary catheter removal after any joint replacement? : yes/no
3) If yes, which is given and how?
4) If yes, what proportion of patients with urinary catheters receive it?
Antibiotic prescribing. 220118
Could you please supply me with the number of each antibiotic prescribed in hospital for the past 10 years?
Could you please break this information down by the name of the drug (eg vancomycin) for each year in the past 10 years? For 2016 could you please give the number of each antibiotic prescribed so far?
Could you also provide me with the cost of each drug for each year?
Please note I am not seeking antibiotics dispensed in the community, but antibiotics prescribed in hospitals.
Download response Antibiotic prescribing. 220118
Antibiotic resistant NDM 2014-2016. 280217
Can you please send details of any cases of antibiotic resistant NDM (New Delhi metallo-ß-lactamase) “superbugs” you have reported to Public Health England in 2014, 2015 and 2016.
We are particularly interested in NDM-1, but would appreciate details of any other NDM incidents if available.
Please break the information down into the three years listed.
Download response Antibiotic resistant NDM 2014-2016. 280217
Antibiotics. 270617
Please could you provide me with a list of all companies currently supplying antibiotics – or that have supplied antibiotics in the last three years – to Maidstone & Tunbridge Wells NHS Trust.
Plus:
– The details, where possible, of the antibiotic products these companies supply or have supplied.
Antifungal Treatments.110722.docx
1) What is the number of patients in the last 12 months treated with the following product lines:
A) anidulafungin
B) caspofungin
C) micafungin
2) What is the split of indication over the last 12 months for the following product lines:
A) anidulafungin
B) caspofungin
C) micafungin
3) For each of the indication splits of the 3 product lines mentioned previously (anidulafungin, caspofungin and micafungin from Q2), please list the average length of treatment time.
Aquatic physiotherapy (hydrotherapy) provision. 280122.docx
1. On behalf of which NHS Trust / Health Board are you responding?
2. Does your Trust / Health Board have access to a hydrotherapy pool?
3. If you do have access are your hydrotherapy pools onsite or offsite? (Tick all that apply)
4. Were all your hydrotherapy pools open prior to the COVID-19 pandemic?
5. If you do not have access to hydrotherapy pools, please tick all answers that apply to answer why that is.
6. How many hydrotherapy pools exist on your NHS Trust / Board’s estate? Include those closed prior to COVID-19.
7. What are your closed hydrotherapy pools / departments now used for?
REOPENING OF HYDROTHERAPY POOLS
8. Will all your hydrotherapy pools be re-opening?
9. When are your hydrotherapy pools scheduled to re-open?
10. If your hydrotherapy pools are not scheduled to reopen, why is that? (Please select all that apply)
11. If your hydrotherapy pools are not scheduled to reopen, has a full public consultation taken place?
12. If your hydrotherapy pools are not scheduled to reopen has an equality impact assessment taken place?
OPERATING HYDROTHERAPY POOLS
13. If your hydrotherapy pools are open or scheduled to open is / will your aquatic physiotherapy (hydrotherapy) service capacity be reduced as a result of COVID-19?
14. What capacity are / will you be able to offer compared to pre pandemic?
Please enter a percentage (%).
15. Is / will your service be provided on a 1:1 basis?
16. Is / will your service be provided with the therapist instructing from poolside
17. Approximately how many sessions did you have access to your hydrotherapy pools on a weekly basis pre pandemic? (Where one session = one morning, afternoon or evening clinic)
18. Approximately how many sessions do you currently have access to your hydrotherapy pools on a weekly basis?
19. Which services use your hydrotherapy pools?
20. Are your hydrotherapy pools used by inpatient or outpatient services?
21. Prior to the pandemic did you provide out of hours access to your hydrotherapy pools to patient groups or private groups? e.g. NASS, Private Clinics (Please provide a list)
22. Have these sessions restarted? (Please provide a list of those which have restarted)
23. Do you currently audit the use and effectiveness of aquatic physiotherapy (hydrotherapy)?
24. Please list outcome measures or tools used to audit the use and effectiveness of aquatic physiotherapy (hydrotherapy)?
25. If you are happy to be contacted for further information to support aquatic physiotherapy (hydrotherapy) services remobilise please provide an email address below.
Aquatic physiotherapy (hydrotherapy) provision. 280122.docx
Aseptic drug compounding or preparation. 290617
1. How much does your aseptic unit cost to run annually?
2. How many aseptically prepared doses does your unit produce per annum?
3. What types of aseptically prepared products does your aseptic unit produce? E.g Parenteral nutrition, antibiotics, cancer chemotherapy?
4. What IT systems does your Aseptic unit currently use to manage the compounding process or help with your prescribing?
5. How many staff do you employ in your aseptic department?
6. How many members of staff are full time equivalents?
7. How many clean rooms do you have in your department?
8. How many isolators do you have in your department?
9. Do you do any outsourcing? Or is all of your compounding carried out in house?
10. Are you a licensed unit? If so, do you compound for any other customers? If yes, who and for how long?
11. What is your unit’s annual drug spend?
Download response Aseptic drug compounding or preparation. 290617
Autopsies. 080519
For each of the years 2017 and 2018 please may you provide me with-
1. The total number of adult (aged 17 and above) deaths within your Trust (on Trust sites) between 1st January and 31st December of each year.
2. The number of Hospital (consent) autopsies carried out on adult (aged 17 and above) deaths which occurred between 1st January and 31st December of each year.
Benzodiazepines. 270617
Prescription of Benzodiazepines (class of psychoactive drugs)
How many patients were given any form of benzodiazepines during treatment in hospital?
Please provide broken-down figures (if possible) for up to the past five years and at least for the past 3 years
Biologic and biosimilar product prescribing in Rheumatology. 211020
Q1. How many patients have been treated with biologics or biosimilar products in the last 12 months for the following conditions:
· Rheumatoid Arthritis
· Psoriatic Arthritis
· Ankylosing Spondylitis
· Non-Radiographic Axial Spondyloarthritis
Q2. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 12 months with the following drugs.
· Abatacept [Orencia]
· Adalimumab [Amgevita]
· Adalimumab [Humira]
· Adalimumab [Hyrimoz]
· Adalimumab [Imraldi]
· Apremilast [Otezla]
· Baricitinib [Olumiant]
· Certolizumab [Cimzia]
· Etanercept [Benepali]
· Etanercept [Enbrel]
· Etanercept [Erelzi]
· Golimumab [Simponi]
· Infliximab [Flixabi]
· Infliximab [Inflectra]
· Infliximab [Remicade]
· Infliximab [Remsima]
· Ixekizumab [Taltz]
· Rituximab [MabThera]
· Rituximab [Rixathon]
· Rituximab [Truxima]
· Sarilumab [Kevzara]
· Secukinumab [Cosentyx]
· Tocilizumab [Ro Actemra]
· Tofacitinib [Xeljanz]
· Upadacitinib [Rinvoq]
· Ustekinumab [Stelara]
Download response Biologic and biosimilar product prescribing in Rheumatology. 211020
Biologic and biosimilar products within Rheumatology. 020222.docx
Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:
a. Abatacept [Orencia]
b. Adalimumab [Humira]
c. Adalimumab Biosimilars
d. Apremilast [Otezla]
e. Baricitinib [Olumiant]
f. Certolizumab [Cimzia]
g. Etanercept [Enbrel]
h. Etanercept Biosimilars
i. Filgotinib [Jyseleca]
j. Golimumab [Simponi]
k. Guselkumab [Tremfya]
l. Infliximab [Remicade]
m. Infliximab Biosimilars
n. Ixekizumab [Taltz]
o. Risankizumab [Skyrizi]
p. Rituximab [MabThera]
q. Rituximab Biosimilars
r. Sarilumab [Kevzara]
s. Secukinumab [Cosentyx]
t. Tocilizumab [Ro Actemra]
u. Tofacitinib [Xeljanz]
v. Upadacitinib [Rinvoq]
w. Ustekinumab [Stelara]
Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis ONLY in the last 3 months with the following drugs.
a. Adalimumab [Humira]
b. Adalimumab Biosimilars
c. Certolizumab [Cimzia]
d. Etanercept [Enbrel]
e. Etanercept Biosimilars
f. Golimumab [Simponi]
g. Infliximab [Remicade]
h. Infliximab Biosimilars
i. Ixekizumab [Taltz]
j. Secukinumab [Cosentyx]
k. Upadacitinib [Rinvoq]
Biologic and biosimilar products within Rheumatology. 020222.docx
Biologic and biosimilar products within Rheumatology. 081021.docx
Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:
a. Abatacept [Orencia]
b. Adalimumab [Humira]
c. Adalimumab Biosimilars
d. Apremilast [Otezla]
e. Baricitinib [Olumiant]
f. Certolizumab [Cimzia]
g. Etanercept [Enbrel]
h. Etanercept Biosimilars
i. Filgotinib [Jyseleca]
j. Golimumab [Simponi]
k. Guselkumab [Tremfya]
l. Infliximab [Remicade]
m. Infliximab Biosimilars
n. Ixekizumab [Taltz]
o. Risankizumab [Skyrizi]
p. Rituximab [MabThera]
q. Rituximab Biosimilars
r. Sarilumab [Kevzara]
s. Secukinumab [Cosentyx]
t. Tocilizumab [Ro Actemra]
u. Tofacitinib [Xeljanz]
v. Upadacitinib [Rinvoq]
w. Ustekinumab [Stelara]
Q2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs.
a. Abatacept [Orencia]
b. Adalimumab [Humira]
c. Adalimumab Biosimilars
d. Apremilast [Otezla]
e. Certolizumab [Cimzia]
f. Etanercept [Enbrel]
g. Etanercept Biosimilars
h. Golimumab [Simponi]
i. Guselkumab [Tremfya]
j. Infliximab [Remicade]
k. Infliximab Biosimilars
l. Ixekizumab [Taltz]
m. Risankizumab [Skyrizi]
n. Secukinumab [Cosentyx]
o. Tofacitinib [Xeljanz]
p. Upadacitinib [Rinvoq]
q. Ustekinumab [Stelara]
Download response Biologic and biosimilar products within Rheumatology. 081021.docx
Biologic and biosimilar products within Rheumatology..docx
We are analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you could provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:
• Abatacept [Orencia]
• Adalimumab [Humira]
• Adalimumab Biosimilars
• Apremilast [Otezla]
• Baricitinib [Olumiant]
• Certolizumab [Cimzia]
• Etanercept [Enbrel]
• Etanercept Biosimilars
• Filgotinib [Jyseleca]
• Golimumab [Simponi]
• Guselkumab [Tremfya]
• Infliximab [Remicade]
• Infliximab Biosimilars
• Ixekizumab [Taltz]
• Risankizumab [Skyrizi]
• Rituximab [MabThera]
• Rituximab Biosimilars
• Sarilumab [Kevzara]
• Secukinumab [Cosentyx]
• Tocilizumab [Ro Actemra]
• Tofacitinib [Xeljanz]
• Upadacitinib [Rinvoq]
• Ustekinumab [Stelara]
Biologic drugs. 010421
Q1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
a. Adalimumab – Humira
b. Adalimumab Biosimilar
c. Apremilast
d. Brodalumab
e. Certolizumab
f. Dimethyl fumarate
g. Etanercept – Enbrel
h. Etanercept Biosimilar
i. Guselkumab
j. Infliximab – Remicade
k. Infliximab Biosimilar
l. Ixekizumab
m. Risankizumab
n. Secukinumab
o. Tildrakizumab
p. Ustekinumab
Q2. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
a. Adalimumab – Humira
b. Adalimumab Biosimilar
c. Golimumab
d. Infliximab – Remicade
e. Infliximab Biosimilar
f. Tofacitinib
g. Ustekinumab
h. Vedolizumab
Q3. If possible, could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department for Ulcerative Colitis ONLY with the following biologic drugs:
a. Adalimumab – Humira
b. Adalimumab Biosimilar
c. Golimumab
d. Infliximab – Remicade
e. Infliximab Biosimilar
f. Tofacitinib
g. Ustekinumab
h. Vedolizumab
biologic drugs. 100621
Q1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
a. Adalimumab – Humira
b. Adalimumab Biosimilar
c. Apremilast
d. Brodalumab
e. Certolizumab
f. Dimethyl fumarate
g. Etanercept – Enbrel
h. Etanercept Biosimilar
i. Guselkumab
j. Infliximab – Remicade
k. Infliximab Biosimilar
l. Ixekizumab
m. Risankizumab
n. Secukinumab
o. Tildrakizumab
p. Ustekinumab
Q2. For the patients treated by the Dermatology department in the last three months with any of the above drugs, can you please provide the total number of paediatric (up to age 16) versus adult patients?
Q3. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
a. Adalimumab – Humira
b. Adalimumab Biosimilar
c. Golimumab
d. Infliximab – Remicade
e. Infliximab Biosimilar
f. Tofacitinib
g. Ustekinumab
h. Vedolizumab
Biologic drugs. 151220
Q1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
· Adalimumab – Humira
· Adalimumab Biosimilar
· Apremilast
· Brodalumab
· Certolizumab
· Dimethyl fumarate
· Etanercept – Enbrel
· Etanercept Biosimilar
· Guselkumab
· Infliximab – Remicade
· Infliximab Biosimilar
· Ixekizumab
· Risankizumab
· Secukinumab
· Tildrakizumab
· Ustekinumab
Q2. For the patients treated by the Dermatology department in the last three months with any of the above drugs, can you please provide the total number of paediatric (up to age 16) versus adult patients?
Q3. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
a. Adalimumab – Humira
b. Adalimumab Biosimilar
c. Golimumab
d. Infliximab – Remicade
e. Infliximab Biosimilar
f. Tofacitinib
g. Ustekinumab
h. Vedolizumab
Biologic drugs in Gastroenterology.140322.docx
Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department for any medical condition, and if possible, for Ulcerative Colitis, with the following biologic drugs:
1. Total Gastroenterology Patients
2. Ulcerative Colitis Patients
a. Adalimumab – Humira
b. Adalimumab Biosimilar
c. Filgotinib
d. Golimumab
e. Infliximab – Remicade
f. Infliximab Biosimilar
g. Ozanimod
h. Tofacitinib
i. Ustekinumab
j. Vedolizumab
Biologic drugs in Gastroenterology.140322.docx
Biologic medicines in gastroenterology.030622.docx
Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
a. Adalimumab – Humira
b. Adalimumab Biosimilar
c. Filgotinib
d. Golimumab
e. Infliximab – Remicade
f. Infliximab Biosimilar
g. Ozanimod
h. Tofacitinib
i. Ustekinumab
j. Vedolizumab
Q2 How many patients were treated in the last 3 months for Crohn’s Disease ONLY with the following biologic drugs:
a. Adalimumab – Humira
b. Adalimumab Biosimilar
c. Golimumab
d. Infliximab – Remicade
e. Infliximab Biosimilars
f. Ustekinumab
g. Vedolizumab
Biologic medicines in gastroenterology.031122.docx
Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
a. Adalimumab – Humira
b. Adalimumab Biosimilar
c. Filgotinib
d. Golimumab
e. Infliximab – Remicade
f. Infliximab Biosimilar
g. Ozanimod
h. Tofacitinib
i. Ustekinumab
j. Vedolizumab
Q2 If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:
a. Adalimumab – Humira
b. Adalimumab Biosimilar
c. Filgotinib
d. Golimumab
e. Infliximab – Remicade
f. Infliximab Biosimilar
g. Ozanimod
h. Tofacitinib
i. Ustekinumab
j. Vedolizumab
Biologic products in respiratory medicine. 100921.docx
Q1. How many patients have been treated (for any condition) in the last four months with:
a. Benralizumab
b. Dupilumab
c. Omalizumab
d. Reslizumab
e. Mepolizumab
Q2. Of the total patients treated in the last four months with any of the products listed in Q1, please can you provide the split of the number of patients in the following age groups:
a. Age 6-11
b. Age 12-17
c. Age 18 and above
Q3. How many patients have been treated in the last four months for asthma ONLY with:
a. Dupilumab
Download response Biologic products in respiratory medicine. 100921.docx
Biological and Biosimilar medicines. 070818
1 – In your Trust, how much did you spend on Biological and biosimilar medicines, in the past financial year ending April 2018?
2 – Have you developed a policy on how prescribers can switch their patients to biosimilars and support them in making informed choices to save resources?
If yes, please provide details
3 – Do you have any specific plans in place for the launch of biosimilar Adalimumab later in 2018?
4 – Are there any agreements in place between you the Provider and CCG that would enable savings in drug costs to be made? (For example, Gainshare agreements where the benefits associated with more efficient use of medicines not reimbursed through national prices is shared between the Provider and the Clinical Commissioning Group party to the agreement. This included agreements for the switch to biosimilar products)
If “Yes”, then please provide the following details:
5 – Are there any other agreements with a CCG, not included in the above, for the following services?
If “Yes”, then please provide the following details:
Download response Biological and Biosimilar medicines. 070818
Biologics 101016
We would like to request from Maidstone and Tunbridge Wells NHS Trust (MTW) the numbers of patients treated in the last 12 months with the following drugs for the conditions listed below:
Biologics and Biosimilar
1. Does your trust run a dedicated Gastroenterology infusion clinic for the treatment of patients with Infliximab [or Vedolizumab] If Yes, how frequently are they run?
2. Could you please provide me with the following numbers of patients treated in the last six months with the following drugs for the conditions listed below?
Rheumatology [Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis] Dermatology [Psoriasis] Hidradenitis suppurativa (sometimes known as acne inversa) L73.2 Gastroenterology
[Crohns / Ulcerative Colitis]
Abatacept (Orencia)
Adalimumab (Humira)
Apremilast (Otezla)
Certolizumab Pegol (Cimzia)
Etanercept (Enbrel)
Golimumab (Simponi)
Infliximab (Remicade)
Infliximab biosimilar (Inflectra)
Infliximab biosimilar (Remsima)
Rituximab (MabThera)
Secukinumab (Cosentyx)
Tocilizumab (RoActemra)
Tofacitinib [Xeljanz]
Ustekinumab (Stelara)
Vedolizumab (Entyvio)
Biologics and Biosimilar. 120919
I have a Freedom of Information request regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs regardless of diagnosis?
Biologics and biosimilar prescribing 01.06.2015 – 31.05.2016
Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the conditions listed below?
• Psoriasis
• Hidradenitis Suppurativa
• Crohn’s disease
• Ulcerative Colitis
Download response Biologics and biosimilar prescribing 01.06.2015 – 31.05.2016 250716
Biologics and Biosimilar prescribing. 031219
Could you please provide me with following numbers of patients treated in the last 12 months (latest) 12 months possible) with the following drugs for either Rheumatology, Dermatology and Gastroenterology departments:
Abatacept (Orencia)
Adalimumab biosimilar (Amgevita)
Adalimumab biosimilar (Hulio)
Adalimumab (Humira)
Adalimumab biosimilar (Hyrimoz)
Adalimumab biosimilar (Imraldi)
Apremilast (Otezla)
Baricitinib (Olumiant)
Brodalumab (Kyntheum)
Certolizumab (Cimzia)
Dimethyl Fumarate (Skilarence)
Etanercept (Enbrel)
Etanercept Biosimilar (Benepali)
Etanercept Biosimilar (Erelzi)
Golimuab (Simponi)
Guselkumab (Tremfya)
Infliximab (Flixabi)
Infliximab (Inflectra)
Infliximab (Remicade)
Infliximab (Remsima)
Ixekizumab (Taltz)
Rituximab (Mabthera)
Rituximab Biosimilar (Rixathon)
Rituximab Biosimilar (Truxima)
Sarilumab (Kevzara)
Secukinumab (Cosentyx)
Tildrakizumab (Ilumetri)
Tocilizumab (Ro Actemra)
Tofacitinib (Xeljanz)
Ustekinumab (Stelara)
Vedolizumab (Entyvio)
Download response Biologics and Biosimilar prescribing. 031219
Biologics and Biosimilar prescribing. 170119
Could you please provide me with the following numbers of patients treated for Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis, Crohn’s Disease, Ulcerative Colitis in the last 12 months (latest 12 months possible) with the following drugs;
Abatacept (Orencia)
Adalimumab (Biosimilar)
Adalimumab (Humira)
Apremilast (Otezla)
Baricitinib (Olumiant)
Brodalumab (Kyntheum)
Certolizumab (Cimzia)
Dimethyl Fumarate (Skilarence)
Etanercept (Enbrel)
Etanercept Biosimilar (Benepali or Erelzi)
Golimumab (Simponi)
Guselkumab (Tremfya)
Infliximab (Remicade)
Infliximab Biosimilar (Inflectra, Remsima or Flixabi)
Ixekizumab (Taltz)
Rituximab (Mabthera)
Rituximab Biosimilar (Rixathon or Truxima)
Sarilumab (Kevzara)
Secukinumab (Cosentyx)
Tildrakizumab (Ilumetri)
Tocilizumab (Ro Actemra)
Tofacitinib (Xeljanz)
Ustekinumab (Stelara)
Vedolizumab (Entyvio)
Download response Biologics and Biosimilar prescribing. 170119
Biologics and biosimilar prescribing in Rheumatology. 020320
Could you please provide me with the following numbers of patients treated in the last 12 months with the following drugs.
· Abatacept [Orencia]
· Adalimumab [Amgevita]
· Adalimumab [Hulio]
· Adalimumab [Humira]
· Adalimumab [Hyrimoz]
· Adalimumab [Imraldi]
· Apremilast [Otezla]
· Baricitinib [Olumiant]
· Brodalumab [Kyntheum]
· Certolizumab [Cimzia]
· Dimethyl fumarate [Skilarence]
· Etanercept [Benepali]
· Etanercept [Enbrel]
· Etanercept [Erelzi]
· Golimumab [Simponi]
· Guselkumab [Tremfya]
· Infliximab [Flixabi]
· Infliximab [Inflectra]
· Infliximab [Remicade]
· Infliximab [Remsima]
· Ixekizumab [Taltz]
· Risankizumab [Skyrizi]
· Rituximab [MabThera]
· Rituximab [Rixathon]
· Rituximab [Truxima]
· Sarilumab [Kevzara]
· Secukinumab [Cosentyx]
· Tildrakizumab [Ilumetri]
· Tocilizumab [Ro Actemra]
· Tofacitinib [Xeljanz]
· Upadacitinib [Rinvoq]
· Ustekinumab [Stelara]
Download response Biologics and biosimilar prescribing in Rheumatology. 020320
Biologics and Biosimilar prescribing. 050718
Could you please provide me with the following numbers of patients treated in the last 12 months (latest 12 months possible) with the following drugs for either Rheumatology, Dermatology or Gastroenterology departments.
Download response Biologics and Biosimilar prescribing. 050718
Biologics and Biosimilar prescribing. 210917
Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the conditions listed below?
• Psoriasis
• Hidradenitis Suppurativa
• Crohn’s disease
• Ulcerative Colitis
Download response Biologics and Biosimilar prescribing. 210917
Biologics and Biosimilar prescribing. 250517
Could you please provide me with the following numbers of patients treated in the last six months (to date) with the following drugs for the conditions listed below?
Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis
Abatacept (Orencia)
Adalimumab (Humira)
Apremilast (Otezla)
Certolizumab Pegol (Cimzia)
Etanercept (Enbrel)
Etanercept biosimilar (Benepali)
Golimumab (Simponi)
Infliximab (Remicade)
Infliximab biosimilar (Inflectra)
Infliximab biosimilar (Remsima)
Rituximab (MabThera)
Secukinumab (Cosentyx)
Ixekizumab (Taltz)
Tocilizumab (RoActemra)
Ustekinumab (Stelara)
Vedolizumab (Entyvio)
Download response Biologics and Biosimilar prescribing. 250517
Biologics and biosimilar prescribing. 290617
Could you please provide me with the numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs within the dermatology or gastroenterology departments?
Abatacept (Orencia)
Adalimumab (Humira)
Apremilast (Otezla)
Certolizumab Pegol (Cimzia)
Etanercept (Enbrel)
Etanercept biosimilar (Benepali)
Fumaric Acid Esters N/A
Golimumab (Simponi)
Infliximab (Remicade)
Infliximab biosimilar (Inflectra)
Infliximab biosimilar (Remsima)
Rituximab (MabThera)
Secukinumab (Cosentyx)
Ixekizumab (Taltz)
Tocilizumab (RoActemra)
Ustekinumab (Stelara)
Vedolizumab (Entyvio)
Download response Biologics and biosimilar prescribing. 290617
Biologics drugs used in the Gastroenterology department. 081021.docx
1. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
a. Adalimumab – Humira
b. Adalimumab Biosimilar
c. Filgotinib
d. Golimumab
e. Infliximab – Remicade
f. Infliximab Biosimilar
g. Tofacitinib
h. Ustekinumab
i. Vedolizumab
2. How many patients were treated in the last 3 months for Crohn’s Disease ONLY with the following biologic drugs:
a. Adalimumab – Humira
b. Adalimumab Biosimilar
c. Golimumab
d. Infliximab – Remicade
e. Infliximab Biosimilars
f. Ustekinumab
g. Vedolizumab
Download response Biologics drugs used in the Gastroenterology department. 081021.docx
Biologics and Homecare. 290118
1. What is the Trust’s annual spend on anti-TNF drugs (most recent year available)?
2. How many patients has the Trust treated with anti-TNF drugs in the last 12 months?
3. What is the % split of anti-TNF patients by the following channels?
4. How many patients has the Trust treated with the following conditions in last 12 months?
5. Are there any gain share agreements in place between the Trust and CCGs for anti-TNF biosimilars?
If yes, please provide:
Biomarker testing. 270318
1. Do you currently offer a biomarker testing for the following, as of the beginning of 2018?
PD-L1 in NSCLC
ALK in NSCLC
BRAF in Melanoma
2. Is predictive biomarker testing conducted at the same lab (or similar location such as in same building) as the initial cytological and histological (H&E stain) assessment, or is this done at a different site?
IHC
FISH /ISH/ NGS / PCR
3. Is biomarker testing performed reflexively or upon request for the following biomarkers?
PD-L1 in NSCLC
ALK for NSCLC
BRAF in Melanoma
4. Which of the following biomarkers are assessed in lung cancer patients in your laboratory? (please select all that apply)
5. Which of the following testing platforms are used at this this laboratory?
6. What IHC staining platform(s) are used in the laboratory for biomarker testing? (please select all that apply)
7. What type of test does the institution prefer to use for biomarker-predictive IHCs?
What is the main factor in this decision?
8. Does your lab / trust seek separate reimbursement from NHS under the “high-cost medicines and tests” provision for biomarker tests that have been excluded from tariff?
9. What is the number of samples being tested (or sent-out) are tested for the following biomarkers?
ALK
EGFR
PD-L1
BRAF
10. Where are archived tissues from lung cancer patients stored?
11. If on-site; how long are tissues stored on site until transferred to other storage facility?
12. What is the typical turn-around time from tissue/specimen extraction to the report of biomarker testing results in lung cancer patients?
13. How are the following biomarker testing funded at your lab?
Biomarker testing.290922.docx
As Maidstone and Tunbridge Wells NHS Trust, is part of the South East Genomic Laboratory Hub, could you please answer the following three questions about biomarker testing that the Trust conducts as part of the NHS England Genomic Laboratory Hubs.
Q1. How many patients has the Trust tested for the following Non-Small Cell Lung Cancer biomarkers in the last 6 months?
a. MET (Test Code M4.3)
b. ALK (Test Code M4.11)
c. ROS1 (Test Code M4.6)
d. EGFR (Test Code M4.4 AND M4.5)
e. RET (Test Code M4.7)
f. BRAF V600E
g. NTRK
h. KRAS
i. HER2
Q2. Of the patients that were tested for each biomarker, how many patients tested positive?
a. MET (Test Code M4.3)
b. ALK (Test Code M4.11)
c. ROS1 (Test Code M4.6)
d. EGFR (Test Code M4.4 AND M4.5)
e. RET (Test Code M4.7)
f. BRAF V600E
g. NTRK
h. KRAS
i. HER2
Q3. Which NHS Trusts do you provide the genomic service for? i.e. Are you able to advise which trusts you carry out biomarker testing for as part of the NHS England Genomic Laboratory Hub network?
Biomedical Science and Pathology agency usage.210622
1: Who is the head of procurement responsible for approving Biomedical Science/Pathology agency usage at Maidstone and Tunbridge Wells NHS Trust?
2: Who are the managers responsible for agency approval for Pathology/Laboratory agency usage (on and off framework) for the following departments at all hospitals associated with the Trust:
– Blood Sciences (Haematology, Biochemistry, and Blood Transfusion):
– Infectious Sciences (Microbiology, Virology, Molecular, Serology, COVID):
– Cellular Pathology
3: Please provide the contact numbers and email addresses in relation to question 1 and 2.
4: Have you used off-framework agency staff for Biomedical Science/Pathology between January 2021 and January 2022?
5: How much was your off-framework agency spend for each of the following departments between January 2021 and January 2022:
(a) Blood Sciences (Haematology, Biochemistry and Blood Transfusion):
(b) Infectious Sciences (Microbiology, Virology, Molecular, Serology, COVID):
(c) Cellular Pathology
6: How many roles were filled by off-framework agency workers between January 2021 and January 2022 for each of the departments outlined in question 5?
7: How many unfilled roles did you have between January 2021 and January 2022 for each of the departments outlined in question 5?
Biomedical Science and Pathology agency usage.210622
Blood bank refrigerators. 030221
I would like to request a list of all blood bank refrigerators currently in use within the NHS trust please.
Specifically:
1. Hospital name
2. Department
3. Refrigerator manufacturer and model
4. Refrigerator serial number
5. Date purchased/installed
Blood collection tubes for liquid biopsies. 250521
1. How do you obtain blood collection tubes for liquid biopsies on cancer patients?
2. From what suppliers do you obtain these products?
3. Were these products purchased through a tender or framework? If so, which one? Please provide details including the name, reference and where this was published.
4. Are you under contract with your current supplier(s) for the above? If so, what is the start and end date of the contract?
5. Can you provide the name and contact details for the person(s) responsible for procuring these products?
6. Can you provide contact details for the department responsible for managing this service?
Download response Blood collection tubes for liquid biopsies. 250521
Blood cultures. 090617
1. Who is the policy or clinical lead for blood culture best practice at your trust? Please provide a name, job title, postal address, email address and phone number.
2. Does your Trust follow the Public Health England SMI guidelines for blood cultures?
3. How many blood culture sets are taken for each suspected case of (a) sepsis and (b) other bacterial infection, and where there is more than one blood culture set taken are these taken from different sites – please provide an answer for both (a) and (b).
4. How many individual blood cultures were taken at your trust in the following years: (a) 2012/13 (b) 2013/14 (c) 2014/15 (d) 2015/16 (e) 2016/17?
5. How many individual blood cultures were identified as being contaminated in the following years: (a) 2012/13 (b) 2013/14 (c) 2014/15 (d) 2015/16 (e) 2016/17?
Blood grouping analyser. 291118
You asked:
Question 1: Does your Trust have a blood transfusion service?
If yes, please answer the following questions about your blood group analysers:
Question 2: Who is the analyser manufacturer?
Question 3: What is the make and model type of analyser?
Question 4: What percentage of false positive results do you see with this analyser for blood grouping and antibody screening? (Only include false positives caused by external contaminants or analyser failures)
Question 5: How many group and screen samples do you test per year?
Question 6: Do you provide electronic issue of red cells?
Question 7: Do you provide automated crossmatching using your analysers?
Question 8: Do you have an agreed blood ordering schedule?
Blood pressure monitors
1. Total number of all types of blood pressure monitors in your institution (e.g. 1000 blood pressure monitors overall)
2. Can you please list all the types of blood pressure monitors and its quantities (e.g. NIBP – x20, SpO2 – x20), its brands (e.g. Omron – x20, Criticare – x20, Datascope – x20), and models (e.g. Criticare 506DXN – x10, Criticare 507DXN – x10, Datascope Accutorr + x20). We would like to ask you kindly if you can state this information in a separate spreadsheet document.
3. In which departments do you use blood pressure monitors? (e.g. 20 Omron in wards, 20 Criticare in ITU, 20 Datascope in outpatient surgery).
4. Types of devices acquired in period of 2014 – 2016 (e.g. 100 Omron monitors in 2014, 150 Criticare monitors in 2015.) if none please state when was the last purchase.
5. Minimum and maximum price of blood pressure monitors. If you can not provide this information, please give us an average price of a single blood pressure monitor
6. Please provide a full contract with supplier of blood pressure equipment
7. Which quality tests or quality standards a blood pressure device must pass in order for you to consider it as a good quality blood pressure monitor (e.g. CE Marked)
8. Can you please provide regulations and guidelines that your institution follow (we would like to know about national, local and your own guidelines + regulations (if it also possible can you please attach medical device management action card + medical equipment pre-registration form))
9. What creates extra costs for the usage of monitors on a yearly basis? Please break it down and relate the expenditure associated to it (e.g. cuffs = £2.000, hoses = £3.000, maintenance = £5.500)
10. Do you provide maintenance in-house or out?
11. How do you provide training to medical staff when a new blood pressure monitor is introduced in your hospital? (e.g. manual handbook, training sessions from suppliers)
12. How the supply chain is established in your organisation when you order new blood pressure monitors? (e.g. supplier delivers the products, currier or take out?)
13. Do you provide feedback to your suppliers? If “yes” how? (e.g. emailing, calling, submitting a form)
14. What is the average useful life of a single blood pressure monitor?
Blood and Transfusion Service. 160818
In order to assess the savings to the taxpayer, could you please provide the number of overnight (19:00-07:00) pick-ups or deliveries, by the below mentioned services, to or from your hospital’s Transfusion Lab/Blood Bank on the date(s) below.
Please include a schedule of documents where possible.
Download response Blood and Transfusion Service. 160818
Bone Morphogenetic Protein BMP2. 070721
Please may you provide me with usage details for 2018-19 and 2019-20 financial year for BMP2, INFUSE (InductOS BMP2), manufacturer MEDTRONIC.
Bowel Cleansers. 031019
Information request – 1
Has the pharmacy of your hospital dispensed any bowel cleansing preparations from January 1, 2018 till December 31, 2018?
Information request – 2
If the answer is ‘yes’ to request 1, could you please send me below details:
• Name of dispensed brand(s) and number of packs dispensed in the 12 month period (January 1, 2018 till December 31, 2018).
Bronchial challenge testing 040117
Can you please advise if the trust performs Bronchial challenge testing? If the trust does perform these tests could you also advise?
1) The number of tests performed in the last 12 months?
2) Which products are used to perform the test?
3) Contact details for the sites performing the test?
Candida Auris. 250419
1. Which hospitals within your Trust have reported Candida Auris cases since 2009?
2. How many patients have been infected with Candida Auris within your Trust since 2009?
3. How many patients have died after being infected with Candida Auris whilst being under the care of your Trust since 2009?
Candida Auris. 250817
I am attempting to discover whether the fungus ‘Candida Auris’ has been found in the Tunbridge Wells hospital.
Is it possible for you to give me any information regarding this matter?
Carboxyhaemoglobin levels
Under the Freedom of Information Act 2000 I request that the NHS Trust provides me with the following information:
• What methods of measuring carboxyhaemoglobin levels do each hospital covered by the Trust use
• Whether or not each hospital covered by the Trust has a Masimo Rad-57 Oximeter in its accident and emergency department.
Cardiology, E-Rostering (staffing), Order Communications, Pathology, and Pharmacy systems.100722.docx
Please enter ‘No System Installed’ under supplier name if your trust does not use the system:
System type – Pharmacy
1. Supplier name
2. System name –
3. Date installed –
4. Contract expiration –
5. Is this contract annually renewed? – Yes/No
6. Do you currently have plans to replace this system? – Yes/No
7. Procurement framework –
8. Other systems it integrates with? –
9. Total value of contract (£) –
10. Notes – e.g. we are currently out to tender
Caspofungin (Generic) and Cancidas (May 2016-April 2017). 070917
I am writing to request details of the quantity of vials prescribed for below products by your Trust.
The period for which data is being requested is May 2016 – April 2017.
Data Requested for below products:
• Caspofungin 50mg powder for concentrate for solution for infusion
• Cancidas 50mg powder for concentrate for solution for infusion
• Caspofungin 70mg powder for concentrate for solution for infusion
• Cancidas 70mg powder for concentrate for solution for infusion
Download response Caspofungin (Generic) and Cancidas (May 2016-April 2017). 070917
CCG2 CQUIN scheme. 100522.docx
Will your NHS trust be collecting performance data for the CCG2 CQUIN scheme titled “Appropriate antibiotic prescribing for UTI in adults aged 16+” between 1st April 2022 and the 1st April 2023?
Charges for ultrasound baby scan pictures for 2011, 2012, 2013, 2014 and 2015. 160617
1) The charges for ultrasound baby scan pictures for the years 2011, 2012, 2013, 2014 and 2015 until now (how much you charge expectant mums/dads).
2) The figures for how much profit has been made from the ultrasound charges for each year from 2011 to now.
3) An explanation for why the charges increased (if they did so).
Chronic Lymphocytic Leukaemia (CLL).110523.docx
Question 1: How many patients has your Organisations treated in the past 3 months for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Organisation do you refer patients needing treatment to?
Question 2: How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:
a. BR (bendamustine + rituximab)
b. Calquence (acalabrutinib)
c. FCR (fludarabine + cyclophosphamide + rituximab)
d. Gazyva (obinutuzumab) + chlorambucil
e. Imbruvica (ibrutinib)
f. Venclexta (venetoclax)
g. Venclexta (venetoclax) + Gazyva (obinutuzumab)
h. Venclexta (venetoclax) + rituximab
i. Zydelig (idelalisib) + rituximab
j. Any other systemic anti-cancer therapy
k. Wait and watch (monitoring only, no active treatment)
Question 3: If your Organisation does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any ongoing clinical trials for the treatment of CLL? If so, can you please provide the name of each trial along with the number of patients taking part?
Chronic Myeloid Leukaemia (CML) 2015 (follow up)
Following your reply, please could you provide the information requested in sections 2, 3 and 5 regardless of indication.
1. In your organisation, how many patients diagnosed with Chronic Myeloid Leukaemia (CML) have been treated in calendar year 2015?
2. Of these patients, how many are currently being treated with each of the following tyrosine kinase inhibitors (TKIs)?
· Dasatinib (Sprycel)
· Imatinib (Glivec)
· Nilotinib (Tasigna)
· Ponatinib (Iclusig)
· Bosutinib (Bosulif)
3. If possible, of these patients on a TKI, how many have had treatment with a previous TKI?
4. In your organisation, how many patients diagnosed with Philadelphia positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) have been treated in calendar year 2015?
5. Of these patients how many are currently being treated with each of the following TKIs?
· Dasatinib (Sprycel)
· Imatinib (Glivec)
· Nilotinib (Tasigna)
· Ponatinib (Iclusig)
· Bosutinib (Bosulif)
· Other (i.e. not on a TKI)
Download response Chronic Myeloid Leukaemia (CML) 2015 (follow up) 230516
Chronic pain service 031016
1. The definition of calculation used for new to follow up ratios for chronic pain referrals.
2. The data for new to follow up for chronic pain referrals for your trust for the years April 2010 to April 2015
3. Is the calculation used for new and follow-up in Chronic Pain a local or national definition?
4. Can you provide the wording of the definition used?
5. Does the New to follow up ratio calculation that is used by your organisation for Chronic Pain also apply to other specialties?
6. If no – please explain the differences in the calculations.
Clinical Insourcing. 260521
1. Total spend on the use of clinical insourcing (not agency/locum or outsourcing) in the current 2020/21 financial year. Please breakdown this FY only into each month.
2. Total spend on the use of clinical insourcing (not agency/locum or outsourcing) in the 2019/20 financial year.
3. Total spend on the use of clinical insourcing (not agency/locum or outsourcing) in the 2018/19 financial year.
4. Total spend on the use of clinical insourcing (not agency/locum or outsourcing) in the 2017/18 financial year.
Clinical thromboembolic events. 020721
1) Please provide data of the absolute numbers of patients with laboratory results for each of the following clinical thromboembolic events, monthly from Jan 2019 until now, and by age cohort:
a) lymphopenia (low lymphocyte levels) (using local laboratory cut offs).
b) thrombocytopenia (low platelet levels) (using local laboratory cut offs).
c) D dimers at each of these levels: <500; 500-999; 1000-1499; 1500+
d) patients coded as having had thrombotic/embolic strokes
e) patients coded as having had a deep venous thrombosis
f) patients coded as having a pulmonary embolism including bilateral DVT
2) Please provide data for the following, monthly from Jan 2019 until now, and by age cohort:
a) the number of FBC requested
b) the number of D-dimer tests requested
Coagulation testing.290622.docx
1. Does your Trust routinely offer Laboratory based Coagulation testing? (please answer either yes or no to this question).
2. If you answered yes to question 1, can you please provide us with a list of the tests that you perform.
3. If you answered yes to question 1, can you please tell us if any of these tests are sent away for testing outside of your trust (please also detail which tests are sent away).
Collection of prescription charges. 120320
1. Do you directly supply pre-labelled medication from stock against a PGD or FP10REC for patients who present at urgent care services?
2. Do you take a prescription charge for medicines directly supplied from stock against a PGD or FP10REC?
3. If the answer to question 2 is YES please provide a brief description of how you collect the prescription charge.
4. Please feel free to add any comments that you think would be useful or if you would like to discuss please do so using the contact details below.
Download response Collection of prescription charges. 120320
Complementary therapy. 240418
1. Do you have a staff Health and Wellbeing Strategy for the Trust? If yes, can you supply an electronic copy?
2. As part of your strategy or through Occupational Health Department, do you or have you considered using Complementary Therapies to support staff? For example, holistic therapeutic massage for staff mental wellbeing and workplace stress, reflexology, sports massage for rehab and recovery or any others
3. If you do use complementary therapy – do you find it useful in reducing sickness absence, reducing stress related absences and expediting return to work?
4. If you don’t currently use complementary therapy, would you consider using them if they could help reduce sickness absence days, help manage workplace stress and help rehab/recovery from MSK related sickness?
5. Would you consider offering complementary therapy as a staff benefit at discounted rates or donations towards your hospital charity?
6. Would you consider employing a Complementary Therapist as part of your Occupational Health Team? If no, would you reconsider this if their qualification was gained via the NHS natural health school which is supported by NHS England?
Complicated skin and soft tissue infections (cSSTI). 151019
1. How many patients have you treated for complicated skin and soft tissue infections (cSSTI ) in the last 12 months with the following:
Ceftaroline (Zinforo)
Flucloxacillin
Meropenem (Meronem)
Teicoplanin (Targocid)
Tigecycline
Vancomycin
2. How many patients have you treated for community acquired pneumonia in the last 12 months with the following:
Ceftaroline (Zinforo)
Ceftriaxone
Ceftobiprole (Zevtera)
Co-Amoxiclav
Isavuconazole (Cresemba)
Meropenem (Meronem)
3. How many patients have you treated mucormycosis with the following in the last 12 months
Amphotericin B/amphotericin liposomal (AmBisome )
Isavuconazole (Cresemba)
Posaconazole (Noxafil)
4. How many patients with Gram negative infections, have you treated in the last 12 months with:
Amoxicillin/clauvanate
Piperacillin/tazobactam
Ceftazidime/avibactam
Ceftolozane/tazobactam
Carbapenems (e.g. Ertapenem, Imipenem, Meropenem etc)
Aminoglycosides (e.g. Gentamicin, Amikacin, Tobramycin)
Cephalosporins (e.g. Cefotaxime, Ceftazidime, Ceftriaxone)
Quinolones (e.g.Ciprofloxacin, Levofloxacin, Ofloxacin)
Download response Complicated skin and soft tissue infections (cSSTI). 151019
Consented adult autopsies. 271020
This request is part of a project to determine the number of consented adult autopsies that took place in the United Kingdom in 2019.
Continence Formulary. 100920
I would like to please request the Continence Formulary of the Maidstone and Tunbridge Wells NHS Trust. May I please have the Continence Formulary attached in a response or may I please be directed to where it is available online? By this, I am specifically interested in continence appliances (catheters etc.).
Continence Product Formulary 011216
1) Does the Trust have a Continence Product Formulary?
2) If yes to Q1, please provide a copy
3) How often is the Continence Product Formulary reviewed?
4) What date was the Continence Product Formulary last reviewed?
5) What date will Continence Product Formulary be next reviewed?
Covid cycle testing for vaccinated and unvaccinated people.221122.docx
All questions are shown exactly as received by the Trust.
i would like all latest data on covid cycle testing for vaccinated and unvaccinated people i am aware there will be 2 separate test cycles of amplification thank you.
Your response is in correct.i asked what are the current test cycle to date for omnicrom variant you have a base number for cycle amplification that you start with .you dont get a cycle numbed AFTER the test ,you have a start point and that is the data i am asking for. The starting amplification cycle number for un vaccinated people and the cycle start number for vaccinated.thank you..this will be fact checked by my associates thank you.
Covid cycle testing for vaccinated and unvaccinated people.221122.docx
CRE infections. 181116
1. How many patients have been?
-colonised
-infected
With CRE infections for each of the past 10 years in your trust?
2. Does your trust have universal screening of patients for CRE when they are admitted, screening of patients with high risk factors or no formal screening policy?
3. How many patients were screened for CRE when they were admitted and deemed high risk for a CRE infection?
4. How many isolation rooms does your hospital have for isolating CRE patients?
5. How many isolation rooms have en suite bathrooms?
6. What is your policy if there is no side room available for isolating patients with CRE?
Ct (Cycle Threshold) being used for PCR testing of SARS Covid-19. 280621
I would like to know the Ct (Cycle Threshold) being used for PCR testing of Sars Covid at the moment and in the past.
Download response Ct (Cycle Threshold) being used for PCR testing of SARS Covid-19. 280621
CT scanner. 301117
Q1. Does your trust have a 64-slice (or above) CT scanner?
Q2. Does your trust perform Coronary CT angiography?
Q3. How many Coronary CT Angiography scans have you performed in the past financial year? (2016-2017)
Q4. Does your Trust have access to Coronary CT Angiography with non-invasive FFR analysis or HeartFlow technology?
Q5. If so how many CT FFR scans have been performed in total in the past financial year (2016-2017)?
CT scanner information – June 2016
• How many CT scanners are in your hospitals?
• Who is the manufacturer of them and what is their model?
• Who has the service maintenance contract for the scanners – is it the supplier or an external service company?
Cyanide antidotes, Levothyroxine and Primidone. 210218
1) Does your trust hold stocks of the following Cyanide poisoning antidotes: Cyanokit (hydroxocobalamin), Sodium Nitrite, Sodium Thiosulfate and Dicobalt Edetate?
• If yes, what is your stock volume and total expenditure by financial year from FY11-12 to present day for each individual medication?
• If yes, what is the price paid per unit for each medication type?
2) Does your trust hold stocks of Levothyroxine in the following forms: Tablets (25mcg, 50mcg & 100mcg), Oral solution (25mcg/5ml, 50mcg/5ml, 100mcg/5ml) and Levothyroxine solution for injection (IV or IM)
• If yes, what is your stock volume and total expenditure by financial year from FY11-12 to present day for each individual medication?
• If yes, what is the price paid per unit for each medication type?
3) Does your trust hold stocks of Primidone in the following forms: tablets (50mg & 250mg?)
• If yes, what is your stock volume and total expenditure by financial year from FY11-12 to present day for each individual medication?
• If yes, what is the price paid per unit for each medication type?
Download response Cyanide antidotes, Levothyroxine and Primidone. 210218
Cycle threshold (Ct) PCR testing. 280621
1. The Cycle threshold (Ct) used by your organisation since 01 March 2020 for each of the Government Pillar classifications.
2. Any changes made to the Ct during this period and when any such changes were made.
Cycle threshold in PCR tests for patients and staff. 040122.docx
which cycle threshold(ct) are you using in your hospital in PCR test for patient and staff since the declaration of the pandemic in 2020.
Download response Cycle threshold in PCR tests for patients and staff. 040122.docx
Cyclotron 221116
This FOI is about the use of Cyclotrons, used for the manufacture of radiopharmaceuticals in PET-CT scanning
Pertains to four main radiopharmaceuticals isotopes (radio-isotopes) used for PET-CT scanning:
18F-Fluorodeoxyglucose = FDG
18F-Choline = FEC for the diagnosis of prostate cancer
18F-Sodium Fluoride = NAF for the diagnosis of skeletal cancers
18F-Florbetaben = FBB for the diagnosis of Alzheimer’s
Defibrillators. 101120
1. Manual Defibrillator Machines manufacturer
2. Manual Defibrillator model
3. Year of purchase
4. Proposed timeframe for replacement
5. AED Defibrillator Machines manufacturer
6. AED Defibrillator model
7. Year of purchase
8. Proposed timeframe for replacement
Dementia services and therapies. 070920
1. Are patients with dementia able to access any of the following therapies (i.e. from dementia services, memory services, memory clinics or mental health services within the Trust)?
a. Group cognitive stimulation therapy
b. Group reminiscence therapy
c. Cognitive rehabilitation or occupation therapy
d. Multi-sensory stimulation
e. Cognitive training
Dermatology and Atopic Dermatitis. 010917
Funding pre-NICE;
For the attention of (FAO): Pharmacy / Dermatology Department Clinical Director
1. Is it your Trust/CCG policy to wait until 90 days post NICE guidance to fund new drugs or do they fund earlier?
2. What is your Trust/CCG policy re use of Zero Risk (ZR)/Early Use Schemes (EUS), i.e. where a medicine is made available free of charge or at a reduced price to the NHS whilst awaiting NICE/SMC approval, in lieu of NICE?
3. What is the process for getting such ZR/EUS schemes implemented/approved/signed off within your Trust/hospital? Who needs to sign the contracts for such schemes?
IFR/Cohort Funding;
FOA: Dermatology Lead Pharmacist / Dermatology Department Clinical Director
4. What is your Trust’s policy re Individual Funding Request and/or Cohort Funding policy? Ref: IFR/Cohort Funding
https://www.engage.england.nhs.uk/consultation/af642939/supporting_documents/genericcommissioningpolicies.pdf
5. Do you have a pathway/preferential prescribing list, illustrating sequential use of Biologics in Dermatology? What does this recommend?
6. How many lines/trials of biologics are allowed/funded for the management of psoriasis within your trust/CCG? What happens if a clinician needs to exceed this?
7. If there is a biologics psoriasis pathway – how often is it updated to reflect changes to NICE status of new therapies?
8. If there is no formulary/pathway – what do the Trust/CCG utilise in order to guide use of biologics in the management of psoriasis?
Atopic Dermatitis
FAO: Dermatology Service Manager
9. How many patients attended for a new outpatient appointment in dermatology Utilising ICD-10 classification – L20 Atopic Dermatitis (Eczema) – from April 2015 – March 2016?
10. The number of paediatric attendances of patients utilising ICD-10 classification – L20 for Atopic Dermatitis (Eczema) – from April 2015 – March 2016?
11. Does your Trust have a paediatric dermatologist? Does your Trust have a paediatrician with a dermatology interest/specialism?
Dermatology Biologics. 130220
I have a Freedom of Information request regarding biologics and biosimilar prescribing in dermatology.
Could you please provide me with the following numbers of patients treated in the last 12 months with the following drugs.
Adalimumab [Amgevita]
Adalimumab [Hulio]
Adalimumab [Humira]
Adalimumab [Hyrimoz]
Adalimumab [Imraldi]
Apremilast [Otezla]
Brodalumab [Kyntheum]
Certolizumab [Cimzia]
Dimethyl fumarate [Skilarence]
Dupilumab [Dupixient]
Etanercept [Benepali]
Etanercept [Enbrel]
Etanercept [Erelzi]
Golimumab [Simponi]
Guselkumab [Tremfya]
Infliximab [Flixabi]
Infliximab [Inflectra]
Infliximab [Remicade]
Infliximab [Remsima]
Ixekizumab [Taltz]
Risankizumab [Skyrizi]
Secukinumab [Cosentyx]
Tildrakizumab [Ilumetri]
Tocilizumab [Ro Actemra]
Upadacitinib [Rinvoq]
Ustekinumab [Stelara]
If you are unable to provide the information above with specific reference to dermatology then please provide me with the numbers of patients treated in the last 12 months with the above drugs, regardless of disease/indication.
Diabetes. 091117
1. The number of patients with Type 1 diabetes that are currently treated as an outpatient in the hospitals in Maidstone and Tunbridge Wells NHS Trust.
2. The number of patients with Type 2 diabetes that are currently treated as an outpatient in the hospitals in Maidstone and Tunbridge Wells NHS Trust.
3. The number of patients with Type 1 diabetes in the hospitals in Maidstone and Tunbridge Wells NHS Trust with an Insulin Infusion Pump.
4. The number of patients with Type 2 diabetes in the hospitals in Maidstone and Tunbridge Wells NHS Trust with an Insulin Infusion Pump.
5. The number of Diabetes Specialist Nurses that are employed in Maidstone and Tunbridge Wells NHS Trust as of the 1st October 2017. Please break down the response to this question by pay band e.g. band 6, band 7.
6. Is structured education for patients with Type 1 diabetes offered within Maidstone and Tunbridge Wells NHS Trust?
7. The number of patients with Type 1 diabetes that have received structured education within Maidstone and Tunbridge Wells NHS Trust between the period October 1st 2016 to October 1st 2017.
Diabetic retinopathy (including DMO).030622.docx
1. How many current diabetic retinopathy (including DMO) patients do you have? *
2. How many diabetic retinopathy (including DMO) patients do you have that are currently being monitored and held at “wait and see” but not yet progressed to needing any treatments (injections/laser/implant)? *
3. How many diabetic retinopathy (including DMO) patients do you have that have received treatment (injections/laser/implants) in the year April 2019-March 2020 inclusive (i.e. pre COVID-19)? *
4. How many diabetic retinopathy (including DMO) patients do you have that have received treatment (injections/laser/implants) in the year April 2020-March 2021 inclusive (i.e. during COVID-19)? *
5. How many injections (Avastin/bevacizumab, Eylea/aflibercept, Lucentis/ranibizumab) have been used for diabetic retinopathy (including DMO) patients in the year April 2019-March 2020 inclusive (i.e. pre COVID-19)? Please break down by treatment. *
6. How many injections (Avastin/bevacizumab, Eylea/aflibercept, Lucentis/ranibizumab) have been used for diabetic retinopathy (including DMO) patients in the year April 2020-March 2021 inclusive (i.e. pre COVID-19)? Please break down by treatment. *
Diagnosis of heart failure in 2015.
1. What was the size of the patient population covered by your Trust in 2015?
2. How many patients were diagnosed with heart failure by your Trust in 2015?
3. Does your Trust follow NICE guidelines to support the diagnosis of suspected heart failure? If not, what guidance does your Trust follow? Please provide a copy
4. Please provide the details – including the manufacturer and brand name – of those tests used to support the diagnosis of heart failure
5. Does your Trust follow NICE guidelines to support the management of chronic heart failure? If not, what guidance does your Trust follow? Please provide a copy
6. Please provide the details – including the manufacturer and brand name – of those tests used to support the management of chronic heart failure
7. Does your Trust use NTproBNP or BNP testing to support the diagnosis of heart failure in patients presenting through A&E?
8. How many NTproBNP tests were performed by your Trust in 2015? Please provide the manufacturer and brand name of the test used
9. Are there any restrictions for using NTproBNP or BNP tests? If yes, please explain
10. How many echocardiographs were performed at your Trust in 2015?
11. What was the average waiting time for an echocardiogram at your Trust in 2015?
Diagnostic data on an MRI technique for men with suspected prostate cancer.270318
1. Please tell us which Trust, Health Board or Health and Social Care Trust you are responding on behalf of?
2. What percentage of men receive mpMRI before biopsy as part of the initial diagnostic process using T2-weighted, diffusion-weighted (multi-b ADC and high/long b) and dynamic contrast enhanced (DCE) sequences?
3. What are your eligibility criteria/exclusion criteria for men to receive pre-biopsy mpMRI?
4. Are you using mpMRI before biopsy to rule some men out of biopsy as part of the initial diagnostic process?
5. What mpMRI scores and/or other clinical factors are used to rule men out of biopsy?
6. Do you intend to use mpMRI to rule men out of biopsy in the future?
7. How many men annually are referred?
8. If you are unable to provide numbers for question 6, please estimate the percentage of all men referred for b, c and d.
9. Do you carry out targeted biopsies in men with mpMRI lesions in addition to systematic biopsies?
(Please indicate with a X below)
If No, what are the reasons for not carrying this out? (e.g. expertise, equipment, don’t believe it makes a difference)
10. If you do not currently carry out targeted biopsies, but wish to in the future, what are the current barriers to doing so?
(Please indicate with a X below)
11. Please indicate the number of uroradiologists undertaking prostate MRI
12. How many scanners do you have available for mpMRI before biopsy?
Has this increased in the last 12 months?
13. What percentage of scanner time is dedicated to mpMRI before biopsy?
Download response Diagnostic data on an MRI technique for men with suspected prostate cancer.270318
Diagnostic imaging 150217
1. What is the approximate local population catchment your hospital trust provides services for?
2. For each MRI, CT, and PET-CT, please set out the location for each scanner located on Trust property using one line per machine:
3. For each scanner listed in Question 2 as per index, please set out the type of ownership and both the year of manufacture and the year of installation in your trust for each machine:
4. For each scanner listed in Question 3 that is not owned by the trust and as per index, please list the name of the company providing the service:
5. For each scanner listed in Question 2 as per index, please set out the current ‘normal opening hours’ of the service per week and indicate whether this includes a non-emergency weekend service or not:
6. Please set out the total number of MRI, CT, and PET/CT scans that were carried out on scanners within your trust in the financial years (April to March) 2012/13, 2013/14, 2014/15, and 2015/16:
7. Please set out the total number of MRI, CT, and PET/CT scans referred by clinicians from your trust, regardless of whether they were carried out at your trust or at another trust or provider, in the financial years (April to March) 2012/13, 2013/14, 2014/15, and 2015/16:
8. Please list the providers outside your trust below that carried out MRI, CT, and PET/CT scans on your trust’s patients trust during the financial year 2015/16:
9. For each of the hospital providers listed in Question 8 as per index, please set out the total number of MRI, CT, or PET/CT scans that were carried there on your behalf in the financial years (April to March) 2012/13, 2013/14, 2014/15, 2015/16:
10. Does your trust currently hold plans to extend its MRI, CT, or PET/CT capacity (e.g. increase number of scanners)?
11. If yes, what is the likely procurement method your trust is likely to take?
12. Does your trust currently hold plans to invest into high value (>£500k) capital diagnostic equipment (both radiological and non-radiological) over the next five years?
13. If your trust has done any assessment/forecasting of the evolution of demand for MRI, CT, and/or PET-CT scanning, either historic or future, please provide a copy.
Diagnostic Imaging (DI) for 2014/2015.
Please provide the information set out below in respect of Diagnostic Imaging (DI) at your Trust for the FY 2014/15:
For each of the key Points of Delivery categories (just EL, SSEL, NEL, SSNEL, DC and OP), the numbers and types (e.g. CT/MR/PET-CT/endoscopy) of DIs performed per Primary Diagnosis (ICD) and the number of patients so investigated in that ICD category.
We would only need the first three characters of the Primary Diagnosis code (e.g. C00 to D49 for Neoplasms).
Download response Diagnostic Imaging (DI) for 2014/2015 270516
Diagnostic imaging system.050523.docx
Could we clarify the new systems details for your new Diagnostic imaging system?
System type – Diagnostic imaging
Supplier name – Sectra
System name –
Date installed –
Contract expiration –
Notes – e.g. we are currently out to tender
Diagnostic and procedure codes. 160518
1) Any diagnosis from the category Z38 (i.e. Z38.0 – Z38.8, I believe obtained by searching for Z38.X, but local procedures may vary). This diagnosis could be in any position, principle or secondary.
Explanation: This is looking at the number of live births in the time period in your trust.
2) The number of episodes from the results of part 1) that has also given the diagnosis code P39.9. This diagnosis could be in any position, principle or secondary.
Explanation: This is looking at the number of the above patients who were screened and treated for sepsis, without diagnosed bacteraemia.
3) The number of episodes from the results of part 1) that has also given a diagnosis from the category P36 (i.e. P36.0 – P36.9, I believe this is searched for by P36.X). This diagnosis could be in any position, principle or secondary.
Explanation: This is looking at the number of patients from part 1) that had a bacterial sepsis.
4) The number of episodes from the results of part 1), which also has the procedure code A55.8 or A55.9
Explanation: This is looking at the number of patients from parts 1) that have had a lumbar puncture, an investigation for meningitis.
5) The number of episodes from the results of part 1), which also has any diagnosis from the category G00, G01, G02, or G03. These diagnoses could be in any position, principle or secondary
Explanation: This is looking at the number of patients from parts 1) that actually were diagnosed with meningitis.
Notes to help complete request:
For each of 1) 2) 3) 4) and 5), you only need to provide one number for the number of episodes for each; they do not need to be broken down in to subcategories. If any of the answers is zero, please state as such (or state you do not hold any information on it). Kindly note this information is not publicly available from other sources, including NHS Digital.
Diagnostic services provided by external providers outside the UK. 260717
Does your trust have any diagnostic services provided by external providers outside the UK (e.g. radiology)?
If yes –
– What services?
– Which provider(s) have been chosen to provide these services?
– How much is each contract worth?
– For what time period will the contract run?
– When did you first enter into these arrangements?
Download response Diagnostic services provided by external providers outside the UK. 260717
Discharge Summaries. 250419
1) How many digital discharge summaries from 1st November 2017 to 1st November 2018 included any of the following terms?
• GHB
• GBL
• gamma-hydroxybutyrate
• gamma-Hydroxybutyric acid
• 4-hydroxybutanoic acid
• 1,4-butanediol
• 1,4-BD
Discrete cylinder regulators. 070921.docx
Name of Trust:
Please note, ALL the following questions relate to Medical Oxygen cylinders ONLY
1. Does your Trust use Medical Oxygen cylinders that have a pin index cylinder valve and require a discrete (removable) regulator to function?
If ‘Yes’ please continue
2. On average, how many discrete regulator cylinders are rented each month on an annual basis?
3. On average, how many of this particular cylinder type is replenished each month?
4. How many discrete regulators are held on inventory for use with this type of cylinder?
5. Do you also rent ‘integrated valve’ cylinders? (e.g. cylinders with regulators already fitted as an integral part of the package – BOC CD cylinder for example)
6. If you have answered ‘yes’ to question 1. And question 5., what is the proportion of each type of cylinder in use? A ratio or percentage would do. (E.g. 70:30 in favour of discrete or 70% discrete, 30% integrated)
7. Has your Trust ever reported a failure to supply or an unexpected cylinder ‘runout’ whilst using a discrete regulator on a cylinder?
Dispensed drugs. 160119
1. Can I ask although the Trust is not commissioned to provide Dermatology services would it be possible to provide data for the number of drugs dispensed regardless of indication / condition in the last three months?
Drug Name
Acitretin
Alitretinoin
Pimecrolimus
Tacrolimus
Dupixent (Dupilumab)
Phototherapy including with ultraviolet (UVB) radiation or psoralen ultraviolet A (PUVA)
Potent Topical Corticosteroids (creams or ointments) total
Amcinonide 0.05% (Cyclocort)
Betamethasone diproprionate 0.05% (Diprosone)
Betamethasone valerate
Clobetasol proionate
Desoximetasone 0.25% (Topicort)
Diflucortolone valerate
Fluocinonide 0.05% (Lidex)
Fluticasone proprionate 0.005% (Cutivate)
Halcinonide 0.05% (Halog)
Mometasone furoate 0.1% (Elocon ointment)
Triamcinalone acetonide 0.5% (Kenalog, Aristocrt cream)
Betamethasone dipropionate 0.25% (Diprolene)
Clobetasol dipropionate 0.05% (Temovate)
Diflorasone diacetate 0.05% (Psorcon)
Halbetasol proprionate 0.05% (Ultravate)
Immunosppressive therapies total
Azathioprine
Ciclosporin
Methotrexate
2. The number of drugs dispensed regardless of indication / condition in the past 3 months?
Drug Name
Etanercept
Infliximab
Adalimumab
Ustekinumab
Disposal of drugs. 070818
1. Please can you provide me information on the quantity of prescription medications, drugs and any other dispensed medical substances (“Drugs”) disposed of during the summer heat wave (from the start of June 2018 until the most recent possible date when the search is made.
2. If you have a register of Drugs being disposed of including dates of the disposal, type and name of Drug, quantities involved, and value of each batch to be disposed of, please provide me with such a register for the given period.
3. Otherwise, please provide information as to the overall quantity and value of Drugs to be disposed, and provide as much of a breakdown into the fields given previously as is possible.
4. Please can you tell me whether (i) all, (ii) some, or (iii) which of the hospitals or medical centres that come under the Trust, have the appropriate facilities to refrigerate Drugs.
Drug resistant infections. 250419
– How many cases of drug resistant infections (both bacterial and fungal) have there been at your NHS trust in each of the past five years (2018, 2017, 2016, 2015, 2014)?
– What were those infections?
– How many of those infections resulted in deaths?
Please could you break the results down by year, rather than providing them as one number?
The Trust requested clarification and received the following response:
The point of this question is to determine whether, in the wake of stories about so-called superbugs and drug-resistant fungi such as Candida Auris, there is any truth to speculation that drug-resistant infections are on the rise, and if so, to what extent.
So, of course I am interested to know about the number of cases of so-called superbugs but I am also looking for trends of other, less well-documented, cases of antimicrobial drug resistance.
Therefore, ideally I would like data on all such cases.
However, if this is impossible, then I would like the data as requested on cases of drug resistance in the following:
1. Acinetobacter baumannii
2. Pseudomonas aeruginosa
3. Enterobacteriaceae
4. Enterococcus faecium
5. Staphylococcus aureus
6. Helicobacter pylori
7. Campylobacter spp.
8. Salmonellae
9. Neisseria gonorrhoeae
10. Candida auris
Drug spend 2014-15 and 2015-16. 081117
a) Total drug spend for financial years 2014-15, and 2015-16
b) Total Off-tariff drug spend for financial years 2014-15, and 2015-16
c) Total Homecare drug spend for financial years 2014-15, and 2015-16
Drug stock. 300518
1. Has your trust accepted or is it currently accepting manufacturer provision of free of charge drug stock between licensing and NICE funding? [Yes/No]
2. Has your trust accepted or is it currently accepting the following list of drugs in psoriasis:
Brodalumab [Kyntheum] [Yes/No]
Guselkumab [Tremfya] [Yes/No]
Ixekizumab [Taltz] [Yes/No]
Secukinumab [Cosentyx] [Yes/No]
3. Has your trust accepted or is it currently accepting the following list of drugs in Rheumatoid Arthritis:
Tofacitinib [Xeljanz] [Yes/No]
Baricitinib [Olumiant] [Yes/No]
Golimumab [Simponi] [Yes/No]
Certolizumab [Cimzia] [Yes/No]
Apremilast [Otezla] [Yes/No]
Tocilizumab [Ro Actemra] [Yes/No]
4. Has your trust accepted or is it currently accepting the following list of drugs in Ankylosing Spondylitis or Psoriatic Arthritis:
Secukinumab [Cosentyx] [Yes/No]
5. Has your trust accepted or is it currently accepting the following list of drugs in Ulcerative Colitis:
Golimumab [Simponi] [Yes/No]
6. If your trust has not accepted manufacturer provision of free of charge drug stock, what have been the reasons for this?
7. In future, will your trust be able to accept manufacturer provision of free of charge drug stock? [Yes/No]
8. What is the preferred distribution channel for the provision of free of charge drug stock?
Homecare [Yes/No]
Delivered directly to hospital/Trust [Yes/No]
Other (please provide details)
9. For how long is free of charge drug stock typically provided for each patient?
First dose [Yes/No]
First month [Yes/No]
First 3 months [Yes/No]
Other
Drug treatments.030622.docx
Question 1.
How many patients were treated by your Trust (for any condition) in the last 3 months with the following drugs:
a. Adalimumab (Amgevita)
b. Adalimumab (Humira)
c. Adalimumab (Hyrimoz)
d. Adalimumab (Idacio)
e. Adalimumab (Imraldi)
Question 2.
How many patients were treated in the last 3 months by the Rheumatology department (for any condition) with the following drugs:
a. Adalimumab (Amgevita)
b. Adalimumab (Humira)
c. Adalimumab (Hyrimoz)
d. Adalimumab (Idacio)
e. Adalimumab (Imraldi)
Question 3.
How many patients were treated in the last 3 months by the Dermatology department (for any condition) with the following drugs:
a. Adalimumab (Amgevita)
b. Adalimumab (Humira)
c. Adalimumab (Hyrimoz)
d. Adalimumab (Idacio)
e. Adalimumab (Imraldi)
Drug treatments.130522.docx
1. How many patients were treated by your Trust in the last 3 months with the following drugs:
Adalimumab (Amgevita)
Adalimumab (Humira)
Adalimumab (Hyrimoz)
Adalimumab (Idacio)
Adalimumab (Imraldi)
2. Of the patients treated with Humira in the last 3 months, how many were new to Adalimumab treatment (patients who had not been treated with any brand of Adalimumab in the past year)? If possible please provide new patients number by:
New Humira patients – all departments
New Humira patients – rheumatology
New Humira patients – dermatology
New Humira patients – gastroenterology
3. Of the patients treated with any Adalimumab Biosimilar (Amgevita, Hyrimioz, Idacio, Imraldi etc) in the last 3 months, how many patients were new to Adalimumab treatment (patients who had not been treated with any brand of Adalimumab in the past year)? If possible provide new patients numbers by department:
New Adalimumab Biosimilar patients – all departments
New Adalimumab Biosimilar patients – rheumatology
New Adalimumab Biosimilar patients – dermatology
New Adalimumab Biosimilar patients – gastroenterology
Drug treatments 2.300522.docx
How many patients has your trust treated in the past 6 months for any disease with the following drugs:
1. Ponvory (ponesimod)
2. Tysabri (natalizumab) pre-filled syringes ONLY
3. Vumerity (diroximel fumarate)
4. Zeposia (ozanimod)
Drug treatments.230922.docx
Question 1
How many patients were treated by your trust (for any condition) in the last 3 months with the following drugs:
a. Adalimumab (Amgevita)
b. Adalimumab (Humira)
c. Adalimumab (Hyrimoz)
d. Adalimumab (Idacio)
e. Adalimumab (Imraldi)
Question 2
How many patients were treated for Hidradenitis Suppurativa in the last 3 months with the following drugs:
a. Adalimumab (Humira)
b. Adalimumab Biosimilar
c. Infliximab (Remicade)
d. Infliximab Biosimilar
e. Ustekinumab (Stelara)
f. Secukinumab (Cosentyx)
Question 3
How many patients were treated for Psoriasis in the last 3 months with the following:
a. Ciclosporin
b. Methotrexate – any form and strength
c. Methotrexate injections 15mg and above
Drug treatments.300522.docx
How many patients has your trust treated in the past 6 months (for any disease) with the following drugs:
a. Aubagio (teriflunomide)
b. Avonex (interferon beta-1a)
c. Betaferon (interferon beta-1b)
d. Brabio (glatiramer acetate)
e. Copaxone (glatiramer acetate)
f. Extavia (beta interferon-1b)
g. Fampyra (fampridine)
h. Gilenya (fingolimod)
i. Lemtrada (alemtuzumab)
j. Kesimpta (ofatumumab)
k. Mavenclad (cladribine)
l. Mayzent (siponimod)
m. Ocrevus (ocrelizumab)
n. Plegridy (peginterferon beta-1a)
o. Rebif (beta interferon-1a)
p. Tecfidera (dimethyl fumarate)
q. Tysabri (natalizumab)
r. Zeposia (ozanimod)
Drug usage. 051119
How many patients have been treated with these drugs in the past 6 months, regardless of diagnosis:
a. Aubagio (teriflunomide)
b. Avonex (interferon beta-1a)
c. Betaferon (interferon beta-1b)
d. Brabio (glatiramer acetate)
e. Copaxone (glatiramer acetate)
f. Extavia (beta interferon-1b)
g. Gilenya (fingolimod)
h. Lemtrada (alemtuzumab)
i. Mavenclad (cladribine)
j. Ocrevus (Ocrelizumab)
k. Plegridy (Peginterferon beta-1a)
l. Rebif (beta interferon-1a)
m. Tecfidera (dimethyl fumarate)
n. Tysabri (natalizumab)
o. Zinbryta (daclizumab)
p. Ampyra (Fampyra)
q. Ozanimod
Drug usage.100523.docx
How many patients has your trust/health board treated in the past 6 months (for any disease) with the following drugs:
1. Aubagio (teriflunomide)
2. Avonex (interferon beta-1a)
3. Betaferon (interferon beta-1b)
4. Brabio (glatiramer acetate)
5. Copaxone (glatiramer acetate)
6. Extavia (beta interferon-1b)
7. Gilenya (fingolimod)
8. Lemtrada (alemtuzumab)
9. Kesimpta (ofatumumab)
10. Mavenclad (cladribine)
11. Mayzent (siponimod)
12. Ocrevus (ocrelizumab)
13. Plegridy (peginterferon beta-1a)
14. Ponvory (ponesimod)
15. Rebif (beta interferon-1a)
16. Tecfidera (dimethyl fumarate)
17. Tysabri (natalizumab)
18. Tysabri (natalizumab) pre-filled syringes ONLY
19. Vumerity (diroximel fumarate)
20. Zeposia (ozanimod)
Drug usage. 130619
Within your health trust how many patients are, within the past 6 months that you have data available, being treated with the following treatments? This is regardless for the disease being treated.
Disodium pamidronate (Aredia)
Ibandronic acid or ibandronate (Bondronat)
Sodium clodronate (Bonefos, Clasteon, Loron)
Zoledronic acid or zoledronate (Zometa)
Denosumab (Xgeva)
Omalizumab [Xolair]
Mepolizumab [Nucala]
Reslizumab [Cinqaero]
Benralizumab [Fasenra]
How many paediatric patients have been treated in the last 6 months with Xolair/omalizumab?
Drug usage. 151118
You asked:
This is a Freedom of Information request regarding usage of certain products in all NHS Trusts, these products are:
• Glycopyrronium bromide 1 mg tablets
• Glycopyrronium bromide 2 mg tablets
• Glycopyrronium bromide 1 mg/5 ml oral solution
• Glycopyrronium bromide 5 mg/5 ml oral solution
• Sialanar 320 mcg/ ml glycopyrronium (400 mcg/ml glycopyrronium bromide) oral solution
• Scopoderm (hyoscine) 1.5 mg patch
• Glycopyrronium bromide 200 micrograms/ml ampoule (for injection)
1. How many units* of these products were dispensed quarterly in 2016 – present?
*tablets: units as number of TABLETS or PACKS
• If packs, please specify pack size e.g. 14 tablets
*oral solution: units as number of bottles
• Please specify bottle size e.g. 60 ml
*patch: units as packs
• Please specify pack size e.g. 5 patches
*ampoule: units as number of AMPOULES or PACKS
• If packs, please specify pack size e.g. pack of 10
Drug usage. 171220
1. How many patients has your trust treated in the last 12 months with the following drugs?
a. Octreotide
b. Lanreotide
c. Pasireotide
d. Pegvisomant
e. Genotropin
f. Humatrope
g. Norditropin
h. Nutropin
i. Omnitrope
j. Saizen
k. Zomacton
2. Please provide the number of patients under the age 16 that were treated in the last 12 months with each of the following drugs:
a. Genotropin
b. Humatrope
c. Norditropin
d. Nutropin
e. Omnitrope
f. Saizen
g. Zomacton
3. How many patients have been treated in the last 12 months with the following drugs for Acromegaly (ICD10 code E22.0) ONLY?
a. Sandostatin LAR
b. Octreotide Long-Acting (Generic)
c. Somatuline Autogel
d. Pasireotide
Drug usage. 2 151118
You asked:
1. How many patients have been treated in the past 6 months [latest 6 months available] with the following, If possible please split by paediatric (less than 18 years) and adult 18+years;
• Genotropin
• Humatrope
• Norditropin
• NutropinAq
• Omnitrope
• Saizen
• Valtropin
• Zomacton
Drugs free of charge or for a nominal charge. 310720
Question 1
Within the last 2 years, has the institution accepted or is it currently accepting any of the following drugs free of charge or for a nominal charge (eg £1):
Risankizumab (Skyrizi)
Guselkumab (Tremfya)
Brodalumab (Kyntheum)
Ixekizumab (Taltz)
Secukinumab (Cosentyx)
Tildrakizumab (Ilumetri)
Question 2
If yes to any of the above, are you able to say how long is the free of charge drug stock typically provided for each patient? For example, is it:
First dose
First month
First 3 months
Some other period?
Question 3
If the Institution has not accepted manufacturer provision of free of charge drug stock, are you able to say what have been the reasons for this?
Download response Drugs free of charge or for a nominal charge. 310720
Drugs usage. 061119
In the past 12 months, how many patients were treated with:
Avelumab + Axitinib
Axinitib
Bevacizumab
Cabozantinib
Doxorubicin
Everolimus
Lapatinib
Lenvantinib
Lenvantinib + Everolimus
Nivolumab
Nivolumab + Ipilimumab
Pazopanib
Pembrolizumab + Axitinib
Regorafenib
Sorafenib
Sunitinib
Temsirolimus
Tivozanib
Vandetanib
Drugs usage. 070318
This is a Freedom of Information request regarding usage of certain products in all NHS Trusts, these products are:
• Iloprost 0.5mg/0.5ml Ampoules
• Melatonin 1mg/ml oral solution,
• Melatonin 2mg Capsules,
• Melatonin 3mg Capsules,
• Melatonin 5mg Capsules,
• Melatonin 3mg Tablets
• Mexiletine 200mg capsules
• Diazoxide 50mg/ml oral suspension
1. How many packs of these products were dispensed quarterly in 2015?
2. How many packs of these products were dispensed quarterly in 2016?
3. How many packs of these products were dispensed quarterly in 2017?
4. What was the annual spend for each product between 2015 and 2017?
5. What was the cost per unit of each product between 2015 and 2017 to your organisation?
Drugs usage. 210218
This is a Freedom of Information request regarding usage of certain products in all NHS Trusts, these products are:
Iloprost 0.5mg/0.5ml Ampoules
Melatonin 1mg/ml oral solution,
Melatonin 2mg Capsules,
Melatonin 3mg Capsules,
Melatonin 5mg Capsules,
Melatonin 3mg Tablets
Mexiletine 200mg capsules
Diazoxide 50mg/ml oral suspension
1. How many packs of these products were dispensed quarterly in 2015?
2. How many packs of these products were dispensed quarterly in 2016?
3. How many packs of these products were dispensed quarterly in 2017?
4. What was the annual spend for each product between 2015 and 2017?
5. What was the cost per unit of each product between 2015 and 2017 to your organisation?
Drugs usage. 271119
Within your trust how many of the following intra-vitreal vials/implants have been used in the latest 4 months, if possible between May to August 2019;
Ranibizuma, Bevacizumab, Aflibercept, Fluocinolone & Dexamethasone
Drugs usage. 2711191
Within your health trust how many patients are currently [within the past 12 months] being treated with the following treatments, regardless of reason.
Amphotericin B/amphotericin liposomal (AmBisome )
Ceftaroline (Zinforo)
Ceftobiprole (Zevtera)
Ceftriaxone
Co-Amoxiclav
Flucloxacillin
Isavuconazole (Cresemba)
Meropenem (Meronem)
Posaconazole (Noxafil)
Teicoplanin (Targocid)
Tigecycline
Vancomycin
Amoxicillin/clauvanate
Piperacillin/tazobactam
Ceftazidime/avibactam
Ceftolozane/tazobactam
Carbapenems (e.g. Ertapenem, Imipenem, Meropenem etc)
Aminoglycosides (e.g. Gentamicin, Amikacin, Tobramycin)
Cephalosporins (e.g. Cefotaxime, Ceftazidime, Ceftriaxone)
Quinolones (e.g.Ciprofloxacin, Levofloxacin, Ofloxacin)
Early Access to Medicines Scheme (EAMS).280423.docx
1) How many patients at your trust have been supplied medicines approved through the Early Access to Medicines Scheme (EAMS) each year between April 2014 and April 2023?
2) How many requests has your trust made to pharmaceutical companies for access to medicines offered through a company-led ‘compassionate use’ or ‘free of charge’ scheme each year between April 2014 and April 2023?
a. How many patients have received treatment with unlicensed medicines obtained this way each year between April 2014 and April 2023?
3) How many requests have clinicians at your trust submitted to pharmaceutical companies for access to an unlicensed medicine to treat patients each year between April 2014 and April 2023, outside of a company-led scheme?
a. How many patients have received treatment with unlicensed medicines obtained this way each year between April 2014 and April 2023?
Eating Disorders. 130619
1. Please provide the number of women who were treated by the NHS for INPATIENT (TIER 4) and COMMUNITY (TIER 1, 2, 3) Eating Disorder services in your region in the last 3 years. Where possible, please provide separate sub-totals for those placed in-area and those placed out-of-area.
2. Please provide the number of men who were treated by the NHS for INPATIENT (TIER 4) and COMMUNITY (TIER 1, 2, 3) Eating Disorder services in your region in the last 3 years. Where possible, please provide separate sub-totals for those placed in-area and those placed out-of-area.
3. Please provide the average waiting time in weeks (time from referral to treatment) for ADULT INPATIENT (TIER 4) and ADULT COMMUNITY (TIER 1, 2, 3) Eating Disorder services in your region in the last 3 years.
4. Please provide a copy of your threshold criteria for access to ADULT INPATIENT (TIER 4) and ADULT COMMUNITY (TIER 1, 2, 3) Eating Disorder services.
5. Please provide the percentage of referrals to ADULT INPATIENT (TIER 4) and ADULT COMMUNITY (TIER 1, 2, 3) Eating Disorder services have been refused in your region in the last 3 years.
6. Please provide the total number of NHS beds in your region that are usable for ADULT INPATIENT (TIER 4) Eating Disorder patients. This does not refer to current occupancy levels, but rather the total capacity of beds.
7. Please provide the total amount spent by your organisation on treating ADULT Eating Disorder patients? Of this spend please can you advise the proportion allocated to ADULT INPATIENT (TIER 4) Eating Disorder services? Of this spend please can you advise the proportion allocated to ADULT COMMUNITY (TIER 1, 2, 3) Eating Disorder services?
8. For the last 3 years of which you have full accounts, please can you name the organisations that you have commissioned to provide ADULT Eating Disorder services?
ECG equipment. 260418
1. The name or your current ECG equipment manufacturer and product name, the year of purchase and installation date?
Do you have plans and timescales to replace?
2. The name of your current Stress Exercise ECG equipment manufacturer and product name, the year of purchase and installation date?
Do you have plans and timescales to replace?
Elastomeric Infusion Devices (E.I.D) 020320
Information request in respect to Elastomeric Infusion Devices
Please could you kindly advise which departments and healthcare professionals within your Trust use elastomeric infusion devices?
Information request in respect of Elastomeric Infusion Devices
1. Please could you also advise if you purchase E.I.D and if so:
a. What brand(s) do you purchase?
b. What quantities do you purchase on an annual basis?
c. Who are the main clinicians responsible within your Trust for the prescribing and administration of elastomeric devices?
d. What medicines do you fill the devices with?
e. Do you fill elastomeric devices in your pharmacy aseptic unit if you have one?
2. Please could you also advise if you purchase pre-filled elastomeric devices from a commercial compounder and if so:
a. What drugs are provided pre-filled?
b. What quantities do you purchase on an annual basis?
Download response Elastomeric Infusion Devices (E.I.D) 020320
Electronic prescribing and medicines administration. 230419
1. Who is the Trust’s current supplier for their Electronic prescribing and medicines administration?
2. What is the contract start and end date for the Electronic prescribing and medicines administration?
3. What is the annual cost for the Electronic prescribing and medicines administration?
Download response Electronic prescribing and medicines administration. 230419
Electronic prescribing and medicines administration system (ePMA). 151221.docx
1. Does your Trust have an electronic prescribing and medicines administration system (ePMA)?
Please tick one option
a. Yes (go to Q2)
b. No (go to Q4)
2. What is the full name of this ePMA system?
Please specify the system name and supplier
3. Which of the following statements best describes the status the data integration of (i) the system that manages clinical patient notes and records and (ii) the pharmacy dispensing system at your Trust?
Please tick one option for (i) and one option for (ii).
(i) Clinical patient records / medical notes (ii) Pharmacy Dispensing System (PDS)
a. Electronic and fully integrated
b. Electronic and partially integrated
c. Electronic and not integrated
d. On paper
4. Which of the following statements best describes your Trust’s overall implementation of the ePMA system?
Please tick one option
a. ePMA system is fully implemented (Go to Q5)
b. ePMA system is partially implemented and progress is ongoing to complete it (Go to Q5)
c. ePMA system has been procured from a named supplier and awaiting implementation (Go to Q5)
d. Selection of suppliers and procurement of ePMA system is underway (Go to Q5)
e. Awaiting funding (Go to Q17)
f. No ePMA systems or plans in place (Go to Q17)
g. Other – please specify below
5. To the best of your knowledge when will an ePMA system be fully implemented at your Trust?
Estimated date of full implementation
6. Which of the following statements best describes the interface between the patient record system and the pharmacy dispensing system?
Please tick one option
a. Patient records are electronic and fully integrated with pharmacy dispensing system.
b. Patient records are electronic and partially integrated with pharmacy dispensing system.
c. Patient records are electronic, but not integrated with the pharmacy dispensing system. □=
d. On paper
7. What is the name of the pharmacy dispensing system at your Trust?
Please specify the system name and supplier
8. Can the Trust export data from these systems and, if so, in which of the following formats?
Please tick all that apply
(i) Patient records system (ii) Pharmacy Dispensing System (PDS)
a. .xls (Excel)
b. .csv or .txt (Text)
c. Not possible
9. In principle are the prescribing systems capable of producing an anonymised report of the number of patients treated by specific drug treatment and by diagnosis a single report?
Please tick one option
a. Yes
b. No
10. In the case of drugs with multiple indications, e.g., a drug indicated for rheumatoid arthritis and haematology, does the system record sufficient detail to report on how much is used for each indication?
Please tick one option
a. Yes
b. No
11. In the case of drugs that are used to treat more than one type of cancer, can the system produce a single report that shows the quantity of drug used for each tumour type?
Please tick one option
a. Yes
b. No
12. In the case of drugs that are used to treat more than one type of cancer, can the system produce a single report that shows the quantity of drug used for each tumour type by cancer stage?
Please tick one option
a. Yes
b. No
13. Which, if any, of the following fields can be exported from the ePMA system?
Please indicate yes or no per item
a. Date (month year)
b. Diagnosis or indication
c. Drug name (&/or SNOMED ID)
d. Drug formulation
e. Drug strength
f. Drug unit of measure (e.g., milligrams, micrograms, vials)
g. Quantity dispensed (in UOM)
h. Quantity prescribed (in UOM)
i. Number of patients treated
14. Do you already produce a report such as this within the Trust?
Please tick one option
c. Yes
d. No
15. What is the name of this report?
Please specify
16. Which team or department is responsible for producing this report?
17. In September 2021 we understand that a new standard is being implemented for the Drugs Patient Level Contract Monitoring (DrPLCM) report, which is submitted monthly by every NHS Trust. Please see DCB2212 Drugs Patient Level Contract Monitoring (DrPLCM) Version 2.0 released 8th April 2021.
To what extent will your Trust be able to submit the data field named ‘Therapeutic indication code (SNOMED CT)’, or a description of the indication, alongside details of drug treatment, as stipulated by NHS England by the end of 2021?
a. Fully
b. Partially
c. Not at all
18. Which of the following diagnoses or indications are detailed in the latest DrPLCM report for your Trust?
We are interested in the level of detail (e.g., medical oncology versus ovarian cancer) as well as the specific diagnoses.
Please indicate yes or no for each diagnosis description
Immunology
Atopic dermatitis
Crohn’s disease
Plaque psoriasis
Rheumatoid arthritis
Severe asthma
Ulcerative colitis
Multiple sclerosis
Primary progressive multiple sclerosis
Relapsing remitting multiple sclerosis
Ophthalmology
Wet age-related macular degeneration
Dry age-related macular degeneration
Diabetic macular oedema
Medical oncology
Breast cancer
Lung cancer
NSCLC
SCLC
Melanoma
Ovarian cancer
Prostate cancer
Renal carcinoma
Haematology
Non Hodgkin Lymphoma
Hodgkin’s Disease
Acute Myeloid Leukaemia
Chronic Lymphocytic Leukaemia
Multiple Myeloma
Download response Electronic prescribing and medicines administration system (ePMA). 151221.docx
Electrophysiology equipment. 300317
1. Does your Trust have an Electrophysiology Lab or perform Electrophysiology Procedures?
2. How many 3D Mapping Systems are installed in your Trust?
3. How many Electrophysiology Recording Systems are installed in your Trust?
On average, what is the lifespan of these EP Recording systems?
What brands are they?
Were there any EP Recording systems purchased in the last 12 months?
If yes, how many?
Were these to replace old machines or new purchases?
4. How many Intracardiac Echocardiography (ICE) Systems are installed in your Trust?
5. How many Radiofrequency (RF) Ablation Generators are installed in your Trust?
6. How many cardiac stimulators are installed in your Trust?
7. How many Remote Navigation Systems (from Stereotaxis) are installed in your Trust?
ePMA Pharmacy Technician role job description.101022.docx
Could you please provide me with your current job descriptions and banding information for your ePMA Pharmacy Technician role(s)
ESBL and CPE infections. 181116
Can you please tell me how many people in your hospital trust:
1. Were admitted to hospital with an ESBL infection
2. Acquired an ESBL infection while in hospital
3. Were admitted to hospital with a CPE infection
4. Acquired a CPE infection while in hospital
Please provide the information for the past 10 years.
EU staff and medicines from the EEA. 151118
You asked:
1. How much does it cost in pounds sterling to recruit one doctor from an EEA country, as of October 2018?
2. How much does it cost in pounds sterling to recruit one nurse from an EEA country, as of October 2018?
3. How much did it cost in pounds sterling to recruit one doctor from an EEA country in October 2015?
4. How much did it cost in pounds sterling to recruit one nurse from an EEA country in October 2015?
5. How much of the overall budget is dedicated to recruitment?
6. How much did you spend on medicines from the EEA in 2015?
7. How much are you projecting to spend on medicines from the EEA in 2018?
8. What percentage of medication came from the EEA in 2015?
9. What percentage of medication came from the EEA in 2018?
Download response EU staff and medicines from the EEA. 151118
FEES (fibreoptic endoscopic evaluation of swallowing) assessments. 290721.docx
1.Please can you tell me whether your trust completes FEES (fibreoptic endoscopic evaluation of swallowing) assessments within the speech and language therapy department?
2.If so, on average, how many inpatient FEES assessments are completed per year and how many outpatient assessments are completed per year?
Download response FEES (fibreoptic endoscopic evaluation of swallowing) assessments. 290721.docx
Foot protection team. 020617
1. Does your trust operate a foot protection service, as recommended by NICE guideline NG19 on ‘Diabetic foot problems: prevention and management’?
2. If the answer to Q1 is yes, please state the number of podiatrists and orthotists employed within this service.
3. If the answer to Q1 is yes, is this service led by a podiatrist with specialist training in diabetic foot problems, as recommended by NICE guideline NG19 on ‘Diabetic foot problems: prevention and management’?
4. If the answer to Q1 is no, please provide a reason for this.
Formaldehyde and Formalin
1. How many reported incidents involving formaldehyde and/or Formalin have occurred in the last 3 years at your trust? Please provide numbers of staff and patients involved in such incidents
2. How many reported illnesses or injury due to formaldehyde and/or formalin has your trust had?
3. Has your trust ever been subject to legal proceedings due to exposure to formaldehyde and and/or formalin? Please supply numbers of incidents
4. Does your trust have a policy or procedure in place to reduce exposure to formaldehyde and/or formalin in the treatment room setting whilst harvesting biopsy samples? If so please supply
5. Does your trust have a policy to purchase the safest practicable solution to reduce harmful exposure to Formaldehyde and/or formalin? If so please supply details
Formularies and committees.241218
1) We understand the CCG/Trust has representation on the following medicines management / prescribing / formulary committees:
a. Maidstone and Tunbridge Wells NHS Trust Drugs and Therapeutic Committee
b. West Kent CCG Prescribing Interface Group
Please confirm if this is correct.
2) Does the CCG/Trust have representation on any other medicines management / prescribing / formulary committees? If so, please advise which.
3) We have the following formularies listed as used by the CCG/Trust:
a. West Kent Interface Adult Formulary
Please confirm if this is correct and if not, please provide a link/copy of relevant formularies.
4) Are any of the above formularies dominant when making prescribing decisions or does this depend on therapy area?
Gamma cameras and SPECT-CT systems. 270821.docx
1. Make and model of all gamma cameras and SPECT-CT systems that are installed in your Nuclear Medicine, Radiology or Medical Physics Department within all your Trust’s locations
2. Date of purchase of above systems and expected replacement dates
3. Price paid for all above systems that have been purchased within the within the last 2 years
4. Names of Consultants, Physicists and Technologists responsible for above systems
Download response Gamma cameras and SPECT-CT systems. 270821.docx
Gaseous anaesthetic agents.011118
In particular, I would like to know the total volume and total amount spent in the last financial year on sevoflurane, Desflurane and isoflurane.
To avoid any commercial sensitivity, I do not want to know who the manufacturer or supplier is, simply the total volume and cost as shown below:
• Total volume purchased in 2017-2018, last 12 months (ml or litres if possible)
• Total amount spent on agent in 2017-2108
Regarding the volume of agent used, millilitres or litres would be preferred. If it is easier to provide another unit of measure, please provide details so that I can calculate the volume.
Also, could you please state whether the total amount spent includes or excludes VAT.
Gout and Bowel Cleanser products. 031219
Information request 1
Has your hospital dispensed the products listed below from January 1 2018 till December 31 2018? If the answer is ‘yes’, could you confirm the number of tablets dispensed?
1. Colchicine 500mcg tablets
2. Allopurinol 100mg tablets
3. Allopurinol 300mg tablets
4. Adenuric 80mg tablets (Febuxostat)
5. Adenuric 120mg tablets (Febuxostat)
Information request 2
Has your hospital dispensed the products listed below from January 1 2018 till December 31 2018? If the answer is ‘yes’, could you confirm the number of sachets dispensed?
1. Moviprep powder for oral solution
2. Moviprep Orange powder for oral solution
3. Klean-Prep 69g sachet powder for oral solution
4. Picolax powder for oral solution
Growth Hormone prescribing. 300720
1. In your Trust how many patients have been treated with the following Somatostatin Analogues in the latest 12-month period for which data are available?
a. Octreotide
b. Lanreotide
c. Pasireotide
2. In the latest 12-month period how many Acromegaly patients have been treated with the following drugs?
a. Sandostatin LAR
b. Octreotide Long-Acting (Generic)
c. Somatuline Autogel
d. Pasireotide
e. Pegvisomant
3. How many patients have received a somatropin treatment for growth hormone deficiency in the latest 12-month period?
a. Genotropin
b. Humatrope
c. Norditropin
d. Nutropin
e. Omnitrope
f. Saizen
g. Zomacton
4. If it is possible, can you provide the number of patients under the age 16 that were treated with each of the following drugs in the latest 12-month period?
a. Genotropin
b. Humatrope
c. Norditropin
d. Nutropin
e. Omnitrope
f. Saizen
g. Zomacton
Growth Hormone Treatments. 111219
In your trust, in the past 12 months [latest 12 months available], how many patients have been treated with the following medications?
• Genotropin
• Humatrope
• Norditropin
• Nutropin
• Omnitrope
• Saizen
• Zomacton
Haemochromatosis. 261016
A. the number of patients treated with Haemochromatosis in 2015 who are in maintenance phase of the treatment (*)
B. the number of patients treated with Haemochromatosis in 2015 who are in PRE-maintenance phase of the treatment (+)
C. a copy of the clinical protocol(s) used to treat haemochromatosis
D. a copy of the clinical protocol(s) for therapeutic venesection
(*) “Maintenance phase” relates to patients whose ferritin is <=50 ug/L
(+) “PRE-maintenance phase” relates to patients whose ferritin is in excess of 50 ug/L
Hartmann IV solution.270422.docx
The total amount paid for Hartmann IV solution for each financial year since April 2017 and the individual bag cost charged for each of these tax years.
HCV testing 151216
1. Do you currently offer a clinical testing service for HCV?
o Yes, In-house service
o Yes, Send-out to another laboratory
o No
If you have selected send-out testing above, to which laboratory do you send samples for HCV testing?
2. What type of clinical HCV testing do you offer?
o HCV Antibody testing
o HCV RNA testing
o HCV Genotyping
o HCV Drug resistance testing
o Other. Please Specify:
3. If you are offering HCV antibody testing as well as HCV RNA testing, what is the laboratory algorithm used for testing?
o RNA testing is automatically performed as a reflex test dependant on the Antibody result
o The HCV antibody result is reported to the clinician and RNA testing is only performed when specifically requested by the clinician
4. HCV antibody testing details:
Is HCV antibody testing performed using a kit or laboratory developed technique?
If appropriate, please specify kit details:
What platform is used for HCV antibody testing?
What is the laboratory turnaround time for HCV antibody testing?
How frequently is HCV antibody testing performed
(on sample receipt, daily, twice a week, monthly)?
5. HCV RNA testing details:
Is HCV RNA testing performed using a kit or laboratory developed technique?
If appropriate, please specify kit details:
What platform is used for HCV RNA testing?
What is the laboratory turnaround time for HCV RNA testing?
How frequently is HCV RNA testing performed
(on sample receipt, daily, twice a week, monthly)?
6. HCV sample volume:
Annual Sample Volume
1st Nov 2015- 1st Nov 2016 Positivity Rate
1st Nov 2015- 1st Nov 2016
HCV
Antibody testing
HCV
RNA testing
HCV
Genotyping
(If applicable)
HCV
Drug resistance testing
(If applicable)
Hepatitis C. 151217
Please could you supply the following information, for patients with hepatitis C, for the latest month available? Please use the tables to enter by genotype if possible thank you.
Treatment Regimens in last month by Genotype
Hepatitis C. 270918
1. Does your trust treat Hepatitis C? [Yes/No]
2. If YES, please could you supply the following information, for patients with hepatitis C, for the latest month available? Please use the tables to enter by genotype if possible thank you.
Hepatitis C. 280417
1. Does your trust treat Hepatitis C? [Yes/No]
2. How many patients with Hepatitis C are registered, or recorded as under you care? [Number]
3. Please could you supply the following information, for patients with hepatitis C, for the last month if possible? Please use the tables to enter by genotype as possible thank you.
By genotype as follows
Interferon Free Treatment
Epclusa
Harvoni
Sovaldi
Sovaldi/Olysio
Sovaldi/Daklinza
Viekirax
Viekirax/Exviera
Zepatier
If your systems do not support the ability to split by treatment, please supply total treated by the genotype split. Similarly, if you are unable to split by genotype, please just split by treatment type.
Hepatitis C Patients 221216
For Hepatitis C patients:
1. How many patients in total are under the institution’s care, but not under any treatment (i.e. no drugs being given for this virus)?
If possible please split by Genotype.
2. For Hepatitis C patients, how many were treated in the month (last month’s available data) with interferon containing therapy and interferon free therapy as listed below. Please use the tables to enter by genotype if possible, thank you.
Hereditary Angioedema (HAE). 040321
Q1. In the past 6 months [latest 6 months available] how many patients have received the following treatments [for any disease]:
a. Berinert (Human C1-esterase inhibitor)
b. Cinryze (Human C1-esterase inhibitor)
c. Takhzyro (Lanadelumab)
d. Ruconest (Recombinant human C1-esterase inhibitor)
e. Firazyr (Icatibant injection)
Q2. In the past 6 months [latest 6 months available] how many patients have received the following immunoglobulin treatments [for any disease]:
a. Cuvitru
b. Gammanorm
c. Gamunex
d. Hizentra
e. Hyqvia
f. Kiovig
g. Octagam
h. Privigen
i. Subgam
Q3. In the past 6 months, how many patients attended A&E for Hereditary Angioedema (ICD10 code: D84.1) or Angioedema (ICD10 code: T78.3)? Of these patients, how many were treated with the following products:
a. Berinert (Human C1-esterase inhibitor)
b. Cinryze (Human C1-esterase inhibitor)
c. Ruconest (Recombinant human C1-esterase inhibitor)
d. Firazyr (Icatibant injection)
Hereditary Angioedema (HAE). 290420
1. In the last 6 months, how many patients with Hereditary angioedema (HAE) have been treated with,
• Berint
• Cinryze
• Firazyr
• Ruconest
• Takhzyro
• Tranexamic acid
• Other
2. Over the past 6 months, how many patients with persistent / chronic* Immune thrombocytopenia purpura [ITP] have you treated [include all treatments such as steroids, splenectomy, immune globulins, Rituximab and TPOs]?
3. Over the past 6 months, how many ITP patients have you treated with;
• Eltrombopag [Revolade]
• Romiplostim [Nplate]
4. Over the past 6 months, how many patients with persistent / chronic* Immune thrombocytopenia purpura [ITP] were new to treatment with the following;
• Eltrombopag [Revolade]
• Romiplostim [Nplate]
*Patient has ITP for over 6 months and does not respond to standard active treatments
Heroin and cocaine prescriptions. 250117
Under the FOI Act, can you please tell me how many times your trust has prescribed either heroin/diamorphine and/or cocaine to patients in the 2015 and 2016 calendar years.
Hidradenitis Suppurativa 230117
In your trust, how many patients with a diagnosis of Hidradenitis Suppurativa* (HS) have been treated in the last 12 months [latest available]?
Of these patients how many have been treated with the following;
Adalimumab
Etanercept
Infliximab
Infliximab Biosimilar
Ustekinumab
High-cost drugs in ophthalmology.220223.docx
1. For the 4 months from September to December 2022, how many patients received the following anti-VEGF treatments for any eye condition:
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Faricimab
Ranibizumab – Lucentis
Ranibizumab – Ongavia
2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Faricimab
Ranibizumab – Lucentis
Ranibizumab – Ongavia
High-cost intra-vitreal treatments in Ophthalmology.030622.docx
1. How many patients over the last 4 months (January to April 2022) have received the following anti-VEGF treatments for any eye condition:
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Ranibizumab
2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Ranibizumab
3. Please provide the number of patients treated for Diabetic Macular Oedema (DMO) ONLY in the last 4 months (January to April 2022) with the following:
a. Aflibercept
b. Bevacizumab
c. Dexamethasone
d. Ranibizumab
4. Please provide the number of patients treated for Retinal Vein Occlusion (RVO) ONLY in the last 4 months (January to April 2022) with the following:
a. Aflibercept
b. Bevacizumab
c. Dexamethasone
d. Ranibizumab
High-cost intra-vitreal treatments in Ophthalmology.030622.docx
Histology. 170320
For the financial year 2018/19 please provide information relating to histology requests reported for patients of the trust.
How much was paid (to the nearest £) in 2018/19 with each of the following in relation to the reporting of histology cases:
A. Consultants employed by the trust being paid for additional sessions
B. Consultants employed by the trust being paid an amount per slide or case for activity outside their contracted programmed activities
C. Consultants employed by other trusts, where the trust contracts with these consultants or their trust
D. Locum agencies (please specify which)
E. Backlogs Limited
F. Unilabs
G. Source Bioscience
H. Cellular Pathology Services Limited
I. LD Path Limited
J. Pathognomics Limited
K. Other private histology providers (please specify which)
Histology Reporting. 240817
For the financial year 2016/17 please provide information relating to histology slides/ cases reported for patients of the trust.
1. How many histology slides and or cases (please state whether the number given is slides or cases or both) were reported by consultant histopathologists for patients treated by the trust. If exact numbers are not available, an estimate to within 5% is acceptable, but please state whether exact numbers or estimates are given. (Cytology should be excluded)
2.Of these slides/ cases how many were reported by: a.Consultants employed by the trust working in their normal NHS programmed activity sessions b.Consultants employed by the trust being paid for additional sessions c.Consultants employed by the trust being paid an amount per slide or case for activity outside their contracted programmed activities d.Consultants employed by other trusts, where the trust contracts with these consultants or their trust e.Backlogs Limited f.Unilabs g.Source Bioscience h.Cellular Pathology Services Limited i.Other private histology providers (please specify which)
3.How much was spent in 2016/17 with each of the following in relation to the reporting of histology slides/ cases a.Consultants employed by the trust being paid for additional sessions b.Consultants employed by the trust being paid an amount per slide or case for activity outside their contracted programmed activities c.Consultants employed by other trusts, where the trust contracts with these consultants or their trust d. Backlogs Limited e.Unilabs f.Source Bioscience g.Cellular Pathology Services Limited h. Other private histology providers (please specify which)
Histopathology Labs.260522.docx
1. Do you have a Histopathology Labs that run Immunohistochemistry diagnostic testing and if so what site/sites they are located?
2. If possible, could you provide a contact email for the relevant person in charge of the Histopathology Lab? For example, a service manager or lead Biomedical scientist in Immunohistochemistry/ Histopathology/ Histology.
Histopathology Speciality Registrars July 2015
Under the Freedom of Information Act I am requesting the following
Monitoring results for the full time Histopathology Specialty Registrars who undertook a monitoring exercise July 2015
Monitoring results for the Less Than Full Time Histopathology Speciality Registrars who undertook monitoring July 2015
Download response Histopathology Speciality Registrars July 2015 211215
HIV patients treated with antiretroviral therapy (ART). 170817
1. Within your Trust for HIV patients treated between August 2016 – May 2017’ and August 2016 – July 2017, the total numbers treated with antiretroviral therapy (ART)
2. For HIV patients treated between August 2016 – May 2017 and August 2016 – July 2017, the total numbers treated with the following drugs.
Download response HIV patients treated with antiretroviral therapy (ART). 170817
Homecare medicine delivery service. 151118
You asked:
1. Which homecare provider(s) do you as a Trust commission and fund for medicines where there is no ‘free of charge’ homecare provision?
2. Which homecare provider(s) do you as an organisation utilise,
2a. Which is pharmaceutical manufacturer-commissioned?
3. Does your organisation commission homecare services for any medicines as an alternative to the pharmaceutical manufacturer’s homecare provision?
4. Are there any homecare providers you have a policy not to work with? If yes, please select/name them
5. In your organisation, which group has the overall responsibility for any homecare provision for your patients?
6. In your organisation, which named individuals have the overall responsibility for any homecare provision for your patients?
7. What are your minimum requirements for accepting a homecare provider?
8. Do you currently have in post an operational lead for homecare services in your organisation – If so, what is their name/role?
9. If you have an outsourced outpatient pharmacy, are they able to provide training for patients on how to self-inject for medicines administered by sub-cutaneous injection as part of their contract?
10. Is it your policy to accept new homecare service level agreements (SLAs) with homecare providers whom you do not currently have an SLA in place with?
11. Any additional comments?
Download response Homecare medicine delivery service. 151118
Hospital Laboratories. 190919
1. How many laboratories (please include breakdown of sites/disciplines if possible) are there in your Trust?
2. What is the headcount of laboratory staff (please include breakdown of sites/departments/roles if possible) in your Trust?
3. How many patient samples or ‘reportable laboratory activities’ are processed (please include breakdown of sites/departments if possible) by your Trust’s laboratories each year (please include the three most recent available years’ numbers)?
4. What number (and percentage) of your Trust’s patients have a sample processed in a laboratory as part of their treatment?
5. How many patient samples are taken by your Trust but not processed/analysed by your Trust’s laboratory staff? (IE: outsourced)
6. If any, where are outsourced patient samples sent? (please include company names/addresses and number of samples sent each year)
Hospital pharmacy provision. 220817
1. Please can you inform me whether your inpatient pharmacy (Discharge Medication not ward-level dispensing) is:
a. A department of the hospital?
b. A wholly owned outsourced subsidiary of the hospital?
c. Contracted-out to a private provider?
2. Please can you inform me whether your out-patient pharmacy is:
a. A department of the hospital?
b. A wholly owned outsourced subsidiary of the hospital?
c. Contracted-out to a private provider?
3. Please can you inform me whether your home care dispensing service is:
a. Provided by the pharmacy as a department of the hospital?
b. Provided by the pharmacy as a wholly owned outsourced subsidiary of the hospital?
c. Contracted-out to a private provider?
Human Milk Product Purchasing. 100122.docx
1. Does your Trust acquire human milk or human milk-based products for infant or paediatric feeding? If so, how?
2. Does your Trust have policy on providing human milk to adult patients for their consumption? If so, please can you attach it.
3.a. If your Trust acquires human milk-based products from private suppliers (e.g., companies), can you provide the annual amount spent on these products by your Trust for the past 5 years, if available?
3.b. If your Trust does not currently use private suppliers, please can you detail if your trust has been approached by any companies to purchase such products for infant, paediatric or adult consumption?
Download response Human Milk Product Purchasing. 100122.docx
Hydrotherapy pools. 011217
– What was the total cost of maintaining the hydrotherapy pools in your NHS trust between October 2016 and October 2017 and how many pools do you have? [Can you specify which hospitals these are at?]
– If possible, can I also have a breakdown of the maintenance cost per pool during the same time period?
– If this total cost include staff costs could you give the total amount relating to staff costs separately for this period?
– How much revenue did you raise between October 2016 and October 2017 from charging people to use the hydrotherapy pools in the hospitals within your NHS trust?
– Have any hydrotherapy pools been closed down in your NHS trust in the time period October 2014- October 2017? If yes, which hospitals had their hydrotherapy pools closed down?
– What were the reasons for the hydrotherapy pool closures at hospitals within your NHS trust?
Hydrotherapy provision in England. 031120
1. On behalf of which Trust are you responding?
2. Does your trust have an on-site hydrotherapy pool?
3. Does your trust have access to an offsite hydrotherapy pool?
4. Was the hydrotherapy pool open prior to the COVID-19 pandemic?
5. Will the hydrotherapy pool be re-opening?
6. When is the pool scheduled to re-open?
7. Why is that? (Please select all that apply)
8. Is / will your service capacity be reduced as a result of COVID-19?
9. What capacity will you be able to offer? Please enter a percentage (%).
10. Why is that? (Please select all that apply)
11. What are the reasons that you don’t have access to a hydrotherapy pool? (Please select all that apply)
12. Approximately how many people with any condition used the pool on a weekly basis?
13. Which condition areas use the hydrotherapy pool?
14. What percentage of users were/are people with axial Spondyloarthritis (axial SpA) including ankylosing spondylitis (AS)? We understand you may not record this level of detail so please do give your best estimate.
15. Do you currently audit the use and effectiveness of hydrotherapy?
16. Please list outcome measures or tools used to audit the use and effectiveness of hydrotherapy.
17. If you are happy to be contacted to discuss your responses please let us know your name, position and email address.
Hypoxic challenge tests.310522.docx
1. Does the Trust provide hypoxic challenge testing services?
2. If yes, is HCT testing provided as an NHS service or as a private service?
3. If HCT testing is offered as a private service, what is the fee?
4. Do patients need a GP referral or consultant referral to access hypoxic challenge testing?
5. How is the HCT/fitness to fly service “marketed” to GPs and private patients?
6. Which patient groups / morbidities typically require HCT testing? e.g. patients with interstitial lung disease etc.
7. How many hypoxic challenge tests have been completed in the last year?
8. What is the current waiting time to access an HCT test?
9. Has the emergence of long Covid added to demand for fit to fly assessments in recent months?
10. For patients referred for a fitness to fly assessment, what outputs does the patient receive? e.g. a letter from a respiratory consultant advising whether they will need supplementary oxygen when flying, a consultation, any other intervention.
IDS Blood Culture.050523.docx
1. Does your Trust have a process for skin preparation/cleaning prior to blood collection? Y/N
2. Do you take two sets of blood cultures each time as recommended in the guidance? Y/N
3. If no, what percentage of patients do have two sets of blood cultures taken?
4. Do you measure the volume of blood taken each time a blood culture is taken (the recommended amount is 20ml per sample)? Y/N
5. Do you measure the time between blood sample collection and the sample being loaded onto an analyser instrument (the recommended maximum time is four hours)? Y/N
6. If yes, what is the average time?
7. Do you collect data on blood sample contamination? Y/N
8. Is the data described above reported at Board level as recommended?
Imaging services. 070317
1. Total number of and the manufacturer and model number(s) of each individual:
o MRI scanner
o CT scanner
o PET scanner
o SPECT scanner
o Ultrasound scanner
o Flexible Endoscope [An estimate of the number and predominant manufacturer brand will suffice]
o Catheter Lab X-ray machines
2. The year each individual scanner was purchased, the purchase method**, cost and the scheduled replacement year for each individual:
o MRI scanner
o CT scanner
o PET scanner
o SPECT scanner
Please state the total cost for trust purchases and annual payments if lease or MES.
Please indicate if equipment was purchased through a group purchasing organisation
3. How each of the following equipment has been purchased (e.g. contract with OEM, NHS Supply Chain catalogue) and how often they are replaced on average:
o Ultrasound scanner
o Sets of Flexible Endoscopes
o Catheter Lab CT machines
An estimate of how often the trust aims to replace the listed equipment would be useful (e.g. once every 2 years).
4. The maintenance provider (e.g. the OEM or a third party) and the annual maintenance cost (if applicable) for each individual:
o MRI scanner
o CT scanner
o PET scanner
o SPECT scanner
o Ultrasound scanner
o Catheter Lab CT machines
Might be done by the Original Equipment Manufacturer (OEM) (e.g. Siemens maintenance for a Siemens MRI machine) or a third party. If so, please state the provider name.
If no listed maintenance provider, please state – possibly the case for ultrasound.
5. Staffed hours for each individual: (Please note which of the individual scanners are available 24/7 for A&E purposes.)
o MRI scanner
o CT scanner
o PET scanner
o SPECT scanner
Please state hours each scanner is manned. (e.g. 9am – 6pm, Mon-Fri). Scanners used by A&E departments presumably must be 24/7, so please indicate these where relevant.
6. Number of scans/procedures performed annually in period financial year 2005/06 – 2015/16 for the following: [See the attachment for the relevant OPCS and modality ID codes].
o MRI scans*
o CT scans*
o PET scans*
o SPECT scans*
o Ultrasound scans
o Endoscopy procedures (Upper GI, Lower GI and Urological)
o Cardiac Angiography and Angioplasty procedures
o Cardiac Electrophysiology procedures
*For MRI, CT, PET and SPECT these may be covered by submissions to HSICIC for the Diagnostic Imaging Dataset (DID) (http://www.hscic.gov.uk/did), but we are looking for more granular data by individual machine if possible.
7. Number of scans/procedures performed by external providers on behalf of the trust in this same period. How much was paid per scan/procedures on average? Please list by external provider name. For the following:
o MRI scans
o CT scans
o PET scans
o SPECT scans
o Ultrasound scans
o Endoscopy procedures (Upper GI, Lower GI and Urological)
o Cardiac Angiography and Angioplasty procedures
o Cardiac Electrophysiology procedures
Number of activities performed by an external provider (NHS or Non-NHS), data may be collected by CCGs.
8. Average cost per scan from by year for the period 2005/06 – 2015/16 for the following:
o MRI scans
o CT scans
o PET scans
o SPECT scans
9. The provider of tracers for PET (e.g. FDG) and annual spend on tracers.
Immunoglobulin vials.170223.docx
I would like to submit an FOI request for the number of immunoglobulin vials distributed to Maidstone and Tunbridge Wells NHS Trust in each month for October, November, and December 2022, broken down by product (see below).
1. Vigam
2. Flebogamma DIF
3. Gammaplex
4. Gamunex-C
5. Octagam
6. Kiovig
7. Intratect
8. Privigen
9. Iqymune
10. Gammanorm
11. Subcuvia
12. Subgam
13. Hizentra
14. Hyqvia
15. Cuvitru
16. Panzyga
17. Xembify
18. Cutaquig
19. Vyvgart (Efgartigimod)
Infected blood enquiry. 280119
a) Copies of all correspondence to/from the Infected Blood Inquiry during the period 1st April 2018 to 7th January 2019.
b) Please advise whether or not you have received any notice or instruction regarding the retention and/or request of documents relevant to the Infected Blood Inquiry?
c) If a request for documentation and/or its retention has been received from the Infected Blood Inquiry, please supply a copy of any such notices or requests.
Infected Blood Inquiry. 310719
a) Copies of all correspondence to/from the Infected Blood Inquiry during the period 1st January 2019 to 17th July 2019.
b) Have you received any notice or instruction regarding the retention and/or request of documents relevant to the Infected Blood Inquiry?
c) If a request for documentation and/or its retention has been received from the Infected Blood Inquiry, please supply a copy of any such notices or requests and copies of any replies to such a request and internal correspondence relating to such.
Emergency and Medical Services
Pain relief prescriptions 031016
For each of the questions, please can you provide answers for each of the financial years 2013/14, 2014/15 and 2015/16:
1. PARACETAMOL
a. Which suppliers did you buy paracetamol from?
b. How many packets of paracetamol did you buy from each supplier? Please disclose how many tablets were in the packets.
c. How many packets of paracetamol did you buy in total? Please disclose how many tablets were in the packets.
d. How much did you pay each supplier for paracetamol?
e. How much did you spend on paracetamol in total?
f. How many prescriptions in total did you make for paracetamol?
g. How many of these prescriptions were free for the patient?
h. How much money were you paid by patients for paracetamol?
2. IBRUPROFEN
a. Which suppliers did you buy ibuprofen from?
b. How many packets of ibuprofen did you buy from each supplier? Please disclose how many tablets were in the packets.
c. How many packets of ibuprofen did you buy in total? Please disclose how many tablets were in the packets.
d. How much did you pay each supplier for ibuprofen?
e. How much did you spend on ibuprofen in total?
f. How many prescriptions in total did you make for ibuprofen?
g. How many of these prescriptions were free for the patient?
h. How much money were you paid by patients for ibuprofen?
3. ASPIRIN
a. Which suppliers did you buy aspirin from?
b. How many packets of aspirin did you buy from each supplier? Please disclose how many tablets were in the packets.
c. How many packets of aspirin did you buy in total? Please disclose how many tablets were in the packets.
d. How much did you pay each supplier for aspirin?
e. How much did you spend on aspirin in total?
f. How many prescriptions in total did you make for aspirin?
g. How many of these prescriptions were free for the patient?
h. How much money were you paid by patients for aspirin?
4. CODEINE PHOSPHATE
a. Which suppliers did you buy codeine phosphate from?
b. How many packets of codeine phosphate did you buy from each supplier? Please disclose how many tablets were in the packets.
c. How many packets of codeine phosphate did you buy in total? Please disclose how many tablets were in the packets.
d. How much did you pay each supplier for codeine phosphate?
e. How much did you spend on codeine phosphate in total?
f. How many prescriptions in total did you make for codeine phosphate?
g. How many of these prescriptions were free for the patient?
h. How much money were you paid by patients for codeine phosphate?
Abdominal aortic aneurysms. 160518
Are you able to provide me with a copy of the protocols the Trust use in terms of monitoring Abdominal Aortic Aneurysms (AAAs)?
Acanthamoeba Keratitis (AK).241218
How many cases of acanthamoeba keratitis (AK) have been diagnosed within your trust over the past five years?
Accident and emergency departments.190822.docx
You asked:
1. How many patients were triaged at your accident and emergency (ED) departments between 1st January 2016 and 30th June 2022?
2. How many patients arrived by ambulance at your accident and emergency departments between 1st January 2016 and 30th June 2022?
Accident and Emergency Diagnosis Code. 091221.docx
1. (a) With regard to the following Accident and Emergency Diagnosis Code (and/or treatment Code; whichever is applicable): ‘8582’ what is the specific name of the respective coding database/data set and the corresponding version and the applicable date range when the Trust used this code?
(b) What is the corresponding full diagnosis descriptor and/or if relevant, treatment descriptor?
(c) Please provide the corresponding word descriptor for each of the numbers within the code “8582”.
2. (a) with regard to the Accident and Emergency diagnosis descriptor: ‘Other Soft Tis Inj. Neck,’ what is the specific name of the database/data set and the corresponding version and applicable date range when the Trust used this diagnosis descriptor?
(b) What is the corresponding code used within the Trust’s patient records?
(c) What is the corresponding code used within Trust information reported to the Secondary Use Service (SUS) and the Hospital Episode Statistics (HES) data?
3. (a) With regard to the Accident and Emergency diagnosis descriptor: ‘Other Soft Tis Inj. Neck, Not applicable’ what is the specific name of the respective database/data set used in 2012 and the corresponding version and applicable date range in which the above diagnosis descriptor was used by the Trust?
(b) What is the corresponding Accident and Emergency diagnosis code relevant to the above diagnosis descriptor within the same database/dataset which was used within patient records by the Trust at the time?
(c) What is the corresponding code used within Trust information reported to the Secondary Use Service (SUS) and the Hospital Episode Statistics (HES) data in 2012?
4(a) With regard to the Accident and Emergency Investigation descriptor: ‘X-ray or Blood tests’ what is the specific name of the database/data set and the corresponding version and applicable date range when this Investigation descriptor was used by the Trust?
(b) What is the corresponding code relevant to the above Investigation descriptor within the same database/dataset?
(c) What is the corresponding code used within Trust information reported to the Secondary Use Service (SUS) and the Hospital Episode Statistics (HES) data?
5(a) With regard to the Accident and Emergency Investigation descriptor: ‘X-ray plain film’ what is the specific name of the database/data set and the corresponding version and applicable date range when the above Investigation descriptor was used by the Trust?
(b) What is the corresponding code relevant to the above Investigation descriptor within the same database/dataset?
(c) What is the corresponding code used within Trust information reported to the Secondary Use Service (SUS) and the Hospital Episode Statistics (HES) data;
6(a) with regard to the possible Accident and Emergency diagnosis descriptor: ‘Other Soft Tis Inj. Shoulder,’
If this is a historically identified diagnosis descriptor, please confirm whether the Trust has ever used this and if so, what is the specific name of the database/data set and the corresponding version and applicable date range when the Trust used this diagnosis descriptor?
(b) If applicable, what is the corresponding code used within the Trust’s patient records?
(c) If applicable, what was the corresponding code used within Trust information reported to the Secondary Use Service (SUS) and the Hospital Episode Statistics (HES) data from April 2012 onwards?
7(a) with regard to the Accident and Emergency diagnosis descriptor: ‘Acute limb injury*, leg,’ *ALI what is the specific name of the database/data set and the corresponding version and applicable date range when the Trust used this diagnosis descriptor?
(b) What is the corresponding code used within the Trust’s patient records?
(c) What is the corresponding code used within Trust information reported to the Secondary Use Service (SUS) and the Hospital Episode Statistics (HES) data?
8(a) with regard to the Accident and Emergency diagnosis descriptor: ‘Whiplash’ what is the specific name of the database/data set and the corresponding version and applicable date range when the Trust used this diagnosis descriptor?
(b) What is the corresponding code used within the Trust’s patient records?
(c) What is the corresponding code used within Trust information reported to the Secondary Use Service (SUS) and the Hospital Episode Statistics (HES) data?
9(a) with regard to the Accident and Emergency diagnosis descriptor: ‘Acute torticollis,’ what is the specific name of the database/data set and the corresponding version and applicable date range when the Trust used this diagnosis descriptor?
(b) What is the corresponding code used within the Trust’s patient records?
(c) What is the corresponding code used within Trust information reported to the Secondary Use Service (SUS) and the Hospital Episode Statistics (HES) data?
Additional questions:
2. Please confirm, so that I know I have understood the Trust’s response to question 14(a) correctly, that the software system which was in use by the Trust in December 2020, in respect of onsite storage, retrieval and printing of historical patient records was ‘eNotes’.
3. In respect of the Trust’s response to question 14(b), please clarify whether the ‘eNotes’ system which the Trust response refers to, accesses historical April 2012 patient letters, and whilst processing them, modifies elements of the original document data automatically, and if so, please specify which fields and how and why these fields are modified.
4. Please indicate if a patient’s original historical letter can be modified on ‘eNotes’ in real time by an individual Trust software user and then be printed off subsequently.
5. In respect of the ‘eNotes’ system that the Trust refers to, please specify the software company who supplies the Trust.
6. With regard to the Trust’s comments relating to software (see Appendix 5), although it is stated that the Trust migrated to Sunrise in July 2021, was this software ever utilised in conjunction with historical patient records, before July 2021?
7. What specific date range did the Trust use the Symphony system provided by EMIS?
8. What specific date range did the Trust use the Symphony system provided by Footman-Walker?
9. Would patient records have been processed by Symphony EMIS or Symphony Footman-Walker at the time in April 2012?
10. Although the A & E response explains that further diagnoses were hand written in the CAS card and scanned in following attendance, it is not clear from the response whether the further diagnoses which were hand written in the CAS card were the same as those original further diagnoses which would have been included in real time (April 2012) within the A & E record ‘Diagnosis Comments’ field’ (which I referred to in my FOI question (b), copied above).
Please provide precise and direct clarification on this point
i.e. was the further diagnoses data entered into both the A & E ‘Diagnosis Comments’ field in real time in April 2012, as well as being hand written subsequently in the CAS card?
Download response Accident and Emergency Diagnosis Code. 091221.docx
Accident and Emergency Diagnosis Coding and Descriptions. 131021.docx
1. (a)With regard to the following Accident and Emergency Diagnosis Code (and/or treatment Code; whichever is applicable): ‘8582’ what is the specific name of the respective coding database/data set and the corresponding version and the applicable date range when the Trust used this code?
(b) What is the corresponding full diagnosis descriptor and/or if relevant, treatment descriptor?
(c) Please provide the corresponding word descriptor for each of the numbers within the code “8582”.
2. (a) with regard to the Accident and Emergency diagnosis descriptor:
‘Other Soft Tis Inj. Neck,’
what is the specific name of the database/data set and the corresponding version and applicable date range when the Trust used this diagnosis descriptor?
(b) What is the corresponding code used within the Trust’s patient records?
(c) What is the corresponding code used within Trust information reported to the Secondary Use Service (SUS) and the Hospital Episode Statistics (HES) data?
3. (a) With regard to the Accident and Emergency diagnosis descriptor:
‘Other Soft Tis Inj. Neck, Not applicable’
what is the specific name of the respective database/data set used in 2012 and the corresponding version and applicable date range in which the above diagnosis descriptor was used by the Trust?
(b) What is the corresponding Accident and Emergency diagnosis code relevant to the above diagnosis descriptor within the same database/dataset which was used within patient records by the Trust at the time?
(c) What is the corresponding code used within Trust information reported to the Secondary Use Service (SUS) and the Hospital Episode Statistics (HES) data in 2012?
4(a) With regard to the Accident and Emergency Investigation descriptor:
‘X-ray or Blood tests’
what is the specific name of the database/data set and the corresponding version and applicable date range when this Investigation descriptor was used by the Trust?
(b) What is the corresponding code relevant to the above Investigation descriptor within the same database/dataset?
(c) What is the corresponding code used within Trust information reported to the Secondary Use Service (SUS) and the Hospital Episode Statistics (HES) data?
5(a) With regard to the Accident and Emergency Investigation descriptor:
‘X-ray plain film’
what is the specific name of the database/data set and the corresponding version and applicable date range when the above Investigation descriptor was used by the Trust?
(b) What is the corresponding code relevant to the above Investigation descriptor within the same database/dataset?
(c) What is the corresponding code used within Trust information reported to the Secondary Use Service (SUS) and the Hospital Episode Statistics (HES) data;
6(a) with regard to the possible Accident and Emergency diagnosis descriptor:
‘Other Soft Tis Inj. Shoulder,’
If this is a historically identified diagnosis descriptor, please confirm whether the Trust has ever used this and if so, what is the specific name of the database/data set and the corresponding version and applicable date range when the Trust used this diagnosis descriptor?
(b) If applicable, what is the corresponding code used within the Trust’s patient records?
(c) If applicable, what was the corresponding code used within Trust information reported to the Secondary Use Service (SUS) and the Hospital Episode Statistics (HES) data from April 2012 onwards?
7(a) with regard to the Accident and Emergency diagnosis descriptor:
‘Acute limb injury*, leg,’ *ALI what is the specific name of the database/data set and the corresponding version and applicable date range when the Trust used this diagnosis descriptor?
(b) What is the corresponding code used within the Trust’s patient records?
(c) What is the corresponding code used within Trust information reported to the Secondary Use Service (SUS) and the Hospital Episode Statistics (HES) data?
8(a) with regard to the Accident and Emergency diagnosis descriptor:
‘Whiplash’ what is the specific name of the database/data set and the corresponding version and applicable date range when the Trust used this diagnosis descriptor?
(b) What is the corresponding code used within the Trust’s patient records?
(c) What is the corresponding code used within Trust information reported to the Secondary Use Service (SUS) and the Hospital Episode Statistics (HES) data?
9(a) with regard to the Accident and Emergency diagnosis descriptor:
‘Acute torticollis,’
what is the specific name of the database/data set and the corresponding version and applicable date range when the Trust used this diagnosis descriptor?
(b) What is the corresponding code used within the Trust’s patient records?
(c) What is the corresponding code used within Trust information reported to the Secondary Use Service (SUS) and the Hospital Episode Statistics (HES) data?
10.(a) What is the corresponding descriptor for Code 19153 (which may be a LOCAL SUB-SPECIALTY CODE within CDS Trust use only?
11. Who, within the Trust, is responsible for the following?
(a) updating accident and emergency data bases
(b) managing and accessing archived data bases/sets
12. (a) who has authorised access to* historical individual patient records stored on the Trust’s onsite systems?
*including the facility to amend historical patient personal data
13. Who within the Trust is currently responsible for:
(a) investigating alleged breaches of the data legislation?
(b) rectifying inaccurate and incomplete personal data?
14. (a) What software system was in use by the Trust in December 2020, in respect of onsite storage, retrieval and printing of historical patient records?
(b) In what data format are historical patient records, which are held onsite, accessed, processed and printed off?
15. (a) Were all Accident & Emergency recorded patient diagnoses reported as diagnostic codes to the Secondary Use Service (and when applicable, the Hospital Episode Statistics) from April 2012 onwards?
(b) Within the Trust’s Accident and Emergency computer system used in April 2012, was there only the facility to record the ‘Primary Diagnosis’ and ‘Diagnosis Comments’, and no facility within the software to record specific secondary and third diagnoses when inputting the data in real time, other than within the ‘Diagnosis Comments’ field?
16. How many historical patient letters*, when copied and sent to patients under a Subject Access Request (SAR) or FOI Request, have been reported to the Trust as containing a different or missing diagnosis descriptor, and/or a different investigation descriptor, to that contained within the corresponding original letter?
*(which were originally written pre-2017 data changes).
Download response Accident and Emergency Diagnosis Coding and Descriptions. 131021.docx
Accident and emergency (ED) departments.300822.docx
1. How many patients were triaged at your accident and emergency (ED) departments between 1st January 2016 and 30th June 2022? Could you please provide a year-on-year breakdown?
2. How many patients arrived by ambulance at your accident and emergency departments between 1st January 2016 and 30th June 2022? Again, could I have a year-on-year breakdown.
Accident and Emergency Quality Indicators.
The indicators published by HSCIC’s report include:
Left department before being seen for treatment (Data quality)
– Total number of attendances in A&E HES (excluding planned follow-up attendances and attendances where the attendance category was unknown)
– Attendances with an unknown attendance disposal category
– % of attendances with unknown attendance disposal categories
– % of attendances with an attendance disposal category of “Other”
Left department before being seen for treatment (Performance)
– Total number of attendances in A&E HES (excluding planned follow-up attendances, attendances where the attendance category was unknown, and attendances where the attendance disposal category was unknown)
– Number of attendances with an attendance disposal of “Left Department before being seen for treatment”
– Left department before being seen for treatment
Re-attendance (Data quality)
– Total number of applicable attendances for this indicator (1st A&E attendance, unplanned follow up attendance and unknown attendance)
– Attendances with unknown attendance category
– % of attendances with an unknown attendance category
Re-attendance (Performance)
– Total number of attendances in A&E HES (excluding planned follow-up attendances and attendances where the attendance category was unknown)
– Number of re-attendances within 7 days of a previous attendance at A&E
– Re-attendance rate
Time to initial assessment [emergency ambulance cases only] (Data quality)
– Total number of attendances in A&E HES that were brought in by ambulance (excluding planned follow-up attendances and attendances where the attendance category was unknown)
– Attendances with an unknown duration to initial assessment
– % of attendances with unknown duration to assessment times
Time to initial assessment [emergency ambulance cases only] (Performance; minutes)
– Median
– 95th Percentile
– Longest wait
Time to Treatment (Data quality)
– Total number of attendances in A&E HES (excluding planned follow-up attendances, attendances where the attendance category was unknown, and attendances where the attendance disposal category was: Left Before Treatment, Left Refusing Treatment, or Unknown)”
– Attendances with unknown duration to treatment
– % of attendances with unknown duration to treatment times
Time to Treatment (Performance; minutes)
– Median
– 95th Percentile
– Longest wait
Total Time in A&E (minutes) [Admitted patients only]
– Median
– 95th Percentile
– Longest wait
Total Time in A&E (minutes) [Non-admitted patients only]
– Median
– 95th Percentile
– Longest wait
Total Time in A&E (Data quality) [All patients]
– Total number of attendances in A&E HES (excluding planned follow-up attendances and attendances where the attendance category was unknown)
– Attendances with unknown duration to departure
– % of attendances with unknown duration to departure times
Total Time in A&E (Performance; minutes) [All patients]
– Median
– 95th Percentile
– Longest wait
Download response Accident and Emergency Quality Indicators 290616
Accidents in the home. 071217
1. A: How many people have died in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
1. B: How many children aged 0-18 have died in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
1. C: How many people aged 65+ have died in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
2. A: How many people have attended A&E in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
2. B: How many children aged 0-18 have attended A&E in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
2. C: How many people aged 65+ have attended A&E in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
3. A: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
3. B: How many children aged 0-18 have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
3. C: How many people over 65 years have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an accident in the home?”
4. A: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to leisure activities?”
4. B: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an accident in education settings?”
4. C: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an accident on the road?”
4. D: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an accident at work?”
5. A: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to a fall in the home?”
5. B: How many adults over 65 have attended A&E in the past year (Oct 2016 – Oct 2017) due to a fall in the home?”
5. C: How many people have died in the past year (Oct 2016 – Oct 2017) due to a fall in the home? ”
6. A: How many cases have attended A&E in the past year (Oct 2016 – Oct 2017) with suspected carbon monoxide poisoning?”
6. B: How many cases of carbon monoxide poisoning have been treated in A&E the past year (Oct 2016 – Oct 2017)?”
6. C: How many cases have been admitted from A&E in the past year (Oct 2016 – Oct 2017) for carbon monoxide poisoning treatment?”
6. D: How many people have died in the past year (Oct 2016 – Oct 2017) due to carbon monoxide poisoning?”
7. A: How many cases of asthma have been treated in A&E the past year (Oct 2016 – Oct 2017)?”
7. B: How many cases have been admitted from A&E in the past year (Oct 2016 – Oct 2017) for asthma? ”
7. C: How many people have died in the past year (Oct 2016 – Oct 2017) due to asthma?”
8. A: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an electrical accident in the home?”
9. A: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to a burn or scalding accident in the home?
10. A: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an injury caused while gardening?
10. B: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an accident with the lawn mower?
10. C: How many people have been treated in A&E in the past year (Oct 2016 – Oct 2017) due to an injury caused by a BBQ?
Acopia and-or social admission or ICD 10 code z73. 250417
With regard to A&E statistics pertaining to presenting complaints can you please provide the number of times ‘acopia’ and/or ‘social admission’ or ICD 10 code z73 were recorded as causes for
a. Admission
b. Noted in the discharge summary
c. Recorded as a diagnosis for the periods of
January 2017- March 2017
2016
2015
Download response Acopia and-or social admission or ICD 10 code z73. 250417
Acute Myocardial Infarction (AMI).
Which test(s) does the Trust use to diagnose patients who present with suspected acute myocardial infarction (AMI)? Please give details of tests used – including the brand and name of the test(s).
What, if any, guidelines or protocols does the Trust follow to support the diagnosis of suspected AMI? Please give details.
Does your Trust use early rule-out protocols to diagnose AMI? If so, please give details.
What is the average waiting time for a diagnosis following a suspected AMI at the Trust?
What is the target turn-around-time for tests used in the diagnosis of AMI in the Trust? What percentage of tests are performed within this target turn-around-time?
How long has the Trust and/or hospitals within the Trust been using their current troponin test(s)?
Download response Acute Myocardial Infarction (AMI) 211215 (AMI)
Admissions and Discharge policies and Venous Thromboembolism (VTE) policy.
Under the Freedom of Information Act, please may you send me a copy of your Admissions Policy and Discharge Policy?
If held, please may you send me your policy on preventing and treating venous thromboembolism (VTE’s).
Download response Admissions and Discharge policies and Venous Thromboembolism (VTE) policy 010216
Admissions of patients over the age of 65. 020518
1. How many people in the following categories had a fall as their primary reason for emergency admission in 2011/2012, 2015/2016, 2016/2017?
People over 65:
People over 65 and with dementia:
2. How many people in the following categories had a urinary tract infection as their primary reason for emergency admission in 2011/2012, 2015/2016 and 2016/2017?
People over 65:
People over 65 and with dementia:
3. How many people in the following categories had delirium as their primary reason for emergency admission in 2011/2012, 2015/2016 and 2016/2017?
People over 65:
People over 65 and with dementia:
4. How many people in the following categories had dehydration or gastroenteritis as their primary reason for emergency admission in 2011/2012, 2015/2016 and 2016/2017?
People over 65:
People over 65 and with dementia:
5. How many people in the following categories had a chest infection or pneumonia as their primary reason for emergency admission in 2011/2012, 2015/2016 and 2016/2017?
People over 65:
People over 65 and with dementia:
Download response Admissions of patients over the age of 65. 020518
Admissions via A&E.
1. How many patients visiting A&E each week who required admission were admitted within four hours? Please also provide the total number of patients attending A&E, for context.
2. What percentage of patients who required admission were admitted within four hours?
3. What was the average (mean) length of time between arrival and admission for patients who required admission each week?
4. How many patients who required admission were in A&E for more than 12 hours? Please note, I would like the number of patients who were in the department for more than 12 hours from the time they arrived, not those who waited more than 12 hours from decision to admit to admission.
Admissions via A&E. 180221
1. How many patients visiting A&E each week who required admission were admitted within four hours? Please also provide the total number of patients attending A&E, for context.
2. What percentage of patients who required admission were admitted within four hours?
3. What was the average (mean) length of time between arrival and admission for patients who required admission each week?
4. How many patients who required admission were in A&E for more than 12 hours? Please note, I would like the number of patients who were in the department for more than 12 hours from the time they arrived, not those who waited more than 12 hours from decision to admit to admission.
5. Each week, what was the longest amount of time a patient spent in A&E between arrival and admission? I would like to know their age and sex.
6. I would appreciate it if you could provide the same information for the financial year 2017/18, 2019/20 and so on, back as far as records allow.
Admissions via A&E. 210218
1. How many patients visiting A&E each week who required admission were admitted within four hours? Please also provide the total number of patients attending A&E, for context.
2. What percentage of patients who required admission were admitted within four hours?
3. What was the average (mean) length of time between arrival and admission for patients who required admission each week?
4. How many patients who required admission were in A&E for more than 12 hours? Please note, I would like the number of patients who were in the department for more than 12 hours from the time they arrived, not those who waited more than 12 hours from decision to admit to admission.
5. Each week, what was the longest amount of time a patient spent in A&E between arrival and admission? I would like to know their age and sex.
6. I would appreciate it if you could provide the same information for the financial year 2016/17, 2015/16 and so on, back as far as records allow.
Adult elective patient pre-operative nil by mouth (or fasting or fluids and feeding) guideline. 150921.docx
Please would it be possible for you to share a copy of your trusts adult elective patient pre-operative nil by mouth (or fasting or fluids and feeding) guideline.
A&E admissions on 8 and 9 December 2016. 080517
How many admissions happened on 8 and 9 December and at what times and how many cubicles are available in A&E.
Download response A&E admissions on 8 and 9 December 2016. 080517
A&E admissions for people in the last year of life. 270618
1. During the financial year 2016/2017 or last full year figures, what:
a. Was the total number of emergency admissions for people in the last year of life?
b. Was the total number of emergency bed days for people in the last year of life?
2. During the financial year 2016/2017 or last full year figures, what was the total number of people in the last year of life admitted from a care home setting as an emergency?
Download response A&E admissions for people in the last year of life. 270618
A&E agency staff 2016. 290317
1. The amount spent on employing agency/temporary/locum doctors in A&E departments in each month in 2016.
2. The number of FTE roles covered by agency/temporary/locum doctors in each month in 2016
3. The total number of FTE doctors working in the A&E department in each month in 2016.
A&E and Mental Health.280722.docx
For each financial year in the period 2016-17, 2017-18, 2018-19, 2019-2020, 2021-22, please provide figures for:
The number of adults (aged 18 and over) attending your A&E department for mental health related issues. Please breakdown the figure according to:
i.) How many were treated/seen by a doctor within 4 hours;
ii.) How many waited longer than 4 hours to be treated – please provide a breakdown for how long those people were waiting by hour e.g. five hours, six hours etc:
2. Please detail the longest period of time an adult attending your A&E department for mental health related issues waited to be treated/seen by a doctor in the years stated above?
3. The number of children attending your A&E department for mental health related issues. Please breakdown the figure according to:
i.) How many were treated/seen by a doctor within 4 hours;
ii.) How many waited longer than 4 hours to be treated – please provide a breakdown for how long those people were waiting by hour e.g. five hours, six hours etc:
4. Please detail the longest period of time a child attending your A&E department for mental health related issues waited to be treated/seen by a doctor in the years stated above?
A&E attendance rates and high intensity users. 180920
• Which programmes or services (either internally developed or commissioned) to tackle high attendance rates at A&E do you possess and are in operation? e.g. To identify and address High Intensity Users (HIUs) at A&E, redirection to other services such as Minor Injury Units, etc.
• How effective have they been for the Trust?
• The cost (how much) of the programme or service to the Trust, per year
I wish for this information to be for the date ranges; April 2018 – March 2019, and, April 2019 – present day
Download response A&E attendance rates and high intensity users. 180920
A&E attendances for assault in 2016. 091216
The data we require are as follows (for period 1st January 2016 and 31st December 2016) in an electronic format that allows us to read the data into a database. Many hospitals respond to our survey and provide data in the form we require. Preferably this format is in an excel file or comma separated text file.
We require the gender of the patient (M or F), the date that they attended due to assault (dd/mm/yyyy) and their age. Age can either be numerical to the nearest year (preferred) or in age bands (“0-10”, “11-17”, “18-30”, “31-50”, “51+”), we can also accept date of birth.
To calculate the level of assault-related injury in England and Wales we also require the total number of attendances for any reason in the year of interest, i.e. 2016.
Download response A&E attendances for assault in 2016. 091216
A&E attendances associated to mental health. 210621
1. The number of patients who were brought to A&E (ED) by the ambulance service/paramedics with a presenting complaint related to mental health, each year, from 2010 to 2020.
Download response A&E attendances associated to mental health. 210621
A&E attendances for alcohol related problems. 010721
For the calendar years 2020, 2019, 2018, 2017 and 2016:
1. How many patients attended A&E for alcohol related problems – for each of the years above?
2. Please can you provide data for each of the A&E departments within your trust and please name them?
3. Can you please break down the figures by age categories – 18-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81+
4. How many patients attended were under the age of 18 – for each of the years above?
Download response A&E attendances for alcohol related problems. 010721
A&E attendances for assault in 2015.
The data we require are as follows (for period 1st January 2015 and 31st December 2015)
ED attendance date
Age or date of birth
Gender
Reason for ED attendance
We also require the total ED attendances for 2015.
Download response A&E attendances for assault in 2015 080216
A&E attendances with mental health issues. 070120
1. For each financial year in the period 2014-15 to 2018-19, please provide figures for:
a. The number of adults (aged 18 and over) attending your A&E department for mental health related issues.
Please breakdown the above figure according to:
i.) How many were treated/seen by a doctor within 4 hours;
ii.) How many waited longer than 4 hours to be treated.
b. For the people in (a.ii.), please provide a breakdown for how long those people were waiting by hour e.g. five hours, six hours etc.
2. Please detail the longest period of time an adult attending your A&E department for mental health related issues waited to be treated/seen by a doctor in
a. Each individual financial year from 2014-15 to 2018-19 inclusive;
b. 2019-2020 to date.
Download response A&E attendances with mental health issues. 070120
A&E attendees with no fixed abode 220818
1. The number of patients presenting at your A&E/urgent care centres whose address is recorded as no fixed abode or any other similar indicator the trust uses to categorise those who do not have a fixed address/are homeless.
2. The number of patients admitted into your hospital/s whose address is recorded as above.
Please provide these figures for each financial year from 2010/11 to the 2017-18.
A&E beds and upfront charging. 250417
Accident and Emergency
1. As of April 2010, the total number of Accident and Emergency beds within the Trust (including predecessor Trusts)
2. As of March 2011, the total number of Accident and Emergency beds within the Trust (including predecessor Trusts)
3. As of April 2017, the total number of Accident and Emergency beds within the Trust
Please split the figures for questions 1-3 into overnight beds and day-only beds. This request includes beds that were temporarily unavailable.
4. Please list any Accident and Emergency wards or units that have been permanently closed since April 2010. Please state how many A&E beds they included at point of closure.
5. Please provide the business case or management report/review underpinning each closure listed in response to question 4
6. Please list any Accident and Emergency wards or units that have been permanently opened since April 2010. Please state how many A&E beds they include.
In this request, Accident and Emergency beds, wards and units are those whose primary usage is for Accident and Emergency cases.
Upfront charging of non-residents
7. What is the Trust’s policy on treating overseas patients who are eligible to be charged upfront for care but are not able or willing to pay upfront?
8. What is the Trust’s policy on upfront charging for overseas patients where it is not possible to establish the cost of care upfront?
9. What is the Trust’s policy towards clinical staff who refuse to enforce upfront payment?
10. What is the Trust’s policy on identifying which patients need to be asked for proof of residency in relation to upfront charging, and what form does that proof take?
A&E by people suffering with mental health related issues 2012-2016. 091216
How many attendances have there been at A&E by people suffering with mental health related issues (for example, categories including, psychiatric conditions, social problems, self-harm) over the last five calendar years (2012/2013/2014/2015/ January 1st – September 30th 2016)?
Please give the breakdown for under 18s and over 18s attendances (and if possible a further breakdown of ages for under 18s).
If possible, for each year, please state how many people waited longer than the four hour waiting target?
If the trust is in charge of more than one hospital, please give separate information per hospital please.
Download response A&E by people suffering with mental health related issues 2012-2016. 091216
A&E coding and diagnosis descriptions. 201021.docx
Within your FOI response letter dated 13 October 2021, you state:
“15.(b) I have been unable to get a response for this question. Please contact me again if you wish me to continue to chase a response.”
The above relates to my following FOI request question:
“(b) Within the Trust’s Accident and Emergency computer system used in April 2012, was there only the facility to record the ‘Primary Diagnosis’ and ‘Diagnosis Comments’, and no facility within the software to record specific secondary and third diagnoses when inputting the data in real time, other than within the ‘Diagnosis Comments’ field?”
I confirm that I would like you to continue to chase for the full and direct response to this question (i.e. not a generalised response).
Download response A&E coding and diagnosis descriptions. 201021.docx
A&E contact details. 270421
Could you please send me the e-mail contacts of all the Emergency Departments/A&Es of the hospitals within your trust.
Both, the e-mail contact of the GP in charge or the general e-mail contact of the EDs/A&Es would be fine.
A&E Department.241218
I would like to request the following information under the Freedom of Information Act.
In the week starting at 00.1am Sunday 7 August through to 11.59pm Saturday 13 August for how many hours was the most senior doctor present in your A&E department
*a consultant;
*a